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Abstract

A constitutively active Cys

Phe mutant of the aiB-adrenoceptor has been shown to not

only activate G-protein coupling in the absence of an agonist, but also activate only a
single effector pathway (phospholipase C but not phospholipase A2). This suggests that in
the case of the aiB-adrenoceptor, a single receptor subtype forms multiple conformations
for G-protein interactions that are specific for a particular G-protein/effector pathway.
The existence of this receptor opens up possibilities for the specific modulation of the
receptor pathway. Specifically, the development of small molecule ligands which activate
a single active conformer would thus provide new signalling-specific therapeutics with
pharmacological diversity.

In order to achieve this, ligands which bound selectively to the Cys Phe mutant OCIBadrenoceptor over the wild-type aiB-adrenoceptor were required. Through molecular
modelling studies and pharmacophore development a range of conformationally
restrained target ligands have been developed which mimic varying conformations of the
endogenous ligand adrenaline. This range of target ligands included a simple cyclic
series, a bicyclic series, a spirocyclic series and a spiro-fused series. Members of the

bicyclic and spirocyclic series were predicted to have particular selectivity potential for
the Cys128Phe mutant otiB-adrenoceptor.

The synthesis of the simple cyclic derivatives was via pynolidinone and piperidone
frameworks. A series of nine new bicyclic tropane-based target derivatives were prepared
from 6-hydroxytropinone. The major step in the approach to the synthesis of the

x

spirocyclic target ligands w a s a pro spirocycle-forming intramolecular palladium-assisted
cyclisation. One such spirocyclic compound was made. The synthetic procedure for the
spiro-fused target derivatives also began from pynolidinone and piperidone frameworks,
involving the formation of a hydroxymethyl aryliodide derivative, and a crucial
palladium-catalysed intramolecular cyclisation. While this last approach was not
completed, a novel indeno-pynole derivative was prepared.

Pharmacological testing of the synthesised simple cyclic and bicyclic derivatives
indicated that whilst some of the simple cyclic ligands exhibited selectivity for the
Cys128Phe mutant cciB-adrenoceptor, the bicyclic ligands displayed no selectivity for this
mutant receptor, and had only weak affinity for both ociB-adrenoceptors. The increased
rigidity and steric bulk of the bicyclic ligands appeared not to be favourable. However,
the set of bicyclic ligands have provided a promising new lead for selective OCIDadrenoceptor ligands.
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Chapter One Introduction

1.1 The Adrenergic Receptor System

1.1.1 Introduction and pharmacology

The adrenergic receptor system consists of adrenoceptors, their endogenous ligands, an
the effects they mediate. The adrenergic receptor system is vital for control of the
and plays a major role in the control of most smooth muscle tissues including blood

vessels and bronchi. The last few decades has seen much research aimed at the design o
selective ligands for the adrenergic system which may provide targeted
chemotherapeutic assistance in controlling the adrenergic system in disease states.

Adrenoceptors (ARs) are membrane-bound, guanine nucleotide binding protein (G
protein)-coupled receptors located throughout the body, on both neuronal and nonneuronal tissues (for an example, see Figure 1.1, Schematic of the hamster ctib-AR).
Adrenoceptors mediate a diverse range of functional responses to the endogenous
catecholamines adrenaline (also known as epinephrine), a circulating hormone released
from the adrenal medulla, and noradrenaline (also known as norepinephrine), a

neurotransmitter released from the pre-synaptic junction of sympathetic nerve termina

upon stimulation. These responses include increased rate and force of cardiac activity

constriction and dilation of smooth muscle, and relaxation of the gastrointestinal tr
and other organ tissues.

Initial investigations subdivided the adrenoceptor family into two subtypes, a andp,

based upon pharmacological studies in isolated tissues1. The a-adrenoceptors were late

further subdivided based upon their anatomical classification, with those a-ARs loca

on post-synaptic nerve terminals designated as cti -adrenoceptors, and those existing
peripheral sympathetic nerve terminals designated as a2-adrenoceptors2. The a2-

adrenoceptors were also later found to occur on liver cells, platelets and smooth musc
2
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cells of blood vessels3. cti-adrenoceptors are coupled mainly to phospholipase C, and

produce their effects mainly by the release of intracellular calcium; their physiologi
effects centre mainly on smooth muscle contraction3. The a2-adrenoceptors are mainly
coupled negatively to adenylate cyclase, and reduce cyclic AMP (cAMP) formation,
leading to a reduction in intracellular calcium; physiological effects include the
inhibition of transmitter release, hypotension, anaesthesia and vasoconstriction3.

Pharmacological differences between the two a-adrenoceptor classes were soon

identified, notably the ability of yohimbine and rauwolscine to act as antagonists upo

the ce2-adrenoceptor. Further subdivision of the ai -adrenoceptors has been facilitate
both molecular biological and pharmacological techniques4. The initial classification
the cti-adrenoceptors as

OCIA-

and ais-subtypes was determined from differences in the

binding characteristics of both the competitive antagonist WB4101 and the site-directe

alkylating agent chloroethylclonidine (CEC). Radioligand binding studies revealed that
the

CCIA

subtype has a high affinity for WB4101 and is CEC sensitive, whilst the

OCIB

subtype is insensitive to CEC and exhibits a low affinity to WB41014. Additionally,
three different cDNA's were isolated, characterised and shown to code for three

functional ai -adrenoceptors: aia5, an,6 "9, and a third subtype aid10, which exhibits a
low affinity for oxymetazoline in contrast to the aiA subtype, and is only partially
sensitive to CEC11. In the heart, the aiA-adrenoceptors appear to promote automaticity
and anhythmias during myocardial ischaemia. The aiA-adrenoceptors are involved in
activation of the sodium/potassium pump which leads to hyperpolarisation of the cell
and a decreased tendency for heart rhythm abnormality .

The first a2-AR cDNA was isolated from human platelet13 and designated as a2C10.
Related genes, designated as a2C2 and a2C414'15 were also shown to encode for a23
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adrenoceptors. These genes were subsequently classified as conesponding to the a2aAR (a2C10)16, the a2b-AR (a2C12)15'17 and the a2c-AR (a2C4)18.

The P-adrenoceptors have been classified as p/9, p220 and p321 using cDNA cloning

techniques. Pi-receptors are found mainly in the heart, where they control the positiv
inotropic and chronotropic effects of catecholamines via stimulation of adenylate
cyclase. p2-receptors are found in the smooth muscle of many organs, where they cause

relaxation, also via stimulation of adenylate cyclase. For an extensive review of a- a

P-ARs, including biology, classification, structure-activity relationships and therap
applications, see Hieble et al}6 and Ruffolo et al.22.

1.1.2 G-protein coupled receptors

The functional responses produced by activation of adrenoceptors are effected by the
interaction of the receptor proteins with G-proteins. Adrenoceptors are thus known as
protein-coupled receptors (GPCRs). GPCRs comprise a superfamily of more than
1000 cell-surface receptors which mediate diverse effects of extracellular signalling
molecules. They share a common structure, characterized by seven transmembrane
(TM) helices with three intracellular and extracellular hydrophilic loops, an
extracellular N-terminus and an intracellular C-terminus (See Figure 1.1 for an
example). GPCRs are involved in almost all of the physiological systems of the body,
including the endocrine system, cardiovascular and brain functions, taste, smell and
light sensing, and are major targets for drugs cunently used or in development24. Each

4
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EXTRACELLULAR

CYTOPLASMIC

Figure 1.1: Secondary structure of the hamster a1B-AR27. Note the highly conserved D R Y
motif at the intracellular end of the transmembrane III helix.

G P C R is specifically activated by a different ligand, including cations, monoamines,

neurotransmitters, lipids, odorant molecules, peptides of various lengths and pro

5
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Accordingly, G P C R s have been classified into one of 5 families (Class A-E) 2 4 . The

adrenoceptors fall into Class A, biogenic amines. The majority of receptors in this c
contain a highly conserved Glu/Asp-Arg-Tyr (E/DRY) motif located at the cytosolic

end of transmembrane helix III (see in Figure 1.1). To date there exists only one crys
structure for any GPCR, that of bovine rhodopsin25'26.

1.1.3 Development of sub-type-selective ligands for the ai-adrenoceptors

The clinical uses of adrenergic compounds are vast, ai-antagonists such as indoramin

and prazosin, and the a2-agonist clonidine have antihypertensive activity; clonidine i

often used as an adjunct to general anaesthetics, ai -Adrenoceptor antagonists are als
used in the treatment of benign prostatic hypertrophy.

In order to discover more about the role of aiA, aiB and aio adrenoceptors in disease

and to improve therapeutic applications, research has been aimed at developing ligands

selective for each of these subtypes. Although there are some selective a^ antagonists
known, such as SNAP5089 and (+)niguldipine, there are no antagonists showing

substantial selectivity for either the aiB or aio adrenoceptors (See Table 1.1). There

thus a need for selective agonists and antagonists for both aiB and aio adrenoceptors.

6
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Table 1.1: Information about ai -adrenoceptors ;NA = Noradrenaline

subtype

Potency Order

Agonists

Antagonists

CtlA

Oti D

OClB

Adrenaline = N A

Adrenaline = N A

Adrenaline = N A

A61603

None available

None available

KMD3213

None available

BMY7378
SKF105854

(+)niguldipine
SNAP5089
SNAP 5272
RS17053

Coupling

Gq/n

Gq/n

Gq/n

1.2 Adrenergic Receptor Activation

1.2.1 Interaction of catecholamines: mechanisms in adrenoceptor activation

Gether and Kobilka29 have suggested a general model for the activation of rhodopsinlike GPCRs, which includes adrenoceptors. Most studies directed towards elucidating

the mode of interaction of agonists and antagonists with adrenoceptors have been base
upon the p-adrenoceptor, specifically the p2-AR subtype, as it is perhaps the best

characterised. The a- and p-adrenoceptors have similar molecular structure (see Figu
1.2). The p-ARs range from 388-477 amino acids in length. The a-ARs (see Figure

1.1), particularly a]B- and a]D-subtypes, are larger than the p-ARs, ranging from 501560 amino acids in length, with longer extracellular amino and cytoplasmic carboxyl
termini. The a2-ARs are comparable in size to the p-ARs (450-461 amino acids) but
with shorter amino and carboxyl termini and very long third intracellular loops.

7
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The transmembrane ( T M ) domains of the p 2 - A R create the ligand binding pocket. This
has been shown by the co-expression of two p2-AR fragments, TM helices I-V and TM

helices VI-VII, which resulted in a functional membrane receptor capable of binding p
AR radioligand [125I]iodocyanopindolol ([125IjICP) and mediating adenylate cyclase30.
Neither fragment alone recognised a p2-AR ligand. Site-directed mutagenesis has
demonstrated that Asp113 in TMIII is required for both agonist and antagonist binding.

is believed that the free carboxyl group of Asp interacts with the protonated amine o
adrenergic ligands. The meta- and j^ara-hydroxyl groups of catecholamines are
postulated to form H-bonds to Ser204 and Ser207 respectively, located in the TMV

helix31. Binding to both Ser204 and Ser207 appears necessary for full agonist activity a
the P-AR32'33. More recently Ser204 and Ser207 have been implicated not only in the
docking site for the agonist, but also in control of the equilibrium of the receptor

inactive to active forms34. A hydrogen bond interaction between the chiral benzylic phydroxyl group of catecholamines and Asn293 in TMVI of the p2-AR may be
responsible for the stereoselective binding of agonists35. In the TMVI helix of p2-ARs

the phenyl ring of Phe290 (equivalent to Phe311 in the am-AR) is postulated to participa
in binding the aromatic ring of agonist ligands ' .

8
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Figure 1.2: Taken from Zhao et al a. A schematic of the chimeric hamster lung p 2 -AR. Residues in
grey, amino acids in the p V A R which are identical to that of the aia-subtype; residues in white, amino
acids unique to the p V A R . Residues in black represent replacements in the extracellular loop (by the
authors) with rat aj a -AR residues to produce a receptor with ai a -AR activity.

The Pi-AR is predicted to have the same structural orientation as the p2-AR and
contains Asp138, Ser229, Ser232 in conesponding positions to those shown to be important
for the binding of agonists in the p2-AR16. It has not been possible to localize any

specific changes in the receptor protein responsible for the relatively subtle differen
in pharmacology that exist between the Pi- and p2-AR subtypes16. It is likely that the
pharmacological differences between Pi- and p2-AR are not due to specific amino acid

substitutions, but rather to subtle changes in orientation of the primary binding sites,
resulting in a slightly different binding pocket16.

Intramolecular interactions contributing to the stability of the inactive receptor
conformation of the aiB-AR have been identified between Asp125 in TMIII and Lys in
TMVII36b"38 (shown in Figure 1.3). Interactions shown to be important in the binding of
catecholamines and activation of the aie-AR include an ionic interaction between the
9
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protonated amine of adrenaline and Asp 1 2 5 in TMIII (equivalent to Asp 1 1 3 in the p 2 -AR),
and a hydrogen bond between the catechol meta-hydroxyl of adrenaline and Ser207 in
97

TMV

(Figure 1.3). In contrast, hydrogen bond interactions involved in the binding of

agonists to the aiA-AR occur between the meta-hydroxyl and Ser188 (equivalent to
Ser203, not Ser204 in the p2-AR), accounting for 70-90% of the wild-type response, and
the/?ara-hydroxyl and Ser192 (equivalent to Ser207 in the p2-AR), which contributes only
minimally to receptor activation39. Although the ai-ARs preserve the stereoselectivity
of catecholamine binding and activation displayed by the P-ARs, the determinants of
stereoselectivity (i.e. interaction with the chiral benzylic p-hydroxyl substituent)
97 9Q^

not been defined

and the A s n

equivalent is replaced by a residue which lacks

97

hydrogen-bonding potential (either leucine or methionine) .
Further modelling and experimental studies by Chen et al.21 have indicated that Phe310
in TMVI, which points into the agonist-binding pocket, interacts directly with the

catechol ring of the catecholamine agonists (Figure 1.3). Although this interaction wa

shown not to be necessary for spontaneous receptor isomerization from the basal state,
R, to a partially activated conformation, R', it was essential for isomerization from
the fully activated R* state. Phe163 (TMIV) and Phe187 (TMV) (residues novel to the
aie-AR) have been reported as binding contacts in the agonist binding pocket, but not
as being directly involved in receptor activation40.
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97

Figure 1.3. Model of the hamster ai B -AR. Taken from Chen et al. : A model of the a 1 B - A R showing
adrenaline docked into the ligand-binding pocket. The receptor is modelled as it would appear looking
down onto the membrane from the extracellular side. White circles with Roman numerals indicate the
respective transmembrane helices. The yellow cylinders represent the projection of the helices from the
extra- to intracellular surface of the membrane. Adrenaline is shown interacting via its protonated amine
with Aspl25 in TMIII, via the catechol ring meta-hydroxyl with Ser207 in T M V , and via K stacking
interactions of the catechol ring with Phe310 in T M V I . The interaction between Asp 125 in TMIII and
Lys331 in T M V I I which stabilises the receptor in the inactive state is shown.

Several different experimental and modelling studies suggest that both negatively and
positively charged residues of the highly conserved E/DRY motif may be involved in
the activation process of GPCRs41'42. An alternate theoretical model of aiB-AR

activation43'44, which deviates from the one just presented, has indicated a network

hydrogen-bonding interactions among polar residues forming a "polar pocket" near th
cytosol (Asn63 in TMI, Asp91 in TM1I, Asn344 and Tyr348 in TMVII) and Arg143 of the

E/DRY motif in TMIII. This set of interactions is suggested45 to constrain the rece

in its ground state by controlling the degree of cytosolic exposure by Arg . The ma

role of Arg143 is thus indicated to be mediation of receptor activation, allowing am
acids of the intracellular loops to attain the correct configuration for G-protein
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interaction. Mutations of Arg 1 4 3 were indicated to drive the a ] B - A R into different

activation states45, further suggesting a role of this residue in the activation proces

the receptor. The mechanism of this activation is hypothesised to consist of protonatio

of the aspartate (Asp142) and a shift of the arginine (Arg143) out of the "polar pocket".
Recent results46 support the hypothesis that a salt bridge between the highly conserved
arginine Arg143 of the E/DRY motif of TMIII and a conserved glutamate (Glu289) in
TMVI constrains the aiB-AR in the inactive state. Mutations of Glu289 that weakened the
1 A*\ 9RQ

Arg

-Glu

interaction constitutively activated the receptor. Residues located in the

environment of the interface between the cytosolic extension of helices III and VI of
aiB-AR are indicated to be largely involved in the activation of the receptor46. This
indicates that a reanangement of helices III and VI represents an important step in
receptor activation.

In the case of the a2-AR, Asp113 in TMIII is also required for specific binding of
ligands47, by an ionic interaction with the protonated amine of the ligand. The
interaction of Ser204 (corcesponding to Ser207 in p2-AR) with the p-hydroxyl of
catecholamine agonists is important, but the interaction of Ser200 (conesponding to
Ser204 in p2-AR) with the m-hydroxyl is not. An interaction of the m-hydroxyl with
Cys201 in the a2-AR has also been postulated47.

A detailed model for the binding of catecholamines to the a2A-AR receptor, based upon
structural, pharmacological, and theoretical evidence, has been proposed . In this

model, the most important interaction in the binding process is that formed between the
positively charged amine of the catecholamine and the negatively charged carboxyl
chain of Asp113 in TMIII (as for other adrenoceptors). The /?-hydroxyl group is
positioned such that it can interact with one side chain oxygen of Asp . The iV-methyl
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group of adrenaline was shown to pack against Phe 411 and Phe 4 1 2 in T M V I I in docking

simulations. These parts of the TMVII are exposed to the binding cavity, favourable f
hydrophobic, aromatic and methyl contacts. The ring plane of the aromatic ring is
proposed to pack against TMVI (as is the case with the a1B-AR27), with additional
interactions with TMIII and TMV. GRID calculations predict interactions between the
aromatic ring and Phe391 and Tyr395 in TMVI, and partially with Phe205 and Cys201 in
TMV. The catecholic hydroxyl groups can co-ordinate with Thr118 in TMIII, and Ser200,
Ser and Cys in TMV. The inactive receptor conformation model suggests the

length of the phenethylamine ligands is too short to easily reach both Asp113 in TMIII
and Ser200, Ser204 and Cys201 in TMV. A proposed rotation of TMV occurring in the
active receptor form therefore exposes both Ser200 and Ser204 to the ligand-binding
cavity.

1.2.2 The process of GPCR-G protein coupling

G-proteins physically and functionally connect the receptor and its effector system.

its resting state, a G-protein exists as a heterotrimer, containing a, P and y subuni

with guanidine diphosphate (GDP) occupying the guanine nucleotide binding site on the
a subunit. When a receptor is occupied by an agonist molecule (endogenous or

synthetic) a conformational change occurs, causing it to acquire high affinity for aP
Association of aPy with the receptor causes a GDP/GTP (guanidine triphosphate)

exchange followed by dissociation of a-GTP from the G-protein. The py subunit is very
hydrophobic and remains complexed with the cytoplasmic surface of the membrane, aGTP (the active form of the protein) diffuses in the membrane and associates with
various enzymes and ion channels, causing activation or inactivation (this will be
Z ?,?.?.? "'™067
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discussed more shortly). The process is terminated w h e n G T P is hydrolysed to G D P :
the resulting a-GDP dissociates from the effector and reassociates with Py, completing
the cycle. Each subunit of the G-protein contains structural diversity, and consequently
the G-protein family is large and both structurally and functionally diverse.

Adrenoceptors interact preferentially with three classes of G-proteins: Gs (padrenoceptor) mediating activation of adenylyl cyclase, G; (a2-adrenoceptors)
mediating inhibition of adenylyl cyclase, and Gq (ai-adrenoceptors) mediating
activation of phospholipase C16. Different receptor subtypes may, however, interact
preferentially with different G-proteins, for example the a2c-adrenoceptor may interact
with G0 rather than with Gj as observed with the other a2-adrenoceptor subtypes49.
Adrenoceptors may also be coupled to other effector systems, such as ion channels
perhaps through G0, and single adrenoceptor subtypes may be coupled to multiple
effector systems through different G-proteins.

It has been indicated that adrenoceptors and G-proteins interact through the second (i2)

and third (i3) intracellular loops44'50, which is the most structurally diverse portion of
the adrenoceptors. The character of this loop determines which G-protein the receptor
will preferentially bind to9'30'51"53. For example, replacing a 27 amino acid segment of
the N-terminus of the i3 loop of the p2 AR with the aiB sequence resulted in a mutant
capable of activating both phospholipase C and adenylate cyclase54. Similarly, small
peptides derived from the intracellular loops of adrenoceptors have been shown to bind
and activate G-proteins55'56, suggesting that in the native receptor these regions may be
shielded from the G-protein until agonist binding induces a change in the conformation
of the receptor57. Point mutations in the i3 carboxy terminus of the aiB AR can result in

constitutively active receptors , receptors which are activated in the absence of agonist
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(discussed in detail in section 1.4). This small change in receptor conformation is

obviously enough to induce receptor-G-protein interaction. Other studies have identifie
hydrophobic amino acids as contributing to the receptor-G protein interface59"61.
9S4 9^8

Recently, Arg

and Lys

in the third intracellular loop were hypothesised to be

contact sites on the aiB receptor for the a-subunit of Gq, playing a direct role in
receptor-G-protein coupling46.

Evidence has also been given that members of the ai-AR may bind antagonists on the
extracellular surface of the receptor . Further replacement of the third extracellular
of the P-AR with the conesponding region of the aiA subtype gave the chimeric

receptor (see Figure 1.2) a higher binding affinity for agonists, an increased potency,
and an agonist-independent higher basal activity of adenylate cyclase363. This activity
(referced to as 'constitutive activity'; see section 1.4.1) suggested a possible role
third extracellular loop of the p2-AR in controlling receptor/G protein activity, most
likely by indirectly influencing the anangement of TMVI and TMVII in the membrane
bilayer.

1.2.3 G-proteins as cellular signallers

Stimulation of aj-ARs and their G-proteins results in the activation of various effecto
enzymes, including Phospholipase C (PLC), Phospholipase A2 (PLA2) and
Phospholipase D (PLD), as well as activation of Ca2+ channels, Na+-H+ and Na+-Ca

+

exchange, and activation or inhibition of K+ channels3. In most cells, the primary

functional response of all aj-ARs to activation is an increase in intracellular Ca +. Th

complexity of ai-AR signalling is due, in part, to the ability of the individual subtyp
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to couple to different effectors via distinct G proteins. The ai-ARs preferentially bind to
Gp/q, PLC mediating G-proteins, but also couple to PLA2 mediating G-protein G;.

PLC is a membrane-bound enzyme which when activated by Gq acts on phosphatidyl
inositol (4,5)-diphosphate (Ptd Ins (4,5) P2) in the membrane to produce two second
messengers: inositol (l,4,5)-triphosphate (l,4,5-rp3), which causes the release of
intracellular Ca2+, and diacyl glycerol (DAG) which activates protein kinase C (PKC)3.
(1,4,5-IP3) is then dephosphorylated producing inositol, and DAG is phosphorylated to
produce phosphatidic acid (PA). Inositol and PA couple, and through a series of

phosphorylation reactions, complete the cycle to produce Ptd Ins (4,5) P2. The increase
94-

Ca

levels effected by the 1,4,5-IP3 can result in physiological changes such as smooth

muscle contraction, increased force of cardiac muscle contraction, secretion from
exocrine glands and neurotransmitter release from neurones and hormone release3. PKC

controls phosphorylation of serine and threonine residues of a variety of intracellular
proteins " . The physiological effects of PKC activation include (but are not limited
to): release of hormones; increase or decrease in neurotransmitter release and in
neuronal excitability; contraction or relaxation of smooth muscle; inflammatory
responses; tumour promotion; and receptor desensitisation.

Receptor mediated activation of PLA2 leads to the production of arachidonic acid

metabolites , which function as intracellular messengers, controlling potassium channe
function in certain neurons and local hormones communicating between cells. It can

be seen therefore, that the stimulation of the aiB-AR can result in the activation of a
number of second messengers, and a myriad of functional responses. In the search for

more selective ligands and improved therapeutics for the adrenergic system (and in fact

any GPCR system) it will be necessary to target the selective activation of G-proteins.
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1.3 Theory of Receptor Activation
1.3.1 The ternary complex model

For many years the classical receptor theory described the process of ligand-

interaction and resulting effector responses. The classical receptor theory69"

upon the existence of a single population of receptors that are activated onl

ligand possessing both affinity and efficacy interacts with the receptor. The

ligand induces a conformational change in the receptor which results in G-pr

coupling and effector stimulus. From this theory developed the ternary comple

now the most widely accepted model describing the activation of GPCRs, propos

that receptor activation requires the agonist-promoted formation of an active
complex of agonist (A), receptor (R) & G-protein (G)72:
A + R->AR + G-> ARG

A further extension of this model73 refened to as the "two-state model"74, prop

receptors exist in equilibrium between two conformations, an inactive (R) for

displays low agonist affinity and does not couple to G-protein, and an active
which displays high agonist affinity and couples to G-protein :

A

+

R

,,=— R* + A ^=^ AR* + G == AR*G

In this model the different efficiencies of agonists to promote second messen

activation are explained by supposing that stronger agonists favour binding t

greater extent than weaker agonists, and hence more readily form the AR*G ter
complex. Inverse agonists bind to and stabilise the inactive R conformation,

reduction in basal effector activity '. Neutral antagonists bind equally well
and R* and do not alter effector activity77. In a strict two-state model, the
17
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for R is identical to that for A R and its affinity for R* is identical to that for A R *
because R and R* represent unique defined conformational states. The AR*G

conformation in a strict two-state model is the same for all agonists, which differ on
the ratio of AR*G to ARGtotai (where ARGtotai = ARG + AR*G)74.

1.3.2 Multiple effector responses and agonist-directed trafficking: extension of the
two-state model to a multi-state model

Agonists are capable of providing multiple stimuli upon receptor activation. There are
several examples of a single receptor coupling to more than one cellular signal
transduction pathway, including: the 5-HTIA receptor, which both inhibits adenylyl
751 •+• 7Q

cyclase activity

and opens K

channels ; members of the serotonin 5-HT 2 receptor

family couple to both PLC and PLA280'81; the thyroid-stimulating hormone (TSH)
receptor stimulates both adenylyl cyclase and PLC . a2-AR agonists have been
observed to both stimulate and inhibit adenylyl cyclase83"86 and the receptor has been
shown to couple both physically and functionally to Gs as well as Gj87. The magnitude

of each of the multiple stimuli elicited can be different and agonist-dependent. It has

been suggested that each agonist stabilises a unique set of receptor conformations wit

range of G-protein-activating abilities88'89. Indeed, functionally different agonists ha
been shown to induce distinct conformations in the G-protein coupling domain of the p2
AR90.

This concept has been termed "agonist-directed trafficking of receptor stimulus" and

has been discussed in detail by Kenakin91'92. Agonist-directed trafficking predicts that

"the efficiency of receptor coupling to each of multiple effector pathways in a cell is
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function of the agonist"

and as a consequence agonist relative efficacy could be

effector pathway dependent.

Although the two-state model of agonist action allows for a receptor to couple to
multiple cellular effectors, the single active receptor conformation does not allow for
77

activation of effectors differentially in an agonist-dependent manner . T o allow for this,
the two-state model has been extended to a three-state model (or multi-state model) in
which receptors are proposed to exist in equilibrium between at least two active
conformations (R* and R**) and an inactive (R) conformation94. In a model with
multiple active conformation states, each of the active conformations is proposed to
interact with a different effector pathway; in this way agonists can promote the
formation of different receptor conformations by having differential affinity for these

conformations. The fluorescent labelling of the p2 AR indicates the receptor can exist in
at least two conformational states88: unliganded and agonist-bound. This data could
support the two-state model, or it could support a multi-state model, in which the
biological efficacy of an agonist is a consequence of the magnitude of conformational
change it induces in the receptor.
Experimental evidence provides support for agonist-directed trafficking95'96 and the
concept of agonist-selective receptor states74'88'97 is becoming more accepted. Data for
5-HT2A

and 5-HT2c receptors treated with a series of agonists strongly supports the

hypothesis that agonists may traffic the receptor stimulus differentially to multiple
effector pathways coupled to the same receptor . The most likely mechanism by which

this may occur is through differential G-protein coupling. Although the agonist-directed
trafficking hypothesis allows for a different receptor conformational state unique to
each agonist, the analysis of the 5-HT2 receptors93 suggests that two active receptor
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conformations are sufficient to explain pathway-dependent agonist efficacy. The basis

for differential agonist efficacies is therefore different efficacies among agonists at t
two active forms R* and R** (Scheme 1.1).

A, + R* A2 + R**

i i
A,R* A2R**
4^ •*• •+• 4'
E] E2 Ei E2

Scheme 1.1 Diagrammatic explanation of the multi-state model of receptor activation. The
and blue represent two different receptor conformation states and their G-protein coupled
effector pathways; each activated receptor may interact with either effector pathway Ej or E 2 .

Agonist directed trafficking has important implications for both normal and
pathological physiological function and for therapeutic drug design. If drugs can be
designed which upon coupling to a receptor preferentially activate or inactivate a
specific G-protein and effector pathway, they should provide more selective results with
mimmised side effects.

1.4 Implications of a constitutively active mutant ais-adrenoceptor

1.4.1 Constitutively active mutants of GPCRs

Constitutive activity is defined as ligand-independent activity, resulting in the

production of a second messenger, even in the absence of an agonist24. It is also referred
to as a 'gain-of-function' phenotype. In a constitutively active mutant receptor (CAM),
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there is an increase in basal activity relative to the wild-type receptor. The structure
adopted by CAMs may therefore often be an approximation of the real active
conformation of the receptor.

Activating mutations can affect any part of the receptor, and there has been an
enormous number of constitutively active mutant GPCRs either found by accident or
created. The positioning of mutations within a GPCR can highlight areas of

conformational constraint in inactive receptor conformations and identify intramolecu

interactions. CAMs have been used to identify constraining intramolecular interaction
that keep ligand-free receptors inactive. For example, CAMs of rhodopsin have
indicated that TMVI and TMVII provide important conformational constraints98.
Details of these interactions have been reviewed recently99'100. Similarly, CAMs of the
angiotensin ATi receptor indicate conformational constraints between TMIII and
TMVII101'102. Random mutagenesis of the whole angiotensin II ATiA receptor has
shown that most activating mutations are present in transmembranes, largely on one
side of TMIII103. Most CAMs of M5 muscarinic receptors affect the 2nd intracellular

loop of TMVI in a pattern suggesting the existence of interacting surfaces in the ina
conformation104"106. Many Class A GPCRs contain a highly conserved D/ERY motif at
the cytoplasmic end of the TMIII. Through characterisation of several CAMs, in which
the first residue of this motif was mutated, including rhodopsin ' , aiB-AR ' , p2AR109'110, gonadotropin-releasing hormone111 and Ml muscarinic receptors112, this motif

has been indicated as a major interaction constraining the inactive conformation of th
receptors.

CAMs may become active by one of two methods. The cunent hypothesis supports the
view that CAMs release the conformational constraints of the GPCR inactive state .
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Whilst in the wild-type receptor the intramolecular interactions that constrain the

receptor in an inactive state are postulated to be overcome by new interactions created
by the presence of an agonist, many CAMs may be activated by simply disrupting the
interaction of the inactive conformation. The conformations of those CAMs may
therefore only be approximations of the real active conformation, giving no indication
of the interactions involved in the ligand-induced active conformation(s). Conversely,
some CAMs may create new interactions which stabilize the active state. CAMs

resulting from an additional intramolecular interaction may be closer models of ligandactivated conformations, and may be more stable than those CAMs which result from
the loss of an intramolecular interaction24.

Mutations at different positions of the parathyroid receptor present an example of the
two ways to produce CAMs. Almost all the substitutions of threonine410 result in
CAMs, in agreement with the disruption of inactivating interactions involving TM6.
Alternatively, substitutions of His223 with only Arg or Lys result in CAMs1 3. Computer
modelling studies suggest these mutations create a new interaction between TM2 and
TM5114.

Constitutive phosphorylation has been demonstrated for many CAMs, including those
of the luteinising hormone receptor115'116 and adrenergic receptors117'118. This suggests

that the conformation they adopt is a good enough representation of the ligand-receptor
active state to be recognized by the specific and non-specific kinases, as well as the
desensitisation and internalisation machineries. Some CAMs however, for example of

the AT] receptor, do not impart either constitutive or agonist-induced phosphorylation,
indicating that the adopted conformation of the CAM is not that of the agonist-induced
wild-type receptor119. The further possibilities of constitutive downregulation and
constitutive internalisation and recycling have recently been addressed.
22
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1.4.2 Constitutively active mutant receptors in pathology

The unregulated and ligand-independent activity of CAMs has been linked with
autonomous hormonal secretion in several endocrine diseases: hyperfunctioning thyroid
adenoma (thyroid-stimulating hormone)123; diabetes insipidus (V2 vasopressin
receptor)124; retinitis pigmentosa and night blindness due to the degradation of retina
19S

cells (rhodopsin)

; and defects in chondrocyte differentiation (parathyroid hormone

1 9f^

receptor)

. Disease has also been associated with C A M s of the luteinising hormone

receptor 7, follicle-stimulating hormone receptor128 and Ca2+ sensing receptor129. The
phenotype resulting from these mutations may be either gain-of-function or loss-of-

function. In many of these cases, the mutation results in a misfolded protein, which can
block other cell functions24.

1.4.3 Constitutively active adrenoceptors and the Cys Phe ais-adrenoceptor

Some constitutively active mutants of the p2-AR36a'54 and the ctiB-AR58 have already
been presented in Section 1.2.2. Their mutation regions (i3 loop and e3 loop) were
implicated in being important for the structural rigidity of the inactive receptor
conformation. Further replacement of the C-terminal portion of the third transmembrane
helix of the p2-adrenoceptor (residues 266-272) with the homologous region of the aiB
adrenoceptor [L266S, K267R, H269K, L272A) led to the formation of a CAM which

indicated activation of adenylyl cyclase57. This CAM exhibited an increased affinity for

agonists (even in the absence of G-protein), but not antagonists, an increased potency o

agonists for the stimulation of adenylyl cyclase, and an increased intrinsic activity of
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partial agonists. Further constitutive activation of adrenoceptors is also conferred by
other mutations in the third intracellular loop45'58130.

A Cys Phe mutation in the third transmembrane domain of the ais-adrenoceptor also
imparts constitutive activity89. This residue is located approximately one helical turn
below Asp125 in the third transmembrane domain (Figure 1.4). Because Asp125 is the
putative counter ion that binds the protonated amine of adrenergic ligands, it is
postulated that an agonist induced conformational change of the third TM segment is

involved in receptor signalling. Disruption of this critical interaction, as may be th
with the Cys128Phe mutation, might induce changes in the conformation of this helix
which may mimic the activated (R* or R**) (also refereed to as Ri* and R2*) form of

the receptor. The constitutive activity of the Cys Phe mutant indicates that it may ver
well be representative of an active form of the receptor.

The constitutive activity of this receptor was initially suggested by the finding that
binds the (agonist) catecholamines adrenaline and noradrenaline and other

phenethylamines with higher affinity than the wild-type receptor, whilst being unalter
in its binding of a range of diverse antagonists (Table 1.2) . As with other CAMs, the
increase in agonist affinity was demonstrated to not be due to enhanced G protein
coupling. Interestingly, the Cys Phe am-AR activates only a single effector pathway,
the PLC pathway (See Scheme 1.2). This is in contrast to another constitutively active
aiB-AR mutant Ala293Glu, which activates both the PLC and PLA2 effector pathways89.
This data was strong evidence for the formation of the multi-state model of receptor
activation.
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Figure 1.4: Model of the constitutively active Cys128Phe ai B -AR mutant (Perez et a/.89),
showing the cysteine residue in TMIII.

GlARi* ^ ^ Gi + A R i * ^ ^ A + Ri* ^ ^ R = ^ ^ R2* + A ^ = ^ A R 2 * + G 2 ^ ^ G 2 A R 2 *

I
1
i
P L C activation

i
I
CyS128phe mutant

Scheme 1.2 Diagrammatic model of the signalling-specificity of the Cys

PLA2 activation

Phe ctiB-AR

Surprisingly, the affinity of the Cys 1 2 8 Phe a i B - A R mutant for the imidazoline class of
adrenoceptor agonists was largely unaltered from that observed with the wild-type

receptor (Table 1.2). With the imidazolines containing a constrained basic nitrogen (s
Figure 1.5), the freely rotating ethylamine side chain of the phenethylamines seems to

be the important factor, suggesting that they are able to adopt a conformation prefened
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by the mutation induced activated Cys

Phe receptor. The Ala

Glu mutant displayed

a similar ligand binding phenotype to that of the Cys128Phe mutant: the affinity for
phenethylamine agonists was increased with the mutants to an extent related to their

degree of intrinsic activity at the wild-type receptor, whilst the affinity for imidazo
ligands was largely unaltered from that of the wild-type receptor (Table 1.2). The
increased affinity observed with the phenylethylamine ligands is thus "not due merely
to changes in the ligand binding pocket but rather indicates that the mutations induce
conformations that partially mimic the R* state" . Because PLC and PLA2 are activated
— Ill

by two distinct G proteins

, these findings demonstrate preferential activation of G

proteins (and coupled effectors) in the mutant Cys128Phe aiB-AR by specific agonists
(phenethylamines, but not imidazolines). This information suggests that it should be

possible to develop agonists that selectively activate only a single effector pathway by

trapping either R*i or R*2 or inverse agonists that selectively inhibit signalling by e
the R*i or R*2 conformations (Scheme 1.2).

\=/ R2R3 \=/±

N

N'
2

H

Phenylethylamines Imidazolines

Figure 1.5 General structures of the phenylethylamine and imidazoline ligands.
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Table 1.2: Binding affinities (Kt) for a range of k n o w n ai-AR agonists and antagonists upon
the wild-type a i B - A R and the Cys 128 Phe a 1 B -AR. Data shown in bold indicates a significantly
different binding affinity for the Cys 128 Phe ociB-AR (indicative of selectivity for the receptor).
Ligand
Agonist
Phenethylamine
R-Adrenaline (1)
i?-Adrenaline (2)
^-Adrenaline (3)
Methoxamine (4)
Phenylephrine (5)
(-)-Dobutamine (6)
SKF(-)-89748 (7)
Imidazoline
Oxymetazoline (8)
Cirazoline (9)
Clonidine (10)
SKF-35886 (11)
SKF-43315
Antagonist
Prazosin
5-Methylurapidil
WB4101
Rauwolscine
Yohimbine

Kt (nM)
Wild-type A R

Ki (nM)
Cys128Phe A R

K, (nM)
Ata293Glu A R

2223
3700
247000
450000
10360
1230
2399

133
373
16000
47000
1913
2042

2223
3700
247000
450000
10360
1230
2399

596

560

596

1337
1506
1995
15850

1066
1113
1122
7943

1337
1506
1995
15850

0.35

0.28

0.35

99
15

60
12

99
15

2993
1230

1660
1323

2993
1230

550
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1.5 Project Aims

The overall aim of this project was therefore to design, synthesise and evaluate sm
molecule ligands which would selectively bind to the Cys128Phe mutant aiB-AR over
the wild-type ai B -AR. Such ligands would selectively interact with only a single
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effector pathway, as agonists that would selectively trap R*i or R* 2 . These selective
ligands may therefore be able to induce activation of only a single effector pathway in

the wild-type aiBAR. In disease states where constitutively active receptors are present
neutral antagonists would not provide any selective control, as they bind to both the

basal and activated states with the same affinity. However, inverse agonists, which bind

to the basal receptor state with higher affinity than the activated state, could trap th

receptor in the basal state, and thus prevent signalling of the active state. This proce

might be slow as it requires the constitutively active receptor to first isomerise to th
basal conformation, which is an infrequent occurrence.

A good initial lead for the design of such ligands was the experimental evidence that
phenylethylamines but not imidazolines bound with greater affinity to the Cys128Phe
mutant aiB-AR . This suggested that selective ligands need to mimic a specific
conformation of the adrenaline motif. It was therefore proposed to prepare a range of
conformationally restricted ligands which mimic extended or folded conformations of
the phenylethylamine-based endogenous ligand adrenaline (Figure 1.6). To ensure a
particular conformation, rigidity is needed in the molecules, which can be provided by
the use of heterocyclic frameworks.

HO I
\=/ I I \
A

B C D

A = Hydrophobic bonding region (Aromatic)
B = Hydrogen Bond acceptor (HBA)/Hydrogen Bond Donor (HBD) region
C = Carbon spacer
D = Basic Amine (forms H-bond reinforced salt bridge when protonated)

Figure 1.6: Design Motif incorporating the adrenaline structure for the design of small
molecule heterocyclic ligands
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The use of molecular modelling was likely to be helpful in determining the important
spatial and conformational differences between the phenethylamine agonists and the
imidazoline agonists. Moreover, the generation of ligand-based pharmacophores for the
1 9S

Cys

Phe mutant a i B A R and the wild-type a i B A R (based upon data from Tablel.2)

may provide valuable leads as to conformational and three-dimensional requirements
for selectivity for the Cys128Phe mutant aiBAR. Catalyst® was therefore to be used to
assist in the design of small molecule heterocyclic ligands based on the adrenaline
motif, which may provide selective binding to the Cys128Phe mutant aiBAR and specific
signalling of the PLC pathway.

Finally, the synthesised ligands were to be assessed for their binding affinities and
selectivities on both the Cys128Phe mutant aiBAR and wild-type a]BAR, as well as for
signalling-specificity. It was hoped these results could then be used in the further
development of more selective ligands, and in the generation of more developed
pharmacophore models. The long term goal of this work was the development of
signalling-specific cardiovascular therapeutics, containing greater selectivity and
imparting fewer side effects than those currently available.
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Chapter Two

Molecular Modelling
and Pharmacophore Generation
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2.1 Introduction

Over the past decade ligand-based drug design has become a popular tool for the
medicinal chemist, especially where the three-dimensional structure of the target
1

TT

1

TT

receptor is not k n o w n

' . With little k n o w n about the tertiary structure of the ai B

adrenoceptor (AR), or the bioactive conformation of adrenaline, it may be advantageous
to use computer modelling techniques to provide a template for ligands which might
1 9R

prefer the Cys

Phe a i B - A R over the wild-type ai B -AR. This m a y be initiated by

developing pharmacophores for both receptor types. In preparing pharmacophores for

the differing receptors, it may be possible to distinguish differences in binding patt
•I TQ

which m a y lead to the design of ligands selective for the Cys

Phe a i B - A R over the

wild-type aiB-AR, and prediction of the bioactive conformations of adrenaline may be
possible.

These aims may be achieved by utilising ligand-based drug design methods using
CATALYST® by Accelrys to rationalise the differences between binding patterns of the
two receptors. Experimentally determined affinities of known aiB AR agonists upon the
two receptors were used to derive a pharmacophore model that describes the threedimensional structure properties required to obtain optimal interactions within the
Cys128Phe a,B AR.

2.2 Generation of the Training Set

The principal lead in this project was the selectivity displayed by phenylethylamine-

type agonists over imidazoline-type agonists for the constitutively active and signall
specific Cys Phe aiB-AR . Experimentally determined binding affinities of the two
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classes of ligands, as well as TIQ (12)133, for both the Cys128Phe aiB-AR and the wildtype aiB-AR are given in Table 2.1, and the structures of the agonists are given in

Figure 2.1. This work, undertaken by collaborators89, was the first indication of an aiB-

AR displaying signalling-specificity, and the first suggestion of a chemical structural
type exhibiting selectivity for a mutant aiB-AR over the wild-type89. It was therefore

apparent that this set of derivatives would provide the best training set for ligand-ba
drug design.

Table 2.1 Binding Affinities for Training Set Ligands: data shown in bold indicates
phenylethylamine ligands displaying selectivity for the Cys128Phe a ^ - A R '
Affinity
WTaIB-AR
Ki(nM)

Affinity
Cys*2SPhe a1B-AR
Ki(nM)

i?-adrenaline (1)

2223

133

20

^-noradrenaline (2)

3700

373

10

5-noradrenaline (3)

247000

16000

20

Methoxamine (4)

450000

47000

10

Phenylephrine (5)

10360

1913

5

S-dobutamine (6)

1230

550

2

SKF89748 (7)

2399

2042

1

Oxymetazoline (8)

596

560

1

Cirazoline (9)

1337

1066

1

Clonidine (10)

1506

1113

1

SKF35886C11)

1995

1122

2

TIO(12)

73600

20400

5

Derivative

R2
Phenylethylamines

33

H

Imidazolines

Selectivity
for mutant
over WT

Chapter 2 Molecular Modelling and Pharmacophore Generation

OH
HO.

OH
NH

A - ^CH,

HO'

HO

R-Adrenaline
1

CH30

R-Noradrenaline
2

AA

S-Noradrenaline
3

OH

?*r-NH^cH3
CH30
Methoxamine
4

Phenylephrine
5

S-dobutamine
6

SCH

OCH,

CH3 O H

SKF-89748
7

cr y

"ci

Oxymetazoline
8

H3C

j"^ CH3
N

N

A,
AJ

HN

~NH

Clonidine
10

Cirazoline
9

A.
AJ

HN

~NH

SKF-35886
11

TIQ
12

Figure 2.1 Structures of Training Set Derivatives

Selection of the training set molecules is one of the most important exercises performed
in hypothesis generation. The ideal training set134,135
' must contain at least 16
compounds to assure statistical power. Additionally, activities should span 4 orders or
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magnitude, with each order of magnitude being represented by at least 3 compounds.
There should be no redundant information included, and no excluded volume problems.

If two compounds have similar structures (collections of features), they must differ i

activity by an order of magnitude to be included in the training set. Similarly, if tw
compounds have similar activities (within one order of magnitude), they must be

structurally distinct (from a chemical feature point of view) in order to be included.

CATALYST® favours models where estimated and measured activities correlate well.

By providing a training set that represents each order of magnitude equally, imbalance
in data correlation may be prevented. CATALYST® also favours the most active

compounds in the training set when it generates the chemical feature space relevant to

particular experiment. This space is defined as the subset of possible chemical featu
based models likely to contain the model which provides the best explanation of the
training set data. CATALYST® assumes this subset can be constructed from the most

active molecules of the training set, which are those compounds meeting the condition:

Activity/Uncertainty ^Activity of most active compound x Uncertainty

CATALYST® tries to map all functions in a hypothesis to one of the most active

training set molecules136. Any other molecule in the training set should map to at leas
one function in the hypothesis. Therefore, in order to have an unbiased active set of
molecules, the top order of magnitude of activity must be well represented in the
training set.

The statistical validity of the training set used here is questionable. There are, by
necessity, only twelve compounds included, rather than the required minimum sixteen,

indicating that the odds of computing a chance correlation are quite high. The wild-ty
aiB-AR data spans four orders of magnitude, however the Cys128Phe aiB-AR data spans
35
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only three orders of magnitude. These orders of magnitude are not equally represent

with 58% (7/12) of the molecules for the wild-type set in the same order of magnitud
1 TO

and 4 2 % (5/12) of the Cys

Phe set in the same order of magnitude. Perhaps more

significant is the fact that the most active molecule in the wild-type set (oxymeta
is the only molecule representing that order of magnitude, leading to a very biased
1 TO

hypothesis. For the Cys

Phe set, of the four most active molecules (all within the same

order of magnitude: ^-adrenaline, ^-noradrenaline, S-dobutamine, oxymetazoline) thr

have similar structures. The hypothesis will therefore be biased toward the chemical
features of i?-adrenaline.

Given the fact that the compounds in the presented training set are the only compoun
1 TO __

to have experimental affinity data for both the wild-type ai B A R and Cys

Phe ai B -AR,

it is not possible to expand or alter the training set. It must therefore be acknow

and kept in mind that this is a minimal, statistically unfavourable training set, a
provide only very preliminary hypotheses.

2.2.1 Conformer generation

In this Thesis, CATALYST® 4.0, CATALYST® 4.5 and CATALYST® 4.7 versions
have been used. CATALYST® 4.0 and CATALYST® 4.5 were used on a Silicon
Graphics Workstation, CATALYST® 4.7 was used on a Silicon Graphics SGI Fuel
Workstation.

Because the biologically active conformation of our training set molecules are not
known, CATALYST® may be used to generate a conformational model for each
molecule that represents the flexibility of the molecule. The conformational model
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consists of a representative set of conformers from the range of energetically reaso

conformations of the molecule, using a standard 20 kcal/mol limit (relative to the l
energy conformer found). CATALYST® provides two methods of conformational

analysis: fast quality and best quality. Best conformational analysis is recommended

the conformational models are to be used for hypothesis generation, and was the metho
used in this work.

The conformational model for each of the training set molecules was generated using
CATALYST® 4.0. These conformational models are outlined in Table 2.1. All the
conformers of each compound were employed in the generation of a set of
pharmacophore hypotheses.

2.3 Pharmacophore Development

CATALYST® is useful as a drug design tool in its ability to generate a hypothesis125.
CATALYST® hypothesis is a model which represents the distinguishing chemical
features of a class of compounds. These features are displayed as coloured spheres

(location constraints) in a three-dimensional spatial orientation, and are represent

of characteristics of the set of training molecules that participate in important bi
interactions. Estimated activities are then computed by comparing how well the
chemical features of a subject molecule overlap with the chemical features in the

hypothesis. In terms of hypothesis significance, the difference between the magnitud
the cost of any returned hypothesis and the null hypothesis represents the validity
data correlation136. If this difference is >60 bits, there is a 90% probability of

representing a true correlation in the data; if this difference is reduced to 40-60 b
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probability drops to 75-90%; if the difference falls below 40 bits, the probability
representing a true correlation is less than 50%.

Using experimental affinity values (Ku nM) and the conformational models for each of
the training set compounds (Table 2.1, 1 - 12), two separate pharmacophores were
generated for the WT aiB-AR and the Cys128Phe am-AR using CATALYST® 4.0137. An

uncertainty value for the training set of three was used. A minimum of four features
nominated for the WT aiB-AR pharmacophore, and a minimum of three features for the
1 78

Cys

Phe a i B - A R pharmacophore. The selected features were hydrophobic, ring

aromatic, hydrogen bond acceptor (HBA), hydrogen bond donor (HBD) and positive
ionisable groups. A ring aromatic feature is one which maps 5- and 6-membered

aromatic rings, and a positive ionisable feature represents any group that is either
positively charged or can become positively charged (through protonation at
1 ^A

physiological p H )

. Catalyst assumes that all chemical features contribute equally in

providing binding energy, therefore all features were weighted equally. All remainin
hypothesis options used were CATALYST® default parameters136.

Each pharmacophore returned ten hypotheses, which were each reduced to two different

hypotheses, based on their lower cost values. The lowest cost hypothesis is consider
to be the best, however hypotheses with costs within 10-15 bits of the lowest cost

hypothesis should be considered good candidates for visual analysis (hypothesis cost

differences could not be provided here due to loss of data from a computer malfuncti

but they were very low, representative of the biased training set, and suggestive of

chance correlation). From these two hypotheses, the best was determined by comparing

the estimated affinities of selected training set molecules with the experimental va
Therefore, as shown in Table 2.2, the estimated affinities of i?-adrenaline,
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oxymetazoline and SKF89748 provided by the wild-type and Cys 128 Phe ai B -AR were
compared to their experimental binding affinities. This provided WT-hypol and
Mutant-hypo4 as the chosen pharmacophores. The pharmacophores differed largely in
the nature of their features: the wild-type pharmacophore (to be referred to as WT1)
contains two hydrophobic regions, a hydrogen bond acceptor (HBA) region, and a
1 TO

hydrogen bond donor ( H B D ) region; the Cys

Phe pharmacophore (to be referred to as

Mul) contains a hydrophobic aromatic ring region, and two HBD regions.

Table 2.2 Comparison of pharmacophores via estimated binding affinities (K,) of R-adrenaline,
oxymetazoline and SKF89748137.

Hypothesis

Molecule

Kj Estimated
(nM)

Wild-type-hypo 1

i?-adrenaline (1)

2000

2200

1.1

Oxymetazoline (8)

1100

600

0.5

SKF89748 (7)

3000

2300

0.8

/?-adrenaline

3300

2200

0.7

Oxymetazoline

4300

600

0.2

SKF89748

3500

2300

0.7

^-adrenaline

38

130

3.4

Oxymetazoline

1200

560

0.5

SKF89748

200

2000

10

.R-adrenaline

67

130

1.9

Oxymetazoline

1600

560

0.4

SKF89748

1600

2000

1.3

Wild-type-hypo4

Mutant-hypo2

Mutant-hypo4

Kj Experimental

(nM)

Ratio
Exp./Est.

These pharmacophores are shown with i?-adrenaline overlayed in Figure 2.2 below. The

predicted binding affinities for each training set derivative upon both pharmacophore
are given in Table 2.4. What is noticeably different about the two pharmacophores is

positioning of these features relative to each other. As detailed in Table 2.3, the d
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between the HBD and the HBA/HBD region is 2.9-4.9 A in the WT pharmacophore and
3.1-5.1 A Cys128Phe aiB-AR; between the HBA/HBD and hydrophobic/ring aromatic
regions 2.0-4.0 A (WT) and 3.9-5.9 A (Cys128Phe); and between the HBD and
hydrophobic/ring aromatic features 4.7-6.7 A (WT) and 2.8-4.8 A (Cys128Phe). The

positioning of this last feature is perhaps the most important difference in the tw
pharmacophores, because, as can be seen in Figure 2.2, it places the adrenaline
molecule in an extended conformation on the WT pharmacophore, but in a much more
folded conformation on the Cys12 Phe pharmacophore. This folded conformation, which

reflects the selectivity of the more flexible phenylethylamine derivatives over th

rigid imidazoline derivatives, provided an initial lead three-dimensional structur

which to base the development of novel aiB AR ligands selective for the Cys Phe aiBAR over the WT aiB-AR. These crude pharmacophores suggest that the bioactive
1 98

conformer of adrenaline, bound to the constitutively active Cys

Phe ai B -AR, might be

1 TO

similar to that represented by the Cys

Phe pharmacophore.
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Hydrophobic

HBA

Hydrophobic

Figure 2.2a: .ft-adrenaline (adopting an extended conformation) overlayed on the wild-type a.iB-AR
pharmacophore, displaying interactions with three of the four proposed binding regions; mesh spheres
represent location constraints (where the feature should be in space); Hydrophobic refers to a
hydrophobic bonding region, HBD refers to a hydrogen bond donor region, HBA refers to a hydrogen
bond acceptor region. In the HBA and HBD regions, the smaller sphere represents the interacting feature
137

of the ligand, and the larger one represents the interacting feature of the protein .

HBD
2.8-4.8

Figure 2.2b: ^-adrenaline (adopting a folded conformation) overlayed on the Cys 128 Phe a i B - A R
pharmacophore, displaying interactions with all three of the proposed binding regions. For explanation of
binding features see Figure 2.2a. Additionally, in this diagram the Hydrophobic feature refers to a
hydrophobic ring aromatic feature: the second hydrophobic sphere indicates the interacting ring aromatic
pi system of the protein137.
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Table 2.3 Distances (A) between important binding regions of the two ai B -AR
pharmacophores .
Binding regions

CCIB-ARWT

Pharmacophore
2.90-4.9
2.0-4.0
4.7-6.7

HBA/HBD - H B D
HBA/HBD - Hydrophobic
Hydrophobic/Ring Aromatic HBD

ccm-AR Cys128Phe
Pharmacophore
3.1-5.1
3.9-5.9
2.8-4.8

2.4 Design of Target Ligands

Rather than constructing structural frameworks to fit the exact dimensions of the thr
1 9R

dimensional outline provided by the Cys

Phe pharmacophore, a number of k n o w n

heterocyclic frameworks were chosen, derivatives constructed, and these derivatives
19ft

assessed against both the W T and Cys

Phe mutant pharmacophores. The purpose of

this method was to discover compounds which not only predicted acceptable affinities
for the receptors, but also selectivity for the Cys Phe pharmacophore over the WT
pharmacophore. These derivatives could then be synthesised, assessed for experimental

affinity, and utilised in the development of a larger training set and a more accurate
pharmacophore. Hopefully, this set of derivatives might also provide a lead compound
on which to base further S AR development.

The only lead in the selective and signalling-specific activation of the Cys128Phe aiBAR receptor was the preference of the receptor for the phenylethylamines over
imidazolines. It therefore seemed logical, and necessary, given the lack of previous

work in this area, to also take cognisance of this observation in designing target li
19R

rather than just trying to construct a molecule tofitthe C y s Phe ai B -AR
pharmacophore. Target ligands would therefore need to mimic the structure of
adrenaline, in varying rigid conformations. Target ligands incorporated the three
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features of the pharmacophores, and were based on the structural motif of adrenaline a
shown below:

HO
HO

r\j®Lv
• A - C C; M
\

A
A
B
C
D

BCD

= Hydrophobic bonding region (aromatic)
= Hydrogen bond acceptor (HBA)/Hydrogen bond donor (HBD) region
= Carbon spacer
= Basic amine (H-bond reinforced salt bridge formed when protonated)

Heterocyclic molecules could provide the desired rigidity. W e also wished to have a

range of new ligands with the ionisable nitrogen in a ring system, the benzo-ring eith
fused or non-fused, and the HBA/HBD feature (oxygen or nitrogen based) either in a

ring or as a substituent. Other conformationally constrained analogues of adrenaline a

noradrenaline (including the imidazoline agonists and IQC used in the training set) ha

been made and studied in the past ' , however we were interested in greater structural
variety.

(OH)

Adrenaline motif

simple cyclic
framework

tropane framework

spirocyclic
framework

spirofused
framework

Figure 2.3 Target frameworks based on the adrenaline design motif
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The heterocyclic frameworks chosen for the target ligands incorporated different
extended and folded conformations of the adrenaline motif (Figure 2.3). They consisted

of 4 major frameworks: a simple cyclic framework, consisting of pyrrolidine (n = 1) and

piperidine (n = 2) derivatives; a bicyclic framework, consisting of tropane derivative
rigid spirocyclic framework; and a [benzo-spirofused] framework, consisting of

spiro[isobenzofuran-pyrrolidine] and spiro[isobenzofuran-piperidine] derivatives. Each
derivative was subjected to a conformational model, best fit, generation within a
20kcal/mol energy range (performed in CATALYST® 4.0). These molecules were then
all assessed for predicted affinities on both the WT and Cys128Phe aiB-AR
pharmacophores, and selectivities calculated. Some derivatives with interesting

predicted binding profiles, those selected for synthetic development, are given in Tab
2.4, together with their structures shown below.

OH

IL/^N
•y\_J
N
H

H
N

y0H

^

r^iv

AD 01ft
OH

13

14

NH

15

16

NH

^A
17

18

19

20
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Table 2.4 Derivatives chosen for synthetic development and their predicted pharmacophore
binding profiles137; values in bold represent significant predicted selectivity.
Ligand

Ki (nM) Wild-type

(nM) Cyst2SPhe

K

Pharmacophore

Pharmacophore

Selectivity for
Cys'28Phe mutant AR

R

2200

R

370

6

S

350000

S

2400

150

R

11000

R

760

10

S

150000

S

2100

70

R

21000

R

760

30

S

340000

S

1100

310

R

12000

R

570

20

S

340000

S

610

560

R

18000

R

2100

10

S

330000

S

1300

250

R

800000

R

1500

530

S

1400000

S

4700

300

R

1000000

R

350

2860

Spirofused 19

R

560000

R

2200

260

Spirofused 20

S

3500000

S

2400

1460

R

2900000

R

3300

880

Epinephrine
Monocyclic 13

Monocyclic 14

Bicyclic 15

Bicyclic 16

Spirocyclic 17

Spirocyclic 18

2.5 Pharmacophore

Re-modelling

In order to gain some estimation of the validity of the pharmacophores, w e investigated

their reproducibility. This exercise was not only a validation of the legitimacy of our
pharmacophores, but also of the reproducibility of different versions of the
CATALYST® program. Additionally, we wished to investigate the effect of using
charged compounds (basic N protonated), as would be the case in a biological system,

as well as be able to test new ligand designs. Therefore, protonated training set liga
were re-built in CATALYST® 4.5 (1999) and their conformational models generated
again using the best fit method and a 20 kcal/mol energy range. This set of molecules
was then submitted again to both WT and Cys128Phe pharmacophore generation
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(CATALYST® 4.51, using the same parameters as previously. A total of nine
hypotheses were returned for both the Cys128Phe and WT pharmacophores. For all

hypotheses (both Cys128Phe and WT) the cost differences were very low, less than thre
bits. In terms of hypothesis significance, this indicated the hypotheses are quite

chance correlated rather than a true correlation. The nine hypotheses were reduced t
1 ^o

one acceptable hypothesis for both the W T pharmacophore ( W T 2 ) and the Cys

Phe

pharmacophore (Mu2), based upon the comparison of estimated binding affinities with
experimental affinities and previously estimated affinities (on WT1 and Mul
pharmacophores) of ^-noradrenaline and ^-noradrenaline. These two training set
ligands were chosen for the fact that both previously estimated affinities and
experimental binding affinities displayed selectivity for the R enantiomer over the
enantiomer. Data for the comparison of estimated binding affinities of training set
198

ligands on the two sets of W T and Cys

Phe pharmacophores is given in Table 2.6.

Surprisingly, these pharmacophores (referred to from here on in as WT 2 and Mu 2)

were different to the original pharmacophores (WT 1 and Mu 1) (Figure 2.4). Mu 1 and
Mu 2 contain only one (of three) common features. Both had a hydrophobic ring
aromatic region (mapped by the aromatic ring). Where Mul had a HBD region (mapped
by the sidechain P-hydroxyl), Mu2 had a HBA region (also mapping the sidechain P-

hydroxyl). Whilst the basic nitrogen of i?-adrenaline was mapped onto a HBD region i
the Mul pharmacophore, in the Mu2 pharmacophore the protonated nitrogen of Radrenaline mapped onto a positive ionisable feature. Despite these differences in
chemical features, the spatial orientation of the two pharmacophores was not too

dissimilar, although the distances between the features do differ somewhat (Table 2
The WT2 and Mu2 pharmacophores are shown comparatively in Figure 2.4. The two
wild-type pharmacophores differ less dramatically. Both pharmacophores contain two
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hydrophobic features, one of which maps the aromatic ring, the other is not mapped for

adrenaline. The sidechain /^-hydroxyl substituent is mapped onto a HBA feature in b
pharmacophores. Whereas the WT1 pharmacophore has the nitrogen mapped onto a

HBD region, in WT2 this is a positive ionisable feature. The spatial orientations o
features in the two pharmacophores are very similar (Figure 2.4 and Table 2.5).

Table 2.5 Comparison of distances (in A ) between important binding regions in the two
sets of pharmacophores.
Binding regions
HBA/HBD HBD/+ve ionisable
HBA/HBD Hydrophobic/Ring
Aromatic
Hydrophobic/Ring
Aromatic HBD/+ve ionisable

Pharmacophore
2.9-4.9

Cys128Phe 1
Pharmacophore
3.1-5.1

Cys128Phe 2
Pharmacophore
1.8-3.8

2.0-4.0

2.4-4.4

3.9-5.9

2.6-4.6

4.7-6.7

3.4-5.4

2.8-4.8

2.6-4.6

WT1

WT2

Pharmacophore
2.9-4.9
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Figure 2.4a: i?-adrenaline overlayed on the W T 2 pharmacophore: Red sphere (+ve ionisable) represents
a positive ionisable feature; blue sphere (hydrophobic) represents a hydrophobic feature; green sphere
(HBA) represents a hydrogen bond acceptor feature, the smaller sphere indicates the hydrogen bond
acceptor on the ligand (in this case a O H group), the larger sphere indicates the interacting hydrogen bond
donor on the protein.

Figure 2.4b: fl-adrenaline overlayed on the Cys Phe mutant 2 pharmacophore: Red sphere (+ve
ionisable) represents a positive ionisable feature; orange sphere (hydrophobic) represents a hydrophobic
ring aromatic feature, the second unmapped sphere represents the interacting pi system in the protein;
green sphere (HBA) represents a hydrogen bond acceptor feature, the smaller sphere indicates the
hydrogen bond acceptor on the ligand (in this case a O H group), the larger sphere indicates the interacting
hydrogen bond donor on the protein.
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The predicted binding affinities of the training set compounds on WT2 and Mu2 are
given in Table 2.6, along with a comparison of WT1 and Mul. Whilst the predicted
affinities of Mul and Mu2 are comparable, those of WT2 are approximately one order

of magnitude lower than WT1, leading to obvious differences between selectivity 1 and
selectivity 2.

Table 2.6 Comparison of predicted affinities (Kt) of training set ligands for the two sets of
pharmacophores.
iicied Affinity A, (nM)
Derivative

WTl

W'P

C\">12sPlu

Selectivity for
Cys"8 Plie A R
I
2

R-adrenaline (I)

8300

7000

310

250

10

30

R-noradrenaline (2)

3500

6200

260

810

10

10

S-noradrenaline (3) 170000

32000

2100

2700

80

10

Methoxamine (4)

16000

9000

2000

2500

10

5

Phenylephrine (5)

15000

13000

2000

550

10

20

S-dobutamine (6)

1600

5300

1700

770

1

10

SKF89748(7)

4100

8600

1700

3400

2

2

Oxymetazoline(8)

2200

3900

1700

2900

1

1

Cirazoline (9)

4100

260

2000

1600

2

1

Clonidine (10)

1700

4800

1800

3300

1

1

SKF35886(11)

1900

4900

1700

2500

1

2

TIQ (12)

17000

29000

76000

17000

1

2

It was certainly curious that the same set of training set compounds had produced

different pharmacophores, and it was thus of interest to investigate the reason for t
occurrence. Considering that the parameters of the pharmacophore generation process

used had been identical (apart from the charge on the nitrogen), and the variables had
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been the different versions of CATALYST®, it appears that different versions of
CATALYST® may generate both different conformational models for each compound
as well as different hypotheses.

To begin investigating this hypothesis, a new (3rd) set of conformers of the trainin
molecules was generated on CATALYST® 4.5, and compared to the 2nd set. More than
half the molecules showed differences in the number of conformers generated within
20 kcal/mol energy range (Table 2.7). This fact provides support that different
conformational models of the same set of compounds may possibly provide different
pharmacophores.

Table 2.7 Comparison of conformers and energy ranges for the two new conformer sets.

Molecule

2 nd Conformer set
No.
Energy Range
Conformers
(kcal/mol)

3rd Conformer set
No.
Energy Range
Conformers
(kcal/mol)

/^-adrenaline (1)

25

19.695

25

19.695

^-noradrenaline (2)

16

19.348

16

19.348

^-noradrenaline (3)

15

16.700

15

16.700

Methoxamine (4)

69

19.830

24

19.810

^-phenylephrine (5)

32

19.053

32

19.053

S-dobutamine (6)

171

19.546

171

19.546

SKF89748 (7)

21

19.851

18

18.824

Oxymetazoline (8)

26

19.784

27

19.539

Cirazoline (9)

45

19.674

41

18.830

Clonidine (10)

23

19.611

12

17.885

SKF35886 (11)

31

19.765

11

19.882

TIQ(12)

27

19.473

17

15.767
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To further investigate the reproducibility of pharmacophores, separate pharmacophores
were generated (CATALYST® A.5) from different conformational models (both
CATALYST 4.5) of the training compounds. This experiment produced wild-type
hypotheses which were essentially identical (same features, same distances between
features, similar cost values) but gave slightly different estimated activities for the
training set molecules. The mutant hypotheses produced were very different from each
other: whereas the Mu2 pharmacophore consisted of three features, HBA, positive
ionisable and ring aromatic (as shown in Fig. 2.4b), the pharmacophore for the 3r set of
training set conformers (referred to as Mu3) consisted of 4 features, 2 hydrophobic
regions, a HBA and a positive ionisable feature (Figure 2.5). The orientation of the
adrenaline molecule was also quite different, with the /?ara-hydroxyl of the aromatic
ring, rather than the benzylic p-hydroxyl, mapping the HBA region.

Figure 2.5 /?-adrenaline overlayed on the Cys Phe Mu3 pharmacophore: Red sphere (+ve ionisable)
represents a positive ionisable feature; blue spheres (hydrophobic) represent hydrophobic features, the
second feature is unmapped; green sphere (HBA) represents a hydrogen bond acceptor feature, the smaller
sphere indicates the hydrogen bond acceptor on the ligand (in this case a O H group), the larger sphere
indicates the interacting hydrogen bond donor on the protein.
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To establish the level of reproducibility between the same set of conformers, and
different versions of CATALYST® hypothesis generation (CATALYST® 4.5 and

CATALYST® 4.7), the 3rd set of training set conformers was re-subjected to hypothesis
generation in CATALYST® 4.7. The WT hypotheses (WT4) proved to be identical,
having the same features, with the same 3-dimensional arrangement of features and
distances between features as the WT3 pharmacophore (Table 2.8). The two
pharmacophores map the same conformers of if-adrenaline, and provide only slightly

different estimated activities for the training set molecules. The mutant agonists a
provided the same hypotheses in both versions of CATALYST®, mapping the same

conformer of i?-adrenaline, although the estimated binding activities were again not
exactly the same.

Table 2.8 Comparison of distances (in A ) between important binding regions in the two
pharmacophores W T 3 and W T 4 .
Pharmacophore

HBAHydrophobic

H B A - +ve
ionisable

Hydrophobic +ve ionisable

Adrenaline
conformer
mapped

Est. affinity
Adrenaline

Ar;(nM)

WT3

2.4-4.4

2.8-4.8

3.4-5.4

9

3300

WT4

2.4-4.4

2.8-4.8

3.4-5.4

9

3800

From this piece of work, there has emerged a trend which indicates that the
reproducibility of pharmacophores is questionable. The same set of molecules can
provide different conformational models. Whilst the same conformer model provided
very similar hypotheses on different CATALYST® versions (versions 4.5 and 4.7) for
the mutant pharmacophore, slightly different hypotheses were provided for the WT
pharmacophore. Different conformer models provided very similar WT hypotheses in
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the same version of CATALYST®, but very different hypotheses for the mutant
pharmacophore. It is therefore not surprising that the WT2 and Mu2 pharmacophores
differ from the WT1 and Mul pharmacophores, which were not only generated on a
different version of CATALYST®, but also from different conformational models, as
well as from basic (neutral) training set molecules.

After the synthesis and biological testing of the designed target ligands, a new an
significant training set of molecules was expected to be available, from which new
pharmacophore models could be derived.
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3.1 Introduction and Design Rationale

To begin investigations of the selective-signalling pathway hypothesis, it was desired

examine a small set of simple cyclic derivatives (based on 13 and 14) for their binding
selectivities and affinities upon the am Cys128Phe mutant adrenoceptor. These
derivatives are based upon simple cyclic analogues of the adrenaline motif presented
earlier. The use of the cyclic system provides a more rigid environment for the

important nitrogen atom than adrenaline does, yet still allows some flexibility in the
of the molecule without adding too much extra steric bulk.

Adrenaline motif

13R = H
21 R = OH

14R = H
22 R = OH

23R = H
24 R = OH

25R = H
26 R = OH

Conformational modelling of the monocyclic derivatives was undertaken using fast
conformational analysis in Catalyst. This exercise provided insight into the preferred
conformations of the compounds. For each ligand a conformational model, containing a

set of conformers representative of the range of energetically reasonable conformations
of the molecule, within a 20kcal/mol range, was generated. Of particular interest were
the conformations of the adrenaline mimics provided by these molecules. As Figure 3.1
shows, the global energy minimum of 13 (Figure 3.1b) and 14 (Figure 3.1c) contain the
adrenaline motif in a more constrained conformation than that of /^-adrenaline itself
(Figure 3.1a). The pyrrolidine derivative 13 consistently displayed a more folded
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conformation than that of the piperidine derivative 14, whose extra ring carbon can be
seen to have a significant effect on the nitrogen positioning. The most folded

conformation of 13 (Fig. 3.1b, right) is not significantly different from that of the g

minimum (Fig. 3.1b, left), and in fact all three conformers shown are similar, especiall

with respect to the spatial disposition of the pyrrolidine rings. Despite the fact that
i ^o

Cys

Phe mutant pharmacophore prefers a folded rather than an extended conformation

of the adrenaline motif, it is not the most folded conformer of 13 which interacts most
favourably with the pharmacophore (Fig. 3.1b, right). Similarly, the most folded
conformer of 14 does not interact most favourably with the pharmacophore either (Fig.
3.1c, right). There is considerable difference between the conformers of 14 shown, and
the preferred piperidine derivative adopts a more extended conformation (Figure 3.1),

with the chair conformation of the piperidine ring lying in the same plane as the phenyl
ring.

The overlaying of the conformational models of these simple cyclic ligands upon the
mutant pharmacophore, shown in Figure 3.2, allows these features to be visualised. The

most striking feature is the fact that the ligands map only two of the binding features:
the positively ionisable nitrogen, and the alpha-hydroxy functionalities. The
hydrophobic feature remains unmapped, and the phenyl rings do not interact at all with
the pharmacophore. So although the conformations of the adrenaline mimics are rigid,
they are not the correct conformation required for active binding to the Cys128Phe
mutant receptor.
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Figure 3.1a: Left: /^-Adrenaline shown in the lowest energy (global energy minimum) conformation
(extended); Right: ^-Adrenaline shown in the folded conformation preferred by the mutant
pharmacophore (18.426 kcal/mol);

Figure 3.1b: Left: 13 shown in the lowest energy (global energy minimum) conformation; Middle: 13
shown in the conformation preferred for the mutant pharmacophore (12.388kcal/mol); Right: 13 shown in
the most folded conformation adopted by the molecule (9.547kcal/mol).

Figure 3.1c: Left: 14 shown in the lowest energy (global energy minimum) conformation; Middle: 14
shown in the conformation preferred for the mutant pharmacophore (2.020kcal/mol); Right: the most
folded conformation of 14 (10.687kcal/mol).
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Figure 3.2a: ^-Adrenaline (preferred folded conformation) overlayed on the Cys Phe mutant
pharmacophore. Red sphere represents a positive ionisable feature; orange sphere represents a
hydrophobic ring aromatic feature, the second unmapped sphere represents the interacting pi system in
the protein; green sphere represents a hydrogen bond acceptor feature, the smaller sphere indicates the
hydrogen bond acceptor on the ligand (hydroxyl substituent), the larger sphere indicates the interacting
hydrogen bond donor on the protein.

Figure 3.2b: 13 (preferred conformation) overlayed on the Cys Phe mutant pharmacophore. The
hydrophobic regions of the pharmacophore are not mapped; the phenyl ring does not interact. For
explanation of spheres, see Figure 3.2a.

Figure 3.2c: 14 (preferred extended conformation) overlayed on the Cys Phe mutant
pharmacophore. The hydrophobic regions of the pharmacophore are not mapped; the phenyl ring does
not interact with the pharmacophore. For explanation of spheres, see Figure 3.2a.
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Data calculations revealed the simple cyclic derivatives to display only moderate
affinity for both the wild-type and mutant adrenoceptors when compared to adrenaline,
and poor selectivity for the mutant adrenoceptor over the wild-type (Table 3.1).
However, because these derivatives do mimic varied extended and folded
conformations of adrenaline, and are straightforward to synthesise, they would allow a
quick initial testing of our hypothesis and our computer experimental methods, via the
comparison between experimental and computer calculated affinity and selectivity data.

Analysis of these derivatives will thus indicate if the chosen testing methods are correc

Table 3.1: Affinities (Kt, n M ) and selectivities for simple cyclic derivatives on wild-type (WT1)
and Cys128Phe mutant (Mul) ai B -AR pharmacophores.

Affinity on a]B-AR W T

Affinity on ot1B-AR Cys128Phe

Selectivity for

Pharmacophore (WT1)

Pharmacophore (Mul)

Cys128Phe a,B-AR

Ki (nM)

K{ (nM)

over W T a1B-AR

S

74000

2900

30

R

230000

3600

60

S

350000

2400

150

R

11000

2300

5

S

1700

4500

1

R

1500

3000

1

S

150000

2100

70

R

21000

760

30

Adrenaline R

3500

2600

10

Derivative

23

13

25

14
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The set of simple cyclic derivatives to be investigated initially included 3-phenyl-

pyrrolidin-3-ol (13), 3-phenyl-piperidin-3-ol (14) and their iV-benzyl derivatives 23 and
25. The 3-aryl-piperidin-3-ol derivative 27 had previously been investigated for
1 TO

potential a-adrenoceptor binding properties

. It was developed as an analogue of 1-

aryl-2-aminoethanol 28 and the corresponding morpholine analogue 29, with the aim of
comparing pharmacological properties, and to propose a steric model for the stimulation
of the a-adrenergic receptor. Compound 27 was shown to contain activity comparable
with those of 28 and 29, although specific a-adrenoceptor sub-types were not specified.

27

28

30

31

32

For other potential therapeutic uses, the hydrochloride salt of l-benzyl-3-phenylpiperidin-3-ol (26) and the quaternary salt l-benzyl-l-isobutyl-3-phenyl-piperidin-3-ol
bromide (30) have been assessed as inhibitors of cholinergic transmission , proving to
have a post-junctional blocking activity which masked any pre-junctional effect at the
cholinergic nerve terminals. The salt 3-(4-fluorophenyl)-piperidin-3-ol hydrochloride
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(31) has been investigated as a sedative140, and iV-alkyl derivatives of 3-phenylpiperidin-3-ol such as 32 have been prepared as antidepressants141.

Neither 3-phenyl-3-hydroxy-pyrrolidine nor other simple aryl-pyrrolidine derivatives
are known as potential pharmacological ligands at the a-adrenergic receptor or indeed
in any other biological system.

3.2 Synthesis of Simple Cyclic Derivatives

3.2.1 Retrosynthesis of simple cyclic derivatives

Retrosynthetically, the preparation of the monocyclic piperidine and pyrrolidine
derivatives is quite straightforward (Scheme 3.1). Incorporation of the phenylhydroxy
moiety into the ring may be achieved readily via a simple Grignard reaction of the
corresponding ^-protected ketones. These ketones may be provided by commercially
available N-benzyl-3-pyrrolidmone (33) and N-benzyl-3-piperidone (34).

.0

V
13 n =1
14 n =2

23n=1
25 n =2

Bn
33n=1
34 n =2

Scheme 3.1: Retrosynthetic analysis of Monocyclic derivatives 13 and 14.
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3.2.2 Synthesis of 3-phenyl-pyrrolidin-3-ol and 3-phenyl-piperidin-3-ol

Beginning then from 7V-benzyl-3-pyrrolidinone and N-benzyl-S-piperidone, the
preparation of 3-phenyl-3-hydroxy-pyrrolidine (13) and 3-phenyl-3-hydroxy-piperidine
(14) involved incorporation of the phenylhydroxy functionality and deprotection of the
benzyl protecting group. When Hemsworth et alm prepared 3-hydroxy-3-phenylpiperidine from its N-benzyl derivative, they reported using phenyl lithium in
preference to the lower yielding arylmagnesium halide method previously established
by Iselin and Hoffman142 in the original synthesis of the compound (74% compared
with ~ 54% respectively). More recently, Sui et alU3 reported using the arylmagnesium
halide method for the preparation of A^-benzyl-3-hydroxy-3-phenyl-piperidine as an
intermediate in the synthesis of A/-aroyl-3-phenyltetrahydropyridines as potential nonsteroidal bone formation promoting agents. They reported only low yields of /V-benzyl3-phenyl-piperidin-3-ol formation from JV-benzyl-3-piperidone (45%). Despite these

reported low yields, it was decided to initially investigate levels of success with the
Grignard reaction to incorporate the desired phenylhydroxy moiety into the simple
cyclic target derivatives.

/V-benzyl-3-pyrrolidinone (33) was therefore treated with phenylmagnesium bromide,
affording the desired alcohol 23 (C17H19NO) as a dark orange oil in 69% yield (Scheme
3.2). !H NMR spectroscopy revealed the introduction of the phenylhydroxy

functionality to the pyrrolidine ring, via an additional five protons seen in the aroma
region and a broad singlet at 82.85. The 13C NMR spectrum indicated the absence of the
ketone peak at 8206, and the presence of the 6 new phenyl carbons at 8125.5 - 129.0,
and 8144.4. Mass spectral analysis (Cf1") confirmed the identity of the newly formed
pyrrolidine derivative as C17H19NO via a molecular ion at m/z 254 (M+l).
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.0

V
Bn
33n=1
34 n =2

23 n =1
25 n =2

13n=1
14 n =2

Reagents and Conditions: a) phenylmagnesium bromide (3.0M in ether, 1.2 eq.), ether, RT,
3hrs, 69-86% yield; b) Pd/C, H 2 , ethanol, RT, 44 hrs, 68-100% yield.

S c h e m e 3.2: Preparation of 3-phenyl-3-pyrrolidinol and 3-phenyl-3-piperidinol

The same method was used for the preparation of the desired phenylpiperidinol
derivative 25 (Scheme 3.2). Thus, treatment of /V-benzyl-3-piperidone (34) with
phenylmagnesium bromide afforded 25 (C18H21NO) as off-white crystals in 86% yield
after chromatographic purification, much improved upon previously reported literature
yields142. ]H NMR spectroscopy again revealed the addition of the phenylhydroxy

functionality to the piperidine ring via an additional five protons at 87.26 - 7.52 an
broad singlet at 83.98. The 13C NMR spectrum also indicated the absence of the ketone
peak at 8207, and the presence of the 6 new phenyl carbons at 8127.2 - 128.9, and
8145.6. Mass spectral analysis (CI^) confirmed the molecular formula of 25 to be
CigHnNO via a molecular ion at m/z 268 (M+l).

Although both 23 and 25 intermediates will provide additional interesting ligands in
themselves for pharmacological evaluation, /V-benzyl protecting groups need to be

removed so as to provide the desired targets 13 and 14. This step was achieved via the
use of palladium on carbon in a hydrogen atmosphere in ethanol solution at room
temperature143. Both 3-phenyl-pyrrolidin-3-ol (13) (C10H13NO) and 3-phenyl-piperidin-
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3-ol (14) (C11H15NO) were obtained as colourless oils in yields of 100% and 68%

respectively. lH NMR spectroscopy clearly revealed the loss of the benzyl methylene at

83.73 (13) and 83.57 (14) and the loss of five aromatic protons in the spectra of bot

and 14. Mass spectral analysis (CI+) confirmed the identity of both the pyrrolidine 1
and piperidine 14 target derivatives via MH+ ions at m/z 164 (C10H13NO) and m/z 178
(C11H15NO) respectively.

The hydrochloride salts of the target derivatives 13, 23, 14 and 25 were prepared for
pharmacological testing purposes. These salts were readily made by the addition of
hydrogen chloride in diethyl ether to the respective bases.

3.2.3 Expansion of the set of simple cyclic derivatives: synthesis of 3-(3,4dihydroxyphenyl)-piperidin-3-ol

After receiving some encouraging pharmacological results for the piperidinol
derivatives 14 and 25 (which shall be presented and discussed in Chapter 6), it was
decided to expand the set of simple cyclic derivatives by preparing the 3-(3,4methylendioxyphenyl)- and 3-(3,4-dihydroxyphenyl)-piperidin-3-ol derivatives 35 and

36. The longer term goal was then to unmask the catechol moieties at a later stage to

give catechols closer in structure to adrenaline. Therefore, following the method use

previously, but altering the Grignard reagent, /V-benzyl-3-piperidone (34) was treate
with 3,4-methylenedioxyphenylmagnesium bromide (Scheme 3.3). After
chromatographic purification the mixture afforded 36 (C19H21NO3) as a yellow oil in
52% yield. The new 3,4-methylenedioxyphenyl substituent in 36 was displayed in the
*H NMR spectrum as a 2 proton singlet at 85.91 and three aromatic peaks at 86.75,
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86.93 and 87.02, and with spin-spin couplings characteristic of a 1,2,3-substituent

disposition in the aromatic ring. Mass spectral analysis (CI*) confirmed the identity
36 via a molecular ion at m/z 312, consistent with the molecular formula C19H21NO3.

N
Bn

34

36

37

35

26

Reagents and Conditions: a) 3,4-methyelenedioxyphenylmagnesium bromide (1M in THF, 1.2 eq.), THF, RT, 3hrs,
5 2 % yield; b) Pd/C, H 2 , ethanol, RT, 44 hrs, % yield; c) BCI3/n-Bu4NI or BBr 3 in D C M .

Scheme 3.3: Preparation of substituted 3-phenyl-3-hydroxy-piperidine derivatives

Subsequent removal of the benzyl protecting group (Pd/C, H 2 ) provided the target
intermediate 35 (C12H15NO3) as a colourless oil in 45% yield. Confirmation of the
benzyl group having been removed was evident in the *H NMR, where the absence of

signals for the benzyl methylene singlet at 83.56 and the five aromatic protons at 87.
was apparent. Mass spectral (CI+) analysis further confirmed the identity of 35 via a
molecular ion peak at m/z 222, consistent with the molecular formula C12H15NO3. 35
was also assessed pharmacologically as the methylenedioxy group could provide some
interesting SAR data in comparison to the dihydroxy derivative 26.
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The dihydroxy derivative 26 m a y be accessed via either methylenedioxy deprotection of
benzyl protected 36 to produce the catechol derivative 27, or deprotection of the
methylenedioxy derivative 35 to produce the catechol derivative 26, as outlined in
Scheme 3.3. It was thus necessary to investigate methods for the removal of the
methylenedioxy group from the aryl functionality to provide the desired catechol
derivative.

3.2.3.1 Methods for deprotection of methylenedioxy groups

A number of known methods are available for effecting the dealkylation of aryl ethers, a
process regarded as one of the most popular deprotecting methods in organic synthesis,
including boron tribromide144"146, sodium ethylsulfide/DMF147'148, trimethylsilyl
iodide149 pyridine-HCl150 and hydrobromic acid/acetic acid151"153. Routine methods for
methylenedioxy cleavage include the use of boron tribromide154, aluminium tribromide
with ethylsulfide155'156 and boron trichloride in the presence of dimethylsulfide157"160.
Boron trichloride alone has been used in refluxing dichloromethane161, however, as it is
not effective at low temperatures162, Brooks et al}63 have developed a mild reagent
combining BC13 with «Bu4NI, which exhibits a greatly enhanced reactivity between that
of BBr3 and BI3 at low temperatures. The vigorous reagents BBr3 and BI3 presumably
dissociate more readily than BC13 "to provide oxonium ion activation (ArOR'BX2)+ and
free nucleophilic halide ion (X"). With the BCI3//1B114NI reagent combination, iodide
may act as both a stabilising ligand on boron, favouring formation of a reactive
oxonium ion species (ArOR'BIX)+, and a source of potent nucleophilic iodide" . Hwu
et alm have developed alkali organoamides NaN(SiMe3)2 and LiN(/-Pr)2 as efficient
deprotecting agents for benzodioxole derivatives, obtaining 93-99% yields of catechols
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in a T H F : D M E U (l,3-dimethyl-2-imidazolidinone) mixture in a sealed tube at 185°C
for 12 hours.

Of these known cleavage methods, the boron trichloride/tetrabutylammonium iodide
method163, being both mild and reactive, seemed to be the most appropriate for our
tertiary alcohol derivatives. Whilst sulfides are unpleasant to work with, high

temperature reactions are also unsuitable due to the presence of other protecting group
on our substrates and the possibility of side-reactions and decomposition. Therefore,
following the method of Brooks et al}63, 36 was treated with «Bu4NI and BC13 at low
temperature (Scheme 3.4) to afford a crude yellow oil. Both !H NMR spectroscopy and
MS(CI+) (m/z 213, 294) revealed 36 only, with no loss of the methylenedioxy
protecting group.

No Reaction

36

37

Reagents and Conditions: /?Bu4NI (1.1 eq.), BCI3 (2.5 eq.), -78°C, 1 hr;
OR nBu4NI (3.1 eq.), BCI3 (5 eq.), -78°C, 1 hr;

Scheme 3.4: Attempted methylenedioxy cleavage of 36 using BCl3/«Bu4NI.

Considering that derivative 36 contains two additional basic sites at which the boron
may complex (Figure 3.2), 4.5 - 5 molar equivalents may be needed in the reaction to
ensure effective cleavage of the methylenedioxy moiety. Thus the reaction was repeated
with 5.0 equivalents BC13 and 3.1 equivalents

WBIMNI.

The isolated crystalline product
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again proved to be 36 via 'H N M R spectroscopy (methylene peak at 85.91) and mass
spectral analysis (Cf) (m/z 312, 294, C19H2iN03).

* basic sites at which boron may complex

Figure 3.2: The basic sites upon 36 where boron may complex are indicated by an asteri

Given the difficulties encountered with this reaction, it was decided to investigate the
reaction conditions with a model compound, the simple methylenedioxy derivative

piperonal (38). Thus, as outlined in the generic Scheme 3.5, piperonal was treated with
tetrabutylammonium iodide and boron trichloride. Unfortunately TLC analysis
indicated no reaction had occurred, and mass spectral analysis (Cf/) confirmed the
presence of only recovered 38 (C^H^O^) via a molecular ion base peak at m/z 151.

38

39

Scheme 3.5: Attempted deprotection of piperonal (38) using «Bu 4 NI and BC1 3

Given that cerium chloride heptahydrate is reported to smoothly cleave 1,3-dioxolane
protecting groups165 and bismuth nitrate pentahydrate readily cleaves dimethyl ketal
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protecting groups166, it was reasoned that these reagents might also effect cleavage of
aryl ethers, in particular methylenedioxy ethers. To investigate this, 36 was initially

treated with bismuth nitrate pentahydrate in ethanol, stirring at 70°C for a total of 7
hours. Mass spectral analysis (CI+) displayed an ion at m/z 312 (M+l, 36). The reaction

mixture was subsequently refluxed in acetonitrile for 2 days, with the addition of furt
bismuth nitrate pentahydrate. Mass spectral analysis (CI+) displayed only a high
molecular mass peak at m/z 357. To investigate if cerium chloride heptahydrate may
effect the desired deprotection, 36 was treated with cerium chloride heptahydrate and
sodium iodide in acetonitrile at room temperature for 24 hours. Mass spectral (Cf/)
analysis indicated that still only starting material 36 was recovered: m/z 312, 294
(Ci9H21N03).

Further investigations of both bismuth nitrate pentahydrate and cerium chloride
heptahydrate were undertaken upon the model compound piperonal (38). Piperonal and

bismuth nitrate pentahydrate (2 equivalents) were refluxed in acetonitrile for 19 hours
Mass spectral analysis (Cf) displayed a small amount of product 39 (C7H603) at m/z
139 (M+l, 17%) with a major peak at m/z 151 as expected for piperonal, suggesting

only a small conversion rate of product. Although reflux continued, no further cleavage
was observed. Microwave irradiation of the reaction was therefore investigated. The
reaction mixture was exposed to microwave radiation at 100°C for 30 minutes. No ether
cleavage was observed, with mass spectral analysis (Cl+) displaying the piperonal
molecular ion at m/z 151 (100%). The cerium chloride heptahydrate was also
investigated with piperonal under microwave conditions. A mixture of piperonal,
cerium chloride heptahydrate and sodium iodide in acetonitrile was exposed to
microwave radiation at 100°C for 30 minutes. Again, mass spectral (CI+) analysis

revealed only piperonal (38) in the reaction mixture, via a base peak at m/z 151. 36 wa
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also treated under analogous conditions, but again failed to furnish any of desired
catechol 37.

Boron tribromide was thus investigated as a more reactive methylenedioxy-cleavage
reagent. Following the method of Neumeyer154d 36 was treated with BBr3 under
anhydrous reflux conditions. Unfortunately, the crude product proved by lU NMR to be
unreacted 36 (Ci9H2iN03). The reaction was repeated on model compound piperonal
(38) at -78°C for 1 hour. The resultant crude residue turned black, and proved to be
insoluble in methylene chloride. However, stirring of the suspension in methylene
chloride overnight, followed by filtration and concentration in vacuo, provided a

colourless oil which rapidly turned brown. The residue proved by mass spectral analysi

(Cf1") to contain desired dihydroxy derivative 39 via a molecular ion base peak at m/z
139. A small amount of unreacted 38 was also noted (m/z 151, 10%). ]H NMR analysis

revealed the crude product to be a 1:1 mixture of 38 and 39: this was evidenced by tw

peaks for the aldehyde proton, of equivalent integration (1H each) at 89.77 and 89.82,
and a peak of 1H integration, ascribed to the methlenedioxy protons, at 86.08.
Additionally, the lR NMR spectrum also contained a large amount of hydrocarbon
contamination, in the regions 81.25 - 2.09 and 81.71 - 2.09. The source of this
contamination could not be determined. Although the crude mixture was not purified,
the evidence of some methylenedioxy deprotection having occurred indicates that this

method is of potential use in preparing future catechol derivatives. Unfortunately, du

time constraints, the initial target catechol derivatives 35 and 37 could not be acces
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Duboisia myoporoides (source of scopolamine)

Chapter Four Synthesis of Bicyclic Tropane Derivatives

4.1 Introduction

The tropane system is a well-known member of the alkaloid class of natural products.

Alkaloids are chemically defined as secondary metabolites of plant, microbial or animal

origin, and typically contain one or more nitrogen atoms, usually in a heterocyclic rin
have a pronounced basic reaction and generally possess strong and varied
pharmacological effects when administered to humans and animals167. There are over
12,000 known alkaloids, with many more being discovered each year. Tropane
alkaloids are structurally related natural products which have in common the
azabicyclo[3.2.1]octane structure; the systematic name for tropane is therefore 8methyl-8-azabicyclo[3.2.1 Joctane.

Tropane

The majority of tropane alkaloids are esters of organic acids and hydroxytropanes, with
3a-hydroxytropane (known as tropine) being the amino alcohol most frequently

encountered. In addition, its 3^-isomer (pseudotropine), the di-(3,6- 3,7- or 6,7-) and

trihydroxylated 3,6,7-tropanes, the 6,7-epoxide and the corresponding N-nor derivative

occur in numerous plant species, in either free base form, or more often esterified wit
wide variety of aliphatic, aromatic and heterocyclic acids1 . Dimeric and trimeric
tropane alkaloids have also been found168. More than 200 tropane alkaloids are known;
i /in

their distribution in the plant kingdom has been investigated

and their biosynthesis

extensively studied over the last few decades169.
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A n e w group of tropane alkaloids, called calystegines, w a s isolated and identified in
1988, from the roots of the morning glory Calystegia sepium170. These alkaloids are
characterized as polyhydroxylated nortropmes with a bridgehead hydroxyl
substituent ~175. The hydroxyl groups vary in both position and stereochemistry. To
date, at least 16 calystegines have been isolated and structurally characterised167. The
natural occurrence and therapeutic applications of other known polyhydroxylated
alkaloids has been reviewed 176

Calystegine skeleton

The most widely recognised tropane alkaloids from a pharmacological point of view are
(-)-scopolamine (hyoscine), (-)-hyoscyamine, atropine and cocaine. Pharmacologically
important tropane alkaloids such as these, in which the nitrogenous base is esterified
1 7*7

with tropic acid (or a derivative), are apparently unique to the solanaceae family .

H3C

H3C

H3K
3C

H3^,
3C

X^C02CH3
CH2OH
H

vCH2OH

(-)-hyoscyamine

o:
H

x£H2OH

0

(-)-scopolamine

(-)-cocaine
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Numerous synthetic approaches to the tropane skeleton have been developed, from the
classical synthesis of tropine by Willstatter178 at the beginning of the century and
comprehensively reviewed by Holmes179, to the effective synthesis of tropinone by
Robinson180. Modification of this latter synthesis by Lehmann181 and then Seebach182,
further led to more recent developments dealing with asymmetric deprotonation of

tropinone, and utilisation of chiral lithium amide bases for the enantioselective synthe
of a range of tropanes .

The optical activity of hyoscyamine and scopolamine arises from the chiral centre in the
acid portion of the molecule, (^-tropic acid. Although tropine itself contains
stereogenic centres, it is a symmetrical and optically inactive molecule and may be
regarded as a meso isomer. Under basic catalysis, racemisation can take place at the
asymmetric centre of the acyl component, and in the case of (-)-hyoscyamine this leads
to the racemic alkaloid atropine. The plant sources generally contain only the
enantiomerically pure alkaloids.

All the main tropic acid-esterified tropane alkaloids including hyoscyamine, atropine,
scopolamine, /V-butylscopolamine and /V-ethylscopolamine, show antimuscarinic
activity. Their mode of action is competitive antagonism of acetylcholine and other
muscarinic agonists such as pilocarpine, physostigmine or arecoline, which are also
natural alkaloids. Generally, the most active forms are the (-)-isomers, with the
peripheral effects of (-)-hyoscyamine being 10 to 20 times stronger than those of (+)hyoscyamine, and with CNS effects 8 to 50 times stronger. The main therapeutic
applications of tropane alkaloids include treatment of motion sickness (scopolamine),
prevention of vagal reflexes (atropine), preanesthetic medication to aid respiration

(atropine), and the treatment of intestinal hypermotility and spasms of the urinary trac
(atropine). Cocaine is a powerful CNS stimulating agent, with both local anaesthetic
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and local vasoconstriction effects. Medicinally, it is used as its hydrochloride salt in 0.14% aqueous solution as a local anaesthetic for topical application. Calystegines, as
polyhydroxylated alkaloids, are currently of interest as glycosidase inhibitors and

particularly as anti-viral agents (Asano, 1996; Asano, 1997). Their role in this context

appears to derive largely from their ability to alter glycoprotein structure by interfer
with the processing of the oligosaccharide moiety (Nash, 1996).
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H
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Figure 4.1 Semisynthetic & synthetic tropane alkaloids

S o m e semisynthetic and synthetic derivatives of scopolamine and atropine have been
prepared with the aim of improving peripheral and reducing CNS effects (Figure 4.1).
For instance, homatropine is 10 times weaker than atropine with correspondingly
decreased toxicity. Likewise the quaternary ammonium tropanes, ipratropium bromide
(a derivative of atropine), oxitropium bromide and tiotropium bromide (derivatives of
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scopolamine) and flutropium bromide, a fluoroethyl derivative, used mainly in the
treatment of chronic obstructive pulmonary disease, have decreased central effects as
they do not readily cross the blood-brain barrier. 7V-alkylated scopolamine derivatives
such as Af-butylscopolamine bromide, jV-methylscopolamine bromide and Nmethylhomotropine bromide have been used to relieve gastrointestinal spasms.

(CH2)2COPh
N

H,C

CH3R

40
H,C
CH 3 0
OCH 3

44

There has been a considerable amount of work done on the synthesis of n e w tropane
derivatives in the search for novel compounds with pharmacological activity. The
earlier work investigated tropane analogues as narcotic antagonists (e.g. 40),
analgesics184"187, and potential opiate agonists and antagonists (e.g. 41)188. There has
also been interest shown in the use of tropanes as anticholinergic, anticonvulsant and
anti-inflammatory agents (e.g. 42)18 "19 , as well as being considered for new
membrane-active substances at the acetylcholine receptor . More recently, there has
been much investigation into the synthesis of cocaine analogues as cocaine antagonists
and potential dopamine transporter (DAT) antagonists (e.g. 43193, 44194)195"199. Such
analogues may be effective as therapeutics in the treatment of cocaine abuse and
neurological disorder, including depression and Parkinson's disease.
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A n e w class of amphibian alkaloid, epibatidine, isolated in 1992 2 0 0 from the skin of the
Ecuadorian poison frog, Epipedobates tricolour, has been reported to be a highly potent
non-opioid analgesic, via its potent agonistic activity at the nicotinic acetylcholine
receptor,201, 202 T h e azabicyclic[2.2.1]heptane (7-azanorbornane)-based ring system of
epibatidine, however, displays high toxicity levels, generating m u c h interest in the
preparation of analogues which may be selective nicotinic receptor analgesics with
reduced toxicity. This has led to numerous syntheses of epibatidine and related 7azabicyclo[2.2.1 ]heptane analogues203-207

Homoepibatidine

Epibatidine

Interestingly, the related compound homoepibatidine2 , containing the 6-pyridinyl-8azabicyclo[3.2.1]octane (tropane) system, displays comparable analgesic activity to
epibatidine. Therefore, in recent years, there has been interest in the development of
tropane-based analogues of epibatidine and homo-epibatidine, including 2-pyridyl
derivatives 45 and 46209"210, 3-pyridyl derivatives such as 47211 and 5-pyridyl derivatives

such as 48212. The therapeutic potential of these nicotinic acetylcholine receptor agonist
extends beyond analgesia, and includes the possibility of preventing the
neurodegeneration associated with Alzheimer's disease " .

H
N

N
45

46

~CI
N

47

"CI

48
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4.2 Design of Bicyclic Tropane Derivatives as ajB-AR Ligands

An important structural feature of tropanes is that of rigidity. Whilst the 6-membered
ring portion of the molecule may equilibrate between chair and boat forms, the fixed
conformation of the 5-membered pyrrolidine ring provides a rigid framework. This
feature renders bicyclic bridged derivatives such as tropanes useful frameworks when a
fixed chemical geometry is desired. This was certainly appealing in the present work
with respect to mimicking a fixed conformation of the adrenaline motif.

Generation of the Cys128Phe cciB-AR mutant pharmacophore (Chapter 2) has revealed
that the predicted conformation of adrenaline upon the Cys Phe <XIB-AR has a folded
conformation, as discussed in Chapter 2. In the development of ligands which
encompass a folded conformation that contains the necessary ionisable nitrogen atom,
derivatives with a tropane framework present an appropriate choice. The tropane
framework may provide a similar geometry to that of a folded conformation of

adrenaline (Figure 4.2), with the additional feature of being held in a relatively rigid
heterocycle.

Figure 4.2 Folded conformation of R-Adrenaline (structure from C A T A L Y S T ).
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The folded conformation of adrenaline appears to be an essential feature for receptor
selectivity, therefore the incorporation of this adrenaline motif is necessary into the

design of our target molecules. In transferring this motif to the tropane skeleton (Figure
4.3), substitution at the 6 and 2 positions would fulfil this requirement. Additionally,
substitution at the 3-position would allow investigation of the effect on the mutant
model of extending the motif by one carbon. Both 2- and 6-substituted tropane
derivatives would provide the adrenaline motif in a folded conformation, whereas the 3substituted tropane derivative mimics a more extended conformation of the motif.
Studying the binding profiles of these related derivatives would allow further
investigation into the hypothesis that adrenaline adopts a folded conformation upon the
mutant receptor.

Adrenaline motif

6-substituted tropane

2-substituted tropane

3-substituted tropane

Figure 4.3 Presence of the adrenaline motif in bicyclic tropane derivatives

The tropane-derived ligands to be investigated computationally were therefore based
upon the 3- and 6-substituted tropane derivatives, together with substituted derivatives
of some of these bicyclic ligands. Whilst 2-arylhydroxytropane derivatives fit the
desired adrenaline motif, their synthetic production would be via a lengthy route from
cocaine derivatives, and was deemed unfeasible. Table 4.1 displays the range of ligands
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investigated and their predicted activity data upon both the wild-type ( W T 1 ) and
.128

Cys

Phe ( M u l ) O C I R - A R pharmacophores.

Table 4.1 Predicted binding affinities and selectivities of tropane derivatives on wild-type
(WT1) and Cys128Phe (Mul) pharmacophores.
Derivative Predicted WT AffinityPredicted Cys128Phe
K (nM)
49

50

51

52

Affinity K (nM)

Selectivity
(for Cys128Phe over WT)

S

340000

1100

310

R

12000

570

20

S

340000

610

560

R

10000

380

30

S

18000

2100

10

R

21000

700

30

S

6400

3900

2

R

4400

4500

1

49

50

51

The most appropriate ligands to be synthesised were chosen to be 50 and 52. In making
this choice synthetic viability, as well as the aim of testing the validity of our
pharmacophores, was taken into account. Target ligands for the bicyclic series was
therefore to include 6-arylhydroxytropane derivatives 50 and 53, with incorporation of

80

Chapter Four Synthesis ofBicyclic Tropane Derivatives

both phenyl and catechol substituents, and their intermediates 54-60, as well as the 3phenylhydroxytropane ligand 52, containing an extra carbon spacer between C and D
(Figure 4.3), as shown in Figure 4.4.

H
N

H
N

HO

,OH HO
OH

O
OH

O

OH
OH

OH
53

50

H
N

54

58

Figure 4.4 3- and 6-substituted tropane derivatives for synthesis.

Examination of the literature revealed that compounds similar to 50 had been
investigated previously; 6/?-aryltropan-6-ols based on 61 were explored some twenty
years ago as low potency morphine-like analgesics215 and later as low potency opiate
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agonists/antagonists188 62. Further 6-phenyl-8-azabicyclo[3.2.1]octanes and octenes
based on 61 were developed, displaying potential antidepressant, analgesic and
unspecified cardiovascular activity216. Whilst there was no evidence for 2-aryltropan-2ol derivatives such as 63 having previously been developed, 3-phenyltropanes such as
64 were investigated as antispasmodic agents some time ago217.

(CH2)2COPh

Me
N
AryK
OH

OAc

61

62

63

64

4.2.1 Retrosynthesis and proposed syntheses

The initial retrosynthetic analysis for the tropane derivative 52 focussed on a crucial C
C disconnection to give a suitable protected ketone as represented in Scheme 4.1. Thus
synthesis of 52 was to be achieved via a relatively short synthetic pathway from
commercially available tropinone. iV-Demethylation of tropinone and subsequent
protection of the nitrogen were necessary, as not only may the JV-methyl provide steric
hindrance to direct Grignard reagent attack on tropinone, but additionally the nitrogen
protecting group must be removable under mild conditions. A suitable protecting group
for the basic nitrogen was therefore 2,2,2-trichloroethyl carbamate, as its introduction
would iV-demethylate and protect the nitrogen in the one step, and the conditions of
removal (zinc/acetic acid) would be sufficiently mild to leave the aryl hydroxyl moiety
intact. Alternatively, the ethyl carbamate protecting group could also provide Ndemethylation, however the aryl hydroxyl moiety would not withstand the removal
conditions (trimethylsilyl iodide)218.
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PhMgBr

52

tropinone

Scheme 4.1 Retrosynthetic analysis and proposed synthesis of 3-phenyl«ortropan-3-ol (52)

Initial analysis of the restrosynthesis of the target 6-aryl substituted tropane diol
derivative 50, indicated that it could be synthesised via commercially available 66hydroxytropan-3-one, which could be synthesised via the Mannich type condensation
reaction of 2,5-dimethoxy-2,5-dihydrofuran with acetone dicarboxylic acid and
methylamine hydrochloride (Scheme 4.2). Alternatively, 6/?-hydroxytropan-3-one could
also be accessed from the natural product 6y5-hydroxyhyoscyamine. All three of these
sources will be discussed (section 4.4.1).
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Scheme 4.2 Retrosynthetic analysis of 6-arylhydroxytropan-3-ol (50).
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4.3 Synthesis of 3a-Phenyltropan-3-ol

As outlined in the retrosynthetic scheme (Scheme 4.1), A'-demethylation was a crucial
step in the synthesis of the 3-aryltropan-3-ol derivative 52. JV-demethylation may be
effected by a number of reagents, and it would be most advantageous to not only Ndemethylate before any Grignard addition, but also to carry out the demethylation and
the protection of the nitrogen in the same step. For many years the synthetic route to
rcortropanes lay primarily in A^-demethylation of tropanes by KMn04, K3Fe(CN)6 or
cyanogen bromide219'220,221. The use of chloroformate esters, such as ethyl
chloroformate or phenyl chloroformate, has often proved to be superior to earlier

methods of tertiary amine dealkylation because of their increased selectivity and clea
reactions222, and are thus the method of choice223. Whilst poor yields were encountered
with the use of benzyl chloroformate in the A'-demethylation of tropan-3-one , the use
of ethyl chloroformate also posed a problem because the hydrolytic step failed to

furnish any of the desired nortropinone. 2,2,2-Trichloroethylchloroformate was reporte

to be the reagent of choice for tropinone 7V-demethylation, producing the trichloroeth
carbamate from tropinone in a high yield (95%). The carbamate protecting group may
then be easily cleaved by zinc in methanol or acetic acid to give the nortropane in a
moderate (62%) yield224. This carbamate was thus ideal for both the desired Ndemethylation of tropan-3-one and successive protection of the nitrogen moiety during

subsequent chemistry, particularly as the deprotection conditions are sufficiently mil
that they would not be expected to dehydrate the arylhydroxyl moiety of target ligand
52.

Accordingly, following the method of Montzka224 as shown in Scheme 4.3, tropinone
was heated under reflux in a suspension of 2,2,2-trichloroethylchloroformate and
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anhydrous potassium carbonate in dry benzene under argon for 68 hours. The product

65 was isolated as crystalline material in 83% yield. ]H NMR analysis revealed the los
of the /V-methyl singlet peak at 82.63, and the presence of the methylene peak of the
trichloroethyl carbamate was seen at 54.67 as a doublet. Mass spectral analysis (Cf/)
indicated the molecular formula of 65 to be C10H12NO3CI3, with distinct chlorine
isotope ions at m/z 300/302/304.

C02CH2CCI3

tropinone

65

H

66

Reagents & Conditions: (a) trichloroethylchloroformate, K 2 C 0 3 , benzene, reflux, 4 days, 83%;
(b) PhMgBr, ether, RT, 3 hrs, 82%; (c) zinc dust, 9 0 % acetic acid,40°C, 2 days, 60%.

Scheme 4.3 Synthesis of 3a-phenyltropan-3-ol 52

Having removed the /V-methyl substituent, it was then possible to arylate the tropane
ring of 65 via Grignard addition to the carbonyl. Although we wished to investigate
both phenyl and catechol ring derivatives, it was initially decided to prepare the 3phenyl-tropan-3-ol derivative 52 as a model study for both synthetic procedures and

potential ligand for the CCIB-AR receptors. As noted in Scheme 4.3, 65 was treated with
phenylmagnesium bromide to furnish the arylated 66 in 82% yield. 'H NMR
spectroscopy revealed the expected aromatic 5H multiplet of the newly formed
1 *)

derivative at 57.20-7.53. C N M R spectroscopy supported this with the disappearance
of the ketone cabonyl peak at 5207.2, and the additional aromatic peaks at 5124.6-

128.6. The reaction proved to be selective for the 3a-phenyltropan-3-ol derivative, as
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shown in Scheme 4.3, and as determined by NOESY 2D NMR (spectrum given in

Appendix). This is not surprising considering the presence of the bulky carbamate gr
would compete sterically with the phenylmagnesium bromide reagents. High resolution
mass spectral analysis (CI+) confirmed the molecular formula of 66 as C16H18NO3CI3.

With removal of the carbamate functionality from the nitrogen, the target ligand 67
would be achieved. A common reagent for the effective removal of trichloroethyl
carbamates has been 48% hydrogen bromide/acetic acid . However, as mentioned a
milder reagent such as zinc in acetic acid is more suitable for derivative 66 so as

avoid dehydration of the tertiary hydroxyl group. Zinc in 90%) acetic acid is report
effect smooth deprotection of trichloroethyl carbamates (90% yield)224. An improved

method for cleavage of the trichloroethoxycarbonyl group uses cadmium dust in acetic

acid:DMF (l.T mixture) instead of zinc dust in acetic acid225. Further, these authors

reported the trichloroethoxycarbonyl group to be unstable to hydrogenation catalysed
Pd-C. With the consideration that a number of compounds may be unstable in, or be

difficult to isolate from, acetic acid, formic acid or DMF, an alternate method deve
by Just & Grozinger226 involves cleavage of 2,2,2-trichloroethylcarbamates to amines
with zinc in a THF/1M KH2P04 /Na2HP04 buffer in 30 mins at pH 4.2, or for 18h at pH
5.5. Investigation into the application of this method for the preparation of the
derivative 52 found that use of Zn/THF/ KH2P04 at pH 4.2 with stirring at RT for 5
hours, failed to produce any of the desired «ortropane derivative.

Therefore, the cleavage of the 2,2,2-trichoroethylcarbamate in 66 was achieved via t
00 A

method of Montzka et al. . A s shown in Scheme 4.3, 66 was treated with zinc dust in

90% acetic aicd to afford 52 in 60% yield. NMR analysis clearly indicated the loss o
the carbamate moiety peaks at 54.64-4.72 (CH2) in the !H NMR spectrum, and at

86

Chapter Four Synthesis of Bicyclic Tropane Derivatives

5151.7 (/VT>0), 695.2 (CC13) and 574.8 (CH2) in the 13C NMR spectrum. The product
52 was further supported by mass spectrometry (CI*) via an MH* ion at m/z 204,
consistent with the formula C13H17NO. Compound 52 rapidly dehydrated under heating
during the mass spectral analysis process, and high resolution mass spectral analysis
(EI+) of the dehydration product (C^H^N1-) confirmed the molecular formula of 52.

4.4 Preparation of 6/3-Arylhydroxynortropane Derivatives

AAA Synthesis of 6p~hydroxytropan-3-one

Initial investigations into the synthesis of 6j/?-hydroxytropan-3-one (67) followed
literature procedures196'227, and details are shown in Scheme 4.4. 2,5-dimethyoxy-2,5dihydrofuran was treated with 3N hydrochloric acid then 6N sodium hydroxide,
followed by a mixture of acetone dicarboxylic acid, methylamine hydrochloride and
anhydrous sodium acetate at pH 4.0 - 5.0. Intense extraction of the reaction mixture

with diethyl ether resulted in the isolation of crude 6/?-hydroxytropan-3-one (67) a

brown oil. Recrystallisation from 2-propanol was unsuccessful as the resulting solid
contained some impurities. Chromatography partially isolated some product, however

clean separation of 6/?-hydroxytropan-3-one from other impurities proved difficult. T
resulting yield was very low (1.2%), with 6/?-hydroxytropan-3-one being obtained as
cream crystals. The ]H NMR data of 67 agreed with literature data227, and mass spectral
analysis (Ct) revealed the molecular ion at m/z 156 (MH+, CgHoNCb).
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(Z)

OCH;
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2,5-dimethyoxy-2,5-dihydrofuran 6(3-hydroxytropan-3-one
67
Reagents & Conditions: (a) 3M HCI, rt, 18hrs; (b) neutralisation with 6M NaOH;
(c) NaOAc, CH 3 NH 3 .HCI, RT, 2 days.

Scheme 4.4 Synthesis of 6/?-hydroxytropan-3-one (67)

This synthesis posed 2 major problems regarding efficiency and success. The first was
the high water solubility of 6/?-hydroxytropan-3-one, which rendered difficult the

extraction of the crude product from the reaction mixture, even with strict control of t
pH at 9. Consequently the crude yield obtained never exceeded 11%. Zhao et al.22% also
experienced this solubility problem, but still managed purified yields of 42%; others
reported yields of 20%227 and 49% 89. Impurity of the crude extract posed another
problem, as it made recrystallisation difficult. Chromatography also proved to be

inefficient with the presence of a number of components of similar polarity in the crude
mixture. The extremely low isolated yields of 6/?-hydroxytropan-3-one from this
synthesis, which was repeated four times, compromised the feasibility of the route, so
an alternate source of 6/?-hydroxytropan-3-one was needed.

It may have been possible to synthesise 6/?-hydroxy-tropan-3-one via a multi-step
synthesis from the natural alkaloid 6/^hydroxyhyoscyamine (68), a derivative of
scopolamine, as shown in Scheme 4.5. However, this method was not utilised because
of the difficulty in obtaining 68.
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67
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Scheme 4.5 Retrosynthetic Analysis for 6/?-hydroxy-tropan-3-one (67)from66hydroxyhyoscyamine (68).

4.4.2 Synthesis of 6-arylhydroxytropane derivatives from 6f3-hydroxytropan-3-one

D u e to the difficulty experienced in the synthesis of 6/?-hydroxytropan-3-one, it was
decided to source the derivative commercially (despite its high cost).
As previously noted in Scheme 4.2, retrosynthetic analysis of the target 6-aryl-6hydroxytropan-3-ol derivatives indicated that 7V-demethylation and subsequent Nprotection was required. This analysis is shown in more detail in Scheme 4.6. The 3ketone would give rise to the 3-hydroxyl derivatives, however, this carbonyl group
would need protection before the oxidation of the 6-hydroxyl substituent to a carbonyl,
and the subsequent Grignard attack to incorporate the aryl moiety.
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C0 2 CH 2 CCI 3

p0 2 CH 2 CCI 3

C0 2 CH 2 CCI 3

N
Ar-
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OH
OH

Ar

OH
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p0 2 CH 2 CCI 3

C0 2 CH 2 CCI 3

p0 2 CH 2 CCI 3

6p-hydroxytropan-3-one
67

Scheme 4.6 Retrosynthetic analysis of 6-arylhydroxytropan-3-ol derivatives.

The forward synthesis planned is outlined in Scheme 4.6. The 6/?-hydroxy functionality

was first protected with a robust tert-butyldimethylsilyl functionality, followed by th
/V-demethylation and re-protection of the 6/?-hydroxytropan-3-one amine functionality

as a 2,2,2-trichlorethylchloroformate. Protection of the carbonyl group as a ketal was t
be followed by deprotection of the silyl group to afford the free 6-hydroxyl. Oxidation
of this secondary alcohol would provide the ketone anchor needed for the Grignard
attack and insertion of the arylhydroxy moiety. Deprotection of the 3-carbonyl and
reduction to an alcohol, followed by the removal of the carbamate, would then provide
the desired target ligands.
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4.4.2.1 Protection of 6/3-hydroxytropan-3-one

Due to the secondary nature of the hydroxyl group of 67, and the close proximity of the

/V-methyl substituent, the 6/?-hydroxyl may be considered relatively hindered. The tert
butyldimethylsilyl functionality is a common protecting group for hydroxyl
substituents, largely due to its stability to many reaction conditions218, and the ease of
removal using tetrabutylammonium fluoride (TBAF). The hindered 6/?-hydroxyl group
may be protected with a tert-butyldimethylsilyl functionality, utilising the highly
reactive tert-butyldimethylsilyltrifluoromethansulfonate (TBDMSOTf) and 2,6-lutidine
in dichloromethane, as shown in Scheme 4.7. The reaction afforded 69 as a pale yellow
oil in 86% yield. The newly silylated product was identified via !H NMR spectroscopy,
with the tert~bvAy\ group of the tert-butyldimethylsilyl functionality appearing as a

typical singlet at 50.87 and the dimethyl silyl methyl protons as a singlet at 50.04. High
resolution mass spectral analysis (CI+) confirmed the molecular formula of 69 as
C14H27N02Si.

C02CH2CCI3

H,c
—

TBDMSO

6p-hydroxytropan-3-one

69

TBDMSO

72

Reagents & Conditions: (a) 2,6-Lutidine,terf-butyldimethylsilyltrifluoromethanesulfonate,D C M , 0°C-RT, N 2 ,
3hrs, 8 6 % yield; (b) 2,2,2-trichloroethylchloroformate, K 2 C 0 3 (anhydrous), benzene (anhydrous), reflux, N 2 ,
4hrs, 8 5 % yield.

S c h e m e 4.7 Synthesis of protected 6/?-hydroxytropinone derivative 72.
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On

one

occasion, to-silylation occurred w h e n

excess tert-butyldimethylsilyl-

trifluoromethansulfonate was used (2.0 equivalents, instead of 1.5 equivalents) and

resulted in formation of the fe-silylated enol ether 70 and its isomer 71 (Scheme 4.

62%» yield. With the excessive presence of the active base lutidine, and the excess o

very reactive silylating agent, it is not surprising that the ketone enol ether func
1 11

was silylated. The 6fs-silylated products were evidenced by both H and

C

NMR

spectroscopy: the ]H NMR spectrum clearly displayed the additional 3 methyl peaks at

50.84 (9H), 2 additional dimethylsilyl peaks at 50.09 (6H), and the two vinylic prot

at 54.73 (d, J= 5.7Hz) (H2 in 70) and 54.83 (d, J= 5.7Hz) (H4 in 71) in a ratio of 2:
respectively. The HI proton is seen in the ]H NMR spectrum as two peaks, at 53.05 (d,

J = 5.4) and 53.09 (d, J = 5.4), in a ratio of 1:2 respectively. The downfield peak i
representative of the HI proton in isomer 70 (C2=C3), indicating 70 as the major
isomer, and identifying the =CH peak at 54.73 as belonging to H2. The 13C NMR
spectrum evidenced the shift of the C3 peak from 5208.4 (C-O) to 5146.3/148.4, and

clearly indicated the presence of the silyl enol ether at 54.5 ((CH3)2), 518.0 (C(CH3)
526.1 ((CH3)3) and 5102.5/5107.0 (=CH). Mass spectral analysis (CI+) of 70 and its

isomer indicated an M+l peak at m/z 364. High resolution mass spectral analysis (CI+)
confirmed the molecular formula of 70 and it's isomer as C22H4)N02Si2.
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H3C

H,C

H3C

2,6-lutidine (2eq.),
T B D M S O T f (2 eq.),
TBDMSO
^

W

TBDMSO
OTBDMS

OTBDMS

D C M , 0°C-RT, N 2 , 5hrs
70

6-hydroxytropan-3-one

71

major (66%)

minor (33%)

2,6-lutidine (1eq.),
T B D M S O T f (1 eq.),

H3C
TBDMS
O

TBDMSO

H3C

M

CH 3

TBDMSO

TBDMS-O-Tf

TBDMS-O-Tf

Scheme 4.8 Formation of silyl enol ether 70 and isomer 71.

With the hydroxyl group protected, /V-demethylation and carbamate formation was
carried out in the same way as previously, according to Scheme 4.7. The carbamate 72

was afforded as a white solid in 85% yield. NMR spectroscopy revealed the loss of the
/V-methyl singlet at 52.63 in the !H NMR spectrum and 538.2 in the 13C NMR spectrum.
The methylene protons of the newly formed carbamate derivative 72 appeared as a
multiplet at 54.67-4.77 in the ]H NMR, and in the 13C NMR this methylene carbon
appeared at 574.7, whilst the carbonyl of the carbamate was seen at 5152, and the

trichlorinated quaternary carbon at 595.8. Mass spectral (CI+) analysis of 72 indicat
the presence of 3 chlorine atoms in the molecular ion of Ci6H26N04SiCl3 at m/z
430/432/434, with relative abundances expected for the chlorine isotopes.
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In an attempt to reduce the reaction time, the A^-demethylation/carbamate formation
reaction was investigated under microwave reaction conditions. A mixture of 69,
potassium carbonate and 2,2,2-trichloroethylchloroformate in acetonitrile under argon
a sealed atmosphere was exposed to microwave radiation at 100°C for 20 mins. The
desired product 72 was furnished, and although the yield was lower, 60%, this method
could produce 72 in minutes rather than days.

4.4.2.2 Protection of the 3-ketone

The next synthetic step was to first protect the 3-ketone group before removing the sil
protecting group ready for hydroxyl oxidation (Scheme 4.10). In protecting the

carbonyl, a ketal functionality may be appropriate, or alternatively the use of reduct
etherification would provide direct access later to the desired 3-hydroxy derivative.
Recent work reported by Miura et al.229 indicated that alkoxydimethylsilanes
(ROSiHMe2) can be used for the Lewis acid-catalysed reductive etherification of
various aldehydes and ketones. Of the four alkoxydimethylsilanes investigated
((ROSiHMe2: R = Bu; Ph(CH2)2; cyclohexane; benzyl), the benzyloxydimethylsilane
would be most appropriate in this circumstance, as it may be cleaved under mild
conditions using palladium and hydrogen. However, the yields of ethers reported as
being formed using benzyloxydimethylsilane were disappointingly low (35-41%).

We thus returned to ketal groups for the protection of the 3-ketone. As important
carbonyl protecting groups in organic synthesis, many methods have been introduced
for both their formation and removal218. The choice of which ketal group to use will
largely depend on available mild deprotection methods, which would retain the tertiary

hydroxyl group in the target molecules in this study. Thus aqueous acidic hydrolysis of
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the ketal was not considered suitable. Although the use of reagents such as molybdenum
(IV) oxide acetylacetone (Mo02(acac)2)230, montmorillonite K10231, FeCl3.6H20232,
O'XT. 0*kA

CuCl 2 .2H 2

and cerium a m m o n i u m nitrate

have been reported, methods using

neutral conditions were required for the deprotection of the potentially acid-sensitiv
substrates.

Cyclic 1,3-dioxolanes have been used previously for the protection of 3-tropanone

derivatives235. Whilst they may be integrated into the tropane skeleton via a number of
methods, a mild method for removal is needed once the aryl group is incorporated,
without causing the dehydration of the accompanying alcohol. Ko and Park report the
use of Magtrieve™ for the deprotection of ketals under neutral conditions; whilst the

cyclic 1,3-dioxolane protecting group was inert to the reagent, acyclic dimethyl ketal
were cleaved in good yields (>90%). Bartoli et al.165, report cerium (III) chloride to
function as an efficient Lewis acid for the cleavage of 1,3-dioxolanes to carbonyl
compounds under neutral conditions, and furthermore, bismuth nitrate pentahydrate166
was shown to be an efficient reagent under neutral conditions for the selective
deprotection of acyclic ketals such as dimethyl ketals, although not with cyclic 1,3dioxolanes. Therefore both 1,3-dioxolane and dimethyl ketal protecting groups were
considered potentially suitable for use in the protection of the ketone of 72, due to

reported ease of removal under neutral conditions. It was decided to investigate first
the 1,3-dioxolane functionality.

There are a number of methods available for the 1,3-dioxolane protection of a carbonyl
functionality, including ethanediol and p-toluenesulfonic acid , ethanediol with
BF3.Et20 in acetic acid237, and ethanediol and trichloromethylsilane2

8

to name a few. It

was important however to employ a method which would not attack the TBDMS and
carbamate protecting groups.
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Stevenson237, using 1,2-ethanediol and boron

Initially, the method of Fieser &

trifluoride etherate in acetic acid was employed to form the 1,3-dioxolane derivative
(Scheme 4.9). However, the presence of the BF3.Et20 also led to the cleavage of the
silyl protecting group to afford 73 in 42% yield. This was evidenced in the lR NMR
spectrum by the loss of the typical tert-butyldimethylsilyl peaks at 50.04 ((CH3)2Si)
50.87 ((CH3)3). The 1,3-dioxolane ketal was represented in the lH NMR spectrum by a
one proton triplet at 53.83 (OCH), a one proton multiplet at 53.91-3.99 (OCH) and a
two proton multiplet at 54.09-4.21 (OCH2). The identity of 73 was further confirmed as
Ci2Hi6N05Cl3 via mass spectral analysis (CI+), with the molecular ion seen at m/z
360/362/364. Alhough this synthetic method shortened the procedure by one step, the
low yield did not render it useful.

C0 2 CH 2 CCI 3

CO2CH2CCI3
ethanediol
BF3.Et20
TBDMSO

Scheme 4.9 1,3-dioxolane protection of ketone 72

A n alternate, non-acidic synthetic procedure for the protection of ketones as 1,3dioxolanes uses ethanediol and chlorotrimethylsilane238 and will not attack the tertbutyldimethylsilyl functionality. As shown in Scheme 4.10, 72 was treated with
ethanediol and chlorotrimethylsilane with heating under reflux to furnish the desired
product 74 in 86% yield. !H NMR spectroscopy revealed the presence of the newly

formed cyclic ketal via a methylene multiplet at 54.09-4.21 and a one proton triplet a
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a one proton multiplet at 53.83 and 53.91-3.99 respectively. The presence of the tertbutyldimethylsilyl group was confirmed via the typical singlets in the ]H NMR at 50.06
and 50.86. In the 3C NMR, the cyclic ketal methylene peaks appeared at 563.5 and
564.5, whilst the C3 carbon had shifted from the typical ketone chemical shift at 5206
upfield to 5106.7. The molecular formula of 74 was confirmed as C18H30NO5CI3 via
mass spectral analysis (CI+), revealing the molecular ion at m/z A7A/A76/A7S.

C02CH2CCI3

TBDMSO

C02CH2CCI3

C02CH2CCI3

TBDMSO

Reagents and Conditions: (a) ethanediol,te/f-butyldimethylsilylchloride, D C M , reflux, 48hrs, 8 6 % yield;
(b) TBAF, THF, 6 9 % yield.

Scheme 4.10 Preparation of 6/?-hydroxy ketal derivative 73 via 1A.

The next synthetic step was to remove theter^butyldimethylsilylprotecting group. The
most common method for removal of this protecting group is via reaction with
tetrabutylammonium fluoride. Therefore, as shown in Scheme 4.10, 74 was treated with
tetrabutylammonium fluoride to yield the desired product 73 in 69% yield.

In order to reduce the reaction time when synthesising 74, it was decided to attempt t
reaction under microwave conditions. Accordingly, 72, ethanediol and tert-

butyldimethylsilyl chloride in dry acetonitrile under argon in a sealed reaction vesse
was exposed to microwave radiation at 80°C for 20 mins. Surprisingly, under the novel

reaction profile achievable with microwave radiation, not only did the reaction produc

contain the desired 1,3-dioxolane ring, but cleavage of the tert-butyldimethylsilyl gr
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had also occurred, resulting in derivative 73. Whilst cleavage of the tertbutyldimethylsilyl group suggested there may have been some hydrogen chloride

formed in situ, this reaction might also be due to superheating effects of the microwa
radiation239'240. That this cleavage had in fact occurred was established by !H NMR
spectroscopy on the product, which clearly revealed the loss of the typical tert-

butyldimethylsilyl methyl singlets at 50.06 and 50.86, and the gain of the two methyle

doublet of doublets of the cyclic ketal at 53.82 and 53.92. Mass spectral analysis (CI
confirmed the molecular ion of 73 at m/z 360/362/364, consistent with the molecular
formula Ci2H16N05Cl3.

With an efficient route to cyclic ketal derivative 73 under microwave conditions in
place, it remained to oxidise the secondary 6-hydroxyl to a ketone, to allow for
incorporation of the aryl substituents at the 6 position of the tropane ring.

4.4.2.3 Oxidation of protected 6-hydroxytropane derivative 73

The literature contains a plethora of methods for the oxidation of secondary alcohols,
from standard oxidising agents such as chromium (VI) reagents241, manganese
dioxide242 and Raney Nickel243, to sodium hypochlorite with acetic acid244 or ruthenium
tetroxide245, or catalytic systems including for example RuCl2(PPh3)3-tBuOOH ' ,
pyridinium dichromate-Me3SiOOSiMe3248 and

PMN^MOO^BUOOH249'250.

The

oxidation of the secondary 6-hydroxyl in tropane systems has previously been
undertaken via a number of methods, including chromic acid188, Pfitzner-Moffat
oxidation, using DCC, phosphoric acid & DMSO184'251'252, and the popular Swern
oxidation196, utilising oxalyl chloride in DMSO. Initially the method of Pfitzner-

98

Chapter Four Synthesis of Bicyclic Tropane Derivatives

Moffat

as used by Montzka 184 was chosen to explore oxidation of the 6-hydroxy

group in 73 to the 6-ketone derivative.

The treatment of 73 with H3P04 in DMSO resulted in formation of the desired product
75 as a white solid in 78% yield. !H NMR spectroscopy confirmed the loss of the 6hydroxy multiplet peak previously at 54.88-5.02, and the C-6 carbon in the 13C NMR

shifted from 573.5 downfield to 5202.9, a position typical of a ketone carbonyl. Mass
spectral analysis (CI4) confirmed the formula Ci2Hi6N05Cl3 via an MH* ion at m/z
358/360/362.

C02CH2CCI3 C02CH2CCI3
N N

HO^/JL^A /^C"\
O-A O^)
73

75

Reagents and Conditions: H3P04, DMSO, RT, 3hrs, 78% yield.

Scheme 4.11 Oxidation of 6/?-hydroxy tropane 73 to 6-tropinone derivative 75.

4.4.2.4 Arylation of 75 to provide 6-arylhydroxytropane derivatives

With the derivative 75 in hand, 6-arylhydroxytropane derivatives were then accessed v

Grignard addition to the 6-ketone functionality. As depicted in Scheme 4.12, attack a
the C6 carbonyl with either phenylmagnesium bromide or 3,4methylenedioxyphenylmagnesium bromide gave rise to 6-arylhydroxy derivatives 76
and 77. Reaction conditions were initially investigated using phenylmagnesium
bromide, affording the desired product 76 in 77% yield. NMR spectroscopy evidenced

the formation of 76, with the ]H NMR spectrum clearly displaying the phenyl protons at
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57.20-7.52, and the tertiary hydroxyl proton was assigned to the broad singlet at 54.
1 ~K

The

C N M R spectrum showed a loss of the C 6 carbonyl peak at 5202.9 and the

additional phenyl carbons at 5123.9-128.1. High resolution mass spectral analysis (C
confirmed the molecular formula CjgH^NOsCL;.

C02CH2CCI3

p02CH2CCI3
N

Ar

TA
• = Phenyl
• = 3,4-(OCH20)-Ph

75

76 Al
77 Ai

Reagents and Conditions: ArMgBr, THF/ether, RT, 3hrs, 75-77% yield.

Scheme 4.12 Arylation of 6-tropinone derivative 75 to afford 76 and 77.

Molecular modelling conformational data was obtained for 75 using global mechanics
in the Spartan program. The lowest energy conformers of 75 were found to be that

shown in Figure 4.3c, with the cyclic ketal ring positioned in part below the bicycli

tropane ring. This conformation blocks the concave face of the tropane ring, suggest
that the large phenyl Grignard reagent would attack solely from the top face of the

tropane skeleton, leading to formation of only the one diastereomer 76. This expecta
was proven to be the case, as NOESY ID !H NMR experiments revealed the OH proton
to have a NOE interaction with the H5, H4 and H2 protons (Figure 4.3a), whereas the
aromatic ortho protons displayed NOE interactions with only the H5 and H7 protons

(Figure 4.3b). This clearly indicated that the phenyl ring functionality is exo to th
tropane skeleton and the hydroxyl group is endo.
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Figure 4.3a N O E S Y I D N M R spectrum of 76: the irradiated O H proton displays a N O E
interaction with H 5 , H 4 and H 2 , indicating the exo stereochemistry of the aryl functionality.
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Figure 4.3b N O E S Y ID N M R spectrum of 76: the irradiated aromatic ortho protons display a
N O E interaction with H 5 and H 7 , indicating exo stereochemistry of the aryl functionality.
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Figure 4.3c Spartan molecular models of the lowest energy conformations of 75 and 76,
indicating the favoured exo aryl functionality in 76.

Synthesis of 77, with the protected catechol moiety, followed the same synthetic route
(Scheme 4.12): treatment of 75 with 3,4-methylenedioxyphenylmagnesium bromide in

THF yielded 77 in 75% yield. High resolution mass spectral (CI+) analysis indicated th
molecular formula to be C19H20NO7CI3. JH NMR analysis of 77 confirmed the
additional aromatic hydrogens at 56.7-7.05, and the presence of the methylenedioxy
function through a downfield singlet at 55.92.

With derivatives 76 and 77 synthesised, access to six target derivatives for testing
feasible (Figure 4.4). Direct hydrolysis of the carbamate protecting group from
derivatives 76 and 77 would yield the ligands 58 and 60. Removal of the cyclic ketal
from 76 and 77 would provide ligands 78 and 79, which may be either hydrolysed to

afford ligands 55 and 57, or reduced to afford the y^-hydroxylic derivatives 80 and 81
which in turn could be converted to target derivatives 50 and 54.
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C0 2 CH 2 CCI 3

76 Ar = Phenyl

58 Ar = Phenyl

77 Ar = 3,4-(OCH20)-Ph

60 Ar = 3,4-(OCH20)-Ph

C0 2 CH 2 CCI 3

78 Ar = Phenyl

55 Ar = Phenyl

79 Ar = 3,4-(OCH20)-Ph

57 Ar = 3,4-(OCH20)-Ph

C0 2 CH 2 CCI 3

80 Ar = Phenyl

50 Ar = Phenyl

81 Ar = 3,4-(OCH20)-Ph

54 Ar = 3,4-(OCH20)-Ph

Figure 4.4 - Route to target Derivatives from 76 and 77

4.4.2.6 Removal of ketal protecting group

With the target ligands n o w in sight, the next step w a s the removal of the 1,3-dioxolane
protecting group. A s previously discussed neutral reaction conditions were required for
this cleavage step, and, in this context, cerium trichloride heptahydrate and sodium
iodide w a s considered, based on the report of Bartoli et al}65. Lanthanide salt-mediated
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Lewis acid reactions have gained increased interest over recent years253 due to their low

toxicity and ease of handling, making them attractive alternatives to classical reagent
such as titanium tetrachloride. Bartoli and co-workers studied the use of cerium
trichloride heptahydrate in organic reactions and have developed new methods for the
deprotection of a number of functional groups, including trialkylsilyl ethers254, pmethoxybenzyl ethers255 and 1,3-dioxolanes165.

For 1,3-dioxolane derivatives, it has been shown165 that cerium trichloride heptahydrate
and a catalytic amount of sodium iodide transforms 1,3-dioxolanes to their parent
ketones in high yields under refluxing conditions (Scheme 4.13). Mechanistically, it is
proposed1

5

that while the Lewis acid-like species cerium trichloride polarises the

dioxolane oxygen, the presence of water effects the deprotection (Scheme 4.13). The
deprotection did not proceed with anhydrous cerium trichloride, however the catalytic
role of the sodium iodide is not clear. It was expected that upon treatment of 76 with
cerium trichloride heptahydrate and sodium iodide in acetonitrile, as shown in Scheme
4.14, the ketone 78 would be furnished. However, after 20 hours at room temperature in
the presence of 1.5 equivalents of cerium trichloride heptahydrate and 0.15 equivalents
of sodium iodide, followed by 22 hours of reflux, no cleavage had occurred, with the ]H
NMR spectrum clearly displaying a quantitative amount of the two cyclic methylene
proton signals at 53.97 (dd) & 54.02-4.18 (m).

i i-r

cO) CeC'3r
R,AR„ H20

0^ ,0-- -CeCU
R' R"

/~A
R'

HO

OH

Scheme 4.13 Mechanism of 1,3-dioxolane removal by CeCl3.7H20
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C0 2 CH 2 CCI 3
N

C0 2 CH 2 CCI 3
N

No Reaction

Reagents and Conditions: CeCI3.7H20 (1.5 eq.), Nal (0.15 eq.),
RT, 20hrs, reflux, 22hrs.

Scheme 4.14 Deprotection of the 1,3-dioxolane derivative 76

To take account of the possible chelation sites in 76, the amount of cerium trichloride
heptahydrate (7.5 molar equivalents) and sodium iodide (0.75 molar equivalents) was
increased. Additionally, although Bartoli et al}65 used refluxing acetonitrile conditions
to obtain quantitative 1,3-dioxolane cleavage, this temperature may not provide enough

energy for the reaction of the more sterically demanding bicyclic derivatives. In order t

achieve a higher reaction profile, it was desired to investigate the cleavage of the 1,3dioxolane derivatives 76 and 77 under microwave conditions. As has been previously
discussed, microwave radiation can provide novel temperature and reaction profiles for
given reaction mixtures, often, in fact, by superheating effects239'2 °. It was hoped that
such superheating effects might aid in the cerium trichloride-mediated cleavage of the
1,3-dioxolane ring. Accordingly, as shown in Scheme 4.15, derivatives 75 and 76 were
separately treated with cerium trichloride heptahydrate (7.5 equivalents) and sodium
iodide (0.75 equivalents) in acetonitrile under microwave radiation at a range of
temperatures (100°C-120°C) for time periods ranging from 20 to 100 minutes.
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CO 2 CH 2 CCI 3
N

C0 2 CH 2 CCI 3
N
N o Reaction

AL-,0

75 R = O

82 K

_

u=

76 R = Phenylhydroxy

78 R =

phenylhydroxy

Reagents and Conditions: CeCI3.7H20 (7.5 eq.), Nal (0.75 eq.),
microwave radiation, 100-120°C, 20-100 mins.

Scheme 4.15 Microwave reaction attempts to remove the 1,3-dioxolane substituent

In the first microwave reaction attempt, 76 was exposed to microwave radiation initiall
for 20 minutes at 100°C. Mass spectral analysis (Cf) of the reaction mixture indicated
small peak at m/z 392/394/306 for the ketone 76 (C16H16NO4CI3), with a major peak for
78 (m/z 436/438/440, C18H20NO5CI3). Microwave radiation continued for 60 minutes at
100°C, followed by another 60 minutes at 120°C. Mass spectral analysis (CI*) of the
reaction mixture indicated only 76 (m/z 392/394/306) to be present, and !H NMR
analysis of the purified product revealed it to be 76 only, with the two dioxolane
methylene peaks indicated at 53.97 (dd) & 54.02-4.18 (m). Repeating the reaction, at
120°C for 60 mins failed to furnish any of the desired ketone 78, with ketal peaks
clearly remaining in the

13

C NMR, at 565.4 and 665.7, and no C=0 at 5200.

In microwave reactions it is optimal to have a homogeneous rather than a heterogeneous

mixture to provide a uniform heating pattern239'240. Due to the dielectric heating method
of microwave chemistry, polar solvents and/or ions are required for microwave heating.

The use of highly polar solvents and the addition of ionic salts to the reaction mixtur

allows the attainment of increased heating rates and reaction profiles. In analysing th
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reaction system then, it may be seen that whilst the ionic salts cerium trichloride
heptahydrate and sodium iodide are both present, they are not soluble in acetonitrile,
which is not a highly polar solvent in comparison to aqueous solvents. Therefore, to

increase the reaction profile of the system it would theoretically be advantageous to u
a more polar solvent, one which would solubilize both the substrate and the reagents.
An acetonitrile:methanol:water (6:3:1) system was chosen, and the resulting reaction
mixture, using 75 as the substrate, was exposed to microwave radiation at 100°C for 20
minutes (Scheme 4.15). Mass spectral (CI+) analysis revealed some of the desired
product 82 to have formed, via an M+l peak at m/z 314/316/318 (C10H10NO4CI3),
though a significant amount of 75 still remained (m/z 358/360/362). Microwave
irradiation was continued for a further 30 minutes at 100°C, and then for 50 minutes at
110°C, however, the reaction did not go to completion (as monitored by mass spectral
analysis) and only starting material could be recovered from the reaction mixture.

An alternate method for 1,3-dioxolane deprotection was thus needed, however with no

other suitably mild and neutral method apparent, it was decided to substitute the cyclic
dioxolane ketal protecting group with the acyclic dimethyl ketal, which is reported to
easily cleaved by bismuth nitrate under neutral conditions16 . To investigate the ease
with which the dimethyl ketal may be introduced to and removed from the 3-carbonyl
group in the tropane skeleton, the carbamate protected tropinone derivative 65 was
firstly investigated as a model compound (Scheme 4.16). Following the method used by
Paquette et al.256, dimethyl ketal formation was achieved by means of
trimethylorthoformate and /?-toluenesulfonic acid, providing 83 as a colourless oil in
good yield. ]H NMR spectroscopy of 83 revealed the two methyl ketal peaks at 53.12
and 53.19 and 13C NMR spectroscopy displayed the loss of the ketone peak at 5207.2,
and the new methoxy groups were assigned to peaks at 547.3 and 548.4. Mass spectral
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(CI ) analysis of the newly formed derivative 83 evidenced an isotopic cluster for the
MH+ ion at m/z 347/349/351, consistent with the molecular formula Ci2Hi8N04Cl3.

CO2CH2CCI3

N

C0 2 CH 2 CCI 3

C0 2 CH 2 CCI 3

,OCH 3

65

83

r
OCH3

65

Reagents and Conditions: (a)Trimethylorthoformate, p-TsOH (cat.), MeOH, RT, O/N, 8 0 % yield;
(b) Bi(N03)3.5H20, DCM, RT, O/N, 100% yield.

Scheme 4.16 Dimethyl ketal protection (and deprotection) of ketone 65

With no problems obtaining the dimethyl ketal derivative 83, investigation of the
cleavage of the protecting ketal was then explored. The method of Eash166, reported to
cleave dimethyl ketals with ease under neutral conditions employing bismuth nitrate
1 1 "X

pentahydrate, furnished ketone 65 in quantitative yield (Scheme 4.16). H N M R and

C

NMR spectroscopy indicated a loss of the two methyl ketal peaks at 53.12, 53.19 and
547.3, 548.4 respectively, and the ketone carbonyl was indicated by a peak in the 13C
NMR spectrum at 5207.

Having proven that the use of the dimethyl ketal protecting group was suitable for these
tropane derivatives, the synthetic scheme was revised to incorporate this protecting
functionality, as shown in Figure 4.5.
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Figure 4.5 Revised Synthetic Scheme
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4.4.3 Revision of Synthesis of 6fi-arylhydroxynortropane derivatives

4.4.3.1 Incorporation of dimethyl ketal protecting group

Previously, when reacting the ketone under microwave conditions to give the 1,3dioxolane 72, the ter?-butyldimethylsilyl protecting group was cleaved, leaving the 6hydroxy derivative 73. This was advantageous as deprotecting the 6-hydroxy
functionality was the next step in the synthesis. It would also prove advantageous if
cleavage of the tert-butyldimethylsilyl group could be achieved during the formation of
the dimethyl ketal derivative. With this reaction requiring the presence of catalytic ptoluenesulfonic acid, acid hydrolysis of the hydroxyl protecting group was certainly a
possibility, the mechanism of which is outlined in Scheme 4.18.

C0 2 CH 2 CCI 3

C0 2 CH 2 CCI 3

C0 2 CH 2 CCI 3

N
TBDMSO

HO

O

OCH3

OCH,

O

OCH3
84

72

OCH,

85

Reagents and Conditions: (a)Trimethylorthoformate, p-TsOH (cat.), MeOH, RT, O/N, 8 0 % yield;
(b) H 3 P0 4 , DMSO, RT, 3hrs, 78% yield.

Scheme 4.17 Preparation of dimethyl ketal protected derivative 85

C0 2 CH 2 CCI 3

TBDMS-0

C0 2 CH 2 CCI 3

C0 2 CH 2 CCI 3

HO

TBDMS

OCH3
OCH3

p-TsO-

HO-H

TBDMSOH
+

p-TsO—H
KJ

HO-H

p-TsOH

Scheme 4.18 Mechanism for silyl ether cleavage of 72 by/?-toluenesulfonic acid
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Ketone 72 was therefore treated with trimethylorthoformate and p-toluenesulfonic acid

monohydrate at room temperature (Scheme 4.17). During the course of the reaction silyl

ether cleavage did in fact occur, and the desired product 84 was achieved in 85% yield

The presence of the newly formed dimethyl ketal derivative was clearly indicated in t
[

H NMR spectrum of the product by new signals at 53.11 and 53.15 for the two

methoxy groups, and in the 13C NMR spectrum by the shift of the C3 carbon from a
signal at 5206.0 to one upfield at 598.3 The high resolution mass spectrum also was
consistent with the molecular formula. Also noticeable was the loss of the tert-

butyldimethylsilyl protecting group from the 6 position via the absence of methyl pea
signals at 5-4.7 and 525.8 in the jH NMR spectrum. The high resolution mass spectrum
(CI*) of 84 was consistent with the molecular formula CnHigNOsCl?.

The oxidation of the secondary 6-hydroxyl group in 84 to the desired ketone had been
established previously with derivative 73 using the Pfitzner-Moffatt oxidation
method251, providing ketone 75 in good yield. Using analogous reaction conditions, the

dimethyl ketal derivative 84 was oxidized to afford 85 in 61% yield. Confirmation that
the oxidation had taken place was forthcoming from the 13C NMR spectrum, in which
the signal for C6 at 573.2 was absent and a new signal, typical of a ketone, appeared

5203.0. Mass spectral analysis (CI*) of 85 also indicated oxidation had occurred with
MH+ ion at m/z 360/362/364, consistent with the molecular formula Ci2Hi6N05Cl3,
confirmed by high resolution mass spectral analysis.
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4.4.3.2 Synthesis of aryl derivatives

With the 6-ketone derivative 85 in hand, the next step in the synthesis led into the

aryl target derivatives and intermediates. The plan was to synthesise target ligands

and 54 via intermediates 86 and 87, 78 and 79, and 80 and 81 (Figure 4.6). In order t
obtain some structure activity relationship (SAR) data, intermediate derivatives 88

89, and 55 and 57 were also to be investigated for their binding activities upon both
and mutant am-adrenergic receptors.

C02CH2CCI3

C02CH2CCI3

OCH3
OCH3

85

86 Ar = Phenyl
87 Ar = 3,4-methylenedioxyphenyl

88 Ar = Phenyl
89 Ar = 3,4-methylenedioxyphenyl

C02CH2CCI3

78 Ar = Phenyl
79 Ar = 3,4-methylenedioxyphenyl

55 Ar = Phenyl
57 Ar = 3,4-methylenedioxyphenyl

C02CH2CCI3

80 Ar = Phenyl
81 Ar = 3,4-methylenedioxyphenyl

50 Ar = Phenyl
54 Ar = 3,4-methylenedioxyphenyl

Figure 4.6 Attainment of target ligands 50 and 54
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Introduction of the aryl moiety into the tropane skeleton of derivatives like 85 (dimethyl
ketal ketone) had previously been established via Grignard reactions of the dioxolane
analogue 75. Therefore, using similar conditions, 85 was treated with the Grignard
reagents phenylmagnesium bromide and 3,4-methylenedioxyphenylmagnesium
bromide, resulting in the formation of 86 and 87 in good yields (Scheme 4.19). !H NMR
spectroscopy clearly identified the additional 5 phenyl protons of 86 at 57.19-7.54,
in the case of 87 the 3 aromatic protons at 56.72-7.05 and the methylene protons at
55.92. The high resolution mass spectra of 86 (CI+) and 87 (EI+) confirmed molecular
formulae of CigH^NOsCL; and Ci9H22N07Cl3 respectively, via ion peaks representative

of the rapid loss of a methoxy substituent from the derivative, a trend also seen in t
low resolution mass spectral data.

C02CH2CCI3 p02CH2CCI3
N N

Ar

\Z^O\
OCH3

J ^A^OCH 3

OH T
OCH3
85 86 Ar = Phenyl
87 Ar = 3,4-methylenedioxyphenyl

OCH3

Reagents & Conditions: ArMgBr, THF or ether, RT, 3hrs, 77-78% yield

Scheme 4.19 Grignard reactions of 85 to afford arylated derivatives 86 and 87.

As with the cyclic dioxolane derivative 75, assessment of the lowest energy conformer
of dimethyl ketal derivative 85 (as determined using the Spartan program) suggested
that Grignard reagent attack by phenylmagnesium bromide on the ketone would occur
preferentially from the exo face (Figure 4.7).
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Figure 4.7 Lowest energy conformer of 85 (left) & preferred exo-aryltropane derivative 86.

Having established the chemistry of dimethyl ketal deprotection using bismuth nitrate
(section 4.4.2.6, Scheme 4.16) on a similar tropinone derivative (83), it was now
possible to deprotect both the dimethyl ketal derivatives 86 & 87. To ensure the same
reaction conditions were appropriate, to a small-scale solution of 86 stirring in
dichloromethane was added 0.25 equivalents bismuth nitrate pentahydrate with stirring
continuing for 20 hours at room temperature. Analysis of the reaction mixture (by both
TLC and mass spectrum) revealed starting material. Despite a further 1.5 molar
equivalents of bismuth nitrate pentahydrate being added and the mixture heated under
reflux for 2 days, no product 78 was observed.

C02CH2CCI3

C02CH2CCI3

OCH,

90

78
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The reaction was repeated, using 25 mol% of bismuth nitrate pentahydrate in
dichloromethane at room temperature, and after 30 minutes yielded a new spot which

corresponded (TLC analysis) with neither 86 or 78. Chromatographic separation of thi
compound and characterization using NMR spectroscopy and mass spectrometry
revealed it to be the cyclic acetal 90. The }H NMR spectrum of 90 displayed only one

methoxy singlet at 53.53, suggesting the cyclic acetal 90 had formed. Additionally, t
signal assigned to the C3 in the C NMR spectrum was a quaternary carbon (from
DEPT analysis), and this signal had moved downfield from 599.3 to 5106.4. Finally,
mass spectral (CI*) analysis of 90 confirmed it to be C17H18NO4CI3 via M+l chlorine
isotope peaks at m/z 406/408/410. The formation of the cyclic acetal derivative 90

suggests that the bismuth nitrate may have complexed with the tertiary hydroxyl oxyg
of 86, rather than with the methoxy oxygen, thus enabling attack of the complexed

oxygen at the C3 carbon, resulting in loss of one methoxy substituent and formation o
the cyclic acetal 90.
o^n

A n alternative method for dimethyl ketal deprotection was thus needed. Ellison et. al.
used 50%o aqueous trifluoroacetic acid (TFA) in chloroform to remove dimethyl ketal
protecting groups. Thus, as shown in Scheme 4.20, 86 was treated with 50% aqueous

TFA in chloroform (1:2) to produce a single product (TLC) in very high yield, indica
by high resolution mass spectral analysis (CI+) to be C16H16NO4CI3. NMR analysis

revealed that this product was actually a mixture of ketone 78 (as the minor isomer)
cyclic hemi-ketal 91 (as the major isomer), both compounds having the same Rf value
(TLC). The predominance of 91 was evident in the C NMR spectra, in particular the
signal at 5203.1 in the 13C NMR ascribed to the C3 carbonyl was weak, with a new

signal ascribed to the C3 carbon in the cyclic hemi-ketal at 5103.6 (See Figure 4.8).
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C0 2 CH 2 CCI 3

C02CH2CCI3

C02CH2CCI3
1:2aq.TFA:CHCI3

OCH,

RT, 4 hrs

OCH,
86

0

I—o
\

91
98% yield

78

l~~0

C0 2 CH 2 CCI 3

C02CH2CCI3

p02CH2CCI3

0

N

1:2 aq. TFA: CHCI 3
OCH,

RT, 30mins.

OCH,
79
crystalline
2 4 % yield

87

92
oily material
6 2 % yield

Scheme 4.20 Removal of dimethyl ketal protection from 86 and 87 using T F A in chloroform.
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Figure 4.8 I3C N M R spectrum of 91

Surprisingly, w h e n the methylenedioxyphenyl derivative 87 w a s treated with the
TFAxhloroform reagent, two products of quite different Rf value (TLC) were isolated.

The first was the crystalline ketone derivative 79 (Rf 0.20), obtained in 24% yield. T
signal representative of the C3 carbonyl was seen in the 13C NMR at 5204.2. Mass
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spectral analysis (CI+) of 79 indicated a molecular ion at m/z 436/438/440, indicative
the molecular formula C17H16NO6CI3. The second, more polar product (Rf 0.08),

obtained in 62% yield, was the crystalline cyclic hemiketal derivative 92, on the basis

the signal for the C3 carbon at 5103.6. Mass spectral analysis (CF") of 92 also indica
the molecular formula C17H16NO6CI3, via a molecular ion at m/z 436/438/440.

The ring system embodied in the new cyclic hemi-ketal is that of the tropane alkaloid
deoxynorscopoline. The related 7-hydroxylated compound, oscine (scopoline), is a
direct product of the hydrolysis of scopolamine2583. The synthesis of both
deoxynorscopoline and oscine have been investigated from non-alkaloid sources .

H CH3
N

N

& "&
deoxynoAscopoline oscine

4.4.4 Selective ketone reduction to yield 3/3-hydroxytropane derivatives

The initial target tropane derivative was that exemplified by structure 50, containing
P-hydroxy substituent at the 3-position of the tropane skeleton. Initial pharmacophore
work predicted that this 3/?-hydroxy derivative of the S-enantiomer would be 65 times
more selective for the mutant pharmacophore over the WT pharmacophore than the 3a-hydroxy derivative 51, (Table 4.1) and 1.8 times more selective than the 3-dihydro

derivative 49. Compound 50 was predicted to display an affinity for the mutant receptor
in the same region as that of 49 and 51. The /^-hydroxy derivative was therefore
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preferred, and so it was necessary that a method be found for selective reduction of
ketone derivatives 78 and 79 (and their hemi-ketal derivatives) to the /^-hydroxy
derivatives.

HO
49

50

51

M a n y options are available for the selective and stereospecific control of ketone
reduction259'260. Since the first report of reduction by diborane261, metal hydrides have
dominated the reduction of aldehydes and ketones to the corresponding alcohol.
Opportunities for variation in the metal, ligands, counterion and reaction conditions
have enabled most problems of stereo-, regio- or chemo-selectivity in synthesis to be
overcome259a. Detailed investigations of carbonyl reductions utilising borane and
derivatives, metal borohydrides, metal aluminohydrides and transition metal
0f\0 Of\f\ •

hydrides

"

have been undertaken. The stereoselective reduction of cyclic ketones is

profoundly influenced by conformational effects, and diastereoselectivity is possible by
the correct choice of reagent . Both conformational homogeneity and temperature
control are also recognized as important factors in achieving high diastereoselectivity.
The search for increased selectivity in sythesis has led to the development of reducing
agents that will discriminate between ketones and other carbonyl groups and between
various classes of ketone259a, including cyclic ketones.

Unhindered cyclohexanones exhibit an intrinsic preference for axial attack by small
hydride reagents (sodium borohydride (NaBH4), lithium aluminium hydride (LiAlH4))
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leading to the equatorial alcohol. Monoalkylborohydrides proved to be superior to these
traditional reagents, but selectivity declined as the ketone became more hindered ' .
Comparatively, axial alcohols, via equatorial attack, have been produced from both
hindered and unhindered ketones with bulky hydride reducing agents, the most
successful being highly branched alkylborohydrides generally with a lithium
0 £Sb OHC\

counterion

(for

example

lithium

trisiamlyborohydride

, txis,(trans-

971

methylcyclopentyl)borohydride, L-selectride and lithium dimesitylborohydride

). In

the reduction of bridged bicyclic ketones, hydride attack from the less hindered side of
the carbonyl group with reagents such as LiAlH*, LiAlH(OC4H9-£)3, or
NaAlH2(OCH2CH2OCH3)2, may be enhanced with the use of LiAlH(OCH3)3260. In the
reduction of 9-isocedran-2-one (93) (which is of similar conformation to those in the
tropanones 78, 79), use of LiAlH(OCH3)3 directs hydride attack almost exclusively

from the exo side (Fig. 4.9), giving the axial hydroxyl derivative (-)-neoisocendran-2-o
010

(94) in 9 9 % isomeric purity, whereas L1AIH4 yields only 9 3 . 6 % of this product .

s\
- Vx o

% ,
fii>\
JLt&L
(R) \

93

c%
S^T

>^H
1"
(S)J

(R) \

OH

94

Figure 4.9 Stereoselectivity of lithium methoxyborohydride reduction of 9-isocedran-2-one
(93)272.

Lanthanoid chlorides, particularly cerium chloride, have been shown to have dramatic
effects on the regioselective and stereoselective outcomes of sodium borohdyride ketone
reduction273"275. In the case of cc-enones sodium borohydride/cerium chloride provides
• 0T\

highly regioselective 1,2 reduction

, and stereoselectively shows a greater preference
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of equatorial alcohols273,276 Saturated ketones were also demonstrated to be attacked on
the axial side, with selectivity greatly enhanced by C e .

In the synthesis of tropan-3-ols with alkyl, alkenyl and alkynyl groups at the
bridgehead, reduction of the ketone (±)-l-methoxymethyltropan-3-one (95) to the 3/3alcohol 96 was achieved in a 90% yield employing sodium and ethanol in boiling
1 no

toluene

, with the high degree of stereocontrol being thermodynamically based. Less

harsh conditions were desired for arylhydroxy derivatives 78 and 79, and the use of
sodium borohydride in the presence of cerium trichloride appeared appropriate.

sodium, ethanol,
toluene
95

96

The basis for the selective reduction with the sodium borohydride/cerium trichloride
complex appeared to lie in the formation of alkoxyborohydride species273.
Alkoxyborohydrides, and particularly monosubstituted BH3OR" species, are known to
Oil

be more reactive than B H 4 "

. In methanol, the reaction rate for ketone reduction was

very high273, and the formation of NaBH4_„(OCH3)„ is favoured, with BH4" being
decomposed before reduction of the ketone occurs. This decomposition of BH4" by the
T_l_

solvent is catalysed by C e

and is the rate-determining step of the reaction. The

substitution of hydrides in BH4" by alkoxy groups increases the "hardness" of the
reagents. Stereoselectivity of the reduction is related to the hardness of the hydride
axial attack in cyclohexanones being favoured with harder reagents278. Gemal et al.
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o i

observed that most enone reductions performed in the presence of C e

favoured the

formation of equatorial alcohols .

To investigate the selectivity achievable with the sodium borohydride/cerium trichlorid
reagent on the tropane derivatives, 65 (tropinone) was treated with sodium borohydride
and cerium trichloride heptahydrate in methanol at room temperature at varying
concentrations of these two reagents (Scheme 4.21). The most favourable conditions
(see Table 4.2) were those employing a cerium trichloride heptahydrate concentration of
0.066M, which yielded a y^-hydroxyl group with 95% selectivity. This was established
by lH NMR spectroscopy. The cc-hydrogen of 97 resonates at 54.14 as a dddd with an
axial-axial coupling with H2/H4 of 10.5Hz and an axial-equatorial coupling with H2/H4

of 5.7Hz. The /2-hydrogen of 98, on the other hand, is characterized by a 53.74 chemical

shift, with an equatorial-axial coupling constant of 6.6Hz, and an equatorial-equatoria
coupling constant of 2.4Hz.

C02CH2CCI3
N

po 2 CH 2 CCl 3

r "^A

0.066M CeCI3.7H20/MeOH

^^^*^\ \

*"

A^

OH

NaBH4, 10 mins., RT
H

r

;95% P-OH

98 OH
5% a-OH

O
65

P02CH2CCI3

97

97°/ o overall yield

Scheme 4.21 Reduction of ketone 65 to the /?-hydroxy derivative 97.
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Table 4.2 Reduction of 65 with sodium borohydride/cerium chloride heptahydrate.
Time

NaBH4

(mins)

(mol. Eq.)

[CeCl3.7H20]a

65

Yield

Yield

Total

recovered % b

/?-hydroxy%b

a-hydroxy % b

Yield %

97

98

10c

2

0.22 M

-

75

25

98

10d

1.2

0.13M

50

33.33

16.67

96

10c

1.0

0.066M

-

95

5

97

a

in methanol;b as determined by *H N M R spectroscopy; c reaction was undertaken at RT;d
reaction began at 0°C for 5 mins, then was warmed to R T for 5 mins.

The 3,4-methylenedioxyphenyl ketone derivative 79 w a s treated with 0.066M cerium
chloride heptahydrate in methanol, followed by sodium borohydride to afford the f3hydroxy derivative 81 (Scheme 4.22). ]H NMR spectroscopy indicated only the /3hydroxyl substituent had formed, via the a-hydrogen indicated by the dddd signal at
53.94 in the spectrum, with an axial-axial coupling of 9.6Hz and an axial-equatorial
coupling of 6.3Hz. The axial H3 proton was in fact represented by two very close but
separate dddd peaks: one at 53.94 (0.75H integration) and the other at 54.07 (0.25H
integration). This downfield peak initially suggested the presence of either numerous
rotamers, or more than one conformer. NOESY ID NMR of the separate peaks further

indicated that whilst the peak at 53.94 displayed interactions with H2, H4, H7ax and th
tertiary hydroxyl proton, the H3 peak at 54.07 displayed interactions with only H2ax/eq
and H4ax/eq- This indicated that the tropane was now possibly partially favouring the

122

Chapter Four Synthesis of Bicyclic Tropane Derivatives

boat conformation, as depicted in Figure 4.10, as a result of H-bonding between the 3hydroxyl and the carbamate carbonyl group. H3 in this conformation now sits
equatorial, and is too far from the 6-hydroxy and H7ax to have a NOE interaction. The
equatorial conformation of H3 is reflected in the H2/H4 equatorial-axial coupling
constant values of 5.4Hz, whilst the equatorial-equatorial coupling constant was too
small to be seen. Confirmation of the product 81 as C17H18NO6CI3 was obtained via
high resolution mass spectrometry (CI+).

r~°

r~9

C-0-CH 2 CCI 3

O
11
p-0-CH
2 CCI 3

0.066M CeCI3.7H20/MeOH,
NaBH 4 , 30 mins, RT, 9 8 % yield

79

81

r~o

C-0-CH 2 CCI 3

-OH

p-0-CH 2 CCI 3

0.4M CeCI3.7H20/MeOH,
NaBH4, 4 hrs, RT, 8 4 % yield

92

81

O
n
C-0-CH
2 CCI 3

O
C-0-CH 2 CCI 3

0.4M CeCI3.7H20/MeOH,
NaBH 4 , 4 hrs, RT, 4 0 % yield
(60% recovered hemi-ketal)

80

Scheme 4.22 Selective /^-reduction of 79, 92 and 91, furnishing diol derivatives 81 and 80.
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CH2CCI3

Chair conformation

Boat conformation

H3 at 53.94 (lH NMR) H3 at 54.07 (!H NMR)

Figure 4.10 Chair and boat conformers of the ^-hydroxy derivative 81.

In the case of the reduction of hemi-ketal derivative 92, the hemi-ketal functionality

must first isomerise to the ketone prior to any reduction. This isomerisation may in fa
be assisted by the presence of cerium chloride in the reaction mixture: cerium chloride
is proposed to complex to the tertiary C6 oxygen, thus promoting formation of the
carbonyl bond as depicted in Scheme 4.23. Following isomerisation, axial attack of the
methoxyborohydride species may then proceed. Hemi-ketal 92 was therefore treated
with a solution of cerium trichloride heptahydrate in methanol followed by sodium
borohydride to afford only the P -hydroxy derivative 81 in 84% yield (based on 43 %
recovered starting material). !H NMR spectroscopy indicated that only one conformer
of the /7-hydroxy had formed, via the a-hydrogen indicated by the broad doublet at
54.19. High resolution mass spectral analysis (CI+) confirmed the molecular formula of
81 to be Ci7Hi8N06Cl3.

There were two major differences in the reduction of the ketone versus the hemiketal
derivative. The first was the reaction time, with the hemi-ketal derivative needing a

longer reaction time than the ketone (4 hours for partial reduction of 92, compared to 3
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minutes for full reduction of 79), due presumably to the isomerisation factor. T h e
second was the concentration of the cerium chloride solution. Whilst the ketone
derivative 79 used a 0.066M cerium chloride solution, the hemi-ketal derivative 92
required a 0.4M cerium chloride solution, with less complete reaction.

p02CH2CCI3

r-°

^-0
O A

C02CH2CCI3
N

/-0
O. \

C02CH2CCI3
N

NaBH4

Q^y^'
Ce
C\X | X CI
CI
92

79

81

Scheme 4.23 Assistance of cerium chloride in the isomerisation of 92 to 79.

It was fortunate that in these reduction reactions only the /?-hydroxyl derivatives were
being produced. It is likely that the presence of the 6-hydroxy substituent was further
directing axial hydride delivery, and perhaps even preventing equatorial hydride
delivery, by interacting with the borohydride species as depicted in Fig. 4.11.
Additionally, the bulky TV-carbamate may hinder somewhat equatorial attack of the
methoxyborohydride species.
P02CH2CCI3

r~9

H3CO

B^
H

H

N H
'
CH 3

Figure 4.11 Borohydride complexing to O H provides axial hydride delivery.
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Reduction of the ketone/hemi-ketal mixture 78/91 with 0.4M cerium chloride
heptahydrate and sodium borohydride in methanol afforded, after an extended reaction
time (16 hours), the /2-hydroxy derivative 80. Again, !H NMR spectroscopy indicated

that only the /^-hydroxy derivative had formed, with the axial a-hydrogen ascribed to
the broad multiplet at 54.24-4.27. High resolution mass spectral analysis (CI+)
confirmed the molecular formula of the product as C16H18NO4CI3.

With the desired dioxolane ketal (76, 77), dimethyl ketal (90, 91), cyclic hemi-ketal
92) and dihydroxy (80, 81) derivatives in hand, it now remained to remove the

carbamate protecting groups to afford the desired target derivatives for the receptor

binding studies. This was achieved utilising zinc in acetic acid, to afford target li
and intermediates 50, 54, 58, 60, 99, 100, 101 and 102, in yields of 60-100%. Both !H
and C NMR spectroscopic analysis of the products confirmed the loss of the
carbamate group. Surprisingly, treatment of the dimethyl ketal derivatives 90 and 91
with zinc in acetic acid led not only to removal of the carbamate moiety, but also to
loss of one of the methoxy substituents, resulting in the hemi-ketal derivatives 101
102 shown in Scheme 4.24. This was clearly seen in the !H NMR spectra, where both
derivatives displayed only one methoxy peak at 53.48. Additionally, DEPT analysis of
the derivatives clearly indicated that the C3 carbon was quaternary. High resolution
mass spectral analysis (CI+) confirmed the molecular formulae of 101 (C14H17NO2) and
102 (C15H17N04).

126

Chapter Four Synthesis of Bicyclic Tropane Derivatives

C-0-CH2CCl3
Zn, acetic acid, 24 hours, 40°C

76R = H
77 R = OCH 2 0

58R = H
60 R = OCH 2 0

C-0-CH2CCI3
Zn, acetic acid, 24 hours, 40°C
OCH,

86R = H
87 R = OCH 2 0

101 R = H
102 R = OCH 2 0

O
n
C-0-CH
2 CCI 3
Zn, acetic acid, 24 hours, 40 C

OH
91 R = H
92 R = OCH 2 0

99 R = H
100R = OCH 2 O

C-0-CH 2 CCI 3
Zn, acetic acid, 24 hours, 40°C

80R=H
81 R = OCH 2 0

50R = H
54 R = OCH 2 0

Scheme 4.24 Removal of the carbamate group of target precursors to afford the target ligands.
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High resolution mass spectral data for the above derivatives were in accordance with
expected values, and are shown in Table 4.3. Each derivative was converted into its
hydrochloride salt for biological testing upon the aie-adrenoceptors.

Table 4.3 High resolution mass spectral data for target ligands.
Derivative

Molecular

Molecular

High Resolution

Calculated

Formula

Mass

Molecular Mass

Values

Observed (CT), M + H +

M+H+

a

58

C15H19N03

261.3208

60

C16H19NOs

305.3335

305.1254b

305.1263

101

C14H17N02

231.2945

231.1266b

231.1259

102

C15H)7N04

275.3043

276.1240

276.1236

99

C13H15N02

217.2676

218.1175

218.1181

100

C14H15N04

261.7744

261.1002 (ET)

261.1001

50

C13H17N02

219.2835

220.1335

220.1338

54

C14H17N04

263.2933

a

a

-

-

The high resolution mass spectrum could not be determined;
b
A n M + ion was observed in the mass spectral data.
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5.1 Introduction

Molecular modelling work indicated that spirocyclic derivatives displayed some
remarkable selectivities for the am Cys128Phe mutant adrenoceptor pharmacophore
(Mu2, Chapter Two). In particular, derivative 18b was shown to be the most selective of

all first generation target ligands, displaying a selectivity for the mutant receptor ov
the WT receptor of 2860, and an affinity for the mutant receptor of 350nM (R-

enantiomer) (Table 5.1). The spirocyclic target ligands of interest for evaluation of th
binding affinities and selectivities upon the aiB Cys128Phe mutant adrenoceptor are
shown below, and their calculated data is given in Table 5.1.

18aS-Me
18b/?-Me

17

103

13

14

50

Table 5.1 Calculated data for spirocyclic ligands in comparison to monocyclic & bicyclic
ligands. £ and R refers to the stereochemistry at the spirocentre for 18 and 17, and at the arylsubstituted carbon for 13,14 and 50. Predictions for 103 were not made.
Derivative Predicted WT AffinityPredicted Cys128Phe
Kt(nM)
18a
18b

17
13
14
50

Selectivity

Affinity K, (nM) (for CysmPhe over WT)

S

370000

3900

R

1400000

4700

S

330000

2900

100
300
110

R
S
R
S
R
S
R
S
R

1000000

350

2860

350000

8100

340000

2200

350000

2400

11000

2300

150000

4500

21000

3000

340000

1100

10000

570

40
160
150
5
1
1
310
20
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The spirocyclic derivatives provide a good model for selective ligands due to the
constrained folded conformation provided by the quaternary spirocyclic carbon,

resulting in the two rings lying in planes at 90° to each other, as shown in Figure 5.
Catalyst pharmacophore generation indicated that the adrenaline molecule probably
adopted a folded conformation on the mutant adrenoceptor, as was discussed in Chapter
Two. The spirocyclic framework enables a good approach to mimicking such a folded

conformation in a synthetic ligand. The orthogonal spatial orientation of the rings pl

the phenyl ring directly opposite one ionisable nitrogen, as depicted in Figure 5.1; t

other nitrogen could serve as a mimic of the alpha-oxygen functionality in adrenaline.
That this folded conformation is indeed likely to be favoured by the mutant
adrenoceptor is reflected in the calculated selectivity values of these spirocyclic
derivatives over some other target ligands containing a more extended conformation of
the adrenaline mimic (for example the monocyclic derivatives, Table 5.1).

Figure 5.1 Lowest energy conformer of target ligand 18b, indicating the two nitrogencontaining rings orthogonal to each other, and the folded conformation of the design
motif contained within the rigid heterocycle.
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Figure 5.2 depicts 18b overlayed on the mutant pharmacophore. All three features of the
pharmacophore (HBD, ring aromatic and positive ionisable groups) are mapped, and the
ligand is a good fit for the pharmacophore. The incorporation of the methyl substituent
1 78

in the target ligand 18 improves the selectivity for the Cys

Phe mutant pharmacophore

over the wild-type pharmacophore dramatically compared to ligand 17 which lacks the
methyl substituent (see data in Table 5.1).

Hydrophobic

Figure 5.2 Target ligand 18b overlayed on the Cysl28Phe mutant a l B - A R pharmacophore.
The ligand interacts with all three binding functions.

5.2 Known Syntheses of Biologically Useful Spirocyclic Derivatives

Due to their highly constrained ring structures, spirocyclic derivatives are likely to
diverse functions in medicinal chemistry where selectivity is desired. Because of the
conformational rigidity of their structures, where small rings are involved, such
spirocyclic derivatives may have a role as not only small molecule ligands, but also
peptide-receptor antagonists, peptide-mimetics and even DNA-interacting molecules.
01Q 09.A

For example spirocycles can act as type-II /?-turn mimics

"

and thus m a y provide a
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popular option for use in peptide- and protein-interacting molecules. Ward et al2*2 have
reported the synthesis of a proline-based derivative as a potent and highly selective
neurokinin antagonist: the (o>spirolactam (104a) was shown to be an effective

replacement for the (I+l)th residue of a classical type-II /?-turn279'280 and as such was
incorporated into peptide analogues. The spiro-forming cyclisation of precursor
derivative 105 was a simple amide bond formation mediated by the use of N[(dimethylamino)propyl]-A^-ethylcarbodimide (EDCI) (Scheme 5.1) and producing the
diastereomeric spirocycles 104a and 104b.

^

HN^C02Me

Z C02H ^ -

H

^A

EDC|

N^C0 2 Me

V V " ^C0 2 Me

g i H '

105

104a

104b

Scheme 5.1 Cyclisation step in the synthesis of neurokinin antagonist 104a

Another peptidomimetic containing a spirolactam type-II /?-turn mimic was reported by
9R4, • •

Genin et al. . The synthetic route to their peptidomimetic 106 was analogous to that
7S1

previously reported by Hinds et al. . The cyclisation step was achieved under
Mitsunobu reaction conditions, as shown in Scheme 5.2. Again based upon the amino

acid proline, this synthesis provides a simple, somewhat generic spirocyclic lactam, an
indicated a possible strategy for the synthetic targets in our work.

o
o
"

"
c

-N

O

C02(CH3)3
106

133

NH 2
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Scheme 5.2 Cyclisation towards a spirolactam type-II /?-turn mimic

Urban and colleagues have repeated work on the development of spirocyclic amino
acids and esters as GABA-analogues " . These selective GABA uptake inhibitors
consisted of spirocyclic amino acids (107-110) which incorporated the GABA skeleton
into a heterocyclic ring (Figure 5.3).

r^r

1 0 7 R = P h C H 2 , n=1
108R = PhCH 2 , n=2
109R = PH 2 CH(CH 2 )2, n=1
110R = PH 2 CH(CH 2 ) 2 , n=2

Figure 5.3 Spirocyclic G A B A uptake inhibitors

The spirocyclic lactam 111 was prepared from /?-keto ester 112 via the use of
benzylamine in toluene at reflux, as shown in Scheme 5.3. Molecular sieves were used

to trap the expelled ethanol, resulting in a high yield (98%) of the spirocyclic keto

(111) and minimising formation of the pyrrolidinone 113286. The spirocyclic ketone 114
was then made by enolisation of the ketone functionality of 111 with
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triphenylmethyllithium, and subsequent reduction of the non-enolisable lactam group
with lithium aluminium hydride.

benzylamine,
toluene, reflux

YV
0

Br
/
0C2Hs

C

2H50\^\

-AY N - P h

111

0

s'
^

113

0
112

^\^
benzylamine,
mol. sieves
toluene, reflux

1. Ph3CLi
^.Ph

o o
111

N_ ^Ph
2. LiAIH4
THF, reflux
83%

114

Scheme 5.3 Preparation of the spirocyclic ketone 111 via lactam 112.

More recent development upon this synthesis28' utilised the methods depicted in
Scheme 5.4. The /?-keto amide 114 already contained the nitrogen functionality in the
desired position for the preparation of the spirocyclic lactam (115). Thus conjugate
addition of the /?-keto amide to acrolein afforded the aldehyde 116 in excellent yields,
which slowly underwent intramolecular addition of the amide to the formyl
functionality. Reduction of the aldehyde 116 (or the already cyclised 115) with LiAlH4
resulted in a mixture of the spirocyclic alcohols 117a and 117b (3:1, 85%). It was

apparent then that established chemistry for the preparation of aza spirocyclic molecules

existed: it just remained to find the best synthetic pathway for our related target ligan
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-Ph

o

o
0 O

114

115

(<S)

OR
117a

-Ph

OR

-Ph

117b

Scheme 5.4 Preparation of the spirocyclic lactam 115

5.3 Retrosynthetic Analysis of the Spirocyclic Target Derivatives

In order to establish a successful synthetic strategy for the spirocyclic class of
derivatives, restrosynthetic analysis must take into consideration the differences
between the target spirocyclic derivatives. Specifically, it was the substitution at the
C8* position which needed to be taken into account when planning the synthesis.
4 9

Retrosynthetic analysis, as depicted in Scheme 5.5 indicated that the precursor
derivative to the intramolecular spiro-cyclisation is a crucial step. As may be seen, in
the case of the 8-methyl derivative, cyclisation may be affected via an allyl derivative,
providing the desired methyl functionality. Similarly, the 8-unsubstituted spiro
derivative may be synthesised from a saturated primary halo- or hydroxy-side chain
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derivative, whilst the 8-hydroxy derivative m a y be achieved via cyclisation of the amide
nitrogen with an aldehyde.

r^rj™'

o9"

i

nr

>

.CH3
NHCH2Ph

NCH2Ph

N

YY

i

Boc 0
139

Boc
1180
R
\
R=H, OH
C02Me
18R=H
138

Jr\

^X/OR
N >r

*COOH
H

Boc O

L-Proline

140

O^H
C0 2 Me

NHBn

X = Br, OH

N
Boc O
145

144
\

QyNc H2 Ph

NCH2Ph
N
i

Boc O
120

rY™
y NH

I
H

Ar

Ar = Ph Ph(OH)2
103Ar=Ph

Boc O
119

A

I

N
H

. .NH

Y

Ar

Ar = Ph Ph(OH)2
17Ar = Ph

Scheme 5.5 Retrosynthetic Analysis of Spirocyclic Target Ligands
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Although there w a s s o m e established chemistry for the synthesis of derivatives similar
to the 8-hydroxy285 and 8-unsubstituted284'286 spiro derivatives 103 and 17, there was no
previous known work outlining the synthesis of 8-methyl- or such substituted spiro
derivatives. At first glance, however, it appeared that cyclisation between the
benzylamide secondary nitrogen and the allyl methine carbon should facilitate
spirocyclic formation with the desired methyl substitution.

Retrosynthetically then, it was planned that the cyclisation precursors may be derived
from functionalised proline-benzylamide derivatives 118, 119 and 120, and that the
Boc-protected amino acid proline would provide these derivatives. Because the S
stereochemistry at the carbon of the spiro centre was desired ultimately, stereosynthesis
may therefore begin with readily commercially available L-proline. However, initially it
was intended to establish a route to the targets with separation of stereoisomers to be
undertaken at appropriate stages.

5.4 Initial steps in the Synthesis of Target Spirocyclic Derivatives

As seen from molecular modelling studies, the stereochemistry of the spiro derivatives
is important, with the S-stereochemistry at the spirocyclic chiral carbon providing much

greater selectivity than the ^-stereochemistry (see Table 5.1). This feature has also been
noted by others286'288 reflected by their preparation of S-stereospecific spirocyclic
analogues.

Beginning with (IS^L-proline, then, it was desired to keep the stereochemistry anchored
throughout the synthesis without risk of racemisation. Enantiomerically pure amino
acids have been reported to pose a problem undergoing a-alkylation without
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racemisation

'

and without the use of a chiral auxiliary291. However, Seebach et

0Q0

al.

have reported the preparation of enantiomerically pure ct-substituted proline

derivatives, via a-alkylation without the loss of optical activity. The synthesis was
based upon the acid-catalysed condensation of L-proline with pivaldehyde to yield a
single stereoisomer of 2-tert-butyl-l-aza-3-oxabicyclo[3.3.0]octan-4-one (121) in a 92%
yield (Scheme 5.6). The bicyclic compound 122 was extremely sensitive to hydrolysis,
leading to the regeneration of proline; thus the azeotropic removal of water during the
reaction was of the utmost importance. Compound 122 was thus reported to be very air
sensitive, with insoluble proline forming spontaneously via hydrolysis; it is also
thermally labile, losing C02 above 100°C. Deprotonation of 122 with LDA led to the
formation of the chiral lithium enolate and subsequent alkylation with various
electrophiles, including iodomethane, allylbromide, benzyl bromide, N,Ndimethylammonium chloride, and oc-halo acetic ester and amide, yielded products

represented by 123 as a single diastereomer. With the (more reactive) electrophiles just
mentioned, yields were reported as moderate to excellent, with 123 (allyl derivative)
obtained in an 87% yield. These enolate derivatives were reported to be much more
stable toward both hydrolysis and thermal decarboxylation, with hydrolysis of the
alkylated derivatives to their corresponding acids (like 124) requiring acidic reaction
conditions of 15%-48% hydrogen bromide at temperatures varying from 25°C to
heating at reflux.
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Reagents & conditions: (i)TFA, pivaldehyde, pentane; (ii) LDA, THF, -78°C; (iii) allybromide;
(iv) 15%-48% aq. HBr, 8hr, RT.

Scheme 5.6 Chiral synthesis of (7?)-2-allylproline from (^-proline via 122

This procedure therefore provides the allylated chiral proline derivative 124 required fo
the generation of the target spirocyclic system, as was depicted in Scheme 5.6. It has
also been used successfully by others in the synthesis of novel spiro-bicyclic
systems ' . With this support it was decided to follow a similar path and use this
method to begin the synthesis. The first intended intermediate was therefore (R)-2allylproline (124), via the intermediate (2.R,5i?)-£-allyl-2-te??-butyl-l-aza-3oxabicyclo[3.3.0]octan-4-one (123).

5.4.1 Attempted synthesis of (2R,5R)-5-allyl-2-tert-butyl-l-aza-3oxabicyclo[3.3.0]octan-4-one (123) and (R)-2-allylproline (124)

The synthesis of (2i?,Ji?)-5-allyl-2-?e^-butyl-l-aza-3-oxabicyclo[3.3.0]octan-4-one
(123) was therefore attempted following the method of Seebach et al. (1983) as outlined
in Scheme 5.6. Crude 122 was obtained as a colourless oil in a low (47%) yield, which
at room temperature very quickly began to hydrolyse on being even only slightly
exposed to air, back to white solid proline. The mixture was identified via mass spectral
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(CI ) analysis, which displayed molecular ion peaks for 121 (proline) and 122 at m/z
184 (M+l) and 116 (M+l) respectively.

This material was nonetheless taken on to be allylated, following the method outlined in
Scheme 5.6. Separation of the crude product gave a low yield of an impure mixture of
allylated 123 and unreacted 121, identified by mass spectral (CI*) analysis (m/z 184
(M+l, 121), 224 (M+l, 123), 288, 367).

With low yields and stability problems encountered in the attempted preparation of the
initial (27?,5^-5-allyl-2-ter?-butyl-l-aza-3-oxabicyclo[3.3.0]octan-4-one, it was

necessary to find an alternate route to the preparation of the desired chiral allylprol
intermediate 124.

Dhaon et al.293 have investigated the esterification of Af-protected a-amino acids with
respect to the effect on racemisation. Previous reports294 had observed "some
racemisation" in the esterification of A^-(benzyloxycarbonyl) a-amino acids with tertbutyl alcohol, but noted that racemisation may be "largely avoided at lower
temperatures and with shorter reaction times". Dhaon et al. however, reported,

amongst other things, that A/-(benzyloxycarbonyl)L-proline readily formed its tert-butyl
ester with no racemisation, using catalytic dimethylamino pyridine (DMAP) (0.1 or 0.5
equivalents), EDCI and tert-butyl alcohol with stirring overnight. They also reported
other Boc-protected amino acids to withstand racemisation during esterification. We
therefore chose to prepare the N-Boc proline tert-bxxty\ ester 125 via this method.
Accordingly, as shown in Scheme 5.7, L-proline was firstly N-Boc protected using ditert-butyldicarbonate to afford 126, then a solution of 126 in dichloromethane was
treated with DMAP, tert-butanol and EDCI at room temperature overnight to afford the
desired tert-bvXy\ ester 125 as a colourless oil. The ]H NMR spectrum displayed the
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typicalferr-butylsignal as a singlet at an upfield chemical shift of 81.47, typical of the
ester moiety. Mass spectral (Cf) analysis confirmed the identity of 125 with a MH+
peak at m/z 273 indicative of the product Ci4H26N04.

(S)V
N
H

121

COOH

a
>-

ASA;
N *COOH
Boc
126

b

L(S)
X.
N^COOR
Boc
125R=tBu(58%)
127R = Et(55%)
128 R = Me (93%)

Reagents and Conditions: a): 10% NaOH, (Boc)20, dioxane/H20, 0°C 5hr, RT O/N,
91 %; b) ROH, DMAP, EDCI, DCM, 0°C 2hr, RT O/N.

Scheme 5.7 Preparation of iV-protected ester derivatives

It was also desired to determine if this method could prepare other esters (namely ethyl
and methyl esters) of the ./V-Boc-proline without racemisation. The degree of
racemisation is dependent on the alcohol used with the order of increased

racemisation being methanol < ethanol < benzyl alcohol < /-butyl alcohol. Additionally,
racemisation levels may be controlled by employing only 0.1 equivalents of DMAP and

shorter reaction times. It is apparent then that the method of Dhaon et al. may also be

applied to the successful preparation of methyl and ethyl ester derivatives of L-prolin
127 and 128. Reaction conditions analogous to those previously used (Scheme 5.7),
substituting /-butyl alcohol with ethanol and methanol, yielded the desired esters 127
(55% yield) and 128 (93% yield) respectively. ]H NMR analysis verified the

esterification, displaying the ethyl ester peaks at 84.12-4.32 (2H, m) and 81.28 (3H, t
and the methyl ester peak at 83.70 (3H, s). Mass spectral analysis (CI+) confirmed the
identities of the new proline ester products, with an MH+ peak at m/z 244 for 127
142
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(C12H21NO4) and an M H

+

peak at m/z 230 for 128 (C11H19NO4). The optical rotation for

128 was measured as -58.11 (at 22°C in ethanol) (compared with the literature value of
-54.54 at 25°C in chloroform), reflecting the retainment of the ^-stereochemistry at
the a-carbon.

While methyl ester production was the higher yielding of the esterification reactions, for
subsequent synthetic steps it was not certain which of the proline ester derivatives
would prove most suitable for further derivatisations to allow cyclisation. Urban and coworkers285'286 utilised the bromoethyl substituted /?-keto ester 129 to provide the
spirocyclic lactam 130 (Scheme 5.8), a method which may be adopted to the proline
derivatives in this work. Similarly, they also used the /?-keto ester 131 (containing an
ethyl ester) in an amino lysis reaction to produce the /?-keto amide 132, which further
yielded aldehyde 133 upon conjugate addition to acrolein, and resulting in isomerization
to the spirocyclic lactam 134 (Scheme 5.9).

N. ^Ph

0

0

£

0

129 130
Reagents & Conditions: benzylamine, toluene, 4A molecular sieves,
reflux, 96%.
Scheme 5.8 Preparation of spirolactam 130 from 6-keto ester 12928'
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oo

n H

oo

131

132

o o

133

134

Reagents & Conditions: (a) benzylamine, D M A P , toluene, reflux, 5 5 % yield;
(b) acrolein, DMF, 20°C, 99% yield.

Scheme 5.9 Preparation of spirolactam 134 from (3-keto ester 131286

In their preparation of spirocyclic derivatives, W a r d et al?%1 employed the proline allyl

'butyl ester derivative 135 as the precursor to the spirolactam derivatives 136a and 136b
as shown in Scheme 5.10, with cyclisation occurring between the ester carbonyl and the
leucine amine nitrogen.

(S) C02Me
HN^

^A

VWBU

" \AC02<Bu T * W :

H

z z
135

137

136a

Reagents & Conditions: (a) 0 3 , DCM then Ph3P; (b) H-Leu-OMe, THF, mol. seives 3A, NaCNBH 3 , MeOH; (c)
CF 3 C0 2 H; (d) EDCI, DCM; (e) H2, 10% Pd/C, MeOH, HCI.

Scheme 5.10 Preparation of Spirolactam derivatives28'

In order to facilitate 8-methyl spiro formation via either the bromoester proline
derivative 138 or the allylated proline benzylamide derivative 139, an allyl side chain
must be incorporated into the a-position of the proline skeleton (derivative 140) (see
retrosynthetic Scheme 5.5). The allyl derivatives of all three proline ester derivatives
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125, 127 and 128, were therefore prepared and their suitability for the desired synthe
assessed.

5.4.2 Allylation of proline ester derivatives

Having established that the synthesis of the chiral allylated derivative 124 by the
0Q0

method of Seebach et al

was unsuitable due to instability and poor yields, it m a y be

seen that with the protected proline ester derivatives 125,127 and 128 in hand, a simpl
a-alkylation employing a strong base and an allyl halide would provide the desired

allylated derivative, albeit in a racemic form. At this stage, it was aimed to undertak

least partial synthesis of the racemic target ligands (in particular the intramolecula

cyclisation), before proceeding further with chiral syntheses, which could be completed
989 • •

once racemic

syntheses had

been

established. W a r d

et al.

used lithium

diisoproplyamine (LDA) to lithiate the a-H of proline before allylating with allyl
iodide. Therefore, a solution of the proline ester derivative 125 was treated with LDA
followed by allyl bromide, as shown in Scheme 5.11, to afford 141 as a yellow oil. !H

NMR analysis revealed the loss of the a-H at 84.11, and the presence of the distinctive
allyl H's at 85.66-5.76 (=CH, m, 1H), 85.10 (=CH2, 2H, dd) and 82.52 and 82.95 (CH2,
2 x dd). 13C NMR displayed the three new carbon atoms downfield at 8133.4 (=CH) &
8118.3 (=CH2) and upfield at 838.2 (CH2). Mass spectral (CI+) analysis revealed an
MH+ peak at m/z 312, consistent with the newly formed derivative 141, Ci7H29N04.
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NVV0R
i II
BocQ
125R = lBu
127R = Et
128R = Me

Boc o
141 R = lBu (85%)
142R=Et(71%)
143 R = M e (75%)

Reagents & Conditions: (a) 1M LDA (1.5 eq.), THF, -78°C, 30 mins.;
(b) allyl bromide, -78 - -30°C, 3hrs.

Scheme 5.11 Allylation of ester derivatives

The other two allyl derivatives 142 and 143 (methyl) were prepared in a similar manner
in yields of 71% and 75% respectively. The additional allyl protons of 142 and 143
were observed in the !H NMR and 13C NMR at identical chemical shifts to that of 141.
Mass spectral analysis (CI+) of 142 revealed an MH+ ion at m/z 284, confirming its
identity as C15H25NO4; whilst the identity of 143 was confirmed by an MH+ ion seen at
m/z 270 (for that of Ci4H23N05).

5.5 Methods of Cyclisation for Spiro Formation

5.5.1 Introduction

Various methods for the production of some spirocyclic derivatives have been

introduced (section 5.2). However, whilst aiming to prepare the spirocycles, it was al
of interest to investigate novel methods of spirocycle formation. The key step in the

spirocyclic derivative synthesis is the cyclisation step, producing a spiro centre and
new 5-membered nitrogen-containing heterocycle. For the 8-dihydro (17) and 8hydroxy (103) target ligands the chemistry for such cyclisations is known, and may be
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adapted for the synthesis of the 8-methyl spiro cyclisation. It w a s therefore proposed
that cyclisation of bromo derivative 138 may be possible, as might cyclisation of the
benzylamide derivative 139.

As was revealed in the retrosynthetic analysis of the target ligands (Scheme 5.5),
derivative 119 may be achieved from 144 via the method of Bendl et a/.285 and 120 may
be achieved from 145 via the methods of Hollauf et al2% . For the 8-methyl substituted
derivative 118, for which no established preparation methods were known, cyclisation
between the benzylamide secondary nitrogen and a tertiary carbon in the alkyl side

chain could be facilitated via a number of different reagents and intermediates. For the
98 S

bromo derivative 139, analogous reaction conditions to that of Bendl et al.

could

provide the desired bond formation as shown in Scheme 5.12.

CH,
NHCH 2 Ph

OMe

99

NCH 2 Ph

Boc 0

139

138

118

NCH 2 Ph
N
i

Boc 0

144

17

OH
NCH2Ph
N
Boc 0

145

103

Reagents and Conditions: (a) Pd(ll) or Bu 3 SnH, AIBN; (b) benzylamine, toluene, 4A
molecular sieves, reflux; (c) benzylamine, DMAP, toluene, reflux

Scheme 5.12 Methods for Spiro cyclisation
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Alternatively, cyclisation between the benzylamide secondary nitrogen and an activated
double bond, in the case of the allyl side chain in 139, should facilitate the desired 8methyl substituted spiro ring. A variety of procedures, including organometallicmediated cyclisation (eg palladium and mercury), or incorporating radical cyclisation,
are available for cyclisation of the allyl benzylamide derivative 139.

5.5.2 Spiro cyclisation via 2-bromopropyl-proline derivative 138

Utilising the method of Bendl et a/.285 and Hollauf et al2%6, it was expected that the
secondary bromoalkyl sidechain would cyclise with benzylamine in the presence of
toluene and molecular sieves to yield the desired spirolactam 118 containing the 8methyl substitution. Addition of hydrogen bromide to the double bond would therefore
need to preferentially provide the desired tertiary bromo-substituted Markovnikov
product rather than the undesired secondary bromo-substituted anti-Markovnikov
product.

Carbon-carbon double bonds readily react with hydrogen bromide, however competing
radical and ionic reactions generally result in a mixture of products, unless the system
symmetrically substituted. Ionic addition may be controlled to provide the Markovnikov
product by use of phase-transfer conditions at high temperature . Alternatively,
competing radical reactions may be avoided by conducting the reaction on the surface
of silica or alumina gels297"299. Surface-mediated additions afford stereoselectivities
often unattainable in solution, and the use of hydrogen bromide precursors with silica or
alumina gel allows for convenient generation of hydrogen bromide in situ297. The use of
this latter method should then easily provide the desired 2-bromopropyl-proline
derivative 138 from the allyl derivative 143. Therefore, following the method of Kropp
148
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9Q8

et al. , a model reaction employing the treatment of cyclohexane (146) with
trimethylsilyl bromide in the presence of anhydrous alumina was undertaken, to afford
bromocyclohexane (147) in high yield (Scheme 5.13). Similarly, 143 was treated with

trimethylsilyl bromide in the presence of dried alumina. The reaction afforded recovere
starting material and a small amount of the Boc-deprotected derivative 148.
Unfortunately repeating the reaction a number of times did not furnish any of the
brominated 138. Iodination of the double bond of 143 was also attempted utilising
trimethylsilyl iodide instead of trimethylsilyl bromide, however again unreacted 143
was recovered. This result was unexpected considering the double bond is not sterically
encumbered.

Br

cyclohexene
146 147
Reagents and Conditions: anhydrous alumina, 1M trimethylsilyl bromide,
dichloromethane, RT, 2 hrs, 90% yield

Scheme 5.13 Model reaction: surface-mediated bromination of cyclohexene

//

N
H

C0 2 Me

Br
N C0 2 Me
Boc

148 138

Instead of further pursuing methods for Markovnikov bromination of the allyl chain, it
was decided to investigate an alternate route for the formation of the spirocycle

149
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functionality, namely via the intramolecular cyclisation between an amide moiety and
the allyl sidechain.

5.5.3 Preparation of allylbenzylamide derivative 139

The next section of work focused upon preparing benzylamide derivative 139 for

cyclisation. Classically, amides have been prepared from either an ester or an amine, or
from an acid. It would be advantageous to prepare the benzylamide derivative directly,
in one step, and as outlined in Scheme 5.14, 139 may be achieved via a number of
methods, from either the ester derivative 143 or the acid 149.

<

1

^ /\ x NHCH 2 Ph

'- ~

Boc 6 Boc 0
149

139

143

Scheme 5.14 Routes to benzylamide 139 via acid or ester derivatives

5.3.3.1 Preparation of benzylamide 139 from ester 143

Because the ester derivative 143 was available, it was decided to initially investigate
synthesis of 139 from the ester 143. Analysis of the literature provided a number of
possible reagents suitable for this transformation. Cossy & Thelland300 reported a one-

pot procedure for the high-yield conversion of P-ketoesters into (3-ketoamides, using t
catalyst DMAP with a variety of primary and secondary amines in refluxing toluene.
This method may be applied to the proline esters 141, 142 and 143. Accordingly, a
150
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mixture of 143, benzylamine and D M A P were heated in refluxing toluene, as shown in
Scheme 5.15. The resultant crude oil was shown to contain 143 and benzylamine only
(unchanged !H NMR). Repeated attempts at this reaction increasing quantities of
benzylamine and reaction times failed to furnish any of the desired amide product.

/ /

- 0Me

Boco
143

*•

(. A\/NHCH 2 Ph

No Reaction

£0CX

139

Reagents and Conditions: benzylamine, DMAP, toluene, reflux, 20hrs

Scheme 5.15 Attempted synthesis of 139 from ester 143

A m o n g m a n y of the methods reported for direct transformation of carboxylic acid esters
to the corresponding amides " the preparation involving dimethylaluminium
I A C *l(Y7

amides

was regarded to give good yields of amides under mild conditions. Sim

and Yoon307b found sodium diethyldiamidoaluminate, readily prepared from sodium
diethyl dihydroaluminate and diethylamine, to be an excellent reagent for amide

synthesis from esters. All esters examined, both aliphatic and aromatic, gave very goo

yields of the corresponding amides in 1-6 hours by refluxing in toluene or THF-toluene
(1:1) using a 10% excess of sodium diethyldiamidoaluminate (10% excess). Primary,
secondary and tertiary amines used gave equally good results, and sterically hindered

esters were also readily converted to the corresponding amide by increasing the amount
of reagent. This method307b should therefore successfully provide the desired
benzylamide derivative 139. To investigate this, the ?-butyl ester derivative 141 was
treated with sodium diethyldibenzylamidoaluminate, as shown in Scheme 5.16.
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NHCH2Ph

No Reaction

141R = «Bu 139
142R=Et
Reagents and Conditions: sodium diethyldibenzylaminoaluminate, toluene, reflux, 1-20hrs

Scheme 5.16 Attempted synthesis of 139 using diethyldibenzylamidoaluminate

To freshly prepared sodium diethyldibenzylamidoalimunate was added a solution of the

?-butyl ester 141 in toluene and the mixture refluxed for 1-6 hours (multiple reactions)
l

E NMR analysis of the crude oily product indicated that the reaction had failed to

furnish any of the desired amide product 139, as the f-butyl ester peak at 81.28 was st
present, and no peaks attributable to the benzylamide were seen. This disappointing
indication was further supported by the mass spectral (CI+) data, which clearly showed
an m/z peak at 312, corresponding to that of the ester 141 (C17H29NO4). Investigations
therefore moved to the ethyl ester derivative 142. Employing analogous reaction
conditions, freshly prepared sodium diethyldibenzylamidoaluminate and 142 in toluene
were refluxed for 16-20 hours. The reaction yielded a crude yellow oil which proved to

be solely unreacted starting material as evidenced by the presence of the ethyl peaks in
the ]H NMR at 81.27 and 84.05-4.25, and the lack of any benzylamide peaks. Mass
spectral analysis (Cf1") also clearly displayed the M+l peak of 142 at m/z 284
(Ci5H25N04).

To determine if the reaction conditions and reagents being used were effective, a model
reaction using freshly prepared sodium diethyldibenzylamidoaluminate and methyl
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phenylacetate 150 was undertaken (Scheme 5.17). The reaction provided an off-white
solid in 93% yield, and lR NMR analysis confirmed the benzylamide derivative to have

formed, with the loss of the methyl ester singlet peak at 83.70, and the presence of th
benzylamide NH singlet at 85.75, as well as an aromatic multiplet at 87.17-7.38, and a
methylene peak at 84.41/4.43. Mass spectral analysis (Cf") revealed an MH+ peak at m/z
226, consistent with the molecular formula of the newly formed derivative 151
(C15H15NO).

OCH3

•

U ,-} ^ N H C H 2 A ^ >

o o
150 151
Reagents and Conditions: sodium diethyldibenzylaminoaluminate, toluene:THF,
reflux, 1hr, 9 3 % yield

Scheme 5.17 Synthesis of benzylamide 151 using diethyldibenzylamidoaluminate

Without having yet achieved the desired derivative 139, it was decided to try a slightly
different reagent, dimethylaluminium benzylamide, as used by Basha et al. , to
attempt smooth amidation. Accordingly, to a solution of freshly prepared
dimethylaluminium benzylamide was added a solution of methyl ester 143 in
dichloromethane and the mixture heated at reflux (Scheme 5.18). JH NMR analysis of
the resultant product unfortunately revealed only starting material present, with no
amide formation having occurred.
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//

NHCH2Ph No Reaction

143

139

Reagents and Conditions: dimethylaluminium benzylamide, DCM, reflux, 20hrs

Scheme 5.18 Attempted synthesis of 139 using dimethylaluminium benzylamide

A return to the sodium diethyldibenzylamidoaluminate reagent was therefore made, and

its reaction with the methyl ester 143 was investigated. Having first-hand confirmation
that the amidation reaction works, using analogous reaction conditions to those
previously used (Scheme 5.16) 143 was refluxed with sodium
diethyldibenzylamidoaluminate (in a 20% excess) in toluene for a total of 60 hrs. The
reaction provided a 30% yield of 152 (Ci6Hi8N202) as a pale yellow oil, indicated by
mass spectral analysis (CI*) (m/z 271 (M+l)), and NMR spectroscopy. *H NMR

indicated loss of the ^-butyl group at 1.27 and the methyl ester at 83.70, and the addi
of the benzyl group by aromatic protons at 87.24-7.35, and the methylene protons at
84.59-4.71. The absence of the NH proton from the spectrum indicated that it had
i -j

become a tertiary nitrogen. The

C N M R spectrum further indicated the presence of

two keto groups (8159.8 and 8175.3), and the loss of the Boc C-0 at 879.5. It thus
appears that once the benzylamide had formed the nitrogen immediately attacked the
Boc group, leading to an intramolecular cyclisation and production of 152 (Scheme
5.19). It was apparent then that it would be necessary to investigate the synthesis of
benzylamide derivative 139 from the acid derivative 149.
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//
OMe
N
Boc O

143

N
J/"-N-CH2Ph
C(CH3)3

Reagents and Conditions: sodium diethyldibenzylamidoaluminate, toluene, reflux, 20hrs

Scheme 5.19 Intramolecular cyclisation to produce bicyclic spirolactam 152

5.5.3.2 Preparation of benzylamide 139 from acid 149

Acid derivative 149 was prepared readily from the methyl ester 143 via base hydrolysis
in high yield and purity (Scheme 5.20). Both the !H NMR and

13

C NMR spectra for 149

displayed the loss of the methyl ester peak at 81.43 and 8175.1 respectively. Mass

spectral (CI*) analysis revealed the MH+ ion of the acid at m/z 256, consistent with the
molecular formula (CoH^NC^).

Boc 0

Boc 0

143

149

Reagents and Conditions: 1M NaOH, THF, 80°C, 72hrs,
8 9 % yield.

Scheme 5.20 Preparation of Acid derivative 149.
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The synthesis of the benzylamide derivative 139 from 149 was initially undertaken
using the common method of dicylcohexylcarbodiimide (DCC) coupling285'300,
employing catalytic dimethylaminopyridine, DCC and benzylamine (Scheme 5.21).
DCC is a common reagent in peptide bond formation, assisting in the linkage of

carbonyl and amino functionalities. The reaction yielded a crude pale yellow oil, whi
from mass spectral analysis (CI*) (m/z 256, MH+ Ci3H2iN04) was shown to be the acid
149. Repeating the reaction with an increase in temperature failed to furnish any of
desired product (mass spectrum (CI+): expected m/z 345 (C2oH28N203)). Further

temperature increases upon the reaction, to refluxing in toluene overnight, again fai
to produce any of the desired amide 139.

N
i

Y°H
II

*

^N^/NHCH2Ph

No Reaction

i

Boc O

Boc O

149

139

Reagents and Conditions: benzylamine, DMAP, DCC, toluene 0°C-reflux.

Scheme 5.21 Attempted preparation of 139 via DCC coupling

1-Hydroxybenzotriazole (HOBt) m a y aid in the formation of amide bonds. It was

decided to first investigate if a procedure utilising this reagent would effect amide
coupling with the un-substituted derivative 126 (Scheme 5.22). Accordingly, 126 was
treated with benzylamine, HOBT, triethylamine and DCC in chloroform at room
temperature. The desired product 153 was afforded as a UV-fluorescing white solid in

67%o yield. ]H NMR analysis revealed the benzylamide protons as a multiplet at 87.257.32 (aromatic protons), and a multiplet at 84.22-4.57 (methylene protons). The NH
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proton was not observed. The 1 3 C N M R displayed the aromatic carbons at 8127.4-128.6,
and the slight upfield shift of the acid carbonyl of 126 from 8180.5 to the amide
carbonyl of 153 at 8174.0. Mass spectral analysis of 153 (CI4) indicated an MH+ ion at
m/z 305, supporting the molecular formula Ci7H24N203.

N Y 0^
Boc O
126

3

*

\X/ N H C H 2Ph
Boc 6
153

b C

' »

t|

I

NHCH;,Ph

Boc O

139

Reagents and Conditions: a) benzylamine, HOBt, NEt3, DCC, CHCI 3 , 6 7 % yield;
b) LDA, THF, -78°C; c) allylbromide, THF, -78°C - -30°C, 1 0 % yield.

Scheme 5.22 Successful preparation of the proline benzylamide 139

With this method proving successful, and with the benzylamide derivative in hand, it
was decided to attempt allylation of 153 in the a-position with allyl bromide (Scheme

5.22). If successful, this would provide the desired derivative 139 in only 3 steps fro
the L-proline starting material, in comparison to the 5 steps needed in the synthesis

going via the ester derivative 143. Therefore, a solution of 153 (amide) was treated wi
freshly prepared lithium diisopropylamine (1.5 equivalents) followed by allyl bromide.
The crude product was extracted as a cream solid, and JH NMR analysis indicated a
mixture of mainly starting material with a small amount (10%) of desired allylated
product 139, represented by a multiplet at 85.65 (=CH), 85.14 (=CH2) and 82.61 (CH2).
Mass spectral (CI4) analysis displayed an MH+ peak at m/z 305 (153, C17H24N2O3) and
345 (C20H28N2O3, 10%) representative of 139.
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Given the low yield of this reaction, it was decided to return to amidation procedures
with the already allylated acid derivative 149.

Using the successful HOBt/DCC coupling method, allyl derivative 149 was treated with
equivalent amounts of benzylamine, HOBt, triethylamine and DCC at room
temperature, yielding the desired product 139 as a white solid in 95% yield. Mass
spectral (CI4) analysis confirmed the identity of 139 via the presence of an MH4 ion at
m/z 345 (C2oH28N2C<3). The !H NMR spectrum clearly displayed the methylene protons
of the benzyl substituent at 84.34-4.52, the aromatic protons at 87.28 and the amide NH
at 82.98-3.10. The 13C NMR displayed the shift of the carbonyl peak from 8180.5 for
the acid to 8173.8 for the amide derivative.

/

,NHCH2Ph

9^

149 139
Reagents and Conditions: benzylamine, HOBt, NEt3, DCC, CHCI3,
RT, 16 hrs, 95% yield.

Scheme 5.23 High yield preparation of benzylamide derivative 139

5.5.4 Palladium-assisted cyclisation of benzylamide derivative 139 to form spirocycles

It was aimed to facilitate intramolecular cyclisation of 139 by utilising the double bond

of the allyl side chain. By rendering the double bond electron deficient, the lone pair o
electrons on the tertiary nitrogen atom may interact with and form a bond with the
methine carbon atom, producing the desired 5-membered spirocycle. Alternatively,
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intramolecular 5-exo-trig radical cyclisation from a nitrogen-centred radical m a y also
effect the desired cyclisation.

5.5.4.1 Introduction

Transition metal organometallic reagents have been used extensively in the synthesis of
heterocyclic compounds (for reviews of work in this area see Hegedus " ). Palladium
(II) has frequently been used to activate simple carbon-carbon double bonds to undergo
attack by a variety of nucleophiles311. Many nucleophiles, including acetate, chloride
and alkoxide, as well as alcohols and amines312 have been reacted with Pd (II)
complexed olefins. Intramolecular adaptations of this reaction have provided effective
methods for synthesising heterocycles. For example, 2-allylphenols have been
converted to benzofurans313, 2-allylamines to indoles314, ^^-unsaturated ketoximes to
isoxazoles315, o-hydroxychalcones to flavones316, and a,p\y,8-unsaturated carboxylic
acids to pyrones317 by treatment with a form of Pd(II) and base to generate a
nucleophilic heteroatom.

Hegedus and coworkers310'311'314'318"320 extensively investigated the role of Pd(II) in the
synthesis of heterocycles, particularly via olefin complexation. They have used
palladium-assisted cyclisation in the synthesis of functionalised heterocycles ' ' ,
including indoles314,320 and isocoumarins321, dihydroisocoumarins and isoquinolines311.
Most of this work employed the use of olefins as both intermolecular and intramolecular
reaction points. Treatment of a number of 2-allylbenzoic acids (such as 154) with
PdCl2(CH3CN)2 and Na2CC>3 in THF led to production of 2-alkylisocoumarins such as
155 in high yield via nucleophilic attack of a carboxylate on the Pd-complexed olefin
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(Scheme 5.24). The reaction was thought to proceed via "co-ordination of the olefin to

Pd(II), generation of the free carboxylate by sodium carbonate, attack of carboxylate on
Pd(II) complexed olefin to produce ring closure and a a-alkyl palladium complex,
followed by elimination of PdH and rearrangement to the observed isocoumarin"311.

COOH

+

PdCl,

2-allylbenzoic acid
154

155

-PdH"

O^. X)

Na2C03
C|A'pd-CIH

I I

Scheme 5.24 Synthesis of 2-alkylisocoumarins

Similar mechanisms have been proposed for the formation of indoles from 2allylanilines314 and benzofurans from 2-allylphenols313. The cyclisation was also made
catalytic with respect to palladium by the addition of cupric acetate and 02 to provide

means for oxidation of the Pd(0) produced in the cyclisation step. This catalytic method
was further developed in subsequent work

310,320

This method was also used for the intramolecular cyclisation of some amide derivatives:
in particular 2-(2-propenyl)benzamide to 3-methylisocarbostyril (Scheme 5.25) and 2(2-propenyl)-Af-methylbenzamide to 3-methyl-A^-methylisoquinoline, by treatment with
PdCl2(CH3CN)2 and sodium hydride in THF311.
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o

OH

2-(2-propenyl)benzamide

/^/\^- PdCI2(CH3CN)2,
|
I

K^K^NHUe

3-methylisocarbostyril

NaH, THF

-

Pd(0)

O O
2-(2-propenyl)-A/-methylbenzamide 3-methyl-A/-methylisoquinoline

Scheme 5.25 Palladium-mediated intramolecular cyclisation of aromatic amide derivatives

The functional group similarity between the allyl and amide reacting groups of 2-(2propenyl)benzamide and 2-(2-propenyl)-iV-methylbenzamide, and the

allylprolinebenzylamide derivative 139 suggested that intramolecular cyclisation of 139

may be achievable using this olefin-Pd complex methodology. Investigations thus began
into the cyclisation of 139 using PdCl2(CH3CN)2 and sodium hydride in THF.

5.5.4.2 Attempts at palladium assisted cyclisation of 139

Initial investigations into the Pd-assisted cyclisation of 139 utilised the method of K
et al3U. Thus, 139, PdCl2(CH3CN)2 and sodium hydride were stirred in THF at room
temperature (Scheme 5.26). The reaction yielded a crude mixture which ]H NMR
spectroscopic analysis revealed to be mainly 139, with the allylic protons being
acscribed to the peaks at 85.64 (1H, dddd, =CH) and 85.14 (2H, dd, =CH2). The
reaction was attempted a second time utilising the same reaction conditions. TLC

analysis indicated no 139 remaining and the formation of two new products, one on the
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baseline, the other just above the baseline. !H NMR analysis suggested a 1:1 mixture of
cyclized product 139 (peak for the methyl substituent at 81.26 (1.5H, s, C H 3 ) and the

vinyl proton at 85.54 (0.5H, t, J= 2.4, =CH)) and allylated 139 (allyl protons present
85.58-5.72 (0.5H, m, =CH), 85.15 (1H, dd, J- 7.5, 9.3, =CH2). The altered TLC Rf
suggested perhaps a palladium complex of 139. Mass spectral analysis (CI4) of the
reaction mixture revealed ions at m/z 345 ( M H 4 , 139), 346, 343 ( M H 4 , 156), 289
(fragment of 139), 287 (fragment of 156).

NHCH2Ph

NCH 2 Ph

f^Y
Boc O

NHCH 2 Ph
Bor. O

139 156 139
Reagents and Conditions: PdCI2.CH3CN, NaH, THF,
RT-reflux, 1-10 days

Scheme 5.26 Attempted cyclisation of 139 using PdCl2(CH3CN)2 and sodium hydride.

Repeating the reaction at 40°C for 4 days again failed to furnish any of the desired
product, mass spectral (CI4) analysis revealing only a loss of the Boc protecting group
as indicated by a peak at m/z 273 (Ci7Hi 9 N 2 0 2 ). Increasing the reaction temperature to
55°C (5 days stirring) still failed to furnish the desired product 156, and a further
increase to reflux for 5 days produced a crude mixture which mass spectral (CI4)
analysis revealed to contain only fragments of 149 at m/z 345 ( M H ), 289, 245.

Subsequent modifications by Hegedus et al. to their initial methodology have been
made in the case of different substrates. In their synthesis of indoles utilising olefm-Pd
"X\r\

complex cyclisation of amines

they found that addition of triethylamine to the

reaction was necessary for the formation of any indole. They also noted that with the
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simple allyl side chain, cyclisation produced only indoles from attack at the secondary
carbon chain of the olefins. This fits in with our requirement for cyclisation via attack at
the secondary olefin carbon, and the subsequent production of a 5-membered ring. It
was thus decided to try the triethylamine reaction system, and see if this would furnish
any of the desired spirocycle 156.

Accordingly, as outlined in Scheme 5.27, to a slurry of PdCl2(CH3CN)2 in THF was
added 139 and sodium hydride. Triethylamine was added at hourly intervals, and
immediately produced a deep cherry red, homogenous solution which began to deposit
-3 1 A

metallic palladium

, and yielded a crude yellow oil. T L C analysis revealed baseline

product which suggested the compound was still palladium-complexed. Mass spectral
(CI4) analysis of the reaction mixture revealed ions at m/z 343 ((MH4,156 C2oH26N203),
345 (MH4, 139) suggesting the presence of some cyclized product 156. A clean sample
of 156 could not be isolated.

a, b, c
NHCH 2 Ph

NCH 2 Ph
Boc 0

139

156

139

Reagents and Conditions: a) PdCI 2 .CH 3 CN (1 mol eq.), THF, NaH (1.65 mol eq.), RT, 1.5 hrs;
b) Et3N (3 mol eq.), 4-5 hrs; c) RT, O/N.

S c h e m e 5.27 Cyclisation of 139 using P d C l 2 ( C H 3 C N ) 2 , sodium hydride and triethylamine.

T h e reaction w a s repeated at a higher temperature (50°C, 2 days) to try to force the
cyclisation, but without the use of sodium hydride (Scheme 5.28). Mass spectral (CI4)
analysis showed the presence of peaks at m/z 343 (C20H26N2O3, MH4), corresponding to
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the desired product 156, as well as m/z 305, 287, 343, and 156 was isolated in a 3 0 %

yield. The newly formed methyl substituent of the spirocyclic derivative was seen in t
!

H NMR as a singlet at 81.24 (13C NMR 823.8), and the single vinyl peak also as a

singlet at 85.29 (13C NMR 8130.9). The NH proton of the benzylamide precursor was
absent from the !H NMR (82.98-3.10). High resolution mass spectral analysis (EI4)
confirmed the molecular formula of 156 as C20H26N2O3. Attempts to improve this
reaction yield increased reaction temperatures (to refluxing) and reaction times, but
not achieved.

y Y NHCh2Ph —~~~—" -v NCH?Ph
Boc 0

139

156

Reagents and Conditions: a) PdCI2.CH3CN (1 mol eq.), THF, RT, 1.5 hrs;
b) Et3N (3 mol eq.), 4-5 hrs; c) RT, 50 h.

Scheme 5.28 Cyclisation of 139 using PdCl 2 (CH 3 CN) and triethylamine

Given the efficiency which Hegedus et al.

had achieved in these reactions (yields up

to 85%>) it appeared that conformational restriction of the amide bond might be a
problem. Given the structural nature of our amide derivative 139, containing a fixed
quaternary carbon and a rotationally hindered carbonyl, it may be that the

conformational restriction of the molecule is such that cyclisation is too unfavourabl

achieve more than a 30% yield. The steric bulk of the phenyl ring may add to this effect
In comparison, the planar nature of the benzamide derivative (157) used310 lends itself
to cyclisation. Additionally, the hindered rotation of the amide carbonyl may in fact
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improve the structural conformation of the molecule for attack of the olefin by the
nitrogen.

A /NHCH2Ph
NHCH
Boc 0
O
157 139

The conformational factors involved in hindering the cyclisation of 139 were
investigated using molecular modelling with the Spartan program. The lowest energy
conformers of 139 are such that cyclisation between the amide and the double bond is
highly unfavoured, as can be clearly seen in Figure 5.4a, where the two functionalities
are pointing away from each other. The rotational hindrance about the amide C-N bond
in 139 means the nitrogen atom has less potential for interacting with the allyl double
bond. Indeed, to achieve a conformation which is favourable for cyclisation (conformer
69), where the nitrogen and allyl methine are pointing toward one another, an energy

increase of 7.04kcal/mol is required (see Figure 5.4b, Table 5.2). Additionally, the lo
energy conformers of 139 favour hydrogen-bonding occurring between the Boc C=0
and N-H, holding the nitrogen down and away from the allyl double bond. This makes
o

the N to C = C distance of 4.41 A too far for intramolecular interaction and hinders
cyclisation (Table 5.2). It should be noted however that with sodium hydride present in
the reaction, amide ion formation would be possible thus negating this H-bond
stabilisation. It was thus suprising that the cyclisation reactions employing sodium
hydride were not successful. The most favourable conformer of 139 for cyclisation is
conformer 87, which has the smallest distance from N to C=C of 3.17A (Table 5.2).
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This is also one of the highest energy conformers, with a relative energy of
8.61 kcal/mol.

Figure 5.4a Spartan Molecular Model of lowest energy conformer of 139; note H-bond
o

o

interaction (NH to C=0 distance = 1.80A) and hindered rotation; distance N to C=C = 4.4

Figure 5.4b Spartan Molecular Model of conformer 69 of 139, the lowest energy conformer
favourable for cyclisation: there is no H-bond interaction between the Boc C=0 and the N
o

the distance from N to C = is 3.24A allowing for intramolecular interaction; a higher energy of
7.42kcal/mol is required for this conformation.
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5.6 Revised Synthetic Strategy

With the cyclisation of benzylamide derivative 139 proving to be low yielding, the next
alternative appeared to be reduction of the amide functionality and cyclisation of the
more freely rotating resultant benzylamine derivative. Reduction of the benzylamide
carbonyl functionality would remove the amide rotamer problem and allow the nitrogen

atom to interact with the allyl double bond. Although there is still potential for hydr
bonding between the carbamate carbonyl oxygen and the N-H in 158, the free rotation
in the amide sidechain of 158 allows for interaction between the N-H and the allyl
double bond, and resulting cyclisation (Figure 5.5). Surprisingly, the energy of the
lowest energy conformer was higher than that of the amide derivative 139 (see Table
5.2).

Figure 5.5 Conformer 61 of amine 158 (relative energy = 5.05kcal/mol); the amine is free of
o

hindered rotation and the N is in a good position to interact with the C=C (distance =
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Table 5.2 Important intramolecular distances and energies for cyclisation precursors
Derivative

N - H to C = 0

distance (A)

distance (A)

Energy
(kcal/mol)

139 (conf. 1)

4.41

1.80

0.38

0.00

139 (conf. 69)

3.24

4.75

7.41

7.04

139 (conf. 87)

3.17

6.17

8.99

8.61

158 (conf. 61)

3.22

-

25.99

5.05

N to C = C

o

o

Relative Energy
(kcal/mol)

A revised synthetic outline for entry to the desired spirocyclic derivative 18 thus
incorporated reduction of amide 158 before effecting palladium-assisted cyclisation,
Grignard reaction, reduction and deprotection as shown in Scheme 5.29.

NHCH 2 Ph

NCH2Ph

NHCH 2 Ph
N
i

Boc

139

158

18

Scheme 5.29 Revised synthetic procedure for cyclisation preparation of 18

5.6.1 Reduction of benzylamide 139

In considering methods for the reduction of the amide functionality to the desired
amine, it must be remembered that both the Boc group and the allyl group may be
sensitive to many reduction agents. For this reason, a selective amide reducing agent
was required. Such reagents include diborane321"324 and lithium aluminium hydride32
328

. Diborane proved to be highly reactive towards the Boc carbamate in refluxing THF,

reducing it to the unprotected derivative 159 (Scheme 5.30). Evidence for the formation
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of 159 included the loss of the entire Boc group from both the J H N M R spectrum (81.34
(3 x CH3)) and the

13

C NMR spectrum (8155.0 (C=0), 880.5 ((CH3)3CO), 828.3 (3 x

CH3)), and the presence in the spectra of the remaining amide carbonyl at 8176.5 (
NMR) and the new NH proton at 82.31 (!H NMR). Mass spectral (CI4) analysis of the
product supported the formation of 159 (Ci5H20N2O) via a molecular ion peak at m/z
245.

(NA.NHCH2Ph OC^NHCH.Ph

oV "

H

°
C(CH 3 ) 3
139

159

Reagents and Conditions: diborane, THF, 0°C, reflux 2hrs.

Scheme 5.30 Carbamate Reduction of 139 using diborane

Lithium aluminium hydride has been used to reduce amides to amines, and is reporte

to be unreactive towards carbamates. It was therefore desired to attempt reductio
benzylamide 139 using lithium aluminium hydride. Accordingly, a solution of 139

(amide) was treated with a solution of lithium aluminium hydride (3 molar equival

in THF (Scheme 5.31). After refluxing for 2 hours, the resultant yellow oil was sh

to be the unprotected amine 160, with the complete loss of the Boc group accompan

reduction of the amide functionality. This was evidenced by the loss of all the Bo
peaks in the !H NMR (9H, s, 81.34, (CH3)3), and the 13C NMR (828.3 (3 x CH3), 8155.0

(C=0), 880.5 ((CH3)3CO)), as well as the amide carbonyl peak at 8173.8). The peak fo
the additional NH proton was evident in the *H NMR at 82.46. The newly formed
methylene from the amide reduction was evidenced at 82.24 in the !H NMR and 864.3
169
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in the C N M R . Mass spectral analysis (CI4) of 160 confirmed the identity of the newly
formed derivative as Ci5H20N2O via a peak at m/z 229 (M, 100%).

//

A

N

,NHCH2Ph

y

Boc 0
139

r^J

ry„ur
H

160 8 4 % yield

Reagents and Conditions: 1M LiAIH4/THF (3eq.), 0°C, reflux 2hrs.

Scheme 5.31 Attempted reduction of 139 using LiAlH4

A second attempt at lithium aluminium hydride reduction of the amide carbonyl reduced

the amount of lithium aluminium hydride in THF (1 molar equivalent) to try to contain
reduction to the cabonyl group only (Scheme 5.32). However, upon XH NMR analysis

of the product it was found that it was in fact the bicyclic derivative 161 which ha
formed, and not amine 160. This was evidenced by the loss in the lH NMR spectra of
the tert-buty\ peak at 81.34, yet the presence in the 13C NMR of a urea carbonyl peak
downfield at 8163.3. Instead of the expected newly formed methylene peak seen in the
!

H NMR, it was a methine proton singlet at 84.63. Additionally, the newly formed

tertiary carbon (established by DEPT NMR analysis) was seen at 882.6 in the 13C NMR.
This unexpected derivative 161 was confirmed by mass spectral (CI4) analysis, which
displayed an MH4 peak at m/z 273 (100%), consistent with the molecular formula
Ci6H2oN02, which was confirmed by high resolution mass spectral (CI4) analysis.
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f/

9
0

^ V ^
^
Boc 0 Wuru

Dh

//

W\,OH

W(>OH

^

^

W
NHCH2Ph

NHCH2Ph

139
161a 17% yield
161b 63% yield
Reagents and Conditions: 1M LiAIH4/THF (1eq.), 0°C, reflux 2hrs.

Scheme 5.32 Preparation of bicyclic diastereomers 161a and 161b via reduction of 139; relative
stereochemistry shown.

The newly formed tertiary carbon in 161 is also a stereogenic centre, and thus with the
other stereogenic centre at the ring fusion point, can give rise to cis and trans
diastereomers. The two diastereomers were easily separated via chromatography on
silica gel. The less polar crystalline product was identified by X-ray crystallography
(Professor A.H. White; University of Western Australia) to be the trans diastereomer
161a, as shown in Figure 5.6a, with the allyl side chain and the hydroxyl functionality
cis to one another and the benzylamide functionality in the ring. The other oily product
appeared to be the cis diastereomer 161b, with the allyl side chain and the hydroxyl

functionality trans to one another, on the basis of a very similar series of chemical shif
and multiplicities in the ]H NMR spectra. The main difference was that whilst the H3
proton on the proline ring of 161b resonated at 81.57, in 161a this proton resonated
upfield at 81.04-1.12. Additionally, whilst the peak of the NH proton of 161b was seen
at 83.03-3.15, in 161a it was downfield at 84.46. High resolution mass spectral analysis
(CI4) of both diastereomers 161a and 161b confirmed their molecular formula as
C16H20NO2.
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The diastereomers were characterised with the assistance of g H M B C (Appendix) and
NOESY ID (Figure 5.6b, 5.6c) NMR analysis. Upon irradiation of the methine CH
proton at 84.63, NOESY ID analysis of 161a indicated NOE interactions between this
proton and one of the benzyl protons at 84.13, the =CH methine proton at 85.82-5.94
and H3 at 81.04-1.12 (Figure 5.6b). This supports the methine proton being in a trans

arrangement to the allyl side chain, as is the case in 161a. Irradiation of the methin

proton at 84.70 in 161b indicated a NOE interaction between this proton and one of the
benzyl protons at 84.13, and the CH2 protons of the allyl side chain at 82.20 (Figure
5.6c). Further irradiation of the =CH proton of 161b displayed NOE interactions

between it and the methine proton at 84.70, as well as the other allyl protons: =CH2 at
84.98 and CH2 at 82.20 (Figure 5.6d). This data supports the methine proton and the
allyl proton residing cis to each other, as is the case in 161b.

Figure 5.6a X-ray structure of the trans diastereomer 161a.
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Figure 5.6b N O E S Y ID N M R spectrum of 161a: irradiation of the C H proton at 54.63
indicates NOE interactions with the allyl methine =CH, the H3 protons, and one benzyl C

CH
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Figure 5.6c N O E S Y ID N M R spectrum of 161b: irradiation of the C H proton at 84.70
indicates NOE interactions with one benzyl CH proton at 64.13 and the allyl CH2 proton
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Figure 5.6d N O E S Y ID N M R spectrum of 161b: irradiation of the allyl = C H proton at 85.65
indicates NOE interactions with the allyl CH2 protons, the =CH2 protons and the CH at 84.
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The trans diastereomer 161a shown in Figure 5.6a should easily be cyclized to produce
the spiro derivative 162, whereas the cis diastereomer 161b is conformationally
restricted and would not be expected to undergo cyclisation due to high levels of ring
strain.

5.6.2 Palladium-catalysed intramolecular cyclisation of 161b

Before the true structural identity of 161b (cis) was known, it had been cyclised using
PdCl2(CH3CN)2 and triethylamine at room temperature by the method previously used
(as shown in Scheme 5.33), to yield the 6-membered ring derivative 163. For 161b to

have formed it was first necessary for it to isomerise to the other diastereomer, befo
undergoing palladium-catalysed cyclisation. That 163 was the 6-membered ring

derivative was evidenced by the presence of an additional methylene peak (2H, s, 82.48)
in the lH NMR spectrum (836.2 in the 13C NMR spectrum, confirmed via DEPT
analysis) rather than the expected methyl peak of the five-membered ring 162 at 82.00.
That this methylene singlet represented a cyclic CH2 of 163 rather than an exocyclic

=CH2 of the intermediate 164 is indicated by its upfield position. This upfield chemic
shift of the methylene singlet also indicates that the double bond resides in the enol
ether position. Additionally, whereas the exocyclic =CH2 would reside downfield at
approximately 8107, and the accompanying quaternary C= at approximately 8150, the

(Z)

JNR)X h

(sy)
NHCH2Ph
J

o

l(R)

N (sA
L_NHCH

Pn

o
162

164
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additional methylene carbon in question is seen at 836.2 in the 13/C N M R spectrum, and
there are n o n e w quaternary carbons present.

5^( >OH
N

(RJy
J
NHCH 2 Ph

PdCI2(CH3CN)2
•
Et3N, THF, RT, 5 h

(R) ,
ix,

\..^0

N (Sy~
X NHCH2Ph

161b

163
PdH

(CNCH3)2

-< > X,
R

Pd-CI

JH

N (S)]
X
NHCH2Ph

SJR> r
vrA.^O
N

(s;y

X NHCH2Ph

Scheme 5.33 Cyclisation to yield 163 using PdCl 2 (CH 3 CN) and triethylamine

It appeared then that at r o o m temperature cyclisation conditions furnished the 6-endo-

trig cyclisation product 163. With this indication, the reaction was repeated under reflux
conditions, in an attempt to yield the 5-exo-trig spirocycle 162. The product of the
reaction displayed a molecular ion at m/z 271 in the mass spectrum (CI4), which was
confirmed by high resolution mass spectrometry (CI4) to be representative of the
molecular formula Ci6Hi8N202, suggestive of desired derivative 162 (Ci6Hi8N202).
Indeed the !H NMR displayed a methyl singlet at 82.00, suggestive of 5-exo-trig
cyclisation. However, the 13C NMR contained a carbonyl peak downfield at 8195 which
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could not be assigned to the 5-exo-trig spirocycle 162, and the identity of the carbon
adjacent to the nitrogen in the pyrrolidine ring (C2) as a methine carbon (DEPT
analysis) indicated that the spirocycle had not formed.

Further extensive NMR analysis, including HMBC and 15N HMBC experiments

(kindly undertaken by Dr. Brent Copp at the University of Auckland), revealed that th
most likely structure for the product of the cyclisation reaction was that of 165.

//
fRj

(
A OH
UfRff
^~NHCH2Ph

PdCI2(CH3CN)2
•

H
^

Et3N, THF, reflux

NHCH2Ph

0
161b

165

Scheme 5.34 Cyclisation of 161b yields 165.

The H M B C experiments undertaken indicated that the carbonyl signal at 8195 in the
carbon NMR spectrum displayed interactions with the singlet representative of the

methyl substituent at 82.00, and some of the pyrrolidine methylene protons (81.93-2.08
and 82.63). The singlet at 85.57 in the !H NMR spectrum, ascribed to a =CH proton,
displayed HMBC interactions with the peaks representative of the carbonyl at 8195.5,
the quaternary carbon at 8156.8 (NC=) and the methine proton at 864.3. The HMBC

spectrum did not indicate that the bicyclic parent structure of 161b had been altered.

The 15N HMBC experimental data of the product 165 indicated interactions of the 15N
peak at 8103, ascribed to that of the pyrrolidine nitrogen, with the methine doublet

(84.82), and the methylene protons of the pyrrolidine ring (83.19, 83.62, 82.63, 82.08).
The other 15N peak at 8132, ascribed to that of the benzyl nitrogen, indicated
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interactions with only the benzyl protons (84.60) and the methine proton represented
the peak at 85.37. This data confirms that the bicyclic parent structure of 161b was
indeed present in 165, and supports the structure of 165 as shown. The gCOSY, HMBC,
15

N NMBC spectra is given in the appendix.

Figure 5.7a indicates the JH and 13C assignments for the derivative 165, as assigned by
the Chemdraw program; these chemical shifts do not agree entirely with that obtained
from the product 165. A three-dimensional representation of the structure of 165 is
given in Figure 5.7b (courtesy of Dr. Brent Copp).

Due to time restrictions, the further investigation into the mechanism of this reacti
and the completion of the synthesis of the spirocyclic target ligand 18 could not be
completed.

126.5

Figure 5.7a: J H N M R and 1 3 C N M R chemical shifts assigned by C h e m d r a w for 165
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Figure 5.7b: Three-dimensional representation of the structure of 165
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6.1 Introduction and Design Rationale

To further extend the range of target ligands, a new set of derivatives which incorporated
varied conformations of the adrenaline motif were designed. With a view to increasing the

rigidity of the motif, particularly in the positioning of the nitrogen and the aromatic rin

these proposed new derivatives contained spiro[isobenzofiiranl structures. Specifically, th

new set of target ligands were based upon spiro[isobenzofuran-l(3//), 3'-pyrrolidine] (166)
and spiro[isobenzofiiran-l(3//),3'-piperidinel (167).

Adrenaline motif

166

167

Figure 6.1 Spirofisobenzofuran] target ligands based upon a constrained adrenaline motif

These molecules mimic the adrenaline motif (Figure 6.1), retaining the oxygenated-amine
sidechain function (B, C and D) within the two spirocycles. The use of both piperidine and
pyrrolidine rings as the nitrogen source would provide slightly different geometrical
environments for the ionisable nitrogen and thus for the motif as a whole.

Additional target ligands to be incorporated in the spiro[isobenzofuranl set included the N

methyl 3'-pyrrolidine (168) and 3'-piperidine (169) derivatives, as well as the 4'-piperid
(170), N-methyl-4'-piperidine (171), 2'-pyrrolidine (172) and JV-methyl-2'-pyrrolidine
(173) derivatives, as well as catechol derivatives 19 and 20. The 2'-piperidine and N180
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methyl-2'-piperidine derivatives will not be assessed because the 2-piperidinone precursor
required was not commercially available. The addition of TV-methyl substituents mimics the

adrenaline TV-methyl, and will provide information on the effect of alkyl substitution on the
nitrogen. Positioning the nitrogen one carbon closer to or one carbon further from the aryl

ring will indicate structure-activity relationships specifically between the ionisable nitro
and the aryl ring. We could thus evaluate the tolerance of the length of the carbon chain,
and whether this tolerance is related to or independent of the conformation of the molecule.

XH3

170

169

168

171

173

172

19

20

181
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To investigate structural aspects of the proposed ligands more clearly, conformational
molecular modelling was undertaken using CATALYST®. The rigidity of these ligands is
reflected in the lower number of conformers each one was able to generate within the
20kcal/mol energy range, as shown in Table 6.1.

Table 6.1 Conformational data for the spiro[isobenzofuran] target ligands

Derivative

Conformers

Energy Range
(kcal/mol)

Derivative

Conformers

Energy Range
(kcal/mol)

166

11

17.366

167

11

16.432

168

8

18.241

169

11

18.204

19

9

18.715

20

10

18.488

172

7

14.559

170

9

17.754

173

6

16.296

171

14

17.400

Representative conformers of 19 and 20 in their most folded arrangements are shown in

Figure 6.2. There is only a small difference in the number of conformations accessible with
the pyrrolidine and piperidine ring derivatives. The presence of either an A^-methyl
substituent or diphenolic substituents appears to have little effect on conformation.
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Figure 6.2 Conformers of 19 (left) (conformer 9, 18.715kcal/mol) and 20 (right) (conformer 7,
17.670kcal/mol).

H o w then do these derivativesfitonto the pharmacophore model? Initial pharmacophores
(WT1 and Mul, see Chapter Two) predicted some of the spiro[isobenzofuran] derivatives
10R

to have remarkable selectivity for the Cys

Phe OCIB A R (Table 6.2). This trend was also

seen in the WT2 and Mu2 pharmacophores. As can be seen in Table 6.2, the majority of
these ligands only map two of the Cys Phe CCIB AR pharmacophore (Mu2) features: the

positive ionisable nitrogen and the HBA (represented by the oxygen of the furan ring). I
contrast to this, they generally map three of the WT ctiB AR pharmacophore (WT2)
features. The mappings on to the WT2 and Mu2 pharmacophores of selected target ligands

are shown in Figures 6.3a-d. This indicated that this class of derivatives would not pr
a suitable paradigm for our model of folded adrenaline mimics. Despite this fact, these

ligands are still of interest for obtaining biological data (experimental affinities) a
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testing our pharmacophore predictions, and building a larger training set for next generation
pharmacophore development.

Table 6.2 Predicted binding affinities and selectivities of the spirofisobenzofuran] target ligands 19,
20,166-173 upon the wild-type ( W T ) and Cys 128 Phe mutant (Mu) pharmacophores.

Derivative

WT Pharmacophore
Affinity*

Features

CysmPhe Pharmacophore
Affinity*

Features

mapped*
WTl

166

WT2

on WT2

Selectivity
(for mutant
over WT)

mapped*
Mul

Mu2

on Mu2

4200

2

1

2

10

20

97000

3

168

96000

3

4100

2

20

172

490000

2

10000

2

50

173

500000

2

13000

2

40

19

560000 630000

2

2200

4100

2

260

150

71000

3

2600

3500

2

10

20

169

44000

3

3500

2

10

170

25000

3

1900

3

10

171

34000

3

5600

3

10

3100

2

26000

167

21000

20

2

2900000 520000
#

2200

3300

880

170

+

*K; (nM) Ofa total of 4 features Ofa total of 3 features
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Figure 6.3a 166 mapped on W T a i B A R Pharmacophore ( W T 2 ) , displaying interactions with three of the four
proposed binding regions; mesh spheres represent location constraints (where the feature should be in space);
Hydrophobic refers to a hydrophobic bonding region; positive ionisable refers to a positive charge feature
which interacts with a negative charge on the receptor protein; HBA refers to a hydrogen bond acceptor
region. In the HBA region, the smaller sphere represents the interacting feature of the ligand, and the larger
one represents the interacting feature of the protein.

Figure 6.3b 166 mapped on Cys 1 2 8 Phe ai B A R Pharmacophore ( M u 2 ) displaying interactions with two of the
three four proposed binding regions; mesh spheres represent location constraints (where the feature should be
in space); Ring aromatic refers to an aromatic bonding region, the second unmapped sphere represents the
interacting pi system in the protein; positive ionisable refers to a positive charge feature which interacts with a
negative charge on the receptor protein; HBA refers to a hydrogen bond acceptor region. In the HBA region,
the smaller sphere represents the interacting feature of the ligand, and the larger one represents the interacting
feature of the protein.
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Figure 6.3c 171 mapped on W T a 1 B A R Pharmacophore (WT2), interacting with three of the four bonding
regions. For identification of the coloured spheres, see Figure 6.3a.

Figure 6.3d 171 mapped on Cys 128 Phe a ] B A R Pharmacophore (Mu2) interacting with two of the three
bonding regions. For identification of the coloured spheres, see Figure 6.3b.
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6.2 General Therapeutic Uses for Spiro[isobenzofurans]

There are no accounts in the literature on bioactivity studies of spiro [isobenzofuran-

1(37-0,3'-pyrrolidines] or spiro[isobenzofuran-l(377),2'-pyrrolidines] such as target ligan
166 and 172. However, there is an abundance of spiro[isobenzofuran-l(377),3'-piperidine]and spiro[isobenzofuran-l(377),4'-piperidine]- based ligands which have been prepared for
potential therapeutic use.

C o m p o u n d s such as 174 have been prepared as modulators of N P Y 5 receptor activity,
useful in the treatment of a variety of disorders including obesity, bulimia, psychiatric
ion _

disorders, diabetes and hypertension

. Spiro-fused piperidines such as 175 have been

developed as antagonists of the orphanin FQ receptor, useful for the treatment of a number

of diverse disorders, including memory and attention deficits, anxiety, stress, depression,

/ri>~H
174

176

175

R = OH, NH2, N02, ON,
CONH2, H, halogen

N-C—(—Me
NH2

NT .Ph

177

178

187
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dementias, epilepsy, convulsions, pain, drug withdrawal, control of water balance, N a

excretion and arterial blood pressure disorders, and metabolic disorders such as obesity
The compound YM-35375 (176)331 displays antagonistic binding to both the NK2 receptor
(IC50 84nM) and NK1 receptor (IC50 710nM). It was used as a lead compound in the
development of the more potent NK2 receptor antagonist332 YM-38336 (177), which shows
10 times more potent NK2 receptor binding affinity. Spiro piperidines such as 178 have

been reported to promote the release of growth hormone in humans, and are of potential us

for the treatment of physiological or medical conditions characterized by a deficiency in
333

growth hormone secretion .

179
R = Me, Bu, aryl
R1 = H, MeO
R2 = H, F, MeO

180
R = Me, Bu, aryl

181

182

R = H,Me

Substituted l,3-dihydrospiro[isobenzofurans] such as 179 and 180 have been reported as

effective tranquilisers and analgesics3343. The compound 181 was developed as a potential
nervous system agent, inhibiting tetrabenazine-induced depression in mice with an50ED
comparable to that of omipramine and desmethylimipramine
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Potent affinity of spiro[isobenzofuran-l(3H),4'-piperidine] derivatives at the al and o 2
receptor binding sites has been achieved with 182, which displays ICsoOrl) of 17nM and
IC5o(o2) of 0.12nM . This ligand also displays affinity for serotonin 5-HTIA (IC50 =
21000nM) and 5-HT2A (IC50 = 2000nM), dopamine D2 (IC50 = 800nM) and, interestingly,
at adrenergic OCIA (IC50 = 330nM) receptors.

6.3 Synthetic Methodologies for the Preparation of Spiro [isobenzofurans]

6.3.1 Previous syntheses of spiro [isobenzofuran-piperidines]

Preparations of spiro[isobenzofuran-l(377),3'-piperidines]336 similar to the target ligand
we wished to prepare have been described in the literature. Both 3-substituted and 4substituted spiro [isobenzofuran-piperidines] have been prepared by Marxer et al. , as

outlined in Schemes 6.1 and 6.2. The 4-substitued piperidone derivatives were accessed via
both Method A and Method B. The method of Meyers337 (Method A, Scheme 6.1),
employed the magnesium derivatives of 2-(2-bromophenyl)-4,4-dimethyloxazoline (183)

and JV-alkylpiperidones (184a, 184b) to yield the piperidinols 185a, 185b, with subsequent
hydrolysis to give the phthalides 186a, 186b. The yields of piperidinols 185 were low
(-35%), but were improved by using a modification of the method of Hauser (Method
B), whereby the aryllithium compound 187 was reacted with N-alkylpiperidones to provide,
upon hydrolysis, the desired phthalide intermediates 186a, 186b. Phthalides 186a, 186b
were then reduced to provide the corresponding phthalans which underwent reductive
cleavage of the benzyl group to afford the parent secondary amine derivative
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spiro[isobenzofuran-l(37/),4'-piperidine] (170), which m a y

be further alkylated on

nitrogen.

R'
R'X, K 2 C 0 3

170

171

| H 2 Pd/C
B2Hg

Method A:

H30+
MgBr
i

R

183

184a R=CH 3
184b R = CH 2 C 6 H 5

186a R=CH 3
186b R = CH 2 C 6 H 5

184a R=CH 3
185b R = C H 2 C 6 H 5

LiO

/^^N-C6H5
l^L^OLi

LiO
N-C 6 H 5

Method B:

+

184a,b

187

336

Scheme 6.1 Methods for the preparation of spiro[isobenzofuran-l(37f)>4,-piperidines]
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In investigating the synthesis of spiro[isobenzofuran-l(377),3'-piperidines] it was also
reported that Method B furnished practically none of the isomeric phthalide 188 from Nbenzyl-3-piperidone (189), whilst method A (Scheme 6.2) provided piperidinol 190 in 47%
yield. Subsequent acid hydrolysis furnished phthalide 188, which may similarly undergo
reduction, followed by reductive removal of the TV-benzyl group, to produce the
spiro[isobenzofuran-l(377),3'-piperidine] (167). This then provides a known and successful
method whereby target ligands 167 (3-NH), 169 (3-NCH3), 170 (4-NH), 171 (4-NCH3)
may be achieved directly.

CH,

o

=4 CH3

NBn
H30+

~NBn

(Z)
MgBr

183

189

190

188
B2H6
H 2 Pd/C

167

336

Scheme 6.2 Methods for the preparation of spiro[isobenzofuran-1 (3H),3 '-piperidines] .

Alternatively, Parhem et al339

have prepared spiro[isobenzofuran-l(3H),4'-piperidine]

(171) via a method involving coupling of o-bromobenzoic acid with JV-methyl-4-piperidone
to afford pthalan 186a, followed by reduction with lithium aluminium hydride (Figure 6.4).
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C o m p o u n d 171 w a s also prepared b y cyclisation of 4-[o-(hydroxymethyl)phenyl]-lmethyl-4-piperidinol (191).

Br

a, b

OH

O
o-bromobenzoic acid

171

186a

Reagents and Conditions: a) BuLi; b) W-methyl-4-piperidone; c) LiAIH4-BF3

H2S04

191

171

Figure 6.4 Alternate methods for the preparation of spiro[isobenzofuran-l(3//),4'-piperidine]
171339.

6.3.2

Synthetic

design

for

the

spiro[isobenzofuran-pyrrolidines]

and

Spiro[isobenzofuran-piperidines]
ii0
Whilst neither Marxer et al.336
nor Parham et al339

extended their methodologies to

investigate the synthesis of spiro[isobenzofuran-pyrrolidine] derivatives, it was possible

these methods could be useful for the preparation of the set of pyrrolidine target derivatives
including 166. Spiro[isobenzofuran-pyrrolidine] derivatives such as 166 and 172 have not
been described previously in the literature. Looking at a retrosynthetic analysis (Figure
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6.5), it can be seen that the desired spirocycle m a y be effected via an intramolecular
cyclisation between an aryl halide substituent and the pyrrolidine (or piperidine) portion
a bicyclic compound. This is a similar tactic to that employed by Parham et al.339 In
investigating novel methods, we further looked to the method of Jin et al.340, who prepared
annulated vinyl sulfone derivatives such as 192 via a key intramolecular Heck reaction of
aryl iodides to vinyl sulfones. As shown in Scheme 6.3, the 0-alkylated precursor 193 was
prepared from the corresponding arylbenzyl bromide derivative 194 and the desired
hydroxy vinyl sulfone 195.

Br

Figure 6.5 Retrosynthetic analysis of spiro[isobenzofuran-l(3#),3 '-pyrrolidines].
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(E)

+

r~9

o.
S02Ph

S0 2 Ph

HO

(E)

IE)

^vS0 2 Ph
194
2 equiv

195

192

Reagents and Conditions: a) (n-Bu)4NI (10%), 5 0 % K O H (aq), DCM, 25C, 1-2 hr;
b) Pd(PPh3)4 5%, A g N 0 3 (5 equiv), NEt3, CH 3 CN, reflux, 3.5 hr

Scheme 6.3 Preparation of annulated vinyl sulfone 192 via intramolecular Heck cyclisation340

This method m a y be modified and applied to the synthesis of target spiro pyrrolidinederivatives such as 166 and 172, as outlined in Scheme 6.4. Reaction of o-iodobenzyl
bromide (196) with the enolate anion of benzyl-3-pyrrolidinone (197) (generated in situ)
should afford the spiro precursor 198. Enolate anion generation and selective O-alkylation
of A^-benzyl-3-pyrrolidinone has successfully been undertaken with the use of both lithium
diisopropylamine and lithium hexamethyldisilazide341,342, to selectively form in the
presence of triethylsilyl chloride, the triethylsilyl enol ether. Butyl lithium may also
generate the desired enolate anion. An intramolecular Heck reaction at the enamine carbon
of 198 should afford the desired spiro derivative 199. Removal of the benzyl protecting
group would then give access to the target spiro[isobenzofuran-l(377),3'-pyrrolidine] (166),
which may be further methylated if desired to the spiro[isobenzofuran-l(3//),3'-(/Vmethyl)-pyrrolidine] (168). The commercial availability of precursors o-iodobenzyl alcohol
and A^-benzyl-3-pyrrolidinone allows for a direct 4-5 step synthesis.

194

Chapter Six Synthesis ofBenzofused Spirocyclic Derivatives

NBn
.OH
iodobenzyl alcohol

O
W-benzyl-3-pyrrolidinone
197

in situ

NBn

NBn

^
Br

196

0"

I y (E)

NBn
c, d

O

198

199

NOB,

168

NH

166

Reagents & Conditions: a) BBr3, DCM; b) BuLi, THF; c) Pd(PPh3)4, Et3N, AgN0 3 , CH 3 CN, reflux;
d) NaBH 4 ; Pd/C, H2(g), CH3I, K 2 C0 3 .

Scheme 6.4 Proposed synthesis for the preparation of spiro pyrrolidine derivatives 166 and 168.

Furthermore, the incorporation of a methylenedioxy group into the iodobenzyl bromide
derivative would potentially furnish, after coupling, Heck reaction and deprotection, the
desired catechol derivatives 19 and 200, as shown in Scheme 6.5. Substitution of the Nbenzyl-3-pyrrolidinone skeleton with jV-benzyl-2-pyrrolidinone would in turn generate
catechols of derivatives spiro[isobenzofuran-l(377),2'-pyrrolidine] (172) and
spiro[isobenzofuran-l(37/),2'-(A^-methyl)-pyrrolidine] (173).

195

Chapter Six Synthesis ofBenzofused Spirocyclic Derivatives

NBn

0
OH

o

O
W-benzyl-3-pyrrolidinone
197

201

in situ

NBn

NBn

ccc

Br

194

NBn

0
202

203

NCH 3

200

19

Scheme 6.5 Proposed synthesis of the spiro pyrrolidine derivatives 19 and 200.

This approach could also provide a route for the preparation of the spiro-piperidine target
ligands. Following the same methodology as just discussed, and as outlined in Scheme 6.6,
the synthesis may begin with o-iodobenzyl bromide (with or without phenolic substituents)
and commercially available TV-benzyl-3-piperidone, to furnish the desired target ligands
spiro[isobenzofuran-l(377),3 '-piperidine] (127) and spiro[isobenzofuran-l(377),3'-(A^methyl)-piperidine] (169), and their catechol derivatives 20 and 205.
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Chapter Six Synthesis ofBenzofused Spirocyclic Derivatives

/NBn

A^NBn
Br

V-

O"

196 R = H
194R = OP

204 R = H
205 R = OP

(

NCH3

NBn
FA

206 R = H
207 R = OP

(

NH

:XAV 167 R = H
20 R = OP

169R = H
208 R = OH

Scheme 6.6 Proposed synthesis for the preparation of spiro piperidine derivatives 167, 20,169 and
208.

Again, substitution of the benzyl-3-piperidone skeleton with 7V-benzyl-4-piperidone would
in turn generate spiro[isobenzofuran-l(377),4'-piperidine] (170) and spiro[isobenzofuranl(377),4'-(7V-methyl)-piperidine] (171), with or without the catechol moiety.

NCH3

170

171

197
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6.4 Synthetic approaches to the Spiro[isobenzofurans]

The synthesis of spiro[isobenzofuran-l(377),3'-pyrrolidine] (166) and spiro[isobenzofuran-

1(377),3'-piperidine] (167) and derivatives were investigated initially using the modified
method of Jin et al. , employing the Heck reaction for effecting intramolecular

cyclisation, as detailed in Schemes 6.4 and 6.5. For synthetic ease, the methodology was to
be established firstly on the phenyl derivatives, before incorporating the catechol
derivatives. Unfortunately, time restraints meant that the synthesis of this set of target
ligands remained largely unfinished.

6.4.1 Preparation of '3-O-substitutedpyrrolidine spiro precursors

The synthesis of 166 therefore began with the high yield preparation of o-iodobenzyl
bromide (196) from o-iodobenzyl alcohol (209) as detailed in Scheme 6.7. !H NMR
analysis of 196 reflected the loss of the alcohol at 82.04 from the o-iodobenzyl alcohol

spectrum, and a slight upfield shift of the benzyl methylene protons (0.68 ppm) consistent

with substitution by the less deshielding bromine. This shift was also clearly displayed in
the

13

C NMR spectrum, where the methylene resonance appeared at 869.3 in 209 and 838.8

in 196. Mass spectral analysis (CI+) supported the formula C7H6Ibr for 196 via a molecular
ion at m/z 296 (79Br) and 298 (81Br).
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LA^OH ~* ^k/Br
iodobenzylalcohol iodobenzylbromide
(209)

(196)

Reagents and Conditions: BBr3 (1M in DCM), DCM, -30°C to RT,
3hr, 92% yield.
Scheme 6.7 Preparation of o-iodobenzyl bromide (196).

Coupling of o-iodobenzyl bromide to the desired pyrrolidinone (either iV-benzyl-3pyrrolidinone 197 or TV-benzyl-2-pyrrolidinone 210) should then lead to formation of the

spiro precursors 198 and 211. In the event, reaction of Af-benzyl-3-pyrrolidinone with but
lithium, followed by o-iodobenzyl bromide (as outlined in Scheme 6.8) afforded not the
desired 198 (Ci8Hi8NOI), but rather the o-iodobenzyl dimer 212 (Ci4H12l2). Dimer
formation was indicated by the (CI*) mass spectrum (MH+ m/z 434) and in the 'H NMR
spectrum by the presence of only 2 benzyl methylene peaks at 83.00 (2H, d, J- 6.3Hz) and
83.03 (2H, d, J = 6.3Hz), and 8 aromatic methine peaks. There was no evidence of any
pyrrolidine derivative whatsoever. This was also reflected in the 13C NMR, which displayed
only 2 methylene peaks (836.5 and 841.0) and the 12 aromatic carbons for the two aryl
rings. The fact that the two benzyl methylenes were represented as separate peaks in both
the !H NMR and 13C NMR spectra indicates that the dimer is not able to freely rotate.
Given the steric bulk of the two iodo-substituents, it is not surprising that rotation is
hindered.

The reaction was repeated twice more, each time the dimer 212 was the product. It

appeared that the butyl lithium had not reacted with iV-benzyl-3 -pyrrolidinone to form the
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required enolate anion, but instead an exchange reaction took place with o-iodobenzyl
bromide followed by coupling (either via nucleophilic displacement or free radical
intermediates) to afford the substituted dibenzyl derivative (Scheme 6.8). The excess of
butyl lithium (1.5 equivalents) allows for this side reaction to have occurred. However,

given the excess of o-iodobenzyl bromide also used (1.5 equivalents), and the fact that the
dimer was formed in only a 39% yield, it was expected that 98 should still be formed in up
to 90% yield.

-NBn
-NBn

benzy l-3-pyrrol id ino ne
197

198

a, b

Li

Br
-LiBr

212
Reagents and Conditions: a) BuLi, THF, -78°C, 30 mins;
b) 196, THF, -78°C to -30°C, 3hrs, 3 9 % yield

Scheme 6.8 Formation of 212 in the attempted synthesis of spiro pyrrolidine precursor 198.
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6.4.2 Preparation of 2-O-substitutedpyrrolidine spiro precursors

In view of the difficulties with the preparation of 198 it was decided to move on to the
preparation of the 2-pyrrolidine derivative 172. Using the same conditions, iV-benzyl-2pyrrolidinone (210) was treated with butyl lithium, followed by o-iodobenzylbromide.
After chromatography, the crude reaction mixture was shown to consist not of the desired
O-alkylated benzyl derivative 211, but rather the C-alkylated derivative 213
(CigHi8NOI)(Scheme 6.9). This was made evident in the

13

C NMR spectrum, where the

presence of the carbonyl functionality remained unchanged at 8175.2. Additionally, the
expected =CH methine proton of the O-alkylated product was absent from both the lH
1 3

N M R and

C N M R spectra, whilst the methine proton of the C-alkylated carbon was

observed as a doublet of doublets (J = 3.0, 7.2 Hz) at 82.86 in the !H NMR and the carbon
itself at 842.7 in the

13

C NMR. That C-alkylation had occurred a to the carbonyl

functionality, and not on the benzyl carbon (as in 214) was indicated by the A^-benzyl
protons resonating in the 'H NMR as doublets (J= 9.6 Hz) at 82.86 and 83.42, as would be
expected for 213. Additionally, the two o-iodobenzyl protons resonated as a singlet at
84.47, only slightly upfield from their position in the ]H NMR spectrum of o-iodobenzyl

bromide. If C-alkylation had produced 214, a single TV-benzyl proton would be expected in
the ]H NMR as a triplet or a doublet of doublets, and the two o-iodobenzyl protons would

probably also be exhibited as triplets or doublets of doublets. High resolution mass spec
analysis (CI+) confirmed that the molecular formula of 213 was indeed CigHigNOI. The
methine proton at the alkylated carbon of 213 is represented by a doublet of doublets at

82.86 in the 'H NMR, with coupling constants to the adjacent carbon of 3.0 Hz and 7.2 Hz,
indicative of equatorial-equatorial and axial-equatorial coupling respectively.
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a, b

C.NBn

NBn

0
/V-benzyl-2-pyrrolidinone
210

Reagents and Conditions: a) BuLi, THF, -78°C, 30 mins;
b) 196, THF, -78°C to -30°C, 3hrs.

NBn

NBn

213

LiBr

215

Scheme 6.9 Synthesis of C-alkylated 213 and the indeno-pyrrole derivative 215.

214

216

202

Chapter Six Synthesis ofBenzofused Spirocyclic Derivatives

While the lithium counter ion is k n o w n

to favour C-alkylation of enolate anions in non-

polar solvents through strong 0~...Lf complexing, it was thought some O-alkylation might
still be observed3 '

45

. However, repeating the reaction a number of times led to a mixtur

of C-alkylated product 213 and another derivative being produced in yields of 84% and
15% respectively. The products were easily separated via chromatography. NMR
spectroscopy established the structure of the new product as 215 (C25H24NOI). lH NMR
confirmed the presence of thirteen aromatic protons, four benzylic protons, two next to

doublets of doublets at 83.57 (J = 13.5, 14.7 Hz), the other two next to O as doublets of

doublets at 83.70 (J= 13.8 Hz), and seven other additional methylene and methine protons,
mostly in complex multiplets. There were no double bonds indicated. The

13

C NMR of 215

and DEPT analysis indicated the presence of two benzylic carbons at 851.3 and 862.8, 3
methylene carbons at 828.9, 832.7 and 858.3, and only one methine carbon at 845.6. The
13

C NMR and DEPT spectra of 215 also indicated thirteen aromatic CH carbons and six

quaternary carbons: suggesting the presence of three aromatic rings, two of which were

disubstituted, and only one of which was iodinated (8100.3). The lack of a ketone carbony
peak in the

13

C NMR indicated that formation of an enolate anion followed by O-alkylation

had occurred. Mass spectrometry (CF") analysis gave a molecular ion peak at m/z 482,
which correspond to a molecular formula of C25H24NOI, confirmed by high resolution mass
spectrometry analysis (CF"). This data supports the structure of the indeno-pyrrole
derivative 215. A proposed mechanism for the formation of 215 is given in Scheme 6.9:

reaction of the iodo-substituent with butyl lithium would lead to intramolecular cyclisa
to provide an alkoxy intermediate, which may react with iodobenzyl bromide by
nucleophilic displacement to provide indeno-pyrrole 215.

203

Chapter Six Synthesis ofBenzofused Spirocyclic Derivatives

The relative stereochemistry of 215 is cis ring fusion (as shown), resulting from the steric

constraint factors present in the intramolecular aryl anion attack on the lactam carbonyl i
213. Having established the structure of the major C-alkylation product of the reaction as

213 rather than 214, it can be concluded that 215, and not 216 (arising from intramolecular
aryl anion attack of 214 and coupling with o-iodobenzyl bromide by the same mechanism
as shown above), which may also fit the NMR spectral data, is the correct structure.

0-Alkylated indenopyrroles like 215 have not been reported previously in the literature. NAlkylated indenopyrrole derivatives 217346 and 218347 have been reported. The amine 217
was prepared by the reductive amination of l-oxo-2-indenylacetic acid, followed by
reduction and alkylation. Derivatives like 218 were prepared via the condensation of oallylbenzaldehyde with 7V-methylamino acids and esters. Amines 218c and 218d exhibit

weak oral hypoglycaemic activity, and interestingly 218a inhibits epinephrine biosynthesis
Another known indenopyrrole derivative is the tricyclic lactam 219 ' , stereoselectively
prepared via condensation of (7s)-3-pentenamide and benzaldehyde in phosphoric acid.

N'

H N7s> C H 2 Ph

i

CH3
»17

R
218a
218b
218c
218d
218e

R=H
R = Me
R=Et
R = Pr
R = Bu

219 R = H , CH 2 Ph
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6 A3 Preparation of piperidine spiro precursors

Although known methodology for the preparation of both spiro [isobenzofuran-3piperidines] and spiro[isobenzofuran-4-piperidines] has been presented, we wished to
investigate the preparation of these derivatives utilising the same Heck coupling as was
planned for the pyrrolidinone derivatives (as was shown in Scheme 6.6).

The synthesis began with the coupling of o-iodobenzylbromide (196) and TV-benzyl-3piperidone (189). Accordingly, N-benzyl-3-pyrrolidinone was treated with butyl lithium
followed by o-iodobenzylbromide (Scheme 6.10). Purification of the crude crystalline
product again furnished the dimer 212 (C14H12I2) as a white solid in 36% yield. High
resolution mass spectral and NMR analysis supported the formation of the dimer. This once
again suggested that enolate anion formation had not been successful.

A^NBn

0- * or
o
A/-benzyl-3-piperidone 220
189

212

Reagents and Conditions: a) BuLi, THF, -78°C, 30 mins;
b) 196, THF, -78°C to -30°C, 3hrs, 36% yield

Scheme 6.10 Formation of 212 in the attempted preparation of spiro piperidine precursor 220.
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Unfortunately time constraints did not allow for further investigation into these Oalkylation reactions of iodobenzyl bromide and piperidone and pyrrolidinone derivatives, or

any further synthesis of this set of target derivatives. For the preparation of 2-pyrrolidin
spiro derivatives, sodium hexamethyldisilazide should be considered as a base to attempt to
induce more O-alkylation of the enolate anion intermediate from 210 and o-iodobenzyl
bromide. For the preparation of 3-pyrrolidine and piperidine spiro derivatives, it may be
necessary to investigate an alternate synthesis, or to use one of those reported in the
literature for the preparation of spiro-piperidine derivatives.
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7.1 Introduction

With the successful synthesis of the simple cyclic derivatives and the bicyclic tropane

derivatives it was possible to obtain experimental in vitro affinities for these target l
upon both the wild-type (WT) and Cys128Phe mutant (Mu) ctiB-AR. In this way it would be
possible to begin to assess the accuracy of the pharmacophores developed and the success

of the design process used. To further examine the potential of these ligands as alternat
adrenoceptor ligands, they were also tested upon the ctiA- and aiD-adrenoceptors.

7.2 General Methods

All binding affinity experiments were undertaken by Dr. Songhai Chen, Dr. Angela Finch,
or Dr. Edwin Willems at the Victor Chang Cardiac Research Institute, Sydney.

The ligand binding characteristics of membrane expressed receptors (OCIA, CCIB, Cys128Phe
OCIB

and am) (Chinese Hamster ovary cells) were determined in a series of radioligand

binding studies using [125IJ-HEAT, an alpha-1-specific antagonist as the radioligand, as
previously described89'350. For competition studies, 200pM of [125I]-HEAT was used with
increasing amounts of non-radioligand competing ligand. The membrane concentration

used in these studies was selected to allow binding of less than 10% of the total radioli
added. After incubation for 1 hour, the reactions were stopped by addition of HEM-buffer
and the membranes collected on Whatman GF/C glass filters using a Brandel
Cell Harvester. The filters were washed 3 times with HEM to remove unbound
radiolabel and then counted for bound activity using a Packard Auto-gamma
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5000

counter. Binding

data

were

analysed

using

the

iterative, non-linear,

curve-fitting program, Prism. The HEM buffer was made up as follows: 20mM HEPES
pH7.5, 1.4mM EGTA and 12.5mM MgCl2.

Although predicted binding affinities for the target ligands were measured in K, value
feature of CATALYST ), in vitro binding affinities were not measured in K;, for two
reasons: the K; determination experiments are time consuming, and because many of the
ligands bound weakly, the experiments were not warranted. Instead the affinity was

measured in terms of IC50, which represents the concentration of unlabelled ligand whic
inhibits 50% of the radioligand binding. IC50 and K; are related by the equation:

K^rCsoAT+C/Kd)

where Kd is the dissociation constant of the radioligand of concentration C. It is exp
that the IC50 value was of the same order of magnitude as the K, value, and therefore
provided a comparative measurement against our preliminary pharmacophore predicted
values.

7.3 Results of binding affinity assays upon wild-type (WT2) and CysmPhe mutant (Mu2)
aiB-AR.

The results from the experimental binding assays of the simple cyclic and bicyclic tar

ligands are given in Table 7.1 and Table 7.2 respectively. They have been compared with
the predicted binding affinities of the WT2 and Mu2 pharmacophores. All experimental
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values are for the racemic compounds. Additionally, experimental data for the bicycli
ligands and some of the monocyclic ligands is given in the Appendix.

Figure 7.1 shows an example of the dose-concentration curve of the assay for adrenali
(epinephrine), and 14.

& Epi
• 4.82

al.

1? \-'
o < 100

S.N'
ta

SO
SO

tt •-

m -a JO
i« S o J
-10 -s -s -? -s s -i
log Cone. (M)

• 4.93
& Epi

80 •

If

40 •

<L1 E C128F

•

f."
CO -

log Cone. (M)

a1E C128F

E i- 100 -

it

-10-B-B-7-6-S-4-S-3

^
\
)1

in -g 20 •

m
*
5 .E

~i

0 •

-10

-e

1

-? -6 -6
log Cone. (M)

-i

-3

-10 -9

-a -r -s -a -4
log Cone. (M)

Figure 7.1 Dose-concentration curves for adrenaline (Epi), 100 (4.93, left graphs) and 99 (4.82,
right graphs) upon the ai B -AR wild-type (top graphs) and Cys128Phe (bottom graphs) receptors.
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Table 7.1 Predicted and Experimental binding affinities for the simple cyclic target ligands.

Ligand

W T a1B-•AR Affinity (nM)
Est (Ki)

13

R

Cys128Phe aiB-AR

Exp. (ICso) Est (Kt)

23000

3000

n.d.*

30000

3700

8

R

22000

3700

6
2

18000

S

24000

3000

8

R

15000

290

5

340

174000

50

S

22000

3100

7

24 R

12000

290

4

35

S

2700

290

1

R

17000

3000

6

S

14000

R

6400
W.B.

S

27000

17

6400

100000

36

n.d.*

>100000

>100000

1800

8

3100

2

#

Exp.

8

S

25000

14

Est

25000

>100000

23

Exp. (ICso)

Selectivity

3500
3100

n.d.*
9

* The selectivity could not be determined due to the poor binding affinity data.
# W.B. The binding affinity was too weak to determine an effective IC50.
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Table 7.2 Predicted and Experimental binding affinities for the bicyclic target ligands.
Ligand*

W T aiB-AR Affinity (nM)
Est (Kt)

52

R

Cys128Phe aiB-AR

Exp. (ICso) Est (Ki)

58

R

22000

60

2

18000

5200

R

18000

3100

*

#

4
6
W.B.

14000

!

7
W.B.

S

'

9

3100
#

Exp.

6

3000

W.B.

Est

160000

300000
2700

Exp. (ICso)

3700

20000

S

Selectivity

*

#

6

S

18000

101 R,S

110000

>30000

4500

>30000

25

*

102 R,R

81000

>30000

4700

>30000

17

*

99 R,R

180000

>30000

3000

>30000

60

*

100 RR

79000

>30000

3100

>30000

26

*

50

R

3200

88000

54 RS

12000

28

3100
>30000

*

>30000

>10000

S

4

3100

11000

3300

>30000

4

*

The stereochemistry defined is for the arylring;where there are two stereogenic centres present,
thefirststereocentre denoted is for the aryl ring.
# W . B . The binding affinity was too weak to determine an effective IC50* The selectivity could not be determined due to the poor binding affinity data.
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OH

OH

ry~4
)
^"N

^•N

* N " //

^N
Bn

14

24

Bn

H

13

23

O-A,

35

OH

OH

^1

CA.

36

52

58

OCH,

60

OCH3

H
N
OH
OH
50
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Table 7.3 Experimental binding affinities for the bicyclic target ligands on a 1A - and ctiDadrenoceptors.
Ligand

OCIA-AR Affinity

aiD-AR Affinity

ICso (nM)

ICso (nM)

58

W.B.*

360

60

W.B.#

W.B.#

101

>30000

2840

102

>30000

>10000

99

43900

>10000

100

>30000

2210

50

13100

2910

54

>30000

>10000

# W.B. The binding affinity was too weak to determine an effective IC5o.
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1A Discussion

1AA Binding of the simple cyclic derivatives

The simple cyclic target ligands bound only weakly to the wild-type aiB-AR, and more
weakly than was predicted by the pharmacophore. Only one ligand, 23, showed an
experimental affinity the same as that predicted. Of significance was that generally the
10R

simple cyclic ligands bound better to the Cys

Phe a ^ mutant receptor than to the wild-

type receptor, which was the trend predicted by the pharmacophores. However, the
experimental affinities for the Cys128Phe aie-AR were generally not as good as had been

predicted. The exceptions were the phenyl-piperidinols 14, 36, and to a lesser extent 35
which the predicted affinity on the Cys!28Phe aiB-AR was very close to the experimental

affinity. Additionally, 14 also demonstrated significant experimental selectivity for the
Cys128Phe aiB-AR mutant (a value of 50). Encouragingly, the methylenedioxy (catechol

protected) piperidinol derivative 35 also demonstrated selectivity for the CysI28Phe aiB-A

mutant (a value of 17). The lower selectivity and binding values indicate two major facts
the additional steric bulk of the methylendioxy substituent is somewhat encumbering the
binding process, and the presence of only hydrogen bond acceptor rather than hydrogen
bond donor or acceptor functions in the protected methylenedioxy group does not improve

binding. Coupled together, these facts present a derivative that has poorer binding abili
than the non-functionalised 3-phenyl-piperidin-3-ol 14.

Interestingly, the binding affinities of the N-benzyl derivatives 23 and 36 did not diffe

markedly from their parent derivatives in either predicted or experimental affinity. Onl
displayed a markedly decreased affinity on the mutant receptor. This trend suggests that
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while the extra aromatic ring is not enhancing affinity of the simple cyclic ligands, it m a y
not be hindering it either.

The 3-phenyl-piperidin-3-ol 14 therefore presents a suitable lead for further structure
activity relationship investigations for selective and signalling-specific aiB-AR ligands.
The 3-phenyl-3-piperidinol derivatives have previously been demonstrated to contain
potential a-adrenergic receptor stimulation properties138 (as discussed in chapter 3). In
particular, the catechol derivatives of 14 and 35 should be synthesised and evaluated for
Cys128Phe am-AR binding affinity.

7.4.2 Receptor binding of the bicyclic derivatives

The 3-phenyl-3-tropanol derivative 52 displayed poor experimental binding affinity for
both the wild-type and the Cys128Phe aiB-adrenoceptors. The experimental affinity was one
to two orders of magnitude worse than that predicted, and there was no notable selectivity
by 52 for the Cys128Phe over the wild-type a1B-AR. This indicated that the extra carbon
spacer between the aryl moiety and the protonated nitrogen in the 3-phenyl-3-tropanol
model (in comparison to the design motif) may be detrimental to binding.

The pharmacophores predicted similar affinities and selectivities for the ketal protected 6phenyl-6-tropanol derivatives 58 and 60. Unfortunately, these derivatives exhibited very
weak binding on both the wild-type and the Cys128Phe ctiB-adrenoceptors, so effective IC50
values could not be determined. It appears that the extra steric bulk of the ketals present
may hinder binding at the adrenaline binding site in these ctiB-adrenoceptors.
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The remaining bicyclic ligands all exhibited weak affinity (>30000nM) on both the wildtype and Cys128Phe mutant aiB-adrenoceptors, indicating no selectivity for the mutant
receptor as had been predicted. This lack of difference in binding results restricts any

stmcture-activity relationship trends from being apparent, except for the general trend that

the tropane ligands appear to be too bulky to effectively bind to the ctiB-adrenoceptors. It
also appears that the lack of selectivity for the Cys128Phe mutant aiB-adrenoceptor

exhibited by these ligands is due either to the steric bulk of the tropane ring, or it may b

reflection of the molecules being too rigid, presenting the potentially interacting feature
an incorrect orientation in space.

7.4.3 Discussion of other ai-adrenoceptor selective ligands

Given the rigidity of the adrenaline motif within the framework of the bicyclic tropane
ligands, it was also of interest to assess their pharmacological activities on the aiA- and
a1D-adrenoceptors. The bicyclic ligands did not exhibit any selectivity for the a!Aadrenoceptor. However, a number of tropane-based derivatives, 100, 101, 50 and 58,
19R

exhibited selectivity for the aiD-adrenoceptor over the ctiA- ociB- and Cys

Phe a m -

adrenoceptors. Whilst 100, 101 and 51 displayed selectivities for the am-AR of 10- to 15 fold, 58 exhibited 100-fold selectivity for the am-AR, with an IC50 of 360nM. Given the
lack of selective a]D-AR ligands available, these derivatives therefore provide a promising
new lead for the development of selective a]D-AR ligands.
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7.5 Examination of the design motif

From the structure-activity relationship data obtained, it appeared that whilst some of the
simple cyclic ligands provided a satisfactory model for the design motif, the conformation

of adrenaline in these derivatives was quite extended. In comparison, the increased rigid
of the bicyclic tropane derivatives appeared to cause too much steric bulk to provide

effective receptor binding, and in fact no selectivity for those derivatives was seen at al
experimentally, despite being predicted by the pharmacophores. To assess the design motif

properly, further experimental structure-activity relationship data on the rigid spirocyc
and spiro-fused sets of derivatives is required.

7.6 Examination of pharmacophore

The preliminary pharmacophores developed were only crude, and this is reflected in the

poor correlation between predicted affinities and experimental affinities for both the si
cyclic and bicyclic derivatives. With a larger set of experimental affinity data for the
Cys128Phe ciiB-adrenoceptors having been obtained, new pharmacophores may be
developed which may provide more accurate information with respect to the design motif.
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A constitutively active Cys

Phe mutant of the a m - A R had previously been identified as a

signalling specific receptor, activating only one biochemical signalling pathway, the PLC
pathway, and in the absence of ligand89. It had also been shown that this mutant receptor
favoured the binding of phenethylamine-type ligands over imidazoline ligands89.

From this lead a set of preliminary pharmacophores was developed to assist in the
generation of novel compounds which were predicted to display selective binding to the
19R

Cys

Phe a i B - A R over the wild-type ai B -AR. Although crude, the pharmacophores

suggested a folded conformation of adrenaline may be important for stronger binding to the
mutant receptor. This was then used as a basis for new ligand design. Ligands were

therefore designed as conformationally restricted heterocycles, incorporating the adrenali
design motif. To allow the investigation of a wider range of adrenaline mimic
conformations (including folding ones), the ligands were based upon four heterocyclic
frameworks: simple cyclic derivatives, bicyclic (tropane) derivatives, spirocyclic
derivatives, and benzo-fused spirocyclic derivatives, the syntheses of which were

undertaken. Some of these derivatives displayed encouraging predicted selectivities for th
Cys128Phe mutant receptor.

In the first category, a total of two pyrrolidinols and four piperidinols were prepared, b

on Grignard reagent additions to introduce the aryl and hydroxyl groups related to those in
adrenaline. These simple cyclic derivatives displayed some interesting experimental
binding affinities, in particular the 3-phenylpiperidin-3-ol derivative 14. Future work
should ensure the preparation of the catechol derivative to allow for analysis of the
importance of the catechol moiety. Being a direct mimic of adrenaline, the catechol
derivative should provide improved binding affinity and interesting selectivity data.
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In the second category, stereocontrolled syntheses were developed to a range of 3- and 3,6disubstituted tropane derivatives, including 6/?-phenyltropane-3/?,6a-diol (50). Some new
related cyclic hemi-ketal and cyclic ketal compounds were also prepared. These compounds
displayed only weak binding to the ai-adrenoceptors, including the wild-type and
Cys128Phe mutant, however a few compounds, in particular the ketal protected 6/?-phenyltropan-6-ol derivative 58, displayed interesting selectivity for the aio receptor. This
compound may provide an initial lead for the design of selective ctio ligands, of which

there are very few. Future work on this set of ligands should again focus on the preparatio
of the catechol target derivative 53, and an investigation of its binding affinity and

selectivity properties on the wild-type and Cys128Phe ctiB-ARs. It would also be of interest
to assess the binding properties of this ligand on the ctiA- and a]D-ARs.

Synthesis of the spirocyclic class of target derivatives was, unfortunately, not completed.
The synthetic pathway to the spirocyclic precursor 2-(2-propenyl)-l-pyrrolidinecarboxylic
acid,l-(l,l-dimethylethyl)-2-benzamide (139) has been established in high yield, and
subsequent palladium-assisted cyclisation to yield l-benzyl-5-methyl-2,3-dihydropyrrol-2one-3-spiro-2'-pyrrolidine-l'-carboxylic acid,l-(l,l-dimethylethyl) ester (156) has been

achieved, albeit in low yield. This cyclisation should be repeated, and the spirocyclic tar

ligand 18 accessed via Grignard reaction and deprotection. In this way the binding affinity
of 18 may be determined. To improve the quality of the preparation of 18, the reduction of
the benzamide 139 to the corresponding amine, 2-(2-propenyl)-l,2-pyrrolidinedicarboxylic

acid, l-( 1,1-dimethylethyl) ester (159) could be further investigated. If experimental bin
affinities support those predicted, the stereoselective synthesis of 18a (and its catechol
derivative) should be pursued, as 18a provides a good lead for selective binding to the
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Cys

Phe aj B -AR. The 8-dihydro (17) and 8-hydroxy (103) ligands (and their catechol

derivatives) should also be prepared and assessed.

Syntheses of the benzo-fused spirocyclic ligands were also unfinished. The desired Oalkylation of the TV-benzyl pyrrolidinones and TV-benzyl piperidone was not achieved and

methods for O-alkylation need to be reassessed with alternate reagents. Alternatively, th
synthesis of these derivatives may be pursued via known literature methods, to allow for

the assessment of binding affinities. The C-alkylation of TV-benzyl pyrrolidine-2-one wit

iodobenzylbromide, followed by intramolecular cyclisation and further O-alkylation, led t
the formation of a new heterocyclic compound, cw-l-benzyl-8b-(2-iodobenzyloxy)l,2,3,3a,4,8b-hexahydroindeno[l,2-o]pyrrole(215).
19R

The experimental binding affinities for 15 n e w ligands upon the wild-type and Cys

Phe

otiB-ARs have been obtained. Although most of the ligands displayed weak affinity, and

some very weak binding, the data will allow for a more realistic, less biased, training s

especially with the larger range of structural variation now available. From the new trai
set, second generation pharmacophores may be developed. Unfortunately time constraints
did not allow for the new pharmacophore to be generated here. These pharmacophores may
be compared with the pharmacophores used in this Thesis, and should be used to further
design ligands selective for the Cys128Phe a]B-adrenoceptor.

Such selective ligands should conform with the activated state of the Cys128Phe receptor,

and it is thought that these ligands might display signalling-specificity in the wild-typ

AR.
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9.1 Methods for Pharmacophore

Development

All pharmacophore development was undertaken using the CATALYST® program,

versions 4.0, 4.5, and 4.7, from Accelrys. CATALYST® 4.0 and 4.3 were used on a Sil
Graphics Workstation, CATALYST® 4.7 was used on a Silicon Graphics SGI Fuel

Workstation. See Chapter Two for methods used for generation of the training set (

2.2), conformer generation (section 2.2.1) and pharmacophore development and eval
(sections 2.3 and 2.5).

9.2 Methods for Pharmacological Assessment of Ligands

Methods for the pharmacological assessment of synthesised target ligands upon cti-

adrenoceptors (including ctiA, cciB, otiB-Cys128Phe and cciD) are given in Chapter Se
(7.2).

9.3 General Experimental for Synthesis

Melting point determinations were carried out on a Griffin melting point apparatus

rotation values were determined on a Jasco DIP-300 polarimeter. Low resolution chem
ionisation (isobutane, CF") mass spectra were obtained on a Shimadzu QP-5000 mass
spectrometer by a direct insertion technique with an electron beam of 70eV. Highresolution mass spectra (HRMS) (methane, CI+ and EI4") were determined on a VG
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Autospec spectrometer using P F K (perfluorokerosene) as the internal standard. The m/z
values are stated with their peak intensities as a percentage in parentheses.

Proton and carbon nuclear magnetic resonance (NMR) spectra were obtained on a Varia
Unity 300 MHz or a Varian Mercury 300 MHz spectrometer. Two dimensional NOESY
spectra were obtained on a Varian Innova 500 MHz spectrometer. HMBC 15N NMR

experiments were undertaken by Dr. Brent Copp at The University of Auckland, on a 4
MHz NMR, according to published methods351. Spectra were recorded in deuterated

chloroform, unless otherwise specified, and referenced to the residual non-deuterat

solvent signal. Chemical shifts (8) in ppm were measured relative to the internal s
Where samples exhibited rotamers, the minor form is recorded in parentheses and is
indicated by an asterisk.

X-Ray crystallography was undertaken by Prof. A.H. White at The University of Weste
Australia.

Analytical thin layer chromatography (TLC) was carried out on Merck Silica gel 60 F
pre-coated aluminium plates with a thickness of 0.2mm. Preparative TLC was done on
Merck Silica gel 60 PF254 coated onto glass plates with a thickness of 0.1mm.
Chromatography refers to column chromatography, performed under 'flash' conditions

Merck Silica gel 60 (230-400 mesh). Chromatography solvent mixtures were measured b

volume, and are reported in parentheses. The Rf values given refer to the determina
sample on TLC in the same solvent as noted for the chromatography.

Organic extracts were dried with anhydrous sodium sulphate, and the solvent was rem
under reduced pressure (in vacuo) with a Biichi rotary evaporator.
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Anhydrous solvents were purified and dried according to Perrin and Armarego 352 and
distilled immediately before use. Other solvents used were AR grade, and were used

received, with the exception of dichloromethane (DCM) and hexane, which were LR gra
and were distilled before use. Starting materials and reagents were purchased from
Aldrich Pty Ltd and were used as received.

Microwave reactions were performed in a Milestone Ethos Sel Microwave Solvent

Extractor, employing Easywave software, and using internal reaction temperature con
Sealed Teflon reaction vessels were used, and were washed with concentrated nitric
between uses.

Molecular modelling was undertaken using Spartan version 5.0 (Wavefunction Inc.) on
Silicon Graphics workstation.

For referencing of the proton and carbon NMR data for all the derivatives in the sp
section, the numbering system used is based upon that of pyrrolidine.

9.4 Experimental for Chapter Three: Synthesis of Monocyclic Derivatives

Synthesis ofl-benzyl-3-phenyl-pyrrolidin-3-ol (23).

To l-benzyl-3-pyrrolidinone (0.092g, 0.525mmol) in anhydrous diethyl ether (5mL) un

nitrogen was added phenylmagnesium bromide (3M in ether, 0.2lmL, 0.63mmol) dropwise

via syringe. Stirring continued at room temperature for 3 hours, after which time t

reaction mixture was taken up in ethyl acetate (20mL) and water (20mL) and separate
The aqueous layer was extracted with ethyl acetate (3x50mL). The combined organic
226

Chapter Nine Experimental Methods and D

extracts were washed with sodium chloride (sat.) (50mL), water (2x50mL), then dried

(sodium sulphate) and concentrated in vacuo to yield a brown oil. Chro

ethyl acetate:hexane) provided 23 (C17H19NO) as a brown oil (0.092g, 6

NMR (5): 2.16-2.25 (1H, m, H4); 2.37 (1H, ddd, JVA = 9.6, J4>,5 = 9.

2.58 (2H, ddddd, J= 9.6, 9.3, 6.0, 6.3, 3.3, H5, H5'); 2.85 (1H, bs, O

9.6, H2); 3.14 (1H, ddd, J = 9.3, 4.8, 4.8, H2'); 3.73 (2H, s, C#2Ph); 7
ArH x 8); 7.48 (1H, d, J= 1.2, ArH); 7.50 (1H, d,J= 0.9, ArH).

13

C NMR

C4); 52.9 (CH2, C5); 60.1 (CH2, C2); 68.7 (CH2Ph); 80.9 (C3); 125.5, 127.3

128.6, 129.0 (ArCH x 10); 138.9 (ipso C (benzyl)); 144.4 (ipso C). MS (

(M+l, 100%); 236 (-H20, 55%). HRMS (Cf): Found: 254.1533; Required: 25
Ci7H20NO.

Synthesis of 3-phenyl-pyrrolidin-3-ol (13).

A suspension of 23 (0.400g, 1.58mmol) and Pd/C (10%) (0.165g) in anhy

(15mL) was flushed with nitrogen, followed by hydrogen, and stirred un
atmosphere at room temperature for 44 hours. The reaction mixture was

celite and concentrated to yield 13 (C10H13NO) as a yellow oil, (0.277

purification was needed. !H NMR (8): 2.09-2.13 (1H, m, H4); 2.16-2.19
(1H, d, J= 11.4, H2); 3.06-3.14 (4H, m, NH, OH, H5, H5'); 3.28 (1H,
7.26-7.37 (3H, m, ArH x 3); 7.45 (1H, d, J= 1.5, ArH); 7.47 (1H, d,

NMR (8): 42.0 (CH2, C4); 46.2 (CH2, C5); 58.3 (CH2, C2); 82.3 (C3); 125.5,

(ArCH x 5); 144.5 (ipso C). MS (CI+): m/z 164 (M+l, 100%); 146 (-H20, 100
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(CI*): Found: 164.1070; Required: 164.1075 for C10H14NO. The hydrochloride salt was
made.

Synthesis ofl-benzyl-3-phenyl-piperidin-3-ol (25).

To l-benzyl-3-piperidone (0.862g, 4.55mmol) in anhydrous diethyl ether (15mL)

nitrogen was added phenylmagnesium bromide (3M in ether, 1.82mL, 5.46mmol) dr
via syringe. Stirring continued at room temperature for 3 hours, after which

reaction mixture was taken up in ethyl acetate (20mL) and water (20mL) and se

The aqueous layer was extracted with ethyl acetate (3x50mL). The combined orga
extracts were washed with sodium chloride (sat.) (50mL), water (2x50mL), then

(sodium sulphate) and concentrated in vacuo to yield a brown oil. Chromatogra

ethyl acetate:hexane) provided 25 (CigH2iNO) as a white solid, which was recr

from ethanol (1.04g, 86% yield). Mp: 116-119°C. !H NMR (8): 1.65-1.71 (1H, m, H

1.76-1.81 (2H, m, H5, H5'); 1.95-2.12 (2H, m, H4\ H6); 2.33 (1H, d, J = 11

(1H, d, J= 11.1, H2'); 2.94 (1H, dd, J= 1.8, 7.5, H6'); 3.59 (2H, 2 x s, C#2Ph); 3.98

s, OH); 7.26-7.38 (8H, m, ArH x 8); 7.50 (1H, d,J= 1.2, ArH); 7.52 (1H, d,J
13

C NMR (8): 21.9 (CH2, C5); 36.2 (CH2, C4); 53.0 (CH2, C6); 62.6 (CH2, C2); 65.

(CH2Ph); 71.1 (C3); 124.7 (Benzyl ArCH); 127.2 (ArCH); 128.1 (Benzyl ArCH x 2); 1

(ArCH x 2); 128.9 (ArCH x 2); 137.8 (ipso C (benzyl)); 145.6 (ipso C). MSfCI*)
(M+l, 100%); 250 (-H20, 50%). HRMS (CI*): Found: 268.1700; Required: 268.1701
Ci8H22N0.
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Synthesis of 3-phenyl-3-piperidin-3-ol (14).

A suspension of 25 (0.550g, 2.06mmol) and Pd/C (10%) (0.55g) in anhydrous ethano

(15mL) was flushed with nitrogen, followed by hydrogen, and stirred under a hydr

atmosphere at room temperature for 44 hours. The reaction mixture was filtered t
celite and concentrated to yield 14 (C11H15NO) as a colourless oil (0.249g, 68%
purification was needed. lR NMR (8): 1.61 (1H, bd, J= 9.0, H4); 1.85-1.97 (3H,
H5', H4'); 2.60 (1H, dd, J- 9.9, 11.1, H6); 2.87 (1H, s, OH); 3.05-3.10 (3H,
H6'); 3.67 (1H, d, J= 6.3, NH); 7.24-7.36 (3H, m, ArH x 3); 7.49 (2H, s, ArH

NMR (8): 22.4 (CH2, C5); 36.9 (CH2, C4); 46.1 (CH2, C6); 57.8 (CH2, C2); 70.8 (C3

124.9, 127.2, 128.4 (ArCH x 5); 146.5 (ipso C). MStCf): m/z 178 (M+l, 100%); 160 (H20, 85%). HRMS (Cf): Found: 178.1228; Required: 178.1232 for CnH16NO. The
hydrochloride salt was made.

Synthesis of l-benzyl-3-(3,4-methylenedioxyphenyl)-piperidin-3-ol (36).

To l-benzyl-3-piperidone (0.39g, 2.06mmol) in anhydrous THF (15mL) under nitroge
was added 3,4-methylenedioxyphenylmagnesium bromide (1M in THF, 2.47mL,

2.47mmol) dropwise via syringe. Stirring continued at room temperature for 3 hou

which time the reaction mixture was taken up in ethyl acetate (20mL) and water (
and separated. The aqueous layer was extracted with ethyl acetate (3x50mL). The
combined organic extracts were washed with sodium chloride (sat.) (50mL), water

(2x50mL), then dried (sodium sulphate) and concentrated in vacuo to yield a brow

Chromatography (1:8 ethyl acetate:hexane) provided 36 (Ci9H2iN03) as a yellow oil
which crystallised to a white solid upon standing, and was recrystallised from
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(0.33g, 5 2 % yield). Mp: 82-84°C. ! H N M R (8): 1.61-1.81 (3H, m, H4, H5, H5'); 1.90-2.0
(2H, m, H6, H4'); 2.24 (1H, d, J= 11.1, H2); 2.70 (1H, d, ./= 11.1,

8.7, H6'); 3.56 (2H, 2 x s, C772Ph); 4.93 (1H, s, OH); 5.91 (2H, s, OCH20); 6

7.8, aryl CH); 6.93 (1H, d,J= 7.8, aryl CH); 7.02 (1H, s, aryl CH); 7
13

C NMR (8): 22.0 (CH2, C5); 36.4 (CH2, C4); 53.0 (CH2, C6); 62.6 (CH2

(CH2Ph); 71.1 (C3); 100.8 (OCH20); 105.8, 107.7, 117.7 (aryl ArCH x 3); 1

128.8 (Benzyl ArCH x 5); 137.7 (ipso C aryl); 139.8 (ipso C benzyl); 146

147.3 (ipso C aryl). MS (CF~): m/z (312, M+l, 100%); (294, -H20, 70%). HRMS
Found: 312.1604; Required: 312.1600 for Ci9H22N03.

Synthesis of 3-(3,4-methylenedioxyphenyl)-piperidin-3-ol (35).

A suspension of 36 (0.200g, 0.642mmol) and Pd/C (10%) (0.200g) in anh

(6mL) was flushed with nitrogen, followed by hydrogen, and stirred und
atmosphere at room temperature for 44 hours. The reaction mixture was

celite and concentrated to yield 35 (Ci2Hi5N03) as a colourless oil (O.

NMR (8): 1.56-2.03 (5H, m, H4, H4', H5, H5\ NH); 2.27-2.73 (2H, m, H

(1H, s, OH); 3.02 (2H, d, J= 13.2, H2, H2'); 5.91 (2H, s, OCH20); 6.75 (1H, d

2.7, aryl CH); 6.94 (1H, ddd, J= 8.1, 9.3, 1.5, aryl CH); 7.03 (1H, d
CH).

13

C NMR (8): 22.5 (CH2, C5); 36.8 (CH2, C4); 46.0 (CH2, C6); 58.0

(C3); 100.7 (OCH20); 105.7, 107.7, 117.6 (aryl ArCH x 3); 140.5 (ipso C

C aryl); 147.3 (ipso C aryl). MS (Cf): m/z 222 (M+l, 100%); 204 (-H20, 9

(Cf): Found: 222.1116; Required: 222.1130 for Ci2H16N03. The hydrochlori
made.
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Attempted synthesis of l-benzyl-3-(3,4-dihydroxyphenyl)-piperidin-3-ol (37) utilis
boron trichloride/tetrabutylammonium iodide.

To a stirred mixture of 36 (0.020g, 0.064mmol) and fe^rabutylammonium iodide (0.073
1.984mmol) in anhydrous DCM (lmL) at -78°C under nitrogen was added boron

trichloride (1M in DCM, 0.32mmol) dropwise over 2 mins. After 5 mins the solution w

slowly warmed to room temperature and stirred for 1.5 hours. The reaction mixture w
quenched with ice and stirred for 30 mins, diluted with aqueous sodium hydrogen

carbonate (sat.) (at which point the solution turned blue in colour) and extracted

The combined organic extracts were washed with water, dried (sodium sulphate) and t

solution was concentrated in vacuo to yield a mixture of colourless crystalline ma

some blue residue (0.070g). !H NMR indicated the presence of neither 37, nor unreac

36. The residue was not identified. !H NMR (8): 1.01 (4H, t,J= 7.2); 1.46 (3H, q, J
15.0, 7.8); 1.63-1.71 (3H, m); 3.35 (3H, dd, J= 8.4, 9.0);

13

C NMR (8): 13.6; 19

59.0; 138.0.

Alternatively, to a stirred mixture of 0.2M 36 (0.22g, 0.707mmol) in anhydrous DCM

(2.36mL) and tetrabutylammonium iodide (0.81g, 2.192mmol) at -78°C under nitrogen w
added boron trichloride (1M in DCM, 3.54mL) dropwise over 2 minutess. Stirring was

continued at -78°C for 1 hour. The reaction mixture was quenched with ice and stirr

30 mins, then diluted with aqueous sodium hydrogen carbonate (sat.) (lOmL) and ext
with DCM (2x20mL). The combined organic extracts were washed with water, dried

(sodium sulphate) and the solution concentrated in vacuo to yield a yellow oil whic
crystallised upon standing. Chromatography (ethyl acetate, followed by 1:10
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methanokethyl acetate, Rf 0.06) yielded colourless crystals (0.190g), which proved to be
unreacted 36. lH NMR (8): 1.61-1.81 (3H, m, H4, H5, H5'); 1.90-2.07 (2H, m, H6,

2.24 (1H, d,J= 11.1, H2); 2.70 (1H, d, J= 11.1, H2'); 2.89 (1H, dd, /= 8.7, H6'
(2H, 2 x s, C#2Ph); 4.93 (1H, s, OH); 5.91 (2H, s, OCH20); 6.75 (1H, d, J= 7.8, aryl
6.93 (1H, d, J= 7.8, aryl CH); 7.02 (1H, s, aryl CH); 7.29 (5H, s, ArH x 5).

Attempted synthesis of l-benzyl-3-(3,4-dihydroxyphenyl)-piperidin-3-ol (37) uti
boron tribromide.

A 1M solution of boron tribromide in DCM (1.64mL) was added to a stirred soluti

(O.lOOg, 0.529mmol) in anhydrous DCM (lOmL) under nitrogen. Stirring was contin
for 22 hours with heating at reflux. To the cooled solution was added methanol
and the solvent was removed in vacuo to yield a crude red oil, which proved to
unreacted 36 (Ci9H2iN03). *H NMR (8): 1.61-1.81 (3H, m, H4, H5, H5'); 1.90-2.07
m, H6, H4'); 2.24 (1H, d, J = 11.1, H2); 2.70 (1H, d, J= 11.1, H2'); 2.89 (1H,
H6'); 3.56 (2H, 2 x s, Ctf2Ph); 4.93 (1H, s, OH); 5.91 (2H, s, OCH20); 6.75 (1H, d, J=

aryl CH); 6.93 (1H, d, J= 7.8, aryl CH); 7.02 (1H, s, aryl CH); 7.29 (5H, s, Ar

Attempted synthesis of l-benzyl-3-(3,4-dihydroxyphenyl)-piperidin-3-ol (37) uti
bismuth nitrate pentahydrate.

To a stirred solution of 36 (O.lOOg, 0.321mmol) in ethanol (lOmL) was added bis
nitrate pentahydrate (0.117g, 0.241mmol). Stirring was continued at 70°C for 70

(CI+) analysis of a sample of the reaction mixture showed no reaction had taken

312). The reaction mixture was then concentrated, taken up in acetonitrile (lOmL
bismuth nitrate pentahydrate (O.lOOg, 0.206mmol) was added and the mixture was
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reflux for 2 days. M S (CI*) analysis of the reaction mixture still showed no reaction had
taken place.

Attempted synthesis of l-benzyl-3-(3,4-dihydroxyphenyl)-piperidin-3-ol (37) utilis
cerium chloride heptahydrate.

To a stirred suspension of 36 (0.020g, 0.064mmol) and sodium iodide (0.0014g,
O.OlOmmol) in acetonitrile (2mL) was added cerium chloride heptahydrate (0.036g,

0.096mmol) and the mixture stirred at room temperature for 24 hours, followed by 1

heating at reflux. MS (Cf1") analysis of the crude reaction mixture showed unreacte
only: m/z 312 (M+l (Ci9H2iN03)), 294 (-H20).

Attempted synthesis of 3,4-dihydroxybenzaldehyde (39) utilising boron
trichloride/tetrabutylammonium iodide.

To a stirred solution of piperonal (38) (O.lOOg, 0.666mmol) and tetrabutylammonium
iodide (0.271g, 0.733mmol) in anhydrous DCM (1.33mL) at -78°C was added boron

trichloride (1M in DCM, 1.665mL) dropwise. Stirring was continued at -78°C for 1 ho

and then the mixture was warmed to room temperature with stirring for 40 hours. TLC
the reaction mixture showed unreacted 38 only (C8H603). MS (Ct): m/z 151 (M+l, 100%).

Attempted synthesis of 3,4-dihydroxybenzaldehyde (39) using boron tribromide.

To a stirred solution of piperonal (O.lOOg, 0.666mmol) in anhydrous DCM (2mL) at -7
was added boron tribromide (1M in DCM, 2.33mL) dropwise. Stirring was continued at
78°C for 1 hour, after which time the mixture was poured into DCM (20mL) and water

(lOmL). The organic extract was separated, dried (sodium sulphate) and concentrated
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vacuo to yield a black residue. The black residue was stirred in D C M overnight, filtered

and concentrated in vacuo to yield a colourless oil, which rapidly turned to a

(0.048g). The crude mixture proved to be a 1:1 mixture of 39 and 38 by !H NMR; M
(Cf): m/z 139 (M+l, 39, 100%); 151 (M+l, 38, 5%).

Attempted synthesis of 3,4-dihydroxybenzaldehyde (39) using bismuth nitrate
pentahydrate.

a) A solution of piperonal (38) (0.050g, 0.333mmol) and bismuth nitrate pentah

(0.323g, 0.666mmol) in acetonitrile (5mL) was heated at reflux for 17 hours. MS
analysis of the reaction mixture: m/z 139 (M+l, 39, 10%), 151 (M+l, 38, 100%).

b) A solution of piperonal (38) (0.025g, 0.167mmol) and bismuth nitrate pentah

(0.041g, 0.084mmol) in acetonitrile (8mL) was irradiated with microwave radiat
100°C for 30 mins. MS (Cf) analysis of the reaction mixture: m/z 151 (100%).

9.5 Experimental for Chapter Four: Synthesis of Bicyclic Derivatives

Synthesis of 8-(2,2,2-trichloroethoxycarbonyl)-8-azabicyclo[3.2. l]octan-3-one

Tropinone (2.0g, 14.38mmol), 2,2,2-trichlorethylchloroformate (2.18ml, 15.82mmo

dry potassium carbonate (2.0g, 14.38mmol) were heated at reflux in anhydrous b

(30mL) under argon for 22 hours. Benzene was removed in vacuo, azeotroping with
methanol. The crude reaction mixture was taken up in ethyl acetate (lOOmL) and

(lOOmL) and separated. The aqueous fraction was extracted with ethyl acetate (
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and the combined organicfractionswere washed with sodium chloride (sat.) (lOOmL),
water (2xl00mL), dried (sodium sulphate) and concentrated in vacuo to yield 65

(CioHi2N03Cl3) as a pale yellow oil, which crystallised under high vacuum to an o

solid (3.59g, 83% yield). Further purification was not required. Mp: 144-146°C. *

(8): 1.76 (2H, q, H7a, H6a, JH7a,7e = 8.1, /H6a,6e = 8.1, Jm^ = Jkea.ve = 3.

H6e, H7e, J= 4.8); 2.42 (2H, d, H2e, H4e, Jma>2e = Ju4tiAc = 16.2); 2.75 (2

Jrnaac = -We = 16.2); 4.67 (2H, dd, JCH,CH» = 4.8); 4.71 (1H, HI, Jm>1 = 12.0);
H5, Jusjs = 12.0). 13C NMR (8): 28.4 (CH2, C7(C6)); 29.3 (CH2, C6(C7)); 48.6, 49.1 (2x
CH2, C2, C4); 53.4 (2xCH, CI, C5); 74.7 (OCH2), 151.6 (NC=0); 207.2 (C=0, C3). MS
(Cf): m/z 300/302/304 (MH+, 34C1, 24%); 302 (MH+,
34

355

C1); 304(MH+, 37C1); 264/266 (-

C1,10%); 126 (100%). HRMS (Cf): Found: 299.9945; Required: 299.9961 for

CioHi3N0335Cl3.

Synthesis of8-(2,2,2-trichloroethoxycarbonyl)-3a-phenyl-8-azabicyclo[3.2.l]octan
(66).

To a stirred solution of 65 (l.OOg, 3.33mmol) in anhydrous diethyl ether (15mL)

nitrogen atmosphere was added phenylmagnesium bromide (3M in diethyl ether) (1.33
4.00mmol) dropwise. Stirring was continued at room temperature for 4 hours. The

mixture was filtered of precipitated magnesium hydroxide, taken up in ethyl acet

and water (50mL) and separated. The aqueous fraction was extracted with ethyl ace
(3xl00mL), and combined organic extracts were washed with sodium chloride (sat.)

(lOOmL), water (2xl00mL), dried (sodium sulphate) and concentrated in vacuo to yi
crude yellow oil. Chromatography (1:4 ethyl acetate:hexane; Rf 0.57) yielded 66
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(Ci 6 H 18 N0 3 Cl 3 ) as a pale yellow oil (0.900g, 7 1 % yield). *H N M R (8): 1.74 (1H, d, H6a, J
= 4.2); 1.91 (2H, dd, H7e, H7a, J= 12.0, 13.5); 2.16 (1H, d, H6e, J= 4.5); 2.40 (3H, dd,
H2e, H4a, H2a, Jm*2* = Jm&= 16.5); 2.73 (1H, dd, H4e, JKeAz= 16.5); 4.49 (1H, bd,

= 15.6); 4.64-4.72 (2H, m, CH2); 4.95 (1H, dd, H5, JH5M= 15.6, JU5,6c= 4.2), 7.

5H, ArHx5).13C NMR (8):27.8 (28.5*) (CH2, C4); 28.7 (29.6*) (CH2, C2); 44.4 (44.

(CH2, C7); 48.9 (49.4*) (CH2, C6); 53.7 (CH, CI); 54.0 (CH, C5); 73.8 (C3); 74.

(CH2CC13), 95.2 (CC13);124.5, 127.3, 128.6 (ArCH x 5); 149.4 (ipso C); 151.7 (151
(NC=0). MS (Cf): m/z 378 (MH+, 35C1, 30%); 380 (MH+,

355

C1); 382 (MFF, 37C1);

360/362/364 (-H20, 7%); 300/302/304 (-Ph, 100%). HRMS (CF~): Found: 380.0403;
Required: 380.0401 for Ci6H19N0335Cl237Cl.

Synthesis of 6/3-hydroxytropan-3-one (67).

A solution of 2,5-dimethoxy-2,5-dihydrofuran (26.00g, 0.2mol) in 3M hydrochlor

(360mL) was stirred at room temperature for 18 hours, the neutralised with 6M s

hydroxide (200mL). This mixture was added to a stirred solution of sodium aceta

(140.00g), acetone dicarboxylic acid (58.00g, 0.4mol), and methylamine hydrochl

(27.00g, 0.4mol) in water (1250mL). The pH was adjusted to 3, and the mixture w

stirring at room temperature for 4 days. The solution was neutralised with pota
carbonate and sodium chloride (150.00g) was added. The solution was extracted

extensively in 250mL portions with diethyl ether (2x200mL) followed by chlorofo

(2x200mL). The combined organic extracts were dried (sodium sulphate) and conc
in vacuo to yield a brown oil. Chromatography (10:1 DCM:methanol) isolated 67

(C8Hi3N02) as an off-white crystalline material (0.37g, 1% yield). Mp: 120-122°C
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121-121°C353). ! H N M R (8): 2.01-2.25(6H, m , H2e, H2a, H4e, H4a, H7e, H7a); 2.63 (3H,

s, 7V-CH3); 2.71-2.74 (1H, bs, OH); 3.38 (1H, d, HI, J= 4.8); 3.60 (lH,bs, H5); 4
dd, H6, J= 3.6). MS (CI+): m/z 156 (MH+, 60%).

Synthesis of 6f3-0-tert-butyldimethylsilyl-8-methyl-8-azabicyclo[3.2.1]octan-

6/?-Hydroxytropan-3-one (0.554g, 3.57mmol) was dissolved in anhydrous DCM (20m

and cooled to 0°C under nitrogen with stirring. 2,6-lutidine (0.833mL, 7.14mm

butyldimethylsilyl-trifluoromethanesulfonate (1.23mL, 5.35mmol) were added dr

consecutively via syringe, and stirring was continued for 3 hours as the solut

allowed to warm to room temperature. The reaction was quenched by the additio

(40mL) and saturated aqueous sodium hydrogen carbonate (lOmL). Extraction with
(lOOmL), drying (sodium sulphate) and concentration in vacuo yielded a yellow

Chromatography (ethyl acetate; Rf 0.31) provided the ketone 69 (CuH27N02Si) as

yellow oil (0.83g, 86% yield). ]H NMR (8): 0.04 (6H, s, (CH3)3Si); 0.87 (9H, s, (CH
2.01-2.06(2H, m, H2e, H4e); 2.13 (2H, dd, H2a, H4a, Jma,2s = JH4a,4e = 15.9);

TV-CH3); 2.57-2.65 (2H, m, H7, H7'); 3.28 (1H, d, HI, J= 4.8); 3.55 (1H, ddd, H
1.5,

JHS,6

= 4.2, JmM = 6.0); 4.08 (1H, dd, H6, Jm>7e = 3.6).

13

C NMR (8): -4.7

18.1 ((CH3)3CSi); 25.9 ((CH3)3); 38.2 (N-CH3); 41.3 (CH2, C4); 44.4 (CH2, C2); 46.3 (C

C7); 60.'8 (CH, CI); 69.4 (CH, C5); 79.6 (CH, C6); 208.4 (CO, C3). MS (Cf): m/

(M+l, 100%); 256 (39%); 224 (26%). HRMS (CI+): Found: 270.1903; Required: 270.1889
for Ci4H28N02Si.
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Synthesis

of

3-0-tert-butyldimethylsilyl-6j3-0-tert-butyldimethylsilyl-8-met

azabicyclo[3.2.1]octane (70).
Following the above procedure, and using an excess of tert-butyldimethylsilyl-

trifluoromethanesulfonate (1.5 equivalents), the bis-silylated tropinone derivative
(C2oH4iN02Si2) and its isomer 71 were produced in 62% yield as a yellow oil; TH NMR

0.01 (3H, s, (CH3)Si); 0.02 (3H, s, (CH3)Si); 0.08 (3H, s, (CH3)Si); 0.10 (3H, s, (CH3)Si)

0.84 (9H, s, (CH3)3); 0.87 (9H, s, (CH3)3); 1.96-1.97 (2H, m, H2(H4)); 2.28 (2H, ddd, H7

H7e, JH7a,i = 7.5, JH7e,i = 4.2, JH7e,6= 7.2); 2.37 (3H, s, TV-CH3); 3.05 (0

3.09 (0.66H, d, HI, J= 5.4); 3.30 (1H, dd, H5, J= 4.2, 3.6); 4.11-4.14 (1H

(0.66H, d, OH, H2, J= 5.4); 4.83 (0.33H, d, OH, H4, /= 5.4). 13C NMR (8): -4.

4.2, -4.2 ((CH3)2Si); 18.0, 18.3, 18.6 ((CH3)3CSi); 25.7, 26.0, 26.1 ((CH3)3); 31.
(CH2, C4); 35.0, 35.3 (CH2, C2); 43.3 (N-CH3); 48.0 (CH2, C7); 57.1, 58.5 (CH, CI);

66.6 (CH, C5); 78.9, 79.2 (CH, C6); 102.5, 107.0 (C3); 146.3 (OH, C2(C4)); 148.
C4(C2)). MS (Cf): m/z 384 (M+l, 24%); 252 (42%, -TBDMSOH); 173 (53%); 133
(100%); HRMS (Cf): Found: 384.2739; Required: 384.2754 for C20H42NO2Si2.

Synthesis of 6-exo-0-tert-butyldimethylsilyl-8-(2,2,2-trichloroethoxycarbonyl)-8~
azabicyclo[3.2.1]octan-3-one(72).

The base 69 (1.33g, 4.94mmol), 2,2,2-trichloroethyl chloroformate (0.748ml, 5.43mmo

and anhydrous potassium carbonate (0.683g, 4.94mmol) were heated at reflux in anhyd

benzene under nitrogen for 4 days. The benzene was then azeotroped with methanol, a
the crude reaction mixture taken up in ethyl acetate (lOOmL) and water (lOOmL) and

separated. The aqueous fraction was extracted with ethyl acetate (3xl00mL) and comb

organic extracts were washed with sodium chloride (sat.) (lOOmL), water (lOOmL) dri
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(sodium sulphate) and concentrated in vacuo to yield a brown oil which crystallised upon
standing. Chromatography (1:4 ethyl acetate:hexane; Rf 0.46) provided 72
(Ci6H26N04SiCl3) as a white solid (1.80g, 85% yield). Mp: 68-70°C. !H NMR (8): 0.05

(6H, s, (CH3)2Si); 0.86 (9H, s, (CH3)3); 2.04-2.13 (2H, m, H2e, H4e); 2.40 (2H, dd, H2

H4a, 4a,2e^H4a,4e= 16.2); 2.65-2.74 (2H, m, H7a, H7e); 4.18 (1H, dd, HI, Jm&

/Hi,2e= 5.4); 4.39 (1H, dd, H5, JmM=5.1, JmM = 6.9); 4.67-4.77 (2H, m, CH
dd, H6, J= 11.7).

13

C NMR (8): -4.7 ((CH3)2Si); 18.1 ((CH3)3CSi); 25.8 ((CH3)3); 4

(42.0*) (CH2, C4); 45.5 (46.0*) (CH2, C2); 48.5 (48.9*) (CH2, C7); 53.0 (5

62.5 (62.5*) (CH, C5); 74.7 (75.4*) (CH2CC13); 74.8 (75.4*) (CH, C6); 95.8 (
(NCO); 206.0 (CO, C3). MS (Cf): m/z 430 (MH+, 35C1); 432 (MH^,

355

C1); 434 (MH+,

37

C1); 396/398 (-34C1); 372/374/376; 298/300/302; 282. HRMS (Cf): Found: 430

Required: 430.0775 for Ci6H26N04Si35Cl3.

Microwave Method: To 69 (0.83g, 3.08mmol) in anhydrous acetonitrile (15mL) under

argon was added 2,2,2-trichloroethyl chloroformate (0.467mL, 3.39mmol) and anhydr

potassium carbonate (0.426g, 3.08mmol). The reaction mixture was exposed to microw

radiation for 2 minutes warming to 100°C, followed by 18 mins at 100°C. The reacti

mixture was allowed to cool, then taken up in ethyl acetate (50mL) and water (50mL

separated. The aqueous fraction was extracted with ethyl acetate (3x50mL) and comb

organic extracts were washed with sodium chloride (sat.) (50mL), water (50mL) drie
(sodoium sulphate) and concentrated in vacuo to yield a brown oil. Chromatography

ethyl acetate:hexane; Rf 0.46) provided 72 (Ci6H26N04SiCl3) as a white solid (0.796g

yield). All spectral and melting point data agreed with that previously determined

239

Chapter Nine Experimental Methods and Data

Synthesis

of

6/3-0-tert-butyldimethylsilyl-8-(2,2,2-trichloroethoxycar

azabicyclo[3.2.1]-3-spiro-2'-(l',3'-dioxolane)-octane (74).

To a stirred solution of ethanediol (0.27mL, 4.91mmol) and anhydrous DCM (15mL

nitrogen was added 72 (0.96g, 2.23mmol). To this mixture was added chlorotrime

(1.25mL, 9.82mmol) and the mixture was heated at reflux for 72 hours. A 5% aqu

solution of sodium hydrogen carbonate (20mL) was added and the mixture extract

diethyl ether (3xl00mL). The combined organic extracts were washed with sodium

chloride (sat.) (lOOmL), water (lOOmL), dried (sodium sulphate) and concentrate

to yield a pale yellow oil. Chromatography (1:6 ethyl acetate:hexane; Rf 0.69)

(Ci8H30NO5SiCl3) as a pale yellow oil (0.90g, 86% yield). !H NMR (8): 0.06 (6H, s,
(CH3)3Si); 0.86 (9H, s, (CH3)3); 1.67-1.90 (2H, m, H2e, H4e); 1.97-2.30 (1H, m,
H2a(H4a)); 2.26-2.42 (1H, m, H4a(H2a)); 2.46-2.75 (2H, m, H7a, H7e); 3.83 (1H,

J= 6.3); 3.91-3.99 (1H, m, OCH); 4.09-4.21 (2H, m, OCH2); 4.39 (1H, t, HI, J= 5.
4.47-4.59 (1H, m, H5); 4.62-4.74 (2H, m, CH2); 4.82-4.98 (1H, m, H6).

13

C NMR

((CH3)2Si); 10.1 ((CH3)3CSi); 25.8 ((CH3)3); 39.5 (40.1*) (CH2, C4); 45.5 (46.0*) (
C2); 48.5 (48.9*) (CH2, C7); 53.0 (53.5*) (CH, CI); 62.5 (62.6*) (CH, C5); 63.5

64.5 (OCH2); 74.0 (74.7*) (CH, C6); 74.8 (75.4*) (CH2CC13); 95.8 (CC13); 106.7 (C3);
151.7 (152.0*) (NCO). MS (CF): m/z 474 (MH+, 35C1); 476 (MH+,
37

355

C1); 478 (MH+,

C1); 416(35C1); 418 (355C1); 420 (37C1); 342 (35C1); 344 (355C1); 346 (37C1); 327; 3

HRMS (CF): Found: 474.1037; Required: 474.0952 for Ci8H3iN05Si35Cl3.
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Synthesis of 8-(2,2,2-trichloroethoxycarbonyl)-8-azabicyclo[3.2.1]octan-3-spiro
dioxolane)-6f5-ol (73).

To a stirred solution of 74 (0.13g, 0.274mmol) in anhydrous THF (5mL) under ni

0°C was added tetrabutylammonium fluoride (1M in THF). The reaction was stirred

room temperature for 3 hours, excess ammonium chloride was added and the mixtur

stirred for 10 minutes. The mixture was filtered and the THF was removed in vac

residue was extracted with ethyl acetate (50mL), washed with water (3x50mL), dr

(sodium sulphate) and concentrated in vacuo to yield a yellow oil. Chromatogra

ethyl acetate:hexane; Rf 0.30) provided 73 (Ci2Hi6N05Cl3) as a colourless oil (0
yield). *H NMR (8): 1.73-2.15 (2H, m, H2e, H4e); 2.32-2.56 (2H, m, H2a, H4a);

(2H, m, H7a, H7e); 3.82 (2H, dd, OCH2, J= 6.0); 3.96 (2H, dd, OCH2, J= 6.0); 4.1
(1H, m, HI); 4.48 (1H, d, H5, J5,6 = 6.3); 4.55-4.70 (2H, m, CH2); 4.88-5.02
13

C NMR (8): 38.4 (40.9*) (CH2, C4); 45.0 (45.5*) (CH2, C2); 48.3 (48.9*) (CH2,

(53.6*) (CH, CI); 62.2 (62.5*) (CH, C5); 63.5 (OCH2); 64.5 (OCH2); 73.5 (74.3*) (C
C6); 74.6 (74.7*) (CH2CC13); 95.8 (CC13); 106.5 (C3); 152.2 (NCO). MS (Cf): m/z 360
(MH+, 35C1); 362 (MH+, 35'5C1); 364 (MH+, 37C1); 316/318/320 (M+l - CH2CH20);

298/300/302 (-H20); 282/284 (-34C1). HRMS (CI+): Found: 360.0153; Required: 360.0
forCi2Hi7N0535Cl3.

Microwave method: To a solution of 72 (0.680g, 1.578mmol) in anhydrous acetonit

(lOmL) under an argon stream was added ethanediol (0.194mL, 3.472mmol) followed

chlorotrimethylsilane (0.878mL, 6.944mmol). The reaction mixture was exposed to

microwave radiation: warming to 80°C for 2 minutes, followed by heating at 80°C
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minutes. The reaction mixture was allowed to cool, then diluted with 5 % aqueous sodium

hydrogen carbonate (20mL) and extracted with diethyl ether (3x50mL). The combined
organic fractions were washed with water (2x5 OmL), dried (sodium sulphate) and

concentrated in vacuo to yield a yellow oil. Chromatography (1:1 ethyl acetate:h

0.43) yielded 73 (Ci2H16N05Cl3) as a colourless oil (0.470g, 83% yield). All spectr
agreed with that previously determined for 73.

Synthesis of 8-(2,2,2-trichloroethoxycarbonyl)-8-azabicyclo[3.2.1]octan-3-spirodioxolane)-6-one (75).

The alcohol 73 (0.46g, 1.28mmol) was dissolved in a stirred solution of anhydrous

dimethylsulfoxide (5mL) and dicyclohexylcarbodiimide (0.79g, 3.83mmol). Phosphori

acid (anhydrous) (0.063g, 0.64mmol) in anhydrous dimethylsulfoxide (lmL) was adde

dropwise and the mixture stirred at room temperature for 3 hours. Ethyl acetate (
was added, followed by a solution of oxalic acid (0.25g) in methanol (lOmL) and

continued for 30 minutes. The precipitated dicyclohexylurea was removed by filtra

washed with ethyl acetate (lOOmL) and the solution was extracted with aqueous sod

hydrogen carbonate (sat.) (50mL), water (50mL), dried (sodium sulphate) and concen

in vacuo to yield an off-white semi-solid. Chromatography (1:3 ethyl acetate:hex

0.40) provided 75 (Ci2Hi4N05Cl3) as a white solid (0.324g, 71% yield). Mp: 87-90°C.
NMR (8): 1.90 (1H, d, H7e, J7e,7a = 13.5); 2.22-2.42 (2H, m, H2e, H4e); 2.51-2.69
H2a, H4a); 2.89 (1H, m, H7a); 3.88-3.91 (2H, m, OCH2); 3.92-3.97 (2H, m, OCH2); 4.60

(1H, d, HI, Ji,2e = 2.1); 4.66-4.91 (2H, m, CH2); 5.03 (1H, bd, H5, J5fi=6.0). 13C NMR

38.9 (39.4*) (CH2, C7); 40.1 (CH2, C4); 42.3 (42.9*) (CH2, C2); 51.4 (CH, CI); 59.
(60.0*) (CH, C5); 64.1 (OCH2); 64.7 (OCH2); 74.7 (74.9*) (CH2CC13); 95.8 (CC13); 105.9
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(C3); 151.8 ( N C O ) ; 202.9 ( C O , C6). M S (Cf): m/z 360 (M+l, 35C1); 362 (M+l, 355 C1);
364 (M+l,

37

C1); 342/344/346 (-H20); 316/318/320; 298/300/302. HRMS (Cf): Found:

358.0018; Required: 358.0016 for Ci2H15N0535Cl3.

Synthesis of 8-(2,2,2-trichloroethoxycarbonyl)-6/3-phenyl-8-azabicyclo[3.2.1]o
spiro-2 '-(1 ',3 '-dioxolane)-6a-ol (76).

The ketone 75 (0.300g, 0.837mmol) was dissolved in anhydrous diethyl ether (lOm

under nitrogen with stirring. Phenylmagnesium bromide (3M in diethyl ether) (0

1.637mmol) was added dropwise and stirring continued for 3 hours. The reaction

was taken up in water (20mL) and extracted with diethyl ether (3x50mL). The com
organic extracts were washed with sodium chloride (sat.) (50mL), water (50mL),

(sodium sulphate) and concentrated in vacuo to yield a pale yellow oil. Chroma
(1:2 ethyl acetate:hexane; Rf 0.65) provided 76 (Ci8H20NO5Cl3) as a white solid

77% yield). 76 was recrystallised from ethyl acetate/hexane. Mp: 110-112°C. !H N

2.00 (1H, dd, H7a, J7aJe = 8.4, J-,^ = 7.5); 2.14-2.23 (2H, m, H2e, H4e); 2.36
H2a, H4a); 2.74 (1H, dt, H7, J7e>1 = 8.7, J7a,i = 4.8); 3.97 (2H, dd, OCH2,

4.02-4.18 (2H, m, OCH2); 4.29 (1H, bs, OH); 4.55 (1H, dd, HI, Jh2 = 10.8, Jh7e =

4.70-4.92 (2H, m, CH2); 5.02 (1H, d, H5, J= 2.7); 7.20-7.35 (3H, m, ArHx3); 7.5
ArHx2, J= 7.2).

13

C NMR (8): 36.9 (37.7*) (CH2, C7); 40.5 (41.4*) (CH2, C4); 44.

(45.8*) (CH2, C2); 52.7 (52.8*) (CH, CI); 62.8 (63.1*) (CH, C5); 63.8 (OCH2); 64.

(OCH2); 74.4 (74.5*) (CH2CC13); 79.8 (80.3*) (C6); 95.5 (95.6*) (CC13); 107.0 (C3);
123.9, 124.0, 125.2, 126.7, 128.1 (ArCHx5); 150.8 (151.1*) (NCO). MS (Cf): m/z
436/438/440 (M+l, 29%); 418/420/422 (-H20, 100%).
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Synthesis

of

8-(2,2,2-trichloroethoxycarbonyl)-6/3-(3,4-methylenedioxyphen

azabicyclo[3.2.1]octan-3-spiro-2 '-(1 ',3 '-dioxolane)-6a-ol (77).

To a stirred solution of 75 (0.090g, 0.251mmol) in anhydrous diethyl ether (4mL)
nitrogen was added 3,4-methylenedioxyphenylmagnesium bromide (1M in THF:toluene)

(0.301mL, 0.301mmol) dropwise, and stirring continued for 3 hours. The reaction m

was taken up in water (lOmL) and extracted with diethyl ether (3x25mL). The combi

organic extracts were washed with sodium chloride (sat.) (25mL), water (25mL), dr

(sodium sulphate) and concentrated in vacuo to yield a pale yellow oil. Chromato

(1:2 ethyl acetate:hexane; Rf 0.45) provided 77 (Ci9H2oN07Cl3) as a colourless oil

75% yield). *H NMR (8): 1.94-2.44 (5H, m, H2a, H2e, H4a, H4e, H7a); 2.63-2.76 (1H
H7e); 3.96-4.00 (2H, m, OCH2); 4.05-4.18 (2H, m, OCH2); 4.23 (1H, dd, OH, J = 3.6);

4.53 (1H, dd, HI, J= 11.4, 9.9); 4.70-4.90 (2H, m, CH2); 4.99 (1H, s, H5); 5.9

OCH20); 6.70-6.80 (1H, m, ArH); 6.85-6.98 (1H, m, ArH); 7.05 (1H, dd, ArH, ./ = 1
13

C NMR (8): 36.9 (37.7*) (CH2, C7); 40.4 (41.4*) (CH2, C4); 45.0 (45.8*) (CH2, C2

(52.8*) (CH, CI); 53.1 (53.3*) (CH, C5); 63.9 (OCH2); 64.7 (OCH2); 74.5 (74.6*)
(CH2CC13); 79.8 (80.4*) (C6); 95.5 (95.6*) (CC13); 100.8 (OCH20); 105.4 (ArCH); 107.0
(C3); 107.6 (ArCH); 117.1 (ArCH); 142.3, 146.1, 147.5 (ipso C x3); 150.8 (151.2*)
(NCO). HRMS (Cf): Found: 483.0247; Required: 483.0246 for Ci9H21N0735Cl37Cl2.

Attempted Synthesis of 8-(2,2,2-trichloroethoxycarbonyl)-6a-hydroxy-6/3-phenyl-8
azabicyclo[3.2.l]-octan-3-one (78).

To a stirred suspension of 76 (0.08g, 0.183mmol) and sodium iodide (0.004g, 0.02

in acetonitrile (2mL) was added cerium chloride heptahydrate (0.102g, 0.275mmol).
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mixture was stirred at room temperature for 20 hours and then heated at reflux for 22 hours.

The reaction mixture was diluted with diethyl ether (20mL) and treated with 0.5M

(lOmL). The organic layer was separated and the aqueous layer extracted with die

(3x20mL). The combined organic fractions were dried (sodium sulphate) and concen

in vacuo to yield an off-white semi-solid (0.04g). The crude sample was shown by

to consist of 76 only. MS (CI^) of the crude sample indicated the presence of so

436/438/440 (76, M+l, 29%); 418/420/422 (-H20, 100%); 392/394/396 (78, M+l, 20%)
384/386/388 (-H20. 30%).

Microwave Method: To a suspension of 76 (0.05g, 0.114mmol) and sodium iodide (0.

0.0043mmol) in acetonitrile (8mL) was added cerium chloride heptahydrate (0.064g

0.172mmol) and the reaction mixture was exposed to microwave radiation in the f

sequence: 2 minutes to 100°C, followed by 18 minutes at 100°C. The reaction mixt
allowed to cool, then it was diluted with diethyl ether (20mL) and treated with

(lOmL). The organic layer was separated and the aqueous layer extracted with die

(3x20mL). The combined organic fractions were dried (sodium sulphate) and concen
in vacuo to yield a yellow oil (0.05g). MS (CF") of the crude product indicated

of some 78 (Ci6H16N04Cl3): m/z 436/438/440 (76, M+l, 29%); 418/420/422 (-H20, 100%

392/394/396 (78, M+l, 20%); 384/386/388 (-H20. 30%). Chromatography (1:2 ethyl

acetate:hexane, Rf 0.65) provided 76 (Ci8H20NO5Cl3) as the only major product (0.0

80% recovery). Spectral data agrees with that of 76. No 78 (Ci6Hi6N04Cl3) was iso
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Synthesis of 8-(2,2,2-trichloroethoxycarbonyl)-3,3-dimethoxy-8-azabicyclo[3.2.1](83).

A stirred solution of 65 (O.lOOg, 0.333mmol) in anhydrous methanol (3mL) was trea

with trimethylorthoformate (0.23mL, 2.083mmol) and p-toluenesulfonic acid monohy

(0.004g, 0.023mmol) and the resulting solution was stirred at room temperature fo
hours. The reaction mixture was treated with diethyl ether (lOmL) and potassium

(0.116g), filtered through a plug of flurosil and concentrated to yield 83 (Ci2Hi

a colourless oil (0.098g, 85% yield). !H NMR (8): 1.83-1.96 (6H, m, H2a, H2e, H4a,
H6a, H7a); 2.06 (2H, dd, H6e, H7e, J= 7.5); 3.12 (3H, s, OCH3); 3.19 (3H, s, OCH3); 4.36
(2H, d, CH2,

JCH,CH'

= 13.5); 4.75 (2H, HI, H5, Jmj = JU5,6 = 12.0). 13C NMR (8): 27.0

(CH2, C6(C7)); 27.9 (CH2, C7(C6)); 37.8 (CH2, C2(C4)), 38.5 (CH2, C4(C2)); 47.3
(OCH3); 48.4 (OCH3); 53.0 (2 x CH, CI, C5); 74,6 (0CH2CC13); 95.8 (CC13); 98.9 (C3);

151.1 (NCO).

Preparation of 8-(2,2,2-trichloroethylformate)-8-azabicyclo[3.2.1]-octan-3-one (
83.

To a stirred solution of 83 (0.040g, 0.115mmol) in DCM (2mL) was added bismuth ni
pentahydrate (0.014g, 0.029mmol) and stirring continued at room temperature for

The reaction mixture was filtered, washed with 10% aqueous sodium hydrogen carbon

(lOmL), sodium chloride (sat.) (lOmL), water (lOmL), then dried (sodium sulphate),

concentrated in vacuo to yield 65 (Ci0Hi2NO3Cl3) as an off-white solid (0.033g, 95
yield). No further purification was required. NMR and mass spectral data agreed
of previously prepared 65.
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Synthesis

of

8-(2,2,2-trichloroethoxycarbonyl)-6fi-hydroxy-3,3-dimeth

azabicyclo[3.2.1]-octane (84).

Following the method used for 83, 84 (Ci2Hi9N05Cl3) (0.300g, 85% yield) was prep

from 72 (0.420g, 0.975mol) as a pale yellow oil after chromatography (ethyl ac

0.79). !H NMR (5): 1.73-1.77 (1H, m, H7e); 1.84 (2H, dd, H2e, H4e, J= 4.2); 1.9

(1H, m, H2a); 2.12-2.20 (1H, dd, H7a, /= 7.2); 3.11 (3H, s, OCH3); 3.15 (3H, s, OCH3)

4.13 (1H, ddd, HI, J= 7.2, 14.4); 4.46 (2H, dd, CH2, J= 6.3, 7.8); 4.47 (1H, H5, J= 7.2);
4.90 (1H, t, H6, J= 11.7).

13

C NMR (8): 35.8 (36.4*) (CH2, C2(C4)), 36.5 (37.2*) (

C4(C2)); 39.5 (40.0*) (CH2, C7); 47.3 (OCH3); 48.1 (OCH3); 53.1 (53.2*) (CH, CI); 6

(62.2*) (CH,C5); 73.2 (74.0*) (C6); 74.5 (74.6*) (0CH2CC13); 95.5 (CC13); 98.3 (C3
151.8 (NCO). MS (CF"): m/z 362 (M+1,35C1), 364 (M+l,

355

C1), 366(M+1, 37C1);

330/332/334 (-CH3OH); 312/314/316 (-H20); 296/298; 278/280. HRMS (Cf): Found:
363.0221; Required: 363.0207 for (Ci2Hi9N0535Cl237Ci).

Synthesis of 8-(2,2,2-trichloroethoxycarbonyl)-3,3-dimethoxy-8-azabicyclo[3.2.
6-one (85).

Following the method used for 75, 85 (C12Hi7N05Cl3) (0.490g, 71% yield) was prep
from 84 (0.700g, 1.93moles) as a colourless oil which crystallised to a white

chromatography (1:2 ethyl acetate:hexane; Rf 0.74). Mp: 62-63°C. lU NMR (8): 1.75

dd, H2e, J2eA = 13.8); 2.03-2.19 (2H, m, H4e, H7e); 2.42-2.65 (3H, m, H2a, H4a

3.04 (3H, s, OCH3); 3.16 (3H, s, OCH3); 4.21 (1H, m, HI); 4.72-4.88 (3H, m, H5, CH2).

C NMR (8): 36.2 (36.8*) (CH2, C4), 36.9 (37.6*) (CH2, C2); 42.7 (43.1*) (CH2, C
(OCH3); 47.7 (OCH3); 51.4 (51.8*) (CH, CI); 59.3 (60.3*) (CH,C5); 74.7 (0CH2CC13);
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95.2 (CC13); 98.3 (C3); 151.4 ( N C O ) ; 203.0 ( C O , C6). M S (CF"): m/z 360 (M+1,35C1),
362 (M+1,355C1), 364 (M+l,

37

C1); 342/344/346 (-H20); 328/330/332 (-CH3OH);

HRMS (Cf): Found: 359.0103; Required: 359.0094 for (Ci2H18N0535Cl3).

Synthesis of 8-(2,2,2-trichloroethoxycarbonyl)-3,3-dimethoxy-6p-phenyl
azabicyclo[3.2.1]-octan-6a-ol(86).

Following the method used for 76, 86 (Ci8H22N05Cl3) (0.293g, 88% yield)
from 85 (0.273g, 0.757moles) as a colourless oil after chromatography

acetate:hexane; Rf 0.42),which crystallised to a white solid upon stand

'H NMR (8): 1.97 (1H, dd, H7a, J = 3.9); 2.02-2.15 (2H, m, H2e, H4e);

H2a(H4a)); 2.51-2.61 (1H, m, H4a(H2a)); 2.75 (1H, ddd, H7e, J7e,7a = 8.4
(3H, s, OCH3); 3.33 (3H, s, OCH3); 4.27 (1H, dd, HI J= 4.2, 5.4); 4.46-4.52

4.79 (2H, dddd, CH2, J = 10.8, 12.0); 7.19-7.36 (3H, m, ArHx3); 7.49-7.54
ArHx2).

13

C NMR (8): 35.3 (35.7*) (CH2, C4), 36.1 (36.5*) (CH2, C2); 45.1

C7); 47.8 (OCH3); 48.1 (OCH3); 52.3 (52.5*) (CH, CI); 62.5 (62.8*) (CH, C5)

(74.6*) (0CH2CC13); 79.5 (80.1*) (CH, C6); 95.5 (CC13); 99.3 (C3); 124.0, 1

128.1, 128.3 (ArCx5); 147.8 (ipso Q; 150.8 (151.1*) (NCO). MS (Cf): m/z 40
CH30H,35C1); 408 (M+l-CH3OH,

355

C1); 410 (M+l-CH3OH,

37

C1); 372/374/376; 354.

HRMS (CF"): Found: 406.0363; Required: 406.0380 for Ci7H19N0435Cl3 (loss of
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Synthesis

of

8-(2,2,2-trichloroethoxycarbonyl)-3,3-dimethoxy-6/3

methylenedioxyphenyl)-8-azabicyclo[3.2.1]-octan-6a-ol (87).

Following the method used for 77, 87 (Ci9H22N07Cl3) (0.199g, 84% yield) was prepa

from 85 (0.177g, 0.491moles) as a colourless oil after chromatography (1:4 eth

acetate:hexane; Rf 0.28). *H NMR (8): 1.92-1.99 (1H, m, H7a); 2.02-2.13 (1H, m,

2.19-2.30 (m, 1H, H4e); 2.49-2.59 (2H, m, H2a, H4a); 2.68 (1H, ddd, H7e, J7e,

= 5.7); 3.22 (3H, s, OCH3); 3.32 (3H, s, OCH3); 4.21 (1H, dd, HI, J= 3.3, 12.3); 4.43(1H, m, H5); 4.79 (2H, dddd, CH2, J= 10.2, 12.0); 5.28 (1H, s, OH) (exchangeable

D20) 5.92 (2H, s, OCH20); 6.72 (1H, dd, ArH, /= 1.8); 6.93-6.98 (1H, m, ArH); 7.05
dd, ArH, J= 1.8, 8.4).

13

C NMR (8): 35.2 (35.7*) (CH2, C4), 36.1 (36.5*) (CH2, C

(46.0*) (CH2, C7); 47.5 (47.8*) (OCH3); 48.1 (OCH3); 52.2 (52.4*) (CH, CI); 62.8 (

(CH, C5); 74.5 (74.6*) (0CH2CC13); 79.5 (80.2*) (CH, C6); 95.5 (CC13); 99.3 (C3); 1

(OCH20); 105.4, 107.6 (ArCH x 2); 117.0 (ArCH); 142.1, 146.1, 147.5 (ipso Cx 3); 1
(NCO). MS (Cf): m/z 390/392/394; 360/362/364; 342/344/346; 328/330/332; 294/296.
HRMS (Ef): Found: 449.0157; Required: 449.0200 for Ci8Hi8N0635Cl3 (loss of CH3OH).

Synthesis of 4-(2,2,2-trichloroethoxycarbonyl)-2-methoxy-6a/3-phenyl-2,5-metha
hexahydro-2H-furo[3,2-b]pyrrol-6aa-ol(90).

Following the method used for the deprotection of 83, 79 (0.02g, 0.0455mmol) w
with 0.25 equivalents of bismuth nitrate pentahydrate in DCM (2mL) and stirred

temperature for 2 hours, after which time all the substrate had reacted (via TL

work-up procedure afforded 90 (Ci7Hi8N04Cl3) as a colourless oil (Rf 0.56, 1:4 e

acetate:hexane) (0.018g, 100 % yield). !H NMR (8): 1.89 (1H, dd, H7a, J7a,7e = 6
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2.4); 2.00 (2H, s, H2e, H4e); 2.18 (2H, dd, H2a, H4a, J =2.1, 3.6); 2.31 (1H, dd, H7e, J7
= 4.8); 3.53 (3H, s, OCH3); 4.56 (1H, d, HI J= 4.8); 4.72-4.89 (3H, m, H5, CH2);
7.45 (5H, m, ArHx5).

13

C NMR (8): 37.1 (37.6*) (CH2, C4), 39.8 (40.4*) (CH2, C2);

(46.1*) (CH2, C7); 50.0 (50.0*) (OCH3); 55.6 (56.1*) (CH, CI); 65.5 (65.5*) (CH

74.6 (0CH2CC13); 87.8 (88.5*) (C6); 95.7 (CC13); 106.4 (106.5*) (C3); 124.6,124.7
128.3 (ArCx5); 140.5 (140.6*) (ipso Q; 150.6 (NCO). MS (Cf): m/z 406 (M+1,35C1,
90%); 408 (M+l,

355

C1); 410 (M+l, 37C1); 372/374/376 (- MeOH, 40%); 232 (55%).

HRMS (Cf): Found: 406.0376; Required: 406.0380 for Ci7H!9N04Cl3.

Synthesis of 8-(2,2,2-trichloroethoxycarbonyl)-6/3-phenyl-8-azabicyclo[3.2.1]

octan-6-ol (78) and 4-(2,2,2-trichloroethoxycarbonyl)-6af}-phenyl-2,5-methano
hexahydro-2H-furo[3,2-b]pyrrol-6aa,2j3-diol(91).

A stirred solution of 86 (0.103g, 0.235mmol) in a 2:1 mixture of chloroform:t

acid (50% aq.) (4mL) was heated at reflux for 20 hours. The cooled solution w

onto chloroform, separated, and the organic layer washed with water (5mL), dri

sulphate) and concentrated in vacuo to yield a pale yellow oil. Chromatograph

EtOAc:Hexane; Rf 0.19) yielded a colourless oil (0.090g, 98% yield), which pro

an inseparable mixture of 78 (Ci6Hi6N04Cl3) and 91 (Ci6Hi6N04Cl3). !H NMR (8): 1.9

(1H, d, H7a, .7=11.4); 2.02-2.19 (5H, m, H2e, H4e, H7e, H2a, H4a); 3.97 (1H, bs
4.56 (1H, s, HI); 4.72-4.88 (3H, m, CH2, H5); 7.26-7.43 (5H, m, ArH x 5);

13

38.4 (38.5*) (CH2, C4), 44.6 (44.9*) (CH2, C2); 45.3 (45.6*) (CH2, C7); 55.4 (

CI); 65.7 (65.7*) (CH, C5); 74.6 (74.9*) (0CH2CC13); 88.4 (89.1*) (C6); 95.5 (9

(CC13); 103.6 (103.7*) (C3); 124.7, 124.8, 127.6, 128.3, 128.5 (ArCH x 5); 140.1
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(ipso Q ; 150.6 (151.0*) ( N C O ) ; 203.1 ( C O , C3). M S (Cf): 392/394/396 (M+l);
374/376/378 (-H20); 358/360/362; 340/342/344; 314/316/318; 218; 200.

Synthesis of 8-(2,2,2-trichloroethoxycarbonyl)-6a-hydroxy-6-/3-(3,4methylenedioxyphenyl)-8-azabicyclo[3.2.1]octan-3-one (79) and 4-(2,2,2-

trichloroethoxycarbonyl)-6ap-(3,4-methylenedioxyphenyl)-2,5-methano-hexahydrofuro[3,2-b]pyrrol-6aa,2P-diol(92).

A solution of 87 (0.179g, 0.371mmol) in a 2:1 mixture of chloroform:trifluoroa

(50% aq.) (4mL) was heated at reflux for 20 hours. The cooled solution was pour

chloroform, separated, and the organic layer washed with water (2x5mL), dried (
sulphate) and concentrated in vacuo to yield a pale yellow oil. Chromatography
EtOAc:Hexane) isolated 2 products: the ketone derivative 79 and the hemi-ketal

92 (4.87fl8-32). 79 (Ci7Hi6N06Cl3) was isolated as an off-white solid, recrystal

DCM/diethyl ether (0.039g, 24% yield); Rf 0.20 (1:4 EtOAc:Hexane). Mp: 106-108°C.
NMR (8): 2.19-2.28 (1H, m, H7a); 2.45-2.60 (3H, m, H2e, H4e, H7e); 2.83-2.92

H2a, H4a); 4.72 (1H, dd, HI, J= 4.8); 4.94-5.09 (2H, dddd, CH2, J= 10.2, 12.0); 5

s, H5); 5.98 (2H, s, OCH20); 6.31 (1H, dd, OH, J= 2.4, 5.7) (exchangeable with D20
6.77-6.89 (3H, m, ArH x 3).

13

C NMR (8): 44.4, 45.0, 45.2, 45.8 (CH2, C4, C2,

(CH, CI, C5); 74.7 (0CH2CC13); 84.5 (CH, C6); 95.4 (CC13); 101.3 (OCH20); 105.8, 108.4

(ArCH x 2); 119.8 (123.3*) (ArCH); 125.0 (ispo C); 145.4, 148.2 (ipso C x 2); 15
(NCO); 204.2 (CO). MS (Cf): m/z 436/438/440 (M+l, 10%); 418/420/422 (-H20,
15%); 384/386/388 (20%); 314/316/318 (20%); 262 (70%); 244 (100%). HRMS (EF):
Found: 435.0026; Required: 435.0043 for Ci7Hi6N06Cl3.
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92 (CnHieNOeCfj) was isolated as a colourless oil (O.lOOg, 6 2 % yield); R f 0.08 (1:4

EtOAc:Hexane); !H NMR (8): 1.89 (1H, bm, H7a); 2.06-2.13 (4H, m, H2e, H

H4a); 2.19-2.31 (1H, m, H7e); 3.75 (1H, d, J= 3.0, OH); 4.50 (1H, s,

m, CH2CC13); 4.87 (1H, dd, J= 6.6, H5); 5.95 (2H, s, OCH20); 6.78 (1H, 2xd, /=
ArH); 6.85 (1H, dd, J = 4.5, 1.5, ArH); 6.89 (1H, d, J = 3.0, ArH).

13

C

(38.8*) (CH2, C4), 44.6 (45.0*) (CH2, C2), 45.1 (45.3*) (CH2, C7); 55.3

65.6 (65.7*) (CH, C5); 74.6 (0CH2CC13); 88.4 (89.1*) (CH, C6); 95.5 (CC13)
(OCH20); 103.6 (103.7*) (C3); 105.7 (105.8*) (ArCH); 108.0 (ArCH); 118.0
(ArCH); 134.2 (ispo C); 146.5, 148.0 (ipso C x 2); 150.8 (NCO). MS (Cf):

436/438/440 (M+l, 60%); 418/420/422 (-H20, 100%); 384/386/388 (60%). HR
Found: 435.0049; Required: 435.0043 for Ci7Hi6N06Cl3.

Synthesis of 8-(2,2,2-trichloroethoxycarbonyl)-8-azabicyclo[3.2.1]octa

To a stirred solution of 65 (0.050g, 0.167mmol) and 0.4M cerium chlori

(0.167mmol) in methanol (2.5mL) at room temperature was added sodium b
(0.007g, 0.167mmol). Stirring continued for 10 minutes, at which time

hydrochloric acid (lmL) was added and the mixture extracted with DCM (3

combined organic extracts were washed with water (2x5mL), dried (sodiu
concentrated in vacuo to yield 97 (Ci0Hi4NO3Cl3) as an off-white solid

in 95% stereoselectivity. Mp: 84-86°C. !H NMR (8): 1.60-1.71 (3H, m, H

1.73-1.84 (2H, m, H6a, H7a); 1.94-2.06 (3H, bm, H6e, H7e, H2e); 2.11
4.14 (1H, dddd, H3a, Jm*j =

JA*Z

=

10 5

- > ^,3

=

-^,3 = 5.7); 4.31-4.43 (2H

(1H, dd, HI, J= 10.2); 4.84(1H, dd, HI, J= 10.2).

13

C NMR (8): 27.8 (27.8*)
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C7(C6)); 28.5 (28.6*) (CH 2 , C6(C7)); 38.4 (39.0*) (CH 2 , C2(C4)); 40.3 (40.9*) (CH 2 ,

C2(C4)); 53.3 (53.4*) (CH, C3); 63.7 (CH, CI); 64.9 (CH, C5); 74.5 (74.6*) (CH2CC

95.7 (CC13); 151.2 (NCO). MS (CI+): m/z 302/304/306 (M+l, 100%); 284/286/288 (-H20,
15%); 268; 270 (loss of

34

C1, 40%). HRMS (CI+): Found: 304.0072; Required: 304.00

forCi2H15N0335Cl237Cl.

Synthesis of 8-(2,2,2-trichloroethylformate)-6j3-phenyl-8-azabicyclo[3.2.l]oct
diol (80).

To a stirred solution of 0.4M cerium chloride heptahydrate in methanol (5mL) u

nitrogen was added 78 (0.120g, 0.306mmol), followed a few minutes later by sod

borohydride (0.021g, 0.547mmol). Stirring continued for 4 hours, after which ti

aqueous hydrochloric acid was added to the mixture, and then the mixture poure

DCM (lOmL) and extracted. The organic layer was washed with water (lOmL), drie

(sodium sulphate) and concentrated in vacuo to yield a colourless oil which cr

upon standing to a white solid. Mp: 131-132°C. Chromatography (1:2 ethyl aceta

yielded unreacted 78 (0.072g, 60% yield) and 80 (Ci6H18N04Cl3) as a colourless o

0.43, 1:2 ethyl acetate:hexane, 0.049g, 40% yield, 100% yield based on recover
NMR (8): 1.87 (1H, m, H7a); 2.16-2.38 (3H, m, H2e, H4e, H7e); 2.48 (1H,

H2a); 2.73 (1H, dddd, J4a,4e = 9.0, H4a); 3.70 (1H, 2 x bs, OH); 4.24-4.27 (

H3a); 4.39-4.47 (1H, m, H5); 4.79 (2H, dddd, J= 12.0, CH2CC13); 5.55 (1H, bd, OH
12.3); 7.22-7.32 (3H, m, ArH x 3); 7.48-7.54 (2H, m, ArH x 2).

13

C NMR (8): 33.4

(CH2, C4), 38.0 (38.9*) (CH2, C2); 45.8 (46.6*) (CH2, C7); 52.6 (52.9*) (CH, CI

(63.1*) (CH, C3); 63.8 (63.9*) (CH, C5); 74.4 (74.5*) (0CH2CC13); 79.7 (80.3*) (
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95.5 (CC13); 124.0, 126.8, 126.8, 128.2, 128.2 (ArCH x 5); 140.1 (ipso Q ; 151.0 ( N C O ) .
MS (Cf): m/z 394/396/398 (M+l, 60%). HRMS (CI4): Found: 395.0274; Required:
395.0272 for Ci6H18N0435Cl237Cl.

Synthesis of 8-(2,2,2-trichloroethoxycarbonyl)-6fi-(3,4-methylenedioxyphenyl)azabicyclo[3.2. l]octane-3f3,6a-diol (81).

To a stirred solution of 0.066M cerium chloride heptahydrate in methanol (3mL)

temperature was added 79 (0.049g, 0.112mmol), followed a few minutes later by s

borohydride (0.009g, 0.224mmol). Stirring continued for 30 minutes, after which

aqueous hydrochloric acid (2mL) was added to the mixture, and the mixture was p
onto DCM (lOmL) and extracted. The organic layer was washed with water (lOmL),

(sodium sulphate) and concentrated in vacuo to yield the crude product as a co

Chromatography (1:1 ethyl acetate:hexane; Rf = 0.48) yielded 81 (CnHi8N06Cl3) as

white solid, recrystallised from ethyl acetate (0.048g, 98% yield). Mp: 131-132

NMR (8): 1.65-1.85 (3H, m, H7a, H2e, H4e); 1.93-2.39 (3H, m, H2a, H4a, H7e);
(0.75H, dddd, J3a,

2e

= 6.3, J3a,

2a

= 9.6, H3a); 4.07 (0.25H, dd, J3e>

2a

= 5.4,

dd, J= 6.0, HI); 4.80-4.96 (2H, m, CH2CC13); 5.05 (1H, dd, J = 3.3, H5); 5.97 (2H
0CH2O); 6.76-6.96 (3H, m, ArH x 3).

13

C NMR (8): 33.9, 34.1, 34.6, 34.9 (CH2 x 3,

C2, C7); 58.2 (58.3*) (CH, CI); 64.8 (CH, C3); 65.4 (CH, C5); 74.6 (0CH2CC13); 95.6
(CC13); 101.3 (101.3*) (OCH20); 105.7 (ArCH); 108.4 (108.6*) (ArCH); 119.7 (119.8*),

121.3 (121.5*) (ArCH); 124.6 (C6), 126.0 (126.1*) (ispo C); 142.0 (142.1*) (isp

(148.1*) (ipso Q; 149.9 (NCO). MS (Cf): m/z 438/440/442 (M+l, 5%); 420/422/424 (
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H 2 0 , 100%); 402/404/406 (-H20, 1 3 % ) ; 386/388/390 (25%). H R M S

(CI*): Found:

421.0040; Required: 421.0065 for Ci7Hi6N0535Cl237Cl (loss of H20).

In the same way, using a 0.4M solution of cerium chloride heptahydrate in methanol

(5mL), 92 (O.lOOg, 0.229mmol) yielded, after chromatography (1:2 ethyl acetate:hexane
unreacted 92 (0.043g, 43% yield) and 81 as a colourless oil (0.048g, 48% yield, 84%
based on recovered 92). All spectral data agreed with that reported above.

General procedure for the removal of the 2,2,2-trichloroethylformate protecting gro
yield secondary amine derivatives:

The 2,2,2-trichloroethoxycarbonyl derivative (0.10-1.50mmol) and zinc dust (10

equivalents) were stirred in 90% acetic acid (2-20mL) at 40°C for 2 days. The reacti

mixture was basified (ammonia, pH 9) and extracted with diethyl ether (3xl00mL). The
combined organic extracts were washed with sodium chloride (sat.) (lOOmL), water
(2xl00mL), dried (sodium sulphate) and concentrated in vacuo to give the desired
secondary amine derivatives. In this way derivatives 52, 72, 60, 101, 102, 99, 100,
54 were prepared.

General procedure for hydrochloride salt formation:

The aryl tropanol derivatives (0.10-1.00mmol) were dissolved in diethyl ether (l-2mL

treated dropwise with 1M hydrochloric acid in diethyl ether (0.50-1.00mL). The preci
was filtered and dried under high vacuum to yield the desired hydrochloride salt.

255

Chapter Nine Experimental Methods and Da

3a-phenyl-8-azabicyclo[3.2.1]octan-3-ol(52).

Reaction of 66 (0.575g, 1.52mmol) yielded 52 (Ci3Hi7NO) as a pale yello
60% yield). *H NMR (8):1.74-1.78 (2H, m, H6e, H7e); 1.85 (2H, d, H6a, H7a,

2.22 (1H, d, OH, J= 3.9); 2.27 (1H, d, NH, /= 3.9); 2.30-2.40 (4H, m
H4e); 3.61 (2H, s, HI, H5); 7.18-7.22 (m, 2H, ArH); 7.27-7.35 (2H, m,
(2H, m, ArHx2).

13

C NMR (8): 28.9 (CH2, C4); 30.1 (CH2, C2); 40.0 (CH2, C7); 5

(CH2, C6); 54.3 (CH, HI); 54.9 (CH, H5); 73.3 (C3); 124.4, 126.7, 127.2, 1
(ArCH x 5); 129.5 (ipso C). MS (Cf): m/z 204 (M+l, 29%); 186 (-H20,

(100%). HRMS (ET"): Found: 186.1268; Required: 186.1283 for Ci3Hi6N (loss
The hydrochloride salt was made.

6j3-phenyl-8-azabicyclo[3.2.1]octan-3-spiro-2'-(l ',3 '-dioxolane)-6-o

Reaction of 76 (0.075g, 0.17mmol) yielded 58 (Ci5Hi9N03) after chromato
acetate) as a colourless oil (0.025g, 51% yield). !H NMR (8): 1.78 (2H,

(2H, dd, H2e, H4e, J= 4.2); 2.05 (1H, d, H7a, J= 7.2); 2.27 (1H, d, H2a(H4a),

2.45(1H, d, H4a(H2a), J= 14.4); 2.62 (1H, dd, H7e, J= 7.8, 8.1); 3.38 (1H,

(1H, t, H5 J= 3.9, 7.8); 3.92-3.99 (2H, m, OCH2); 4.03-4.14 (2H, m, OCH2);
ArH, J= 7.2); 7.33 (2H, dd, ArHx2, J = 7.2, 8.1); 7.67 (2H, d, ArHx2, J=

(8): 39.5 (CH2, C7); 43.4 (CH2, C4); 44.9 (CH2, C2); 53.5 (CHx2, CI, C5); 63

64.4 (OCH2); 82.2 (C6); 107.5 (C3); 124.7, 126.4, 127.9 (ArCHx5); 148.9 (i
(CF): m/z 262 (M+l); 244 (-H20); 184. The hydrochloride salt was made.
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6p-(3,4-methylenedioxy)-8-azabicyclo[3.2.1]octan-3-spiro-2,-(l ',3 '-dio

Reaction of 77 (0.09g, 0.19mmol) yielded 60 (Ci6Hi9N05) after chromatog

acetate) as a white solid (0.021g, 37% yield). Mp: 218-220°C. JH NMR (8)

OH, NH); 1.91 (2H, dd, H2e, H4e, J = 4.2); 2.03 (1H, d, H7a, J = 6.6); 2.

H2a(H4a), J= 14.4); 2.41 (1H, d, H4a(H2a), J= 14.4); 2.55 (1H, dd, H7e, J= 8.
(1H, d, HI, J= 4.2); 3.69 (1H, dd, H5 J= 4.2); 3.94-3.99 (2H, m, OCH2);

m, OCH2); 5.92 (2H, s, OCH20) 6.75 (1H, d, ArH5, J= 8.1); 7.10 (1H, dd, ArH
8.1); 7.27 (1H, d, ArH2, J= 2.1).

13

C NMR (8): 37.4 (CH2, C7); 40.8 (CH2, C4

C2); 56.2 (CHx2, CI, C5); 61.3 (OCH2); 67.3 (OCH2); 66.5 (C6); 101.2 (OCH20);

106.2 (ArCHx2); 107.6 (C3); 118.1 (ArCH); 135.8, 147.0, 147.9 (ipso-C x3).

m/z 306 (M+l); 288 (-H20); 244, 184. HRMS (CI*): Found: 305.1254; Require
for Ci6Hi8N05. The hydrochloride salt was made.

2-methoxy-6afi-phenyl-2,5-methano-hexahydro-2H-furo[3,2-b]pyrrol-6a-ol (1

Reaction of 90 (0.05g, 0.114mmol) yielded 101 (C^nNO^ after chromatogra
acetate) as a pale yellow oil (0.022g, 85% yield). *H NMR (8): 1.78 (1H,

1.92-2.04 (3H, m, H2e, H4e, H7e); 2.23-2.29 (2H, m, H2a, H4a); 2.50 (

(3H, s, OCH3); 3.79 (1H, d, HI, J = 5.1); 3.88 (1H, d, H5, J= 2.7); 7.24-7
ArHx5).

13

C NMR (8): 38.1 (CH2, C4), 41.4 (CH2, C2); 48.5 (CH2, C7); 49.7 (OCH3)

(CH, CI); 67.3 (CH, C5); 88.7 (C6); 106.2 (C3); 124.6, 126.9, 128.1, 128.3
(ipso Q. MS (CI+): m/z 232 (M+l, 100%); 200 (M+l - MeOH, 40%). HRMS (Cf):

Found: 231.1266; Required: 231.1260 for Ci4Hi7N02. The hydrochloride sal
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2-methoxy-6aP-(3,4-methylenedioxyphenyl)-2,5-methano-hexahydro-2H-furo
b]pyrrol-6a-ol (102).

Reaction of 91 (0.058g, 0.120mmol) yielded 102 (Ci5Hi7N04) as a pale ye

78 % yield). !H NMR (8): 1.91-2.01 (3H, m, H2e, H4e, H7a); 2.11-2.28 (3

H7e); 2.62 (1H, bs, TVH); 3.48 (3H, s, OCH3); 3.74 (1H, bd, HI, J= 3.6); 3.87 (1

5.95 (2H, s, OCH2Q); 6.77-6.80 (1H, m, ArH); 6.88-6.95 (2H, m, ArH x 2)

37.9 (CH2, C4), 41.4 (CH2, C2); 48.0 (CH2, C7); 49.7 (OCH3); 56.2 (CH, CI); 67.
C5); 88.6 (C6); 100.9 (OCH20); 105.8, 106.2 (ArCH x 2); 107.9 (C3); 117.8
136.0, 146.4, 147.5 (ipso C x 3). MS (Cf): m/z 276 (M+l, 70%); 244 (M+l

65%); 154 (55%). HRMS (CF"): Found: 276.1240; Required: 276.136 for Ci5Hi
hydrochloride salt was made.

6af3-phenyl-2,5-methano-hexahydro-2H-furo[3,2-b]pyrrol-6aa,2/3-diol(99)

Reaction of 93 (0.090g, 0.229mmol) yielded hemi-ketal 99 (Ci3Hi5N02) af

chromatography (10:2 ethyl acetate methanol; Rf 0.12) as a colourless o

yield). *H NMR (8): 1.88 (1H, d, H7a, J= 12.3); 1.89-2.20 (4H, m, H2e, H4e

2.24 (1H, d, J =11.7, H7e); 2.99 (2H, bs, TVH, OH); 3.81 (1H, s, HI); 3.89
7.23-7.44 (5H, m, ArHx5).

13

C NMR (8): 39.5 (CH2, C4), 46.1 (CH2, C2); 47.

56.1 (CH, CI); 67.3 (CH, C5); 89.3 (C6); 103.5 (C3); 124.8, 126.8, 127.1,
(ArCH x 5); 141.6 (ipso Q. MS (CF): m/z 218 (M+l, %); 200 (M+l - H20,

(CI*): Found: 218.1175; Required: 218.1181 for Ci3Hi6N02. The hydrochlori
made.
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6aP-(3,4-methylenedioxyphenyl)-2,5-methano-hexahydro-2H-furo[3,2-b]pyrrol-6aa,
diol (100).

Reaction of 94 (0.040g, 0.092mmol) yielded 100 (C14H15NO4) after chromatograph

ethyl acetate:methanol; Rf 0.13) as a colourless oil (0.014g, 58% yield). 'H NMR
(1H, dd, H7a, J7a,

7e

= 12.0, JlAt , = 3.3 ); 1.95-2.03 (4H, m, H2e, H4e, H2a, H

d, J7a,7e =11.7, H7e); 3.07 (2H, bs, TVH, OH); 3.75 (1H, s, HI); 3.86 (1H, s,
s, OCH20); 6.76 (1H, d,J= 8.1, ArH); 6.66 (1H, d, J= 1.5, ArH); 6.90 (1H, dd, J= 8.1,
1.5 ArH).

13

C NMR (8): 39.3 (CH2, C4), 46.1 (CH2, C2); 47.3 (CH2, C7); 55.9 (CH,

67.1 (CH, C5); 89.3 (C6); 101.0 (OCH20); 103.5 (C3); 106.0 (ArCH); 107.9 (ArCH);

118.1 (ArCH); 135.7.0, 146.7, 147.8 {ipso Cx3). MS (CI*): m/z 262 (M+l, 40%); 244 (
- H20, 80%). HRMS (CI*): Found: 261.1002; Required: 261.1001 for Ci4H15N04. The
hydrochloride salt was made.

6fi-phenyl-8-azabicyclo[3.2. l]octane-3 a, 6/3-diol (50).

Reaction of 80 (0.059g, 0.149mmol) yielded 50 (Ci3HnN02) after chromatography (

ethyl acetate:methanol, Rf 0.18) as a colourless oil, which was recrystallised

(0.012g, 36% yield); mp: lR NMR (8): 1.89 (1H, dd, J= 11.1, 14.7, H7a); 2.03 (1H, 2

dd, J= 4.5, 4.8, H4e); 2.13 (1H, 2 x dd, J= 4.5, 4.8, H2e); 2.36 (2H, dd, J= 14

H2a, H4a); 2.64 (1H, dd, J= 7.5, H7e); 3.29 (1H, s, OH); 3.53-3.56 (4H, m, H

OH); 4.17 (1H, dd, J = 5.1, 10.2, H3a); 7.25 (1H, d, J= 7.2, ArH); 7.34 (2H, dd
7.8, ArH x 2); 7.60 (2H, dd, J= 7.2, 1.2, ArH x 2).

13

C NMR (8): 33.5 (CH2, C4),

(CH2, C2); 45.5 (CH2, C7); 53.0 (CH, CI); 63.7 (CH, C3); 64.1 (CH, C5); 82.8 (C6);

126.7, 128.3 (ArCH x 5); 148.7 (ipso Q. MS (CI*): m/z 220 (M+l, 40%); 202 (-H20
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100%). H R M S

(CI*): Found: 220.1335; Required: 220.1338 for C 1 3 Hi 8 N0 2 . The

hydrochloride salt was made.

6f3-(3,4-methlenedioxyphenyl)-8-azabicyclo[3.2.1]octane-3a,6f3-diol (54).

Reaction of 81 (0.048g, 0.109mmol) yielded 54 (C14H17N02) after chromatography
ethyl acetate:methanol; Rf 0.12) as a colourless oil which was recrystallised

ether, (0.015g, 52% yield); mp:. !H NMR (8): 1.90 (1H, dd, J= 15.0, 16.5, H7a); 2

2 x dd, J= 3.9, H4e); 2.16 (1H, 2 x dd, J= 4.2, H2e); 2.35 (2H, dd, J= 14.4, H
2.60 (1H, dd, J= 7.8, H7e); 3.23 (1H, s, OH); 3.56 (1H, dd, J= 3.9, HI); 3.77
NH, OH); 4.18 (1H, dd, J = 4.5, 9.9, H3a); 5.94 (2H, s, OCH20); 6.75 (1H, d, J = 8.4,
ArH); 7.00 (1H, dd, J= 1.8, 8.1, ArH); 7.19 (1H, dd, J= 1.8, ArH).

13

C NMR (8):

(CH2, C4), 40.4 (CH2, C2); 45.4 (CH2, C7); 52.8 (CH, CI); 63.7 (CH, C3); 64.1 (
82.5 (C6); 100.9 (OCH20); 106.3 (ArCH); 107.5 (ArCH); 117.5 (ArCH); 142.8 (ipso Q;

146.3 (ipso Q; 147.8 (ipso Q. MS (Cf): m/z 246 (M+1-H20, 10%). The hydrochlorid
was made.

9.6 Experimental for Chapter Five: Synthesis of Spirocyclic Derivatives

Synthesis of (2R,5R)-5-allyl-2-tert-butyl-l-aza-3-oxabicyclo[3.3.0]octan-4-one

L-Proline (anhydrous) (5.0g, 0.043mol) was suspended in anhydrous n-pentane (

under argon. Pivaldehyde (23ml, 0.215mol) was added, followed by triflouroacet

(0.077mL, 1.892mmol). The mixture was heated at reflux for 66 hours with the a

removal of water using a dean-stark apparatus. The clear solution was filtered
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remaining white solid and concentrated in vacuo to yield 122 (Ci 0 Hi 7 NO 2 ) as a colourless

oil (3.66g, 47%) yield). The colourless oil immediately began to hydrolyse, produc

white solid (proline), and was used immediately without purification. Freshly pre

lithium diisopropylamine (21mL, 0.021mol) was added to a 0.17M solution of 122 (
0.02mol) in anhydrous THF (120ml) at -78°C. After 30 mins, allyl bromide (1.9mL,

0.022mol) was added dropwise and the temperature was allowed to warm to -30°C ove
hours. The mixture was partitioned between DCM (lOOmL) and water (lOOmL). The

organic layer was washed with water (lOOmL), dried (sodium sulphate) and concentr

vacuo to yield a crude yellow oil which was dried under high vacuum. Chromatograp

(1:1 DCM:hexane) yielded a yellow powder (0.1 lg), which ]H NMR indicated consist
a mixture of 123 (Ci3H2,N02) and some 121 (Ci0Hi7NO2). MS (CI*): m/z 184 (M+l, 121,
60%); 216 (40%); 224 (M+l, 123, 20%).

Synthesis of S-l,2-pyrrolidinedicarboxylic acid,l-(l,l-dimethylethyl)ester (126).

Proline (2.0g, 17.37mmol) was dissolved in distilled water (45mL) and cooled in

bath. To this solution was added 10% sodium hydroxide (9mL), followed by a soluti

di-tert-butyldicarbonate (4.32g, 19.80mmol) in dioxane (45mL). The reaction was s

0°C for 5 hours and room temperature overnight. The mixture was washed with dieth

ether (lOOmL) and the aqueous phase acidified with 2M hydrochloric acid to pH3, a

extracted with ethyl acetate (4xl50mL). Combined organic extracts were washed wit
sodium chloride (sat.) (150mL), water (150mL), the dried (sodium sulphate) and

concentrated in vacuo to yield 126 (Ci0Hi7NO4) as a white solid, which was recrys

form diethyl ether (3.42g, 91% yield); m.p. 133°C (lit. m.p. 133-135°C353). *H NMR
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1.43 (3H, s, C H 3 ) ; 1.49 (6H, s, 2xCH 3 ); 1.92-2.00 (2H, m , H 3 , H3'); 2.03-2.14 (1H, m,

H4,); 2.26-2.32 (1H, m, H4'); 3.35-3.57 (2H, m, H5, H5'); 4.25 (4.35*) (1H, d

3.9 (2.7*), J2,y = 8.1); 9.27 (1H, bs, COOH). 13C NMR (8): 23.6 (24.3*) (CH2, C4); 28.

x CH3); 30.8 (CH2, C3); 46.3 (46.9*) (CH2, C5); 59.0 (C2); 80.3 (81.2*) ((CH3)3CO)
(165.2*) (OCO); 175.2 (178.7*) (CO, COOH). MS (Cf): m/z 216 (M+l, 29%); 198 (H20, 10%); 160 (100%); 116 (60%).

Procedure for the esterification of 126

Synthesis of S-l,2-pyrrolidinedicarboxylic acid,l-(l,l-dimethylethyl)-2-methyl
(128).

A solution of 126 (3.42g, 15.89mmol), dimethylaminopyridine (0.97g, 7.94mmol) a
methanol (1.93mL, 47.67mmol) was cooled in an ice-bath with stirring. l-(3-

Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (3.35g, 17.48mmol) was a
and the mixture was stirred at 0°C for 2 hours and room temperature overnight.

reaction mixture was evaporated to dryness, taken up in ethyl acetate (lOOmL) a

(lOOmL), separated, and the water fraction further extracted with ethyl acetate

Combined organic fractions were washed with sodium chloride (sat.) (2xl00mL), w

(2xl00mL), then dried (sodium sulphate) and concentrated in vacuo to yield a co

oil which partially crystallised upon standing. Chromatography (1:4 ethyl aceta
Rf 0.27) yielded 128 (CiiHi9N04) as a colourless oil (3.39g, 93%); aD = -58.110

22°C, 5cm2 path length); !H NMR (8): 1.39 (6H, s, 2 x CH3); 1.44 (3H, s, CH3); 1.

(3H, m, H3, H3\ H4); 2.15-2.23 (1H, m, H4'); 3.38-3.55 (2H, m, H5, H5'); 3.70
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(3H, s, OCH 3 ); 4.20 (4.31*) (1H, dd, H2, J2>3 = 3.9 (3.3*)). 1JC N M R (8): 23.6 (24.3*)

(CH2, C4); 28.2 (3 x CH3); 29.9 (30.8*) (CH2, C3); 46.3 (46.5*) (CH2, C5

(OCH3); 58.7 (59.1*) (CH, C2); 79.8 ((CH3)3CO); 153.8 (NCO); 173.4 (173.7*)
COOMe). MS (CI4): m/z 230 (M+l, 100%).

Synthesis of S-l,2-pyrrolidinedicarboxylic acid,l-(l,l-dimethylethyl)-2

In the same manner, 126 (2.04g, 9mmol) was reacted to form 127 (Ci2H2iN0
isolated after chromatography (1:4 ethyl acetate:hexane; Rf 0.48) as a

55% yield). !H NMR (8): 1.28 (3H, t, CH3, J = 7.2); 1.42 (6H, s, 2 x CH3); 1.4

CH3); 1.83-2.08 (3H, m, H3, H3', H4); 2.15-2.27 (1H, m, H4'); 3.36-3.
H5'); 4.12-4.32 (3H, m, H2, OCH2).

13

C NMR (8): 14.1 (14.2*) (CH2CH3); 23.6

(CH2, C4); 28.2, 28.4 (3 x CH3); 29.9 (30.8*) (CH2, C3); 46.3 (46.5*) (C

(59.1*) (CH, C2); 60.8 (OCH2); 79.8 ((CH3)3CO); 153.8 (154.3*) (NCO); 172.9
(CO). MS (CI4): m/z 244 (M+l, 100%).

Synthesis of S-l,2-pyrrolidinedicarboxylic acid,l-(l,l-dimethylethyl)-2
(125).

In the same manner, 126 (3.542g, 16.5mmol) was reacted to form 125 (Ci4H

was isolated after chromatography (1:4 ethyl acetate:hexane; Rf 0.59) a
(2.478g, 55% yield). !H NMR (8): 1.44 (6H, s, 2 x CH3); 1.46 (3H, s, CH3);

CH3); 1.85-1.97 (3H, m, H3, H3', H4); 2.13-2.25 (1H, m, H4'); 3.38-3.
H5'); 4.11 (4.19*) (1H, dd, H2, J= 3.6 (3.0*), 8.4).

13

C NMR (8): 23.4 (24.

27.0 (3 x CH3); 28.3 (3 x CH3); 29.8 (30.8*) (CH2, C3); 46.2 (46.4*) (CH
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C2); 79.3 (79.5*) ((CH 3 ) 3 CO); 80.7 ((CH 3 ) 3 CO); 153.9 ( N C O ) ; 172.3 ( C O ) . M S (CI4):
m/z 272 (M+l, 100%).

Procedure for the allylation of 128,127 and 125.

THF (4.82mL) was syringed into a flask under argon. Diisopropylamine (1.48mL,

10.5mmol) was added and the solution cooled to 0°C with stirring. n-Butyl lithium
in Hexane, 4.2mL, 10.5mmol) was added and the solution was stirred for 30 mins at
1M solution of lithium diisopropylamine was thus prepared.

Freshly prepared lithium diisopropylamine (1M, 1.5 molar equivalents) was added to
0.17M stirred solution of the Boc-protected proline ester substrate in anhydrous

an argon atmosphere at -78°C. After 30 minutes, allyl bromide (1.5 molar equivalen

added, and the solution stirred at -78°C, with the temperature warming to -30°C ov

The mixture was partitioned between DCM (150mL) and water (150mL), and the organic

layer was washed with water (2xl00mL), then dried (sodium sulphate) and concentrat

vacuo, leaving the crude product as a yellow oil. Chromatography provided the desi
product as a pale yellow oil.

Synthesis of (±) 2-(2-propenyl)-l,2-pyrrolidinedicarboxylic acid, 1-(1,1-dimethy
methyl ester (143).

The methyl ester 128 (1.45g, 6.32mmol) was reacted to afford 143 (Ci4H23N04) after

chromatography (1:4 ethyl acetate:hexane; Rf 0.55) as a yellow oil (1.28g, 75% yiel

-0.033 (ethanol, 22°C, 5cm2 path length); !H NMR (8): 1.40 (6H, s, 2 x CH3); 1.43 (3

CH3); 1.78-1.87 (3H, m, H3, H3', H4); 2.01-2.19 (2H, m, H4', CH); 2.58 (1H, dd,
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CH'); 2.90 (3.08*) (1H, dd, J = 6.6, H5); 3.30-3.40 (1H, m , H5); 3.70 (3H, s, O C H 3 ) ; 5.075.13 (2H, m, OH2); 5.67-5.79 (1H, m, OH).

13

C NMR (8): 22.6 (23.0*) (CH2, C4); 28.

28.4 (3 x CH3); 35.6 (36.9*) (CH2, C3); 38.3 (39.5*) (CH2); 48.4 (48.5*) (CH2, C5);

(52.1*) (OCH3); 66.9 (67.4*) (C2); 79.5 (80.0*) ((CH3)3CO); 118.7 (119.0*) (OH2); 133
(133.6*) (OH); 153.5 (NCO); 175.1 (CO). MS (CI4): m/z 270 (M+l, 60%); 242 (-*Bu,
10%); 214 (100%).

Synthesis of (+) 2-(2-propenyl)-l,2-pyrrolidinedicarboxylic acid,l-(l,l-dimethyl
ethyl ester (142).

The ethyl ester 127 (3.471g, 14.27mmol) was reacted to afford 142 (Ci5H25N04) afte

chromatography (1:7 ethyl acetate:hexane; Rf 0.43) as a yellow oil (2.87g, 71% yie

NMR (8): 1.27 (3H, t, CH3, J= 7.2); 1.41 (6H, s, 2 x CH3); 1.44 (3H, s, CH3); 1.7

(2H, m, H3, H3'); 2.01-2.19 (2H, m, H4, H4'); 2.58 (1H, dd, J= 8.1, CH); 2.92 (3

(1H, dd, J= 6.6, CH'); 3.23-3.41 (1H, m, H5); 3.54-3..61 (3.64-3.72*) (1H, m, H
4.25 (2H, m, OCH2); 5.11 (2H, dd, J = 6.0, 12.3, OH2); 5.67-5.81 (1H, m, OH). 13C

NMR (8): 14.2 (CH2CH3); 22.5 (23.1*) (CH2, C4); 28.3, 28.4 (3 x CH3); 35.7 (37.1*) (

C3); 38.2 (39.4*) (CH2); 48.5 (CH2, C5); 60.9 (61.0*) (OCH2); 66.9 (67.4*) (C2); 79.4
(80.0*) ((CH3)3CO); 118.6 (118.9*) (OH2); 133.4 (133.8*) (OH); 153.8 (OCO); 174.2
(CO). MS (CI4): m/z 232 (100%), 228 (-'Bu, 80%).

Synthesis of (±) 2-(2-propenyl)-l,2-pyrrolidinedicarboxylic acid,l-(l,l-dimethyl
tert-butyl ester (141).

The tert-butyl ester 125 (1.681g, 6.17mmol) was reacted to afford 141 (Ci7H29N04),

chromatography (1:4 diethyl ether:hexane; Rf 0.36) as a yellow oil (0.782g, 85% y
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based upon 4 8 % 125 recovered). ! H N M R (8): 1.44, 1.46, 1.47 (18H, s, 6 x CH 3 ); 1.73-1.

(2H, m, H3, H3'); 1.96-2.06 (1H, m, H4); 2.09-2.18 (m, 1H, H4'); 2.5
9.0, 14.1, CH); 2.95 (3.05*) (1H, dd, J= 6.6, 14.1, CH'); 3.29-3.41

(3.63-3.71*) (1H, m H5'); 5.10 (2H, dd, OH2, J= 8.4, 12.3); 5.66-5.76 (1
NMR (8): 22.3 (23.1*) (CH2, C4); 27.9 (3 x CH3); 28.3 (3 x CH3); 35.6

38.2 (39.0*) (CH2); 48.5 (48.6*) (CH2, C5); 67.1 (67.7*) (C2); 79.1 (79.

80.5 (80.8*) ((CH3)3CO); 118.3 (118.8*) (OH2); 133.4 (134.0*) (OH); 153.7

173.4 (173.6*) (CO). MS (CI4): m/z 312 (M+l, 5%); 256 (-*Bu, 10%); 200
(100%).

Synthesis of bromo cyclohexane (146).

Alumina (2.00g) was equilibrated with the atmosphere at 120°C for 68

was stoppered and the contents cooled to room temperature. A solution

cyclohexane (O.lOlmL, l.OOmmol) in dichloromethane (lmL) was added an

suspension was stirred under nitrogen. A solution of 1M trimethylsily
4mmol, in 4mL anhydrous DCM) was added dropwise over 20 minutes, then
continued for 2 hours. The suspension was filtered, and the filtrate

(3x25ml). The combined organic fractions were washed with sodium hydr

(sat.) (2x50mL), followed by water (50mL), then dried (sodium sulphate

in vacuo to yield 146 (C6HnBr) as a colourless oil (0.147g, 90% yield)

(1H, s, CH); 1.34-1.43 (2H, m, CH2); 1.55-1.60 (1H, m, CH); 1.76-1.
2.13-2.18 (2H, m, CH2); 4.16-4.23 (1H, m, HC-Br).
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Synthesis

of

(±)

2-(2-bromopropyl)-l,2-pyrrolidinedicarboxylic

acid,

dimethylethyl)-2-methyl ester (138).

Following the above procedure, a solution of 143 (0.500g, 1.855mmol) in anhydr
(15mL) was added to dried alumina and the resulting suspension was stirred at

temperature. A 1M solution of trimethylsilyl bromide (7.42mmol) in anhydrous D

added dropwise over 20 minutes and the solution was stirred at room temperatur

hours. After the usual work-up, chromatography (1:4 ethyl acetate:hexane) affo

recovered 143 (0.300g, 60% yield) and 148 (C9H15N02) as a pale yellow oil (Rf 0

ethyl acetate:hexane) (O.lOOg, 32% yield). Spectral data for 148: !H NMR (8): 1

(3H, m, H3, H3\ H4); 2.09-2.14 (1H, m, H4'); 2.29 (1H, dd, J = 8.4, CH); 2.4

NH); 2.52 (1H, dd, J= 8.4, CH); 2.93 (2H, dd, J= 6.9, H5, H5'); 3.66 (3H, s, OCH3); 5.00
5.07 (2H, m, OH2); 5.62-5.73 (1H, m, OH);

13

C NMR (8): 27.8 (CH2, C4); 35.1 (

C3); 43.9 (CH2); 46.3 (CH2, C5); 52.1 (OCH3); 69.1 (C2); 118.1 (OH2); 133.7 (OH);
177.0 (CO). MS(CI): m/z 170 (M+l, 100%); 128 (30%).

Synthesis of N-(phenylmethyl)benzamide (151).

Sodium diethyldibenzylamidoaluminate (1.83mmol) was prepared by heating at ref

under argon for 1 hour the mixture of 2M toluene sodium diethyldihydroaluminat

(0.915mL, 1.83mmol) and benzylamine (0.398mL, 3.66mmol) in THF:toluene (1:1) (

150 (0.500g, 3.33mmol) in THF:toluene (1:1) (lmL) was added, and the mixture w

heated at reflux for 1 hour. The reaction mixture was quenched with dilute hyd

acid (5mL) and extracted with ethyl acetate (3x50mL). Combined extracts were w

with water (2x50mL), then dried (sodium sulphate) and concentrated in vacuo to
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(Ci 5 Hi 5 NO) as an off-white solid (0.70g, 9 3 % yield). M p : 104-105°C (lit. M p : 104-

106°C353) !H NMR (8): 3.64 (2H, s, PhCH20); 4.41 (1H, s, NCHPh); 4.43 (1H, s, NCHPh);
5.75 (1H, bs, NH); 7.17-7.38 (10H, m, ArH x 10).

13

C NMR (8): 43.6, 43.8 (PhCH2

127.4, 127.5, 128.6, 129.0,129.4 (ArCH x 10); 134.8 (ipso C); 138.1 (ipso C); 1
MS (CI*): m/z 226 (M+l, 100%).

Attempted synthesis of (+) 2-(2-propenyl)-l-pyrrolidinecarboxylic acid,l-(l,ldimethylethyl)-2-benzamide (139) via sodium diethyldibenzylamidoaluminate.

Sodium diethyldibenzylamidoaluminate (1.49mmol) was prepared by heating at ref

under argon for 1 hour the mixture of 2M toluene sodium diethyldihydroaluminat
(0.740mL, 1.49mmol) and benzylamine (0.324mL, 2.97mmol) in toluene (4mL). 141

(0.827g, 2.70mmol) in toluene (2ml) was added, and the mixture refluxed for 21

reaction mixture was quenched with dilute hydrochloric acid (5mL) and extracte

ethyl acetate (3x50mL). The combined extracts were washed with water (2x50mL),

dried (sodium sulphate) and concentrated in vacuo to yield a crude yellow oil.

Chromatography (1:4 ethyl acetate) recovered 141 as a yellow oil (0.65g, 79% r
identified by !H NMR.

In an analogous preparation, 143 (O.lOOg, 0.41mmol) was added to a solution o

prepared sodium diethyldibenzylamidoaluminate (0.615mmol) in toluene and heate

reflux for 21 hours. The usual work up, followed by chromatography (preparativ

ethyl acetate:hexane; Rf 0.17) afforded 152 (Ci6H18N202) as a pale yellow oil (0

yield). ]H NMR (8): 1.26-2.10 (3H, m, H3, H3', H4); 2.19-2.30 (1H, m, H4'); 2.3

J= 6.6, 13.8, CH); 2.56 (1H, dd, J= 7.5, 13.8, CH'); 3.15-3.24 (1H, m, H5);
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m, H5'); 4.59 (2H, dd, J = 7.2, 14.7, PhC# 2 ); 4.71 (1H, dd, J= 15.0, 7.5, PhCH); 5.08 (2H,
dd, /= 10.2, 15.9, OH2); 5.54-5.66 (1H, m, OH); 7.24-7.35 (5H, m, ArH x 5).

1

(8): 26.1 (CH2, C4); 32.1 (CH2, C3); 39.5 (CH2); 42.5 (CH2Ph); 45.0 (CH2, C5); 72.2 (C2);
121.1 (OH2); 127.6, 128.1, 128.4 (ArCH x 5); 130.9 (OH); 135.8 (ipsoQ; 159.8
(NC(N)=0); 175.3 (CO). MS (CI4): m/z 111 (M+l, 100%), 229 (30%).

Attempted synthesis of 139 via dimethylaluminium benzylamide.

Dimethylaluminium benzylamide was prepared by slowly adding trimethylaluminium
in hexane, 0.288mL, 0.576mmol) to a stirred solution of benzylamine (0.078mL,

0.72mmol) in anhydrous DCM (3mL) at room temperature under nitrogen. The mixtur
was stirred at room temperature for 15 minutes, then 143 (O.lOOg, 0.36mmol) in

(lmL) was added dropwise. The mixture was heated at reflux for 16 hours. The re

was quenched with dilute hydrochloric acid (2mL) and extracted with DCM (3x20mL

combined extracts were washed with water (5mL), then dried (sodium sulphate) an

concentrated in vacuo to recover 143 as a yellow oil (O.lOOg), as identified by

Synthesis of (±)-2-(2-propenyl)-l,2-pyrrolidinedicarboxylic acid,l-(l,l-dimeth
ester (149).

Lithium hydroxide method: A solution of 143 (1.09g, 4.05mmol) in dry THF (5mL)
stirred in a 0.2M solution of lithium hydroxide (lOOmL) at 55°C for 24 hours.
mixture was evaporated to dryness, taken up in diethyl ether (50mL) and water

separated. The aqueous mixture was acidified with dilute hydrochloric acid and

with diethyl ether (4x100ml). The combined organic extracts were washed with so
chloride (sat.), water, then dried (sodium sulphate) and concentrated in vacuo
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(Ci 3 H 22 N0 4 ) as an off-white solid (0.60g, 5 8 % yield). Unreacted 143 was recovered from

the initial diethyl ether separation (0.46g, 42% recovery). 143 was recrystall

ethanol-water to afford white crystals. Mp: 94-97°C. !H NMR (8): 1.41, 1.45 (9H
CH3); 1.75-1.98 (3H, m, H3, H3\ H4); 2.13 (1H, dd, J = 6.9, H4'); 2.40-2.46

2.51-2.69 (1H, m, CH'); 2.88-2.98 (1H, m, H5); 3.23-3.40 (1H, m H5'); 5.14 (

OH2, J= 6.3, 9.0, 15.3); 5.58-5.78 (1H, m, OH); 7.77 (1H, bs, OH). 13C NMR (8): 22.

(22.9*) (CH2, C4); 28.5 (28.6*) (3 x CH3); 35.0 (37.3*) (CH2, C3); 38.3 (39.4*)

48.9 (49.4*) (CH2, C5); 66.1 (67.1*) (C2); 80.8 (81.7*) ((CH3)3CO); 119.4 (120.
(OH2); 132.2 (133.3*) (OH); 153.9 (NCO); 176.5 (180.5*) (CO, COOH). MS (CI4):
m/z 256 (M+l, 10%); 214 (100%); 200 (40%); 170 (80%).

Sodium hydroxide method: To a solution of 143 (3.65g, 13.55mmol) in THF (40mL)

added 1M sodium hydroxide (40mL) and the mixture was stirred at 80°C for 72 ho

reaction mixture was concentrated in vacuo, then taken up in diethyl ether (lO
water (lOOmL). The diethyl ether layer was separated and the aqueous fraction

acidified to pH3 with 2M hydrochloric acid, and extracted with diethyl ether (

The combined organic fractions were washed with sodium chloride (sat.) (2xl00m

(2xl00mL), then dried (sodium sulphate) and concentrated in vacuo to yield 149

(Ci3H22N04) as a pale yellow oil which crystallised off-white upon standing, an

recrystallised from ethanol-water (3.07g, 89% yield); All spectroscopic and mel
data agreed with that given above.
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Synthesis of 139 from 149.

The acid 149 (1.50g, 5.875mmol), benzylamine (0.642mL, 5.875mmol), 1-

hydroxybenzotriazole (0.794g, 5.875mmol) and triethylamine (0.819mL, 5.875mmo

dissolved in anhydrous chloroform (30mL). A solution of dicyclohexylcarbodiimi

(1.21g, 5.875mmol) in anhydrous chloroform (lOmL) was added and the solution w

stirred at room temperature under nitrogen for 16 hours. Precipitated dicycloh

filtered off, and the filtrate was diluted with chloroform (lOOmL) before bein

1M aqueous sodium hydrogen carbonate (50mL), 10% aqueous citric acid (50mL), so

chloride (sat.) (50mL) and water (50mL), then dried (sodium sulphate) and conc
vacuo to yield an orange oil which crystallised upon standing. Chromatography

acetate:hexane; Rf 0.41) provided 139 (C20H28N2O3) as a white solid (2.00g, 99% y

which was recrystallised from diethyl ether/hexane to yield white crystals. Mp
!

H NMR (8): 1.34 (1.43*) (9H, s, 3 x CH3); 1.73-1.96 (3H, m, H3, H3', H4); 2.

(1H, m, H4'); 2.61 (2.75*) (2H, dd, J= 7.5, 8.1, CH CH'); 2.98-3.10 (1H, m, N

3.43 (1H, m, H5); 3.45-3.52 (3.61-3.64*) (1H, m H5'); 4.34-4.52 (2H, bm, CH2Ph)
(2H, dd, J= 16.8, 9.0, OH2); 5.65 (1H, dddd, J= 8.1, 9.3, 8.7, 7.2, OH); 7.28
x 5).

13

C NMR (8): 22.2 (22.5*) (CH2, C4); 28.3 (3 x CH3); 34.5 (37.6*) (CH2, C3

(38.7*) (CH2); 43.5 (43.7*) (CH2Ph); 49.0 (49.5*) (CH2, C5); 68.3 (69.9*) (C2); 8
(80.8*) ((CH3)3CO); 119.3 (119.5*) (OH2); 126.9, 127.1, 127.4, 127.8, 128.3 (ArCH
132.5 (132.7*) (OH); 138.4 (ipsoQ; 155.0 (NC(O)O); 173.8 (NCO amide). MS (CI4):
m/z 345 (M+l, 64%), 289 (-'Bu, 100%), 245 (80%). HRMS (CI4): Found: 345.2180;
Required: 345.2180 for C20H29N2O3.
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Alternatively, to a stirred solution of 149 (0.08g, 0.313mmol) in anhydrous D C M (5mL)
was added dimethylaminopyridine (0.004g, 0.031mmol) and benzylamine (0.041mL,
0.376mmol) and the mixture was cooled to 0°C. Dicyclohexylcarbodiimide (0.07lg,

0.345mmol) was added and stirring continued at 0°C for 5 minutes and 40°C for 24 hou

Precipitated dicyclohexylurea was filtered off and the filtrate was evaporated in v

residue was taken up in DCM (30mL) and further filtered of precipitated urea. The re
was washed with dilute hydrochloric acid (30mL), aqueous sodium hydrogen carbonate

(sat.) (30mL), water (2x3 OmL), then dried (sodium sulphate) and concentrated in vac

yield a pale yellow oil. Chromatography (1:4 ethyl acetate:hexane; Rf 0.41) provided

(C20H28N2O3) as a yellow oil (0.035g, 32% yield). All spectroscopic data agreed with t
above for 139.

Synthesis of S-2-[[(phenylmethyl)amino]carbonyl]-l-pyrrolidinediearboxylic acid, 1dimethylethyl) ester (153).

The acid 126 (l.OOg, 4.64mmol), benzylamine (0.507mL, 4.64mmol), 1hydroxybenzotriazole (0.627g, 4.64mmol) and triethylamine (0.647mL, 4.64mmol) were
dissolved in anhydrous chloroform (3 OmL) under nitrogen. A solution of

dicyclohexylcarbodiimide (0.957g, 4.64mmol) in anhydrous chloroform (15mL) was added

and the reaction was stirred at room temperature for a total of 48 hours. Precipitat
dicyclohexylurea was filtered off, the filtrate was diluted with chloroform (5OmL),
with 1M aqueous sodium hydrogen carbonate (100ml), 10% aqueous citric acid (lOOmL),

water (lOOmL), then dried (sodium sulphate) and concentrated in vacuo to yield a pal
yellow solid. Chromatography (1:4 ethyl acetate:hexane; Rf 0.07) provided the amide

(C17H24N203) as a white solid (0.95g, 67% yield). Mp: 130-131°C (lit. mp: 130-131°C354)
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!

H N M R (8): 1.40 (1.43*) (9H, 2 x s, 3 x CH 3 ); 1.90 (3H, bs, H3, H3', H4); 2.18 (2.3

(1H, 2 x s, H4'); 2.98-3.10 (1H, m. NH); 3.42 (2H, bs, H5, H5'); 4.22
H2); 7.25-7.32 (5H, s, ArH x 5).

13

C NMR (8): 24.6 (25.6*) (CH2, C4);

31.0 (33.9*) (CH2, C3); 43.2 (C#2Ph); 47.1 (48.9*) (CH2, C5); 59.8 (61.3*
((CH3)3CO); 127.4, 128.6 (ArCH x 5); 138.2 (ipsoC); 153.8 (NC(O)O); 174.0
amide). MS (CI4): m/z 305 (MH4, 80%), 249 (MH4- 'Bu 100%), 205 (85%).

Synthesis of 139 from 153.

Freshly prepared lithium diisopropylamine (1M in THF:hexane, 3.28mL, 3

added to a 0.17M solution of 153 (0.50g, 1.64mmol) in anhydrous THF (9

nitrogen at -78°C with stirring. After 30 minutes allylbromide (0.14mL

added, and the solution was stirred at -78°C, with the temperature ris

hours. The mixture was partitioned between DCM (lOOmL) and water (lOOmL

organic layer was washed with water (2xl00mL), then dried (sodium sulp

concentrated in vacuo to yield the crude product as an off-white solid

product (1:4 ethyl acetate:hexane) revealed the presence of 153 (Rf 0.

product (Rf 0.41). !H NMR and MS (CI4) analysis of the crude product mix

153 and some 139 (approx. 10%). MS (CI4): m/z 345 (MH4, 10%), 305 (MH4, SM
(100%), 205.
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Attempted

synthesis

of

l-(2,2-dimethylethyl)-7-benzyl-8-methyl-6-oxo-l,

diazaspiro[4.4]non-8-en-l-carboxylate (156) utilising palladium (II) chloride
bisacetonitrile and sodium hydride.

A solution of 139 (O.lOOg, 0.290mmol), sodium hydride (0.0115g, 0.479mmol) and

palladium (II) chloride toacetonitrile (0.113g, 0.435mmol) were stirred in THF at
temperature under nitrogen for 16 hours. The mixture was filtered of palladium(O)

concentrated to yield a crude brown oil (0.150g) which TH NMR indicated consisted o

1:1 mixture of 156 and 139. TLC analysis (1:4 ethyl acetate:hexane) revealed three
components: Rf 0.64, Rf 0.33, Rf 0.03. ]HNMR (8): 1.26 (1.5H, s, CH3); 1.34 (3H, s,

1.44 (6H, s, 2 x CH3); 1.80-1.94 (3H, m, H3, H3\ H4); 2.28 (1H, dd, J= 7.2, 7.8
2.56-2.60 (0.5H, m, CH); 2.72-2.81 (0.5H, m, CH); 3.03 (0.5H, bs, NH); 3.28-3.30

H5), 3.48-3.53 (0.5H, m. H5'); 3.71-3.75 (0.5H, m, H5); 4.35 (1H, dd, J = 6.6, 7.2
CH2Ph); 4.45-4.52 (1H, m, CH2Ph); 5.15 (1H, dd, J= 7.5, 9.3, OH2); 5.54 (0.5H, t, J =

2.4, OH); 5.58-5.72 (0.5H, m, OH); 7.28 (5H, s, ArH x 5); MS(CI*): m/z 345 (M+l, 13
50%), 343 (M+l, 156, 15%), 287 (30%), 245 (90%).

Attempted synthesis of 156 utilising palladium (IT) chloride bisacetonitrile, sod
hydride and triethylamine.

Palladium (II) chloride feacetonitrile (0.113g, 0.435mmol) was transferred to a f

stoppered and blown with nitrogen for 10 mins. Anhydrous THF (5mL) was added and t

mixture was stirred under nitrogen for 10 minutes. 139 (O.lOOg, 0.290mmol) in anhy

THF (4mL) was added via syringe and the mixture was stirred at room temperature fo

minutes. Sodium hydride was added and the mixture was stirred at 50°C for 45 minut
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Triethylamine (0.061ml, 0.435mmol) was added via syringe and the mixture was heated to

reflux. Further triethylamine (0.061ml, 0.435mmol) was added at 1 hour intervals f

hours. The mixture continued to be heated at reflux for 20 hours. The reaction mix

filtered of precipitated palladium (0) through celite and rinsed with ethyl acetat

The combined filtrate and ethyl acetate was washed with water (2x50mL), then dried
(sodium sulphate) and concentrated in vacuo to yield a yellow oil. Chromatography

ethyl acetate) yielded 156 (C2oH26N203) (0.008g), however a clean NMR sample could n

be obtained. The sample was identified by MS (CI4): m/z 3A3 (M+l, 20 %); 305 (55%); 28
(100%).

Synthesis of 156 utilising palladium (II) chloride bisacetonitrile and triethylami

Palladium (II) chloride feacetonitrile (0.150g, 0.578mmol) was transferred to a fl

stoppered and blown with nitrogen for 10 minutes. Anhydrous THF (8.09mL) was added

and the mixture was stirred under nitrogen for 10 minutes. A solution of 139 (0.19

0.578mmol) in THF (2.02mL) was added via syringe and the mixture was stirred at 40
for 90 minutes, after which time triethylamine (0.080mL, 1.734mmol) was added via
syringe. After 90 mins triethylamine (0.080mL) was again added, and after another

further triethylamine (0.200mL) was added. The mixture was heated at 50°C for 48 h

The reaction mixture was filtered of precipitated palladium (0) through celite and

with ethyl acetate (3x20mL). The combined filtrate and ethyl acetate was washed wi
water (2x50mL), then dried (sodium sulphate) and concentrated in vacuo to yield a

oil. Chromatography (1:2 ethyl acetate:hexane; Rf 0.05) afforded 156 as a yellow oi
(0.06g, 30% yield). lU NMR (8): 1.24 (3H, s, CH3); 1.43 (6H, s, 2 x CH3); 1.47 (3H, s,
CH3); 1.79-1.88 (3H, m, H3, H3', H4); 1.94-2.00 (1H, m, H4'); 3.54 (2H, ddd, J
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5.7, H5, H5'); 4.32 (1H, d, J = 15.6, CHPh); 4.82 (1H, d, J = 15.6, CHPh); 5.29 (1H,
OH); 7.21-7.30 (5H, m, ArH x 5);

13

C NMR (8): 23.0 (23.7*) (CH2, C4); 23.8

(28.9*) (3 x CH3); 36.5 (37.0*) (CH2, C3); 44.0 (44.4*) (CH2Ph); 48.0 (48

64.7 (65.3*) (C2); 85.5 (85.8*) (=CCH3); 79.7 (80.5*) ((CH3)3CO); 127.5, 12

(128.3*), 128.8, 128.9 (ArCH x 5); 130.9 (OH); 135.8 (ipsoQ; 153.5 (153.6

(NC(O)O); 175.0 (175.2*) (NCO amide). MS (CI4): m/z 343 (M+l, 20%); 305 (55%)

287 (100%). HRMS (EI4): Found: 342.1934; Required: 342.1940 for (C20H26N2O3)

Synthesis of2-(2-propenyl)-2-benzyl-pyrrolidine-2-carboxamide (159): red
using diborane.

To a solution of diborane in THF (1M, 0.484mL, 0.484mmol) under nitroge

solution of 139 (O.lOOg, 0.29mmol) in anhydrous THF (2mL) over 15 minut

temperature being maintained at 0°C. The solution was then heated at re

The reaction mixture was cooled to room temperature and hydrochloric ac

was added. The THF was removed with rotary evaporation at atmospheric p

Sodium hydroxide pellets were added to the saturated aqueous phase, and

phase was extracted with ethyl acetate (3x3 0ml). The combined extracts
water (2x50mL), then dried (sodium sulphate), concentrated in vacuo and

vacuum to yield crude 159 (Ci5H20N2O) as a yellow oil (0.080g). *H NMR (8

(3H, m, H3, H3', H4); 2.14-2.31 (3H, m, H4', CH2); 2.77-2.87 (2H, m, H

(1H, m, NH); 4.41 (2H, d,J= 6.0, CH2Ph); 5.10 (2H, dd, J = 12.3, 2.1, OH2)
(1H, m, OH); 7.23-7.35 (5H, m, ArH x 5);

13

C NMR (8): 26.2 (CH2, C4);

42.8 (43.1*) (CH2); 47.0 (CH2Ph); 61.7 (62.5*) (CH2, C5); 68.6 (C2); 118.9 (O
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127.2, 128.4 (ArCH x 5); 133.3 ( O H ) ; 138.4 (ipsoQ; 176.5 ( C O ) . M S (CI4): m/z 245
(M+l, 15%); 149 (60%).

Synthesis of 2-(benzylaminomethyl)-2-(2-propenyl)-pyrrolidine (160): Re
using excess lithium aluminium hydride.

In an argon atmosphere a stirred solution of 139 (O.lOOg, 0.29mmol) in

(2mL) was cooled to 0°C, and lithium aluminium hydride (1M, 0.033g) in

(0.87ml) was added dropwise. Stirring continued for 16 hours at room t
precipitate was filtered off and washed with ethyl acetate (50mL). The

filtrates were dried (sodium sulphate) and concentrated in vacuo to yi

(Ci5H22N2) as a yellow oil (0.054g, 84% yield). ]H NMR (8): 1.67-1.88 (3H

H4); 2.17 (1H, d, J = 8.7, H4'); 2.24 (2H, d, J= 7.5, CH2); 2.46 (1H,

(2H, m, H5, H5'); 2.96 (1H, bm, NH); 3.12-3.18 (1H, m, CH); 3.24 (1H

3.53 (2H, dd, J= 11.7, 12.0, CH2Ph); 5.02-5.10 (2H, m, OH2); 5.70-5.82 (
7.24-7.38 (5H, m, ArH x 5);

13

C NMR (8): 25.7 (CH2, C4); 37.1 (CH2, C3

(CH2Ph); 56.8 (CH2, C5); 64.3 (N-CH2); 72.4 (C2); 117.3 (OH2); 126.7, 127.9,
128.2 (ArCH x 5); 135.1 (OH); 139.0 (ipsoQ. MS (CI4): m/z 229 (M+l, 100%),

Synthesis of 2-benzyl-2,3,3a,4,5,6-hexahydro-3-(R)-hydroxy-3a-(S)-(2-p

pyrrolo[l,2-c]imidazol-l-one (161a) and 2-benzyl-2,3,3a,4,5,6-hexahydr
3a-(S)-(2-propenyl)-lH-pyrrolo[l,2-c]imidazol-l-one(161b).

A solution of 139 (1.1 lg, 3.22mmol) in anhydrous THF (15mL) was coole

nitrogen atmosphere, and lithium aluminium hydride (0.158g, 4.186mmol,

(4.19ml) was added dropwise. After heating at reflux for 4 hours, water
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and the mixture was stirred at room temperature for 1 hour. The precipitate wasfilteredof

and washed with ethyl acetate (lOOmL). The ethyl acetate solution was w

(50mL), then dried (sodium sulphate) and concentrated in vacuo to yield

Chromatography (1:1 ethyl acetate:hexane) isolated two compounds (diast

(trans diastereomers) and 161b (cis diastereomers). 161a (Ci6H20N2O2) (R
acetate:hexane) was isolated as a white solid, and was recrystallised

17% yield). Mp: 118-120°C. *H NMR (8): 1.04-1.12 (1H, m, H3); 1.81-1.94

H4, H4'); 2.19 (1H, dd, J= 13.5, 9.3, CH); 2.67 (1H, bd, J= 13.2, CH

H5); 3.77-3.85 (1H, m, H5'); 4.13 (1H, d, J= 15.0, PhCH); 4.46 (1H, bs, N

CH); 4.77 (1H, d, J = 15.0, PhCH); 5.11 (2H, dd, /= 15.9, 9.3, OH2); 5.82
OH); 7.23-7.34 (5H, m, ArH x 5).

13

C NMR (8): 23.7 (CH2, C4); 31.0 (31.

36.2 (CH2); 43.9 (CH2Ph); 44.7 (CH2, C5); 70.3 (70.3*) (C2); 82.6 (82.7*) (

118.5 (OH2); 127.3, 128.1, 128.5 (ArCH x 5); 134.2 (OH); 136.8 (ipsoQ; 16

(NC(O)O). MS (CI4): m/z 273 (M+l, 100%); 255 (-H20, 25%); 231 (20%). HRMS (
Found: 273.1600; required: 273.1600 for Ci6H2iN202.

161b (Ci6H2oN202) (Rf 0.33, 1:1 ethyl acetate:hexane) was isolated as a

63% yield). !H NMR (8): 1.57 (1H, ddd, J= 6.3, 6.6, 12.6, H3); 1.93 (2H, m, H

2.04-2.12 (1H, m, H3'); 2.20 (2H, J= 7.5, CH2); 3.03-3.15 (2H, m, NH,

ddd, /5e,5a = 9.0, J5e,4a = 6.0, J5e,4e = 2.4, H5e); 4.11 (1H, d,J= 15.3, P
CH); 4.75 (1H, d, J= 15.3, PhCH); 4.98 (2H, ddd, J= 15.6, J= 11.4, J= 4.2, OH2);
5.72 (1H, m, OH); 7.25-7.31 (5H, m, ArH x 5).

13

C NMR (8): 26.1 (CH2, C4

C3); 42.9 (CH2); 43.4 (CH2Ph); 45.9 (CH2, C5); 69.8 (C2); 82.9 (HC(O)N); 118.9 (OH

127.2, 127.9, 128.3 (ArCH x 5); 132.6 (OH); 137.1 (ipsoQ; 161.6 (NC(O)O). MS
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m/z 273 (M+l, 100%); 255 (-H20, 2 5 % ) ; 231 (20%). H R M S (CI4): Found: 273.1603;
required: 273.1603 for Ci6H2iN202.

Synthesis of 6-benzyl-l,2-dihydro-5H,l 0H-pyrano[2,3-c]pyrrolo[l,2-c]imidazol(163).

Using similar conditions to those used for the synthesis of 156,161b (0.090g,

in THF (5mL) was added via syringe to a stirred slurry of palladium (II) chlori

fcacetonitrile (0.094g, 0.363mmol) in THF (5mL) under a nitrogen atmosphere. Th

mixture was stirred at room temperature for 45 minutes, after which time trieth

(0.046mL, 0.330mmol) was added via syringe. Stirring at room temperature contin
after 1 hour triethylamine (0.046mL) was again added, and after another 1 hour

triethylamine (0.046mL) was added. Stirring continued at room temperature for 1
The reaction mixture was filtered of precipitated palladium (0) through celite

with ethyl acetate (2x30mL). The combined filtrate and ethyl acetate was washed

water (2x3 OmL), then dried (sodium sulphate) and concentrated in vacuo to yiel

oil. Chromatography (1:1 ethyl acetate:hexane; Rf 0.25) afforded 163 (Ci6Hi8N20

yellow oil (0.078g, 88% yield). ]H NMR (8): 1.50-1.58 (1H, m, H3); 1.65-1.95 (3H

H3', H4, H4'); 2.48 (2H, s, CH2); 3.05 (1H, ddd, J5a,5e = 9.0, J5a,4a = 8.7, J5

3.81 (1H, ddd, J5e,5a= 9.0, J5^ = 6.3, J5eAe = 2.4, H5e); 4.38 (1H, d, J= 14.7,

(1H, s, CH); 4.82 (1H, d, J= 14.7, PhCH); 5.50 (1H, d, J= 15.0, OH); 5.87-5.96 (1
OH); 7.21-7.26 (5H, m, ArH x 5).

13

C NMR (8): 24.9 (CH2, C4); 35.2 (CH2, C3);

(CH2Ph); 46.2 (CH2, C5); 73.1 (OH); 75.9 (C2); 107.4 (HC(0)N); 127.3 (OH); 128.3,
128.4 (ArCH x 5); 137.2 (ipsoQ; 163.2 (NC(O)O). MS(CT*): m/z 211 (M+l, 30%); 255
(100%).
279

Chapter Nine Experimental Methods and Data

Synthesis

of

2-benzyl-3-(2-oxopropylidene)-2,3,3a,4,5,6-hexahydro-lH-pyrro

c]imidazole-l-one (165).

Palladium (II) chloride toacetonitrile (0.158g, 0.610mmol) was transferred to

stoppered and blown with nitrogen for 10 minutes. Anhydrous THF (5mL) was adde

the mixture was stirred under nitrogen for 10 minutes. 161b (0.151g, 0.554mmo

(4mL) was added via syringe and the mixture was stirred at room temperature fo

minutes, after which time triethylamine (0.116mL, 0.831mmol) was added via sy

mixture was heated at reflux, and after 1 hour triethylamine (0.116mL) was ag

and after another 1 hour further triethylamine (0.116mL) was added. Heating a

continued for 2 hours. The reaction mixture was filtered of precipitated pall
through celite and rinsed with ethyl acetate (2x3OmL). The combined filtrate

acetate was washed with water (2x3 OmL), then dried (sodium sulphate) and con

vacuo to yield a yellow oil. Chromatography (1:1 ethyl acetate:hexane; Rf 0.5

(Ci6H]8N202) as the major product, as a yellow oil (0.045g, 30% yield). lH NMR (8
1.30 (1H, m, H3); 1.93-2.08 (2H, m, H3', H4); 2.00 (3H, s, CH3); 2.63 (1H,

6.3,1.5, H4'); 3.19 (1H, ddd, J= 1.2, 6.9, H5); 3.62 (1H, ddd, J= 1.1.4, 10.8

4.60 (2H, s, PhCH2); 4.82 (1H, dd, J= 1.5, 6.6, CH); 5.37 (1H, s, OH); 7.12-7.28
ArH x 5); 13C NMR (8): 26.9 (CH2, C4); 30.3 (CH2, C3); 31.5 (CH3); 45.4 (CH2, C5); 45.8

(CH2Ph); 64.3 (CH, C2); 97.6 (HCO); 126.8, 127.1, 127.9, 129.0, (ArCH x 5); 135.3
(ipsoQ; 156.8 (COH); 160.5 (NC(N)O); 195.5 (CO). MS (CI4): m/z 271 (M+l, 100%);
287 (30%). HRMS (CI4): Found: 271.1447; Required: 271.1447 for (Ci6Hi9N202).
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9.7 Experimental for Chapter Six: Synthesis of Spiro[isobenzofuran] Derivatives

Synthesis ofo- iodobenzyl bromide (196)

A stirred solution of o-iodobenzyl alcohol (2.00g, 8.56mmol) in anhydrous DCM (
was cooled to -30°C under nitrogen, and boron tribromide (1M in DCM, 9.00mmol)

added dropwise via syringe. The mixture was allowed to warm to room temperature

stirring continued for 3 hours. The mixture was carefully poured onto ice-wate

and extracted with DCM (50mL), then dried (sodium sulphate) and concentrated in

to yield a white solid. Chromatography (1:4 ethyl acetate:hexane; Rf 0.91) aff

(C7H6BrI) as a white solid (2.34g, 92% yield), recrystallised from diethyl ethe

56°C (lit. mp: 55-57°C355). *H NMR (8): 4.60 (2H, s, CH2PhI); 6.98 (1H, ddd, 7= 1.5

7.5, ArH); 7.33 (1H, ddd, / = 1.5, 1.8, 7.5, ArH); 7.47 (1H, dd, J= 1.5, 8.1, A

(1H, dd, J= 0.9, 8.1, ArH); 13C NMR (8): 38.8 (CH2Br), 99.8 (ArC-I); 128.8 (ArCH, C5

para to I); 130.0 (ArCH, C6); 130.4 (ArCH, C4); 139.1 (ArCH, C3); 140.0 (ipso C
CH2Br). MS (CI4): m/z 296/298 (M+l, 79Br,81Br, 17%); 217 (100%, loss of Br).

Synthesis of 1,1 '-(l,2-ethandiyl)bis-[2-iodo]benzene (212).

To a stirred solution of benzyl-3-pyrrolidinone (0.17M, 0.157g, 0.898 mmol) i
THF (5.30mL) at -78°C under nitrogen was added butyl lithium (2.5M in hexane,

1.347mmol). After 30 minutes, o-iodobenzyl bromide (0.400g, 1.347mmol) in anhyd

THF (LOmL) was added and the solution was stirred at -78°C, with the temperatu

to -30°C over 3 hours. The mixture was partitioned between DCM (50ml) and water

(50ml), and the organic layer was washed with sodium chloride (sat.) (50mL), fo
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water (50mL), and was then dried (Na 2 S0 4 ) and concentrated in vacuo, providing the crude

product as a brown oil which crystallised upon standing. Chromatography (1:4 eth

acetate:hexane; Rf 0.92) afforded 212 (Ci4Hi2I2) as an off-white crystalline soli

39% yield). Mp: 102-103°C (lit. m.p. 102°C354). !H NMR (8): 3.00 (2H, d, J= 6.3, CH2Ph)

3.03 (2H, d,J= 6.3, CH2Ph); 6.87-6.93 (1H, m ArH); 7.04-7.10(lH, m, ArH); 7.18-7.
(4H, m, ArH x 4); 7.55 (1H, d, J= 8.1, ArH); 7.83 (1H, d, /= 8.1).

13

C NMR (8): 36

(CH2, CH2Ph); 41.0 (CH2Ph); 100.4 (ArC-I); 127.3, 127.7, 127.9, 128.3, 129.6, 130.5,

132.7, 139.4 (ArCH x 8); 140.3 (ipso Q, 140.4 (ipso Q. MS (CI4): m/z 434 (M+, 21%
386, 340; 217 (10%); 185 (50%). HRMS (CI4): Found: 433.9018; Required: 433.9029 for
(Ci4Hi2I2).

Additionally, to a stirred solution of benzyl-3-piperidone (0.17M, 0.170g, 0.89
anhydrous THF (5.30mL) at -78°C under nitrogen was added butyl lithium (2.5M in
hexane, 1.347mmol). After 30 minutess, o-iodobenzyl bromide (0.400g, 1.347mmol)
anhydrous THF (LOmL) was added and the solution was stirred at -78°C, with the
temperature rising to -30°C over 3 hours. The usual work-up provided, after

chromatography (1:4 ethyl acetate:hexane; Rf 0.87), 212 (Ci4Hi2I2) as a white crys

solid (0.21 lg, 36% yield). All spectral data agreed with that previously report

Synthesis of N-benzyl-3-(2-iodobenzyl)-pyrrolidin-2-one (213) and cis-l-benzyliodobenzyloxy)-l,2,3,3a,4,8b-hexahydroindeno[l,2-b]pyrrole(215).

To a stirred solution of benzyl-2-pyrrolidinone (0.17M, 0.314g, 1.796 mmol) in

THF (10.60mL) at -78°C under nitrogen with stirring was added butyl lithium (2.5

Hexane, 2.694mmol). After 30 minutes, o-iodobenzyl bromide (0.700g, 2.358mmol) i
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anhydrous THF (LOmL) was added and the solution was stirred at -78°C, with the

temperature rising to -30°C over 3 hours. The mixture was partitioned

(50ml) and water (50ml), and the organic layer was washed with sodium

(50mL), followed by water (50mL), and was then dried (sodium sulphate)

in vacuo, providing the crude product as a yellow oil. Chromatography
acetate:hexane) isolated 215 (C25H24NOI, Rf 0.70) as a pale yellow oil

and 213 (Ci8Hi8NOI, Rf 0.24) also as a pale yellow oil (0.590g, 84% yie

213: XR NMR (8): 1.71-1.81 (1H, m, H4); 1.96-2.03 (1H, m, H4'); 2.8
7.2, CH); 2.86 (1H, d,J= 9.9, CHPhI); 3.13 (2H, dd, /= 8.7, 5.4, H5, H5');

= 9.6, CHPhI); 4.47 (2H, s, TV-CH2Ph); 6.87-6.92 (1H, m, ArH); 7.21-7.3
7); 7.82 (1H, d, J= 7.8, ArH).

13

C NMR (8): 24.3 (CH2, C4); 41.2 (CH2,

C3); 44.8 (CH2Ph), 46.8 (CH2Ph), 101.4 (ArC-I); 127.4, 127.9, 128.0, 128.2

(ArCH x 8); 136.4 (ipso Q; 139.5 (ArCH, C3, ortho to C-I); 142.1 (ips

MS (CI4): m/z 392 (M+l, 100%); 264/266 (10%); 174 (40%). HRMS (EI4): Found:
391.0395; Required: 391.0433 for (Ci8Hi8NOI).

215: !H NMR (8):2.17-2.37 (2H, m, CH2 (3 to TV); 2.50 (1H, dd, J= 3.9,

2.61-2.66 (2H, m, CH2 a to phenyl); 2.72-2.78 (1H, m, CH); 2.95 (1H, d

AO; 3.57 (2H, dd, J= 13.5, 14.7, CHPh, CHPh); 3.70 (2H, dd, J = 13.8, CHP

6.93 (2H, t, J= 7.5, ArH x 2); 7.26-7.37 (7H, m, ArH x 7); 7.49-7.5
7.77 (2H, dd, J= 2.1, 8.1, ArH x 2).

13

C NMR (8): 28.9 (CH2, (3 to TV);

45.6 (CH, y to TV); 51.3 (CH2Ph); 58.3 (CH2, a to phenyl); 62.8 (0-CH2Ph),

123.7 (AiCU,para to I); 126.4, 126.8,127.2, 128.0, 128.1, 128.5, 128.9,
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131.3 (ipso C); 134.4 (ArCH); 136.7 (ipso C); 139.1, 139.2 (ArCH x 2); 141.5 (ipso

142.2 (ipso Q, 153.5 (N-C-O). MS (CI4): m/z 482 (M+l, 17%); 391 (44%); 288 (5
264 (-CH2PhI, 21%). HRMS (EI4): Found: 480.0831; Required: 480.0824 for
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Appendix 1: NOESY 2-Dimensional Spectrum of 66
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Appendix 2a: gHMBC spectrum of 161a
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Appendix 2b: gHMBC

spectrum of 161b
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Appendix 3a: gCOSY spectrum of 165
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Appendix 3b: HMBC

spectrum of 165

4wiMrti«H.wiEwwl^
•
<5®
00

»«

»•
0

• »

.

0

•

ft

0

a.

>

•© a

1t

t

*
: 0

1

1

§
«

a
,

f
•

•ft

i

I>0

Q
9

a

i

0

•

3
8

@

a
a

0

i

.9.

X J

i

§

V

li •

4t>
0

•

L

<*>

•

a

' .1
- 0

*

t

8

#

r•

0

S

•

#

'
II iT[riTFT m i |in ITII n|i i M i CTI 111 n 1111 IT |i r 11 J i n i j i n Tt TT IT j i tin ITI T n i r FI 11 ii | i ITHI TI ri| ITT 11 n T r^ i T in iTfTpn tin 11 [ 1111 rn T i| 111 n u i I^TMIT m n i re r n-rnpTiiTiMi j m m L n) 1111 u

iliggSS

ssggsgs

!

|"3] a §

sssggws
2

i I

a

2

3

§

g r >BI i

is!=5-sg| og.sadg; s.s.iiis: tilfiii.*

:llM»g

=§§S|||SgS||| g£ 3 g g? s 'S j||SBS»»s»|a»«»*Iff»»ga||Sfg ]({
-«-;
•
|
"
-, a S 3 °

8=88

8888888882 31 8 3 K - S 8 8 » S -

| | > I { 1>I ] |•

Ia|lis»?lll? B«I8l=Ii

as

SslsliisSsSISsKBstilisS^ _„!?
3
I

!

317

Appenaix

Appendix 3c:

N HMBC

spectrum of 165
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Appendix 4: Data for Pharmacological Testing ofLigands
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Data for Compound 35
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Data for Compound 36
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Data for Compound 58
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Data for Compound 60
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- log [SJB 3-116]/M

BOTTOM
TOP
LOGEC50
EC50
Std. Error
BOTTOM

TOP
LOGEC50

AlphalA
62.05
95.98
6.293
1.965e+006

AlphalB
96.27
92.99
-6.768
1.705e-007

Alphal B-Cys128Phe
97.96
105.2
-6.993
1.017e-007

AlphalD
53.67
87.85
-5.599
2.518e-006

7.908e-007
3.306
2.406e+009

4.403
5.234
4.276

2.058
3.005
0.9480

9.968
4.221
0.5417
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Relative affinity0

-log IC 50

ICsoOiM) 1

5.09±0.09

8.2

3

100 (SJB 4.93)

>3O0

3

99 (SJB 4.82)

>300

3

54 (SJB 4.05)

>300

3

101 (SJB 4.26)

>300

3

102 (SJB 4.25)

>300

3

50 (SJB 4.92)

>100

3

aiB
Epinephrine

a IC50, concentration of compound resulting in 5 0 % of m a x i m u m inhibition
b mean log concentration ratio ± S E (-logIC5o Epinephrine minus -logIC5o compound)
c relative affinity of compound as % Epinephrine
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log IC 5 0

IC50(uM)a

7.48±0.07

0.03

3

100 (SJB 4.93)

>300

3

99 (SJB 4.82)

>300

3

54 (SJB 4.05)

>300

3

101 (SJB 4.26)

>300

3

102 (SJB 4.25)

>300

3

50 (SJB 4.92)

>300

3

aiB C128F
Epinephrine

Relative affinity'

a IC50, concentration of compound resulting in 5 0 % of m a x i m u m inhibition
b mean log concentration ratio ± S E (-loglCso Epinephrine minus -loglCso compound)
c relative affinity of compound as % Epinephrine
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alA
Epinephrine

IC50(uM)a

5.10±0.04

8.00

3

>300

3

100 (SJB 4.93)
99 (SJB 4.82)

Ab

-log IC 5 0

3.36±0.15

439

2.86±1.08

Relative affinityc

n

3

0.001

54 (SJB 4.05)

>300

3

101 (SJB 4.26)

>300

3

102 (SJB 4.25)

>300

3

50 (SJB 4.92)

3.88±0.03

131

2.51±1.25

3

0.003

alCso, concentration of compound resulting in 5 0 % of maximum inhibition
b mean log concentration ratio ± S E (-loglCso Epinephrine minus -loglCso compound)
c relative affinity of compound as % Epinephrine
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-log IC 50

IC 5 0 (uM) a

Epinephrine

6.10±0.57

0.79

100 (SJB 4.93)

4.66±0.20

22.1

alD

Ab

Relative affinityc

n
2

1.45±0.77

2

0.03

99 (SJB 4.82)

>100

2

54 (SJB 4.05)

>100

2

101 (SJB 4.26)

4.55±0.34

1.56±0.92

2

0.03

2

>100

(SJB 4.25)
50 (SJB 4.92)

28.4

4.54±0.27

29.1

1.57±0.84

2

0.03

aIC5o, concentration of compound resulting in 5 0 % of maximum inhibition
b mean log concentration ratio ± SE (-loglCso Epinephrine minus -loglCso compound)
c relative affinity of compound as % Epinephrine
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